UI/LS -/: 92043714/CD 
TI/LS -/: Charybdotoxin-sensitive/JJ ,/, Ca(2+)-dependent/JJ membrane/NN potential/JJ changes/NNS are/VBP not/RB involved/VBN in/IN human/JJ T/NN or/CC B/NN cell/NN activation/NN and/CC proliferation/NN ./. 
AB/LS -/: The/DT involvement/NN of/IN ion/NN channels/NNS in/IN B/NN and/CC T/NN lymphocyte/NN activation/NN is/VBZ supported/VBN by/IN many/JJ reports/NNS of/IN changes/NNS in/IN ion/NN fluxes/NNS and/CC membrane/NN potential/NN after/IN mitogen/NN binding/NN ./. 
Human/JJ T/NN and/CC B/NN lymphocytes/NNS demonstrate/VBP an/DT early/JJ and/CC transient/JJ hyperpolarization/NN after/IN ligand/JJ binding/NN ./. 
Inasmuch/RB as/IN the/DT change/NN in/IN membrane/NN potential/NN is/VBZ dependent/JJ on/IN elevation/NN of/IN free/JJ cytosolic/JJ calcium/NN ,/, the/DT hyperpolarization/NN is/VBZ presumably/RB through/IN opening/NN of/IN Ca(2+)-stimulated/JJ K+/NN channels/NNS ./. 
We/PRP have/VBP used/VBN charybdotoxin/NN ,/, a/DT known/JJ inhibitor/NN of/IN Ca(2+)-dependent/JJ K+/NN channels/NNS ,/, to/TO study/VB the/DT role/NN of/IN these/DT channels/NNS in/IN lymphocyte/NN activation/NN and/CC mitogenesis/NN ./. 
We/PRP demonstrate/VBP that/IN charybdotoxin/NN inhibits/VBZ the/DT ligand-induced/JJ transient/JJ membrane/NN hyperpolarization/NN in/IN B/NN and/CC T/NN cells/NNS in/IN a/DT dose-dependent/JJ fashion/NN ,/, without/IN affecting/VBG changes/NNS in/IN cytosolic/JJ Ca2+/NN ./. 
However/RB ,/, blockade/NN of/IN the/DT Ca(2+)-activated/JJ K+/NN channel/NN is/VBZ not/RB associated/VBN with/IN changes/NNS in/IN cell-cycle/JJ gene/NN activation/NN ,/, IL-2/NN production/NN ,/, IL-2R/NN expression/NN or/CC B/NN and/CC T/NN cell/NN mitogenesis/NN ./. 
These/DT results/NNS imply/VBP that/IN membrane/NN potential/JJ changes/NNS secondary/JJ to/TO the/DT ligand-dependent/JJ opening/NN of/IN Ca(2+)-activated/JJ K+/NN channels/NNS are/VBP not/RB involved/VBN in/IN B/NN and/CC T/NN lymphocyte/NN activation/NN and/CC mitogenesis/NN ./. 
UI/LS -/: 92135145/CD 
TI/LS -/: Activity/NN of/IN the/DT kappa/NN B/NN enhancer/NN of/IN the/DT interleukin-2/NN receptor/NN alpha/NN chain/NN in/IN somatic/JJ cell/NN hybrids/NNS is/VBZ accompanied/VBN by/IN the/DT nuclear/JJ localization/NN of/IN NF-kappa/NN B/NN ./. 
AB/LS -/: The/DT two/CD nuclear/JJ proteins/NNS NF-kappa/NN B/NN (/( consisting/VBG of/IN subunits/NNS p50/NN an/DT dp65/NN )/) and/CC the/DT DNA-binding/JJ subunit/NN of/IN NF-kappa/NN B/NN (/( p50/NN )/) by/IN itself/PRP ,/, also/RB called/VBN KBF1/NN ,/, are/VBP constitutively/RB expressed/VBN and/CC localized/JJ in/IN the/DT nucleus/NN of/IN the/DT human/JJ T-cell/NN line/NN IARC/NN 301.5/CD ./. 
In/IN order/NN to/TO define/VB the/DT roles/NNS of/IN these/DT two/CD factors/NNS ,/, which/WDT bind/VBP to/TO the/DT same/JJ kappa/NN B/NN enhancers/NNS ,/, in/IN transcription/NN activation/NN we/PRP have/VBP prepared/VBN somatic/JJ cell/NN hybrids/NNS between/IN IARC/NN 301.5/CD and/CC a/DT murine/JJ myeloma/NN ./. 
Most/JJS hybrids/NNS express/VBP both/CC KBF1/NN and/CC NF-kappa/NN B/NN in/IN their/PRP$ nuclei/NNS ,/, but/CC one/CD hybrid/NN expresses/VBZ only/RB KBF1/NN ./. 
The/DT kappa/NN B/NN enhancer/NN of/IN the/DT gene/NN encoding/VBG the/DT interleukin-2/NN (/( IL-2/NN )/) receptor/NN alpha/NN chain/NN (/( IL-2R/NN alpha/NN )/) is/VBZ functional/JJ only/RB in/IN the/DT hybrids/NNS expressing/VBG nuclear/JJ NF-kappa/NN B/NN ./. 
These/DT findings/NNS show/VBP that/IN nuclear/JJ NF-kappa/NN B/NN is/VBZ necessary/JJ to/TO activate/VB the/DT kappa/NN B/NN enhancer/NN ,/, while/IN KBF1/NN by/IN itself/PRP is/VBZ not/RB sufficient/JJ ./. 
We/PRP propose/VBP that/IN KBF1/NN is/VBZ a/DT competitive/JJ inhibitor/NN of/IN NF-kappa/NN B/NN and/CC discuss/VB how/WRB these/DT factors/NNS may/MD be/VB involved/VBN in/IN the/DT transient/JJ expression/NN of/IN IL-2/NN and/CC IL-2/NN alpha/NN genes/NNS during/IN the/DT immune/JJ response/NN ./. 
UI/LS -/: 92022337/CD 
TI/LS -/: T-helper-cell/JJ determinants/NNS in/IN protein/NN antigens/NNS are/VBP preferentially/RB located/JJ in/IN cysteine-rich/JJ antigen/NN segments/NNS resistant/JJ to/TO proteolytic/JJ cleavage/NN by/IN cathepsin/NN B/NN ,/, L/NN ,/, and/CC D/NN ./. 
AB/LS -/: We/PRP report/VBP on/IN a/DT computer/NN algorithm/NN capable/JJ of/IN predicting/VBG the/DT location/NN of/IN T-helper-cell/NN epitopes/NNS in/IN protein/NN antigen/NN (/( Ag/NN )/) by/IN analysing/VBG the/DT Ag/NN amino/NN acid/NN sequence/NN ./. 
The/DT algorithm/NN was/VBD constructed/VBN with/IN the/DT aim/NN of/IN identifying/VBG segments/NNS in/IN Ag/NN which/WDT are/VBP resistant/JJ to/TO proteolytic/JJ degradation/NN by/IN the/DT enzymes/NNS cathepsin/NN B/NN ,/, L/NN ,/, and/CC D/NN ./. 
These/DT are/VBP prominent/JJ enzymes/NNS in/IN the/DT endocytic/JJ pathway/NN through/IN which/WDT soluble/JJ protein/NN Ag/NN enter/VBP APC/NN ,/, and/CC resistant/JJ segments/NNS in/IN Ag/NN may/MD ,/, therefore/RB ,/, be/VB expected/VBN to/TO contain/VB more/JJR T-cell/NN determinants/NNS than/IN susceptible/JJ segments/NNS ./. 
From/IN information/NN available/JJ in/IN the/DT literature/NN on/IN the/DT substrate/JJ specificity/NN of/IN the/DT three/CD enzymes/NNS ,/, it/PRP is/VBZ clear/JJ that/IN a/DT cysteine/NN is/VBZ not/RB accepted/VBN in/IN any/DT of/IN the/DT S2/NN ,/, S1/NN ,/, S1'/NN ,/, and/CC S2'/NN subsites/NNS of/IN cathepsin/NN B/NN and/CC L/NN ,/, and/CC not/RB in/IN the/DT S1/NN and/CC S1'/NN subsites/NNS of/IN cathepsin/NN D/NN ./. 
Moreover/RB ,/, we/PRP have/VBP noticed/VBN that/IN cysteine-containing/JJ T-cell/NN determinants/NNS in/IN a/DT number/NN of/IN protein/NN Ag/NN are/VBP particularly/RB rich/JJ in/IN the/DT amino/NN acids/NNS alanine/NN ,/, glycine/NN ,/, lysine/NN ,/, leucine/NN ,/, serine/NN ,/, threonine/NN ,/, and/CC valine/NN ./. 
By/IN searching/VBG protein/NN Ag/NN for/IN clusters/NNS of/IN amino/NN acids/NNS containing/VBG cysteine/NN and/CC two/CD of/IN the/DT other/JJ amino/NN acids/NNS we/PRP were/VBD able/JJ to/TO predict/VB 17/CD out/IN of/IN 23/CD empirically/RB known/VBN T-cell/NN determinants/NNS in/IN the/DT Ag/NN with/IN a/DT relatively/RB low/JJ number/NN of/IN false/JJ (/( positive/JJ )/) predictions/NNS ./. 
Furthermore/RB ,/, we/PRP present/VBP a/DT new/JJ principle/NN for/IN searching/VBG Ag/NN for/IN potential/JJ amphipatic/JJ alpha-helical/JJ protein/NN segments/NNS ./. 
Such/JJ segments/NNS accord/VBP well/RB with/IN empirically/RB known/JJ T-cell/NN determinants/NNS and/CC our/PRP$ algorithm/NN produces/VBZ a/DT lower/JJR number/NN of/IN false/JJ positive/JJ predictions/NNS than/IN the/DT principle/NN based/VBN on/IN discrete/JJ Fourier/NN transformations/NNS previously/RB described/VBN ./. 
UI/LS -/: 91303691/CD 
TI/LS -/: Contribution/NN of/IN NF-kappa/NN B/NN and/CC Sp1/NN binding/NN motifs/NNS to/TO the/DT replicative/JJ capacity/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD :/: distinct/JJ patterns/NNS of/IN viral/JJ growth/NN are/VBP determined/VBN by/IN T-cell/NN types/NNS ./. 
AB/LS -/: Starting/VBG with/IN a/DT replication-incompetent/JJ molecular/JJ clone/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD ,/, lacking/VBG all/PDT the/DT NF-kappa/NN B/NN and/CC Sp1/NN binding/NN sites/NNS present/JJ in/IN the/DT native/JJ long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) ,/, proviruses/NNS containing/VBG reconstructed/VBN LTRs/NNS with/IN individual/JJ or/CC combinations/NNS of/IN NF-kappa/NN B/NN and/CC Sp1/NN elements/NNS were/VBD generated/VBN and/CC evaluated/VBN for/IN their/PRP$ capacity/NN to/TO produce/VB virus/NN progeny/NN following/VBG transfection-cocultivation/NN ./. 
Virus/NN stocks/NNS obtained/VBN from/IN these/DT experiments/NNS exhibited/VBD a/DT continuum/NN of/IN replicative/JJ capacities/NNS in/IN different/JJ human/JJ T-cell/NN types/NNS depending/VBG on/IN which/WDT element/NN (/( s/NNS )/) was/VBD present/JJ in/IN the/DT LTR/NN ./. 
For/IN example/NN ,/, in/IN experiments/NNS involving/VBG proviral/JJ clones/NNS with/IN LTRs/NNS containing/VBG one/CD or/CC two/CD NF-kappa/NN B/NN elements/NNS (/( and/CC no/DT Sp1/NN binding/NN sites/NNS )/) ,/, a/DT hierarchy/NN of/IN cellular/JJ permissivity/NN to/TO virus/NN replication/NN (/( peripheral/JJ blood/NN lymphocytes/NNS =/JJ MT4/NN greater/JJR than/IN H9/NN greater/JJR than/IN CEM/NN greater/JJR than/IN Jurkat/NN )/) was/VBD observed/VBN ./. 
Of/IN note/NN was/VBD the/DT associated/VBN emergence/NN of/IN second-site/JJ LTR/NN revertants/NNS which/WDT involved/VBD an/DT alteration/NN of/IN the/DT TATA/NN box/NN ./. 
These/DT results/NNS suggest/VBP that/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD LTR/NN possesses/VBZ functional/JJ redundancy/NN which/WDT ensures/VBZ virus/NN replication/NN in/IN different/JJ T-cell/NN types/NNS and/CC is/VBZ capable/JJ of/IN changing/VBG depending/VBG on/IN the/DT particular/JJ combination/NN of/IN transcriptional/JJ factors/NNS present/JJ ./. 
UI/LS -/: 92144438/CD 
TI/LS -/: Stimulation/NN of/IN interferon/NN beta/NN gene/NN transcription/NN in/FW vitro/FW by/IN purified/VBN NF-kappa/NN B/NN and/CC a/DT novel/JJ TH/NN protein/NN ./. 
AB/LS -/: The/DT human/JJ interferon/NN beta/NN (/( IFN-beta/NN )/) regulatory/JJ element/NN consists/VBZ of/IN multiple/JJ enhanson/NN domains/NNS which/WDT are/VBP targets/NNS for/IN transcription/NN factors/NNS involved/VBN in/IN inducible/JJ expression/NN of/IN the/DT promoter/NN ./. 
To/TO further/RB characterize/VB the/DT protein-DNA/JJ interactions/NNS mediating/VBG IFN-beta/NN induction/NN ,/, positive/JJ regulatory/JJ domain/NN (/( PRD/NN )/) II/CD binding/NN proteins/NNS were/VBD purified/VBN from/IN phorbol/NN ester/NN induced/JJ Jurkat/NN T-cells/NNS and/CC from/IN IFN/NN primed/VBN ,/, cycloheximide/polyinosinic-polycytidylic/JJ acid/NN treated/VBN HeLa/NN S3/NN cells/NNS ./. 
From/IN HeLa/NN cells/NNS ,/, two/CD major/JJ proteins/NNS of/IN 52/CD and/CC 45/CD kilodaltons/NNS (/( kD/NN )/) copurified/VBD with/IN DNA/NN binding/NN activity/NN ,/, whereas/IN from/IN T-cells/NNS ,/, four/CD proteins/NNS --/: a/DT major/JJ protein/NN of/IN 52/CD kD/NN and/CC three/CD minor/JJ proteins/NNS of/IN 82/CD ,/, 67/CD ,/, and/CC 43-47/CD kD/NN --/: were/VBD purified/VBN ./. 
Also/RB ,/, an/DT induction/NN specific/JJ DNA/NN binding/NN protein/NN was/VBD purified/VBN from/IN HeLa/NN cells/NNS that/WDT interacted/VBD with/IN the/DT (/( AAGTGA/NN )/) 4/CD tetrahexamer/NN sequence/NN and/CC the/DT PRDI/NN domain/NN ./. 
This/DT protein/NN is/VBZ immunologically/RB distinct/JJ from/IN IRF-1/ISGF2/NN ./. 
Uninduced/JJ or/CC Sendai/NN virus/NN induced/JJ HeLa/NN extracts/NNS were/VBD used/VBN to/TO examine/VB transcription/NN in/FW vitro/FW using/VBG a/DT series/NN of/IN IFN/NN beta/NN promoter/NN deletions/NNS ./. 
Deletions/NNS upstream/JJ of/IN the/DT PRDII/NN element/NN increased/VBD transcription/NN in/IN the/DT uninduced/JJ extract/NN ,/, indicating/VBG predominantly/RB negative/JJ regulation/NN of/IN the/DT promoter/NN ./. 
A/DT 2-4-fold/JJ increase/NN in/IN IFN-beta/NN promoter/NN transcription/NN was/VBD observed/VBN in/IN Sendai/NN virus/NN induced/JJ extracts/NNS ,/, and/CC deletion/NN of/IN PRDI/NN and/CC PRDII/NN elements/NNS decreased/VBD this/DT induced/VBN level/NN of/IN transcription/NN ./. 
When/WRB purified/VBN PRDII/NN and/CC tetrahexamer/NN binding/NN proteins/NNS were/VBD added/VBN to/TO the/DT induced/VBN extract/NN ,/, a/DT 4-fold/JJ increase/NN in/IN transcription/NN was/VBD observed/VBN ./. 
These/DT experiments/NNS demonstrate/VBP that/IN it/PRP is/VBZ possible/JJ to/TO modulate/VB IFN-beta/NN transcription/NN in/FW vitro/FW but/CC indicate/VBP that/IN additional/JJ proteins/NNS may/MD be/VB required/VBN to/TO fully/RB activate/VB IFN-beta/NN transcription/NN ./. 
UI/LS -/: 91239569/CD 
TI/LS -/: The/DT rhombotin/NN family/NN of/IN cysteine-rich/JJ LIM-domain/JJ oncogenes/NNS :/: distinct/JJ members/NNS are/VBP involved/VBN in/IN T-cell/NN translocations/NNS to/TO human/JJ chromosomes/NNS 11p15/NN and/CC 11p13/NN ./. 
AB/LS -/: A/DT chromosomal/NN translocation/NN in/IN a/DT T-cell/NN leukemia/NN involving/VBG the/DT short/JJ arm/NN of/IN human/JJ chromosome/NN 11/CD at/IN band/NN 11p15/NN disrupts/VBZ the/DT rhombotin/NN gene/NN ./. 
This/DT gene/NN encodes/VBZ a/DT protein/NN with/IN duplicated/JJ cysteine-rich/JJ regions/NNS called/VBN LIM/NN domains/NNS ,/, which/WDT show/VBP homology/NN to/TO zinc-binding/JJ proteins/NNS and/CC to/TO iron-sulfur/JJ centers/NNS of/IN ferredoxins/NNS ./. 
Two/CD homologues/NNS of/IN the/DT rhombotin/NN gene/NN have/VBP now/RB been/VBN isolated/VBN ./. 
One/CD of/IN these/DT ,/, designated/VBN Rhom-2/NN ,/, is/VBZ located/JJ on/IN human/JJ chromosome/NN 11/CD at/IN band/NN 11p13/NN ,/, where/WRB a/DT cluster/NN of/IN T-cell/NN leukemia-specific/JJ translocations/NNS occur/VBP ;/: all/DT translocation/NN breakpoints/NNS at/IN 11p13/NN are/VBP upstream/JJ of/IN the/DT Rhom-2/NN gene/NN ./. 
Human/JJ and/CC mouse/NN Rhom-2/NN are/VBP highly/RB conserved/VBN and/CC ,/, like/IN rhombotin/NN ,/, encode/VBP two/CD tandem/JJ cysteine-rich/JJ LIM/NN domains/NNS ./. 
Rhom-2/NN mRNA/NN is/VBZ expressed/VBN in/IN early/JJ mouse/NN development/NN in/IN central/JJ nervous/JJ system/NN ,/, lung/NN ,/, kidney/NN ,/, liver/NN ,/, and/CC spleen/NN but/CC only/RB very/RB low/JJ levels/NNS occur/VBP in/IN thymus/NN ./. 
The/DT other/JJ gene/NN ,/, designated/VBN Rhom-3/NN ,/, is/VBZ not/RB on/IN chromosome/NN 11/CD but/CC also/RB retains/VBZ homology/NN to/TO the/DT LIM/NN domain/NN of/IN rhombotin/NN ./. 
Since/IN the/DT Rhom-2/NN gene/NN is/VBZ such/JJ a/DT common/JJ site/NN of/IN chromosomal/JJ damage/NN in/IN T-cell/NN tumors/NNS ,/, the/DT consistency/NN of/IN translocations/NNS near/IN the/DT rhombotin/NN gene/NN was/VBD further/RB examined/VBN ./. 
A/DT second/JJ translocation/NN adjacent/JJ to/TO rhombotin/NN was/VBD found/VBN and/CC at/IN the/DT same/JJ position/NN as/IN in/IN the/DT previous/JJ example/NN ./. 
Therefore/RB ,/, chromosome/NN bands/NNS 11p15/NN (/( rhombotin/NN )/) and/CC 11p13/NN (/( Rhom-2/NN )/) are/VBP consistent/JJ sites/NNS of/IN chromosome/NN translocation/NN in/IN T-cell/NN leukemia/NN ,/, with/IN the/DT 11p15/NN target/NN more/RBR rarely/RB involved/VBN ./. 
The/DT results/NNS define/VBP the/DT rhombotin/NN gene/NN family/NN as/IN a/DT class/NN of/IN T-cell/NN oncogenes/NNS with/IN duplicated/JJ cysteine-rich/JJ LIM/NN domains/NNS ./. 
UI/LS -/: 91355651/CD 
TI/LS -/: NF-kappa/NN B/NN activation/NN by/IN tumor/NN necrosis/NN factor/NN alpha/NN in/IN the/DT Jurkat/NN T/NN cell/NN line/NN is/VBZ independent/JJ of/IN protein/NN kinase/NN A/NN ,/, protein/NN kinase/NN C/NN ,/, and/CC Ca(2+)-regulated/JJ kinases/NNS ./. 
AB/LS -/: NF-kappa/NN B/NN is/VBZ a/DT DNA-binding/JJ regulatory/JJ factor/NN able/JJ to/TO control/VB transcription/NN of/IN a/DT number/NN of/IN genes/NNS ,/, including/VBG human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) genes/NNS ./. 
In/IN T/NN cells/NNS ,/, NF-kappa/NN B/NN is/VBZ activated/VBN upon/IN cellular/JJ treatment/NN by/IN phorbol/NN esters/NNS and/CC the/DT cytokine/NN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF/NN alpha/NN )/) ./. 
In/IN the/DT present/JJ work/NN ,/, we/PRP investigated/VBD the/DT molecular/JJ events/NNS leading/VBG to/TO NF-kappa/NN B/NN activation/NN by/IN TNF/NN alpha/NN in/IN a/DT human/JJ T/NN cell/NN line/NN (/( Jurkat/NN )/) and/CC its/PRP$ subclone/JJ JCT6/NN ,/, which/WDT presents/VBZ a/DT deficiency/NN in/IN the/DT PKA/NN transduction/NN pathway/NN ./. 
We/PRP found/VBD that/IN in/IN both/DT cell/NN lines/NNS ,/, both/CC phorbol/NN ester/NN and/CC TNF/NN alpha/NN were/VBD able/JJ to/TO activate/VB NF-kappa/NN B/NN ./. 
Phorbol/NN activation/NN was/VBD positively/RB modulated/VBN by/IN Ca2+/NN influx/NN while/IN TNF/NN alpha/NN activation/NN was/VBD not/RB ./. 
Furthermore/RB ,/, while/IN PMA/NN activation/NN was/VBD inhibited/VBN by/IN the/DT PKC/NN inhibitor/NN staurosporin/NN ,/, the/DT TNF/NN alpha/NN effect/NN was/VBD unchanged/JJ ./. 
TNF/NN alpha/NN did/VBD not/RB activate/VB cAMP/NN production/NN and/CC its/PRP$ signal/NN was/VBD not/RB modulated/VBN by/IN cAMP/NN activators/NNS ./. 
Moreover/RB ,/, cAMP/NN activators/NNS did/VBD not/RB activate/VB NF-kappa/NN B/NN in/IN Jurkat/NN cells/NNS ./. 
Thus/RB ,/, TNF/NN alpha-induced/JJ NF-kappa/NN B/NN activation/NN was/VBD found/VBN to/TO be/VB mediated/VBN by/IN none/NN of/IN the/DT major/JJ signal-mediating/JJ kinases/NNS such/JJ as/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) ,/, protein/NN kinase/NN A/NN ,/, or/CC Ca(2+)-regulated/JJ kinases/NNS ./. 
Furthermore/RB ,/, we/PRP found/VBD that/IN cytoplasmic/JJ acidification/NN facilitated/VBD NF-kappa/NN B/NN activation/NN by/IN both/CC TNF/NN alpha/NN and/CC PKC/NN ,/, by/IN a/DT mechanism/NN that/WDT increases/VBZ NF-kappa/NN B/I/NN kappa/NN B/NN dissociation/NN without/IN affecting/VBG the/DT NF-kappa/NN B/NN translocation/NN step/NN ./. 
UI/LS -/: 91172211/CD 
TI/LS -/: The/DT functional/JJ domains/NNS of/IN the/DT murine/JJ Thy-1/NN gene/NN promoter/NN ./. 
AB/LS -/: The/DT Thy-1/NN gene/NN promoter/NN resembles/VBZ a/DT "/`` housekeeping/JJ "/'' promoter/NN in/IN that/IN it/PRP is/VBZ located/JJ within/IN a/DT methylation-free/JJ island/NN ,/, lacks/VBZ a/DT canonical/JJ TATA/NN box/NN ,/, and/CC displays/VBZ heterogeneity/NN in/IN the/DT 5'-end/JJ termini/NNS of/IN the/DT mRNA/NN ./. 
Using/VBG transgenic/JJ mice/NNS ,/, we/PRP show/VBP that/IN this/DT promoter/NN does/VBZ not/RB confer/VB any/DT tissue/NN specificity/NN and/CC is/VBZ active/JJ only/RB in/IN a/DT position-dependent/JJ manner/NN ./. 
It/PRP can/MD only/RB be/VB activated/VBN in/IN a/DT tissue-specific/JJ manner/NN by/IN elements/NNS that/WDT lie/VBP downstream/RB of/IN the/DT initiation/NN site/NN ./. 
We/PRP have/VBP analyzed/VBN the/DT functional/JJ domains/NNS of/IN the/DT minimal/JJ Thy-1/NN promoter/NN and/CC show/VB that/IN the/DT dominant/JJ promoter/NN elements/NNS consist/VBP of/IN multiple/JJ binding/VBG sites/NNS for/IN the/DT transcription/NN factor/NN Sp1/NN ,/, an/DT inverted/JJ CCAAT/NN box/NN ,/, and/CC sequences/VBZ proximal/JJ to/TO the/DT transcription/NN start/NN site/NN ./. 
DNase/NN I/CD and/CC gel/NN mobility/NN shift/NN assays/NNS show/VBP the/DT binding/NN of/IN a/DT number/NN of/IN nuclear/JJ factors/NNS to/TO these/DT elements/NNS ,/, including/VBG Sp1/NN and/CC CP1/NN ./. 
Our/PRP$ results/NNS show/VBP that/IN the/DT structure/NN of/IN this/DT promoter/NN only/RB permits/VBZ productive/JJ interactions/NNS of/IN the/DT two/CD transcription/NN factors/NNS Sp1/NN and/CC CP1/NN with/IN the/DT basal/JJ transcription/NN machinery/NN in/IN the/DT presence/NN of/IN enhancer/NN sequences/NNS ./. 
UI/LS -/: 91117203/CD 
TI/LS -/: Nuclear/JJ factor/NN kappa/NN B/NN activates/VBZ proenkephalin/NN transcription/NN in/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: Upon/IN activation/NN ,/, T/NN lymphocytes/NNS accumulate/VBP high/JJ levels/NNS of/IN the/DT neuropeptide/NN enkephalin/NN which/WDT correlate/VBP with/IN high/JJ levels/NNS of/IN proenkephalin/NN mRNA/NN in/IN the/DT cells/NNS ./. 
Here/RB we/PRP investigated/VBD the/DT transcriptional/JJ basis/NN for/IN these/DT changes/NNS ./. 
The/DT proenkephalin/NN promoter/NN contains/VBZ a/DT sequence/NN GGGGACGTCCCC/NN ,/, named/VBN B2/NN ,/, which/WDT is/VBZ similar/JJ to/TO the/DT kappa/NN B/NN sequence/NN GGGGACTTTCC/NN ,/, the/DT binding/VBG site/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN ./. 
Activation/NN of/IN T/NN lymphocytes/NNS induces/VBZ an/DT NF-kappa/NN B-like/JJ binding/NN activity/NN to/TO the/DT B2/NN site/NN ,/, concomitant/JJ with/IN activation/NN of/IN the/DT proenkephalin/NN promoter/NN ./. 
Mutations/NNS at/IN the/DT B2/NN site/NN abolish/VBP this/DT transcriptional/JJ activation/NN ./. 
The/DT purified/VBN homodimer/NN (/( two/CD p50s/NNS )/) of/IN the/DT DNA-binding/JJ subunit/NN of/IN NF-kappa/NN B/NN binds/VBZ the/DT B2/NN site/NN of/IN proenkephalin/NN relatively/RB better/JJR than/IN does/VBZ the/DT heterotetramer/NN (/( two/CD p65s/NNS plus/CC two/CD p50s/NNS )/) form/NN of/IN the/DT factor/NN ./. 
Thus/RB ,/, it/PRP appears/VBZ that/IN the/DT T-cell-specific/JJ activation/NN of/IN the/DT proenkephalin/NN promoter/NN is/VBZ mediated/VBN by/IN NF-kappa/NN B/NN ./. 
However/RB ,/, as/IN NF-kappa/NN B/NN is/VBZ ubiquitous/JJ and/CC the/DT transcriptional/JJ activation/NN through/IN the/DT B2/NN site/NN is/VBZ T/NN cell/NN specific/JJ ,/, yet/RB another/DT T-cell-specific/JJ factor/NN which/WDT synergizes/VBZ with/IN NF-kappa/NN B/NN should/MD be/VB considered/VBN ./. 
UI/LS -/: 91079577/CD 
TI/LS -/: Induction/NN of/IN NF-KB/NN during/IN monocyte/NN differentiation/NN by/IN HIV/NN type/NN 1/CD infection/NN ./. 
AB/LS -/: The/DT production/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) progeny/NN was/VBD followed/VBN in/IN the/DT U937/NN promonocytic/JJ cell/NN line/NN after/IN stimulation/NN either/CC with/IN retinoic/JJ acid/NN or/CC PMA/NN ,/, and/CC in/IN purified/VBN human/JJ monocytes/NNS and/CC macrophages/NNS ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS and/CC Southwestern/NN blotting/NN experiments/NNS were/VBD used/VBN to/TO detect/VB the/DT binding/NN of/IN cellular/JJ transactivation/NN factor/NN NF-KB/NN to/TO the/DT double/JJ repeat-KB/JJ|NN enhancer/NN sequence/NN located/JJ in/IN the/DT long/JJ terminal/JJ repeat/NN ./. 
PMA/NN treatment/NN ,/, and/CC not/RB retinoic/JJ acid/NN treatment/NN of/IN the/DT U937/NN cells/NNS acts/VBZ in/IN inducing/VBG NF-KB/NN expression/NN in/IN the/DT nuclei/NNS ./. 
In/IN nuclear/JJ extracts/NNS from/IN monocytes/NNS or/CC macrophages/NNS ,/, induction/NN of/IN NF-KB/NN occurred/VBD only/RB if/IN the/DT cells/NNS were/VBD previously/RB infected/VBN with/IN HIV-1/NN ./. 
When/WRB U937/NN cells/NNS were/VBD infected/VBN with/IN HIV-1/NN ,/, no/DT induction/NN of/IN NF-KB/NN factor/NN was/VBD detected/VBN ,/, whereas/IN high/JJ level/NN of/IN progeny/NN virions/NNS was/VBD produced/VBN ,/, suggesting/VBG that/IN this/DT factor/NN was/VBD not/RB required/VBN for/IN viral/JJ replication/NN ./. 
These/DT results/NNS indicate/VBP that/IN in/IN monocytic/JJ cell/NN lineage/NN ,/, HIV-1/NN could/MD mimic/VB some/DT differentiation/activation/JJ stimuli/NNS allowing/VBG nuclear/JJ NF-KB/NN expression/NN ./. 
UI/LS -/: 91075236/CD 
TI/LS -/: Disruption/NN of/IN the/DT human/JJ SCL/NN locus/NN by/IN "/`` illegitimate/JJ "/'' V-(D)-J/NN recombinase/NN activity/NN ./. 
AB/LS -/: A/DT fusion/NN complementary/JJ DNA/NN in/IN the/DT T/NN cell/NN line/NN HSB-2/NN elucidates/VBZ a/DT provocative/JJ mechanism/NN for/IN the/DT disruption/NN of/IN the/DT putative/JJ hematopoietic/JJ transcription/NN factor/NN SCL/NN ./. 
The/DT fusion/NN cDNA/NN results/VBZ from/IN an/DT interstitial/JJ deletion/NN between/IN a/DT previously/RB unknown/JJ locus/NN ,/, SIL/NN (/( SCL/NN interrupting/NN locus/NN )/) ,/, and/CC the/DT 5'/JJ untranslated/JJ region/NN of/IN SCL/NN ./. 
Similar/JJ to/TO 1/CD ;/: 14/CD translocations/NNS ,/, this/DT deletion/NN disrupts/VBZ the/DT SCL/NN 5'/JJ regulatory/JJ region/NN ./. 
This/DT event/NN is/VBZ probably/RB mediated/VBN by/IN V-(D)-J/NN recombinase/NN activity/NN ,/, although/IN neither/DT locus/NN is/VBZ an/DT immunoglobulin/NN or/CC a/DT T/NN cell/NN receptor/NN ./. 
Two/CD other/JJ T/NN cell/NN lines/NNS ,/, CEM/NN and/CC RPMI/NN 8402/CD ,/, have/VBP essentially/RB identical/JJ deletions/NNS ./. 
Thus/RB ,/, in/IN lymphocytes/NNS ,/, growth-affecting/JJ genes/NNS other/JJ than/IN immune/JJ receptors/NNS risk/VBP rearrangements/NNS ./. 
UI/LS -/: 91125342/CD 
TI/LS -/: Thyroid/NN hormone/NN receptors/NNS form/VBP distinct/JJ nuclear/JJ protein-dependent/JJ and/CC independent/JJ complexes/NNS with/IN a/DT thyroid/NN hormone/NN response/NN element/NN ./. 
AB/LS -/: We/PRP have/VBP examined/VBN the/DT binding/NN of/IN nuclear/JJ proteins/NNS and/CC recombinant/JJ thyroid/NN hormone/NN receptors/NNS (/( TRs/NNS )/) to/TO the/DT palindromic/JJ thyroid/NN hormone/NN responsive/JJ element/NN AGGTCATGACCT/NN (/( TREp/NN )/) using/VBG a/DT gel/NN electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
Four/CD specific/JJ protein-DNA/JJ complexes/NNS were/VBD detected/VBN after/IN incubation/NN of/IN nuclear/JJ extracts/NNS (/( NE/NNS )/) from/IN T3-responsive/JJ pituitary/NN (/( GH3/NN )/) cells/NNS with/IN a/DT TREp-containing/JJ DNA/NN fragment/NN ./. 
This/DT was/VBD compared/VBN with/IN the/DT TREp/NN binding/NN of/IN reticulocyte/NN lysate-synthesized/JJ TRs/NNS ./. 
TR/NN alpha/NN 1/CD and/CC TR/NN beta/NN 2/CD each/DT formed/VBD a/DT single/JJ major/JJ TR/NN :/: TREp/NN complex/NN which/WDT comigrated/VBD with/IN the/DT least/RBS retarded/VBN complex/NN formed/VBN by/IN GH3/NN NE/NNS ,/, while/IN TR/NN beta/NN 1/CD formed/VBD multiple/JJ complexes/NNS suggesting/VBG that/IN it/PRP can/MD bind/VB to/TO TREp/NN as/IN an/DT oligomer/NN ./. 
Interestingly/RB ,/, coincubation/NN of/IN 35S-TR/NN alpha/NN 1/CD ,/, GH3/NN NE/NNS ,/, and/CC unlabeled/JJ TREp/NN resulted/VBD in/IN not/RB only/RB the/DT 35S-TR/NN :/: TREp/NN complex/NN ,/, but/CC in/IN two/CD additional/JJ more/RBR greatly/RB retarded/VBN complexes/NNS containing/VBG 35S-TR/NN alpha/NN 1/CD and/CC comigrating/VBG with/IN those/DT formed/VBN by/IN GH3/NN extract/NN alone/RB ./. 
Incubation/NN of/IN each/DT of/IN the/DT TRs/NNS with/IN NE/NNS from/IN COS-7/NN cells/NNS ,/, which/WDT do/VBP not/RB possess/VB sufficient/JJ endogenous/JJ TRs/NNS to/TO mediate/VB T3-responses/NNS ,/, resulted/VBD in/IN formation/NN of/IN a/DT new/JJ ,/, more/RBR greatly/RB shifted/VBN complex/NN ./. 
A/DT similar/JJ ,/, heat/NN labile/JJ activity/NN which/WDT altered/VBD mobility/NN of/IN the/DT TR/NN :/: TRE/NN complex/NN was/VBD also/RB present/JJ in/IN NE/NNS from/IN T3-unresponsive/JJ JEG-3/NN cells/NNS ./. 
At/IN high/JJ concentration/NN of/IN NE/NNS ,/, all/DT of/IN the/DT TR/NN bound/VBN to/TO TREp/NN was/VBD more/JJR greatly/RB retarded/VBN than/IN in/IN the/DT absence/NN of/IN NE/NNS ./. 
Truncation/NN of/IN TR/NN alpha/NN 1/CD at/IN amino/NN acid/NN 210/CD prevented/VBD additional/JJ complex/NN formation/NN in/IN the/DT presence/NN of/IN NE/NNS without/IN affecting/VBG DNA/NN binding/NN ,/, suggesting/VBG that/IN the/DT carboxyl-terminus/NN of/IN the/DT TRs/NNS is/VBZ essential/JJ for/IN interaction/NN with/IN nuclear/JJ proteins/NNS ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 90376424/CD 
TI/LS -/: Cell-specific/JJ differences/NNS in/IN activation/NN of/IN NF-kappa/NN B/NN regulatory/JJ elements/NNS of/IN human/JJ immunodeficiency/NN virus/NN and/CC beta/NN interferon/NN promoters/NNS by/IN tumor/NN necrosis/NN factor/NN ./. 
AB/LS -/: Three/CD aspects/NNS of/IN the/DT involvement/NN of/IN tumor/NN necrosis/NN factor/NN in/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) pathogenesis/NN were/VBD examined/VBN ./. 
Tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) mRNA/NN production/NN was/VBD analyzed/VBN by/IN polymerase/NN chain/NN reaction/NN amplification/NN in/IN monocytic/JJ U937/NN cells/NNS and/CC in/IN a/DT chronically/RB HIV/NN infected/JJ U937/NN cell/NN line/NN (/( U9-IIIB/NN )/) ./. 
TNF-alpha/NN RNA/NN was/VBD undetectable/JJ in/IN U937/NN cells/NNS ,/, whereas/IN a/DT low/JJ constitutive/JJ level/NN was/VBD detected/VBN in/IN U9-IIIB/NN cells/NNS ./. 
Paramyxovirus/NN infection/NN induced/VBD a/DT 5-/CD to/TO 10-fold/JJ increase/NN in/IN the/DT steady-state/JJ level/NN of/IN TNF-alpha/NN RNA/NN in/IN U9-IIIB/NN cells/NNS compared/VBN with/IN U937/NN cells/NNS ,/, suggesting/VBG that/IN HIV-infected/JJ monocytic/JJ cells/NNS produced/VBD higher/JJR levels/NNS of/IN TNF-alpha/NN than/IN did/VBD normal/JJ cells/NNS after/IN a/DT secondary/JJ virus/NN infection/NN ./. 
The/DT effects/NNS of/IN TNF-alpha/NN on/IN gene/NN expression/NN were/VBD examined/VBN by/IN transient/JJ expression/NN assays/NNS using/VBG reporter/NN chloramphenicol/NN acetyltransferase/NN plasmids/NNS linked/VBN to/TO regulatory/JJ elements/NNS from/IN the/DT HIV/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) and/CC the/DT beta/NN interferon/NN promoter/NN ./. 
In/IN U937/NN and/CC Jurkat/NN T/NN lymphoid/JJ cells/NNS ,/, the/DT inducibility/NN of/IN the/DT different/JJ hybrid/NN promoters/NNS by/IN TNF-alpha/NN or/CC phorbol/NN ester/NN varied/VBD in/IN a/DT cell/NN type-/NN and/CC promoter/NN context-specific/JJ manner/NN ;/: the/DT levels/NNS of/IN gene/NN activity/NN of/IN NF-kappa/NN B-containing/JJ plasmids/NNS correlated/VBD directly/RB with/IN induction/NN of/IN NF-kappa/NN B/NN DNA-binding/JJ activity/NN ./. 
Although/IN the/DT intact/JJ beta/NN interferon/NN promoter/NN was/VBD only/RB weakly/RB stimulated/VBN by/IN phorbol/NN ester/NN or/CC TNF-alpha/NN ,/, multimers/NNS of/IN the/DT PRDII/NN NF-kappa/NN B-binding/JJ domain/NN were/VBD inducible/JJ by/IN both/DT agents/NNS ./. 
TNF-alpha/NN was/VBD able/JJ to/TO increase/VB expression/NN of/IN the/DT HIV/NN LTR/NN in/IN T/NN cells/NNS ,/, but/CC in/IN monocytic/JJ cells/NNS ,/, TNF-alpha/NN did/VBD not/RB induce/VB the/DT HIV/NN LTR/NN above/IN a/DT constitutive/JJ level/NN of/IN activity/NN ./. 
This/DT level/NN of/IN NF-kappa/NN B-independent/JJ activity/NN appears/VBZ to/TO be/VB sufficient/JJ for/IN virus/NN multiplication/NN ,/, since/IN TNF-alpha/NN treatment/NN had/VBD no/DT effect/NN on/IN the/DT kinetics/NNS of/IN de/FW novo/FW HIV/NN type/NN 1/CD (/( HIV-1/NN )/) infection/NN and/CC viral/JJ RNA/NN production/NN in/IN U937/NN cells/NNS ./. 
However/RB ,/, in/IN Jurkat/NN cells/NNS ,/, TNF-alpha/NN dramatically/RB enhanced/VBD the/DT spread/NN of/IN HIV-1/NN through/IN the/DT cell/NN population/NN and/CC increased/VBD viral/JJ RNA/NN synthesis/NN ,/, indicating/VBG that/IN in/IN T/NN cells/NNS HIV-1/NN multiplication/NN was/VBD stimulated/VBN by/IN TNF-alpha/NN treatment/NN ./. 
UI/LS -/: 91118160/CD 
TI/LS -/: Functional/JJ analysis/NN of/IN cis-linked/JJ regulatory/JJ sequences/NNS in/IN the/DT HLA/NN DRA/NN promoter/NN by/IN transcription/NN in/FW vitro/FW ./. 
AB/LS -/: Two/CD consensus/NN sequences/NNS ,/, called/VBN X/NN and/CC Y/NN boxes/NNS ,/, capable/JJ of/IN binding/VBG nuclear/JJ proteins/NNS and/CC regulating/VBG expression/NN in/IN B/NN cells/NNS have/VBP been/VBN defined/VBN within/IN the/DT immediate/JJ upstream/JJ region/NN of/IN major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN II/CD promoters/NNS ./. 
Unlike/IN other/JJ class/NN II/CD promoters/NNS ,/, the/DT HLA-DR/NN alpha/NN (/( DRA/NN )/) promoter/NN also/RB contains/VBZ one/CD element/NN identical/JJ to/TO the/DT "/`` octamer/NN "/'' motif/NN of/IN immunoglobulin/NN variable/JJ region/NN promoters/NNS that/WDT is/VBZ responsible/JJ for/IN B/NN cell-specific/JJ transcription/NN ./. 
This/DT "/`` octamer/NN "/'' in/IN the/DT context/NN of/IN DRA/NN appears/VBZ capable/JJ of/IN binding/VBG both/CC the/DT ubiquitous/JJ (/( OTF-1/NN )/) and/CC lymphoid-specific/JJ (/( OTF-2/NN )/) "/`` octamer/NN "/'' binding/NN proteins/NNS ,/, but/CC at/IN least/JJS one/CD other/JJ distinct/JJ "/`` octamer/NN "/'' complex/NN was/VBD found/VBN ./. 
In/IN order/NN to/TO characterize/VB the/DT function/NN of/IN cis-acting/JJ elements/NNS ,/, we/PRP have/VBP developed/VBN an/DT in/FW vitro/FW system/NN in/IN which/WDT a/DT DRA/NN promoter/NN construct/NN is/VBZ transcribed/VBN more/RBR efficiently/RB in/IN extracts/NNS from/IN B/NN cells/NNS than/IN in/IN extracts/NNS from/IN class/NN II-negative/JJ HeLa/NN cells/NNS ./. 
5'/JJ deletion/NN constructs/NNS which/WDT lacked/VBD the/DT Y/NN box/NN ,/, but/CC retained/VBD the/DT "/`` octamer/NN "/'' motif/NN and/CC TATA/NN box/NN were/VBD completely/RB inactive/JJ ,/, and/CC internal/JJ deletion/NN of/IN the/DT Y/NN box/NN reduced/VBD transcription/NN by/IN 95/CD %/NN ./. 
Using/VBG supercoiled/JJ ,/, but/CC not/RB linear/JJ templates/NNS ,/, we/PRP observed/VBD differences/NNS in/IN transcription/NN efficiencies/NNS from/IN templates/NNS lacking/VBG or/CC disrupting/VBG the/DT X/NN consensus/NN element/NN that/WDT reflect/VBP effects/NNS of/IN random/JJ replacement/NN of/IN X/NN box/NN sequences/NNS in/IN transient/JJ expression/NN assays/NNS ./. 
Demonstration/NN of/IN the/DT complete/JJ dependence/NN on/IN the/DT Y/NN box/NN in/IN this/DT system/NN suggests/VBZ that/IN ,/, despite/IN its/PRP$ demonstrated/VBN importance/NN in/IN the/DT DRA/NN promoter/NN ,/, the/DT DRA/NN "/`` octamer/NN "/'' does/VBZ not/RB utilize/VB OTF-2/NNP in/IN a/DT manner/NN analogous/JJ to/TO immunoglobulin/NN promoters/NNS in/IN B/NN cells/NNS ./. 
UI/LS -/: 90293687/CD 
TI/LS -/: Lipopolysaccharide/NN is/VBZ a/DT potent/JJ monocyte/macrophage-specific/JJ stimulator/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD expression/NN ./. 
AB/LS -/: Lipopolysaccharide/NN (/( LPS/NN )/) potently/RB stimulates/VBZ human/JJ immunodeficiency/NN virus/NN type/NN 1-long/JJ terminal/JJ repeat/NN (/( HIV-1-LTR/NN )/) CAT/NN constructs/NNS transfected/VBN into/IN monocyte/macrophage-like/JJ cell/NN lines/NNS but/CC not/RB a/DT T/NN cell/NN line/NN ./. 
This/DT effect/NN appears/VBZ to/TO be/VB mediated/VBN through/IN the/DT induction/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS demonstrate/VBP that/IN LPS/NN induces/VBZ a/DT DNA/NN binding/NN activity/NN indistinguishable/JJ from/IN NF-kappa/NN B/NN in/IN U937/NN and/CC THP-1/NN cells/NNS ./. 
LPS/NN is/VBZ also/RB shown/VBN to/TO dramatically/RB increase/VB HIV-1/NN production/NN from/IN a/DT chronically/RB infected/JJ monocyte/macrophage-like/JJ cloned/VBN cell/NN line/NN ,/, U1/NN ,/, which/WDT produces/VBZ very/RB low/JJ levels/NNS of/IN HIV-1/NN at/IN baseline/NN ./. 
The/DT stimulation/NN of/IN viral/JJ production/NN from/IN this/DT cell/NN line/NN occurs/VBZ only/RB if/IN these/DT cells/NNS are/VBP treated/VBN with/IN granulocyte/macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) before/IN treatment/NN with/IN LPS/NN ./. 
This/DT stimulation/NN of/IN HIV-1/NN production/NN is/VBZ correlated/VBN with/IN an/DT increase/NN in/IN the/DT level/NN of/IN HIV-1/NN RNA/NN and/CC and/CC activation/NN of/IN NF-kappa/NN B/NN ./. 
LPS/NN is/VBZ not/RB able/JJ to/TO induce/VB HIV-1/NN production/NN in/IN a/DT cloned/VBN T/NN cell/NN line/NN ./. 
The/DT effect/NN of/IN LPS/NN on/IN HIV-1/NN replication/NN occurs/VBZ at/IN picogram/NN per/IN milliliter/NN concentrations/NNS and/CC may/MD be/VB clinically/RB significant/JJ in/IN understanding/VBG the/DT variability/NN of/IN the/DT natural/JJ history/NN of/IN HIV-1/NN infection/NN ./. 
UI/LS -/: 90285430/CD 
TI/LS -/: Steroid/NN dose/NN sparing/NN :/: pharmacodynamic/JJ responses/NNS to/TO single/JJ versus/CC divided/JJ doses/NNS of/IN methylprednisolone/NN in/IN man/NN ./. 
AB/LS -/: Inhibitory/JJ drug/NN interactions/NNS affecting/VBG the/DT metabolism/NN of/IN methylprednisolone/NN (/( MP/NN )/) may/MD produce/VB either/CC steroid/NN sparing/NN or/CC adverse/JJ effects/NNS partly/RB by/IN increasing/VBG the/DT exposure/NN time/NN to/TO the/DT steroid/NN ./. 
This/DT phenomenon/NN can/MD be/VB mimicked/VBN by/IN administering/VBG MP/NN in/IN divided/JJ doses/NNS ./. 
Two/CD types/NNS of/IN responses/NNS were/VBD compared/VBN after/IN a/DT single/JJ MP/NN dose/NN (/( 40/CD mg/NN bolus/NN )/) and/CC a/DT divided/JJ regimen/NN (/( 20/CD mg/NN bolus/NN and/CC a/DT 5/CD mg/NN bolus/NN 8/CD hours/NNS later/RB )/) in/IN six/CD healthy/JJ male/JJ volunteers/NNS ./. 
The/DT suppression/NN of/IN basophils/NNS measured/VBN as/IN whole/JJ blood/NN histamine/NN and/CC plasma/NN cortisol/NN concentrations/NNS was/VBD assessed/VBN during/IN 32/CD hours/NNS ./. 
The/DT 37.5/CD %/NN reduction/NN in/IN dose/NN produced/VBD a/DT 23/CD %/NN overall/RB decreased/VBN blood/NN histamine/NN response/NN ./. 
A/DT pharmacodynamic/JJ model/NN for/IN basophil/NN cell/NN distribution/NN to/TO and/CC from/IN an/DT extravascular/JJ compartment/NN describes/VBZ the/DT effects/NNS of/IN MP/NN after/IN both/DT regimens/NNS ./. 
A/DT slower/JJR initial/JJ decline/NN in/IN blood/NN histamine/NN after/IN the/DT divided/JJ regimen/NNS may/MD be/VB related/JJ to/TO incomplete/JJ suppression/NN of/IN basophil/NN cell/NN return/NN to/TO blood/NN ./. 
The/DT 50/CD %/NN inhibitory/JJ concentrations/NNS of/IN MP/NN of/IN about/RB 5/CD ng/ml/NN were/VBD similar/JJ for/IN both/DT regimens/NNS ./. 
The/DT decline/NN and/CC return/NN of/IN cortisol/NN concentrations/NNS were/VBD similar/JJ between/IN MP/NN treatments/NNS with/IN suppression/NN continuing/VBG for/IN 24/CD hours/NNS ./. 
The/DT 50/CD %/NN inhibitory/JJ concentrations/NNS of/IN MP/NN values/NNS for/IN adrenal/JJ suppression/NN were/VBD about/RB 1/CD ng/ml/NN ./. 
Pharmacodynamic/JJ modeling/NN is/VBZ useful/JJ in/IN quantitating/VBG corticosteroid/NN responses/NNS and/CC generally/RB predicted/VBD the/DT "/`` dose-sparing/JJ "/'' effects/NNS that/WDT were/VBD achieved/VBN by/IN prolonging/VBG MP/NN plasma/NN concentrations/NNS ./. 
This/DT study/NN supports/VBZ previous/JJ clinical/JJ observations/NNS that/IN patients/NNS may/MD require/VB morning/NN through/IN evening/NN exposure/NN to/TO MP/NN to/TO optimize/VB efficacy/NN while/IN adrenal/JJ suppression/NN is/VBZ being/VBG minimized/VBN ./. 
UI/LS -/: 90237240/CD 
TI/LS -/: 1,25(OH)2D2/NN production/NN by/IN T/NN lymphocytes/NNS and/CC alveolar/JJ macrophages/NNS recovered/VBN by/IN lavage/NN from/IN normocalcemic/JJ patients/NNS with/IN tuberculosis/NN ./. 
AB/LS -/: To/TO compare/VB extra-renal/JJ 1,25(OH)2D3/NN production/NN in/IN different/JJ types/NNS of/IN granulomatous/JJ disease/NN ,/, and/CC to/TO identify/VB the/DT cell/NN types/NNS responsible/JJ ,/, we/PRP have/VBP evaluated/VBN the/DT conversion/NN of/IN 25(OH)D3/NN in/IN 1,25(OH)2D3/NN by/IN uncultured/JJ cells/NNS recovered/VBN by/IN bronchoalveolar/JJ lavage/NN and/CC blood/NN mononuclear/JJ cells/NNS from/IN normocalcemic/JJ patients/NNS with/IN sarcoidosis/NN and/CC tuberculosis/NN ./. 
1,25(OH)2D3/NN was/VBD produced/VBN both/CC by/IN lavage/NN cells/NNS (/( 12/12/CD tuberculosis/NN patients/NNS ,/, 2/6/CD sarcoidosis/NN patients/NNS )/) and/CC blood/NN mononuclear/JJ cells/NNS (/( 3/5/CD tuberculosis/NN patients/NNS ,/, 0/3/CD sarcoidosis/NN patients/NNS )/) from/IN patients/NNS but/CC not/RB controls/NNS ,/, but/CC significantly/RB greater/JJR amounts/NNS were/VBD produced/VBN by/IN lavage/NN cells/NNS from/IN tuberculosis/NN patients/NNS than/IN those/DT of/IN sarcoidosis/NN patients/NNS (/( P/NN less/JJR than/IN 0.001/CD )/) ./. 
1,25(OH)2D3/NN production/NN by/IN lavage/NN cells/NNS from/IN tuberculosis/NN patients/NNS correlated/VBD with/IN the/DT number/NN of/IN CD8+/JJ T/NN lymphocytes/NNS present/JJ but/CC not/RB other/JJ cell/NN types/NNS ./. 
T/NN lymphocytes/NNS appeared/VBD to/TO be/VB an/DT important/JJ source/NN of/IN 1,25(OH)2D3/NN production/NN ,/, since/IN purified/VBN T/NN lymphocytes/NNS from/IN all/DT patients/NNS with/IN tuberculosis/NN produced/VBD 1,25(OH)2D3/NN ,/, and/CC 1,25(OH)2D3/NN production/NN by/IN these/DT cells/NNS correlated/VBD closely/RB with/IN that/DT produced/VBN by/IN unseparated/JJ lavage/NN cells/NNS ./. 
Because/IN 1,25(OH)2D3/NN can/MD improve/VB the/DT capacity/NN of/IN macrophages/NNS to/TO kill/VB mycobacteria/NNS ,/, our/PRP$ results/NNS support/VBP the/DT conclusion/NN that/IN macrophage-lymphocyte/JJ interactions/NNS ,/, mediated/VBN at/IN least/JJS in/IN part/NN by/IN 1,25(OH)2D3/NN ,/, may/MD be/VB an/DT important/JJ component/NN of/IN a/DT successful/JJ antituberculous/JJ immune/JJ response/NN ./. 
UI/LS -/: 90206049/CD 
TI/LS -/: Megakaryocytic/JJ and/CC erythrocytic/JJ lineages/NNS share/VBP specific/JJ transcription/NN factors/NNS ./. 
AB/LS -/: Erythroid-specific/JJ genes/NNS contain/VBP binding/VBG sites/NNS for/IN NF-E1/NN (/( also/RB called/VBN GF-1/NN and/CC Eryf-1/NN ;/: refs/NNS 1-3/CD respectively/RB )/) ,/, the/DT principal/JJ DNA-binding/JJ protein/NN of/IN the/DT erythrocytic/JJ lineage/NN ./. 
NF-E1/NN expression/NN seems/VBZ to/TO be/VB restricted/JJ to/TO the/DT erythrocytic/JJ lineage/NN ./. 
A/DT closely/RB related/JJ (/( if/IN not/RB identical/JJ )/) protein/NN is/VBZ found/VBN in/IN both/CC a/DT human/JJ megakaryocytic/JJ cell/NN line/NN and/CC purified/VBN human/JJ megakaryocytes/NNS ;/: it/PRP binds/VBZ to/TO promoter/NN regions/NNS of/IN two/CD megakaryocytic-specific/JJ genes/NNS ./. 
The/DT binding/VBG sites/NNS and/CC partial/JJ proteolysis/NN profile/NN of/IN this/DT protein/NN are/VBP indistinguishable/JJ from/IN those/DT of/IN the/DT erythroid/JJ protein/NN ;/: also/RB ,/, NF-E1/NN messenger/NN RNA/NN is/VBZ the/DT same/JJ size/NN in/IN both/CC the/DT megakaryocytic/JJ and/CC erythroid/JJ cell/NN lines/NNS ./. 
Furthermore/RB ,/, point/NN mutations/NNS that/WDT abolish/VBP binding/NN of/IN NF-E1/NN result/VBP in/IN a/DT 70/CD %/NN decrease/NN in/IN the/DT transcriptional/JJ activity/NN of/IN a/DT megakaryocytic-specific/JJ promoter/NN ./. 
We/PRP also/RB find/VBP that/IN NF-E2/NN ,/, another/DT trans-acting/JJ factor/NN of/IN the/DT erythrocytic/JJ lineage/NN ,/, is/VBZ present/JJ in/IN megakaryocytes/NNS ./. 
Transcriptional/JJ effects/NNS in/IN both/DT lineages/NNS might/MD then/RB be/VB mediated/VBN in/IN part/NN by/IN the/DT same/JJ specific/JJ trans-acting/JJ factors/NNS ./. 
Our/PRP$ data/NNS strengthen/VBP the/DT idea/NN of/IN a/DT close/JJ association/NN between/IN the/DT erythrocytic/JJ and/CC the/DT megakaryocytic/JJ lineages/NNS and/CC could/MD also/RB explain/VB the/DT expression/NN of/IN markers/NNS specific/JJ to/TO the/DT erythrocytic/JJ and/CC megakaryocytic/JJ lineages/NNS in/IN most/JJS erythroblastic/JJ and/CC megakaryoblastic/JJ permanent/JJ cell/NN lines/NNS ./. 
UI/LS -/: 91175478/CD 
TI/LS -/: Transcriptional/JJ down-regulation/NN of/IN c-myc/NN expression/NN by/IN protein/NN synthesis-dependent/JJ and/CC -independent/JJ pathways/NNS in/IN a/DT human/JJ T/NN lymphoblastic/JJ tumor/NN cell/NN line/NN ./. 
AB/LS -/: We/PRP show/VBP that/IN in/IN the/DT human/JJ T/NN lymphoblastic/JJ tumor/NN cell/NN line/NN Molt4/NN c-myc/NN mRNA/NN and/CC protein/NN expression/NN is/VBZ down-regulated/VBN after/IN exposure/NN to/TO dimethyl/JJ sulfoxide/NN ,/, to/TO phorbol/NN myristate/NN acetate/NN ,/, or/CC to/TO the/DT calcium/NN ionophore/NN A23187/NN ,/, which/WDT raises/VBZ the/DT intracellular/JJ calcium/NN concentration/NN ./. 
A/DT block/NN to/TO RNA/NN elongation/NN is/VBZ largely/RB responsible/JJ for/IN decreased/VBN c-myc/NN transcription/NN ./. 
Although/IN negative/JJ regulation/NN by/IN dimethyl/JJ sulfoxide/NN takes/VBZ place/NN even/RB when/WRB protein/NN synthesis/NN is/VBZ inhibited/VBN by/IN cycloheximide/NN ,/, the/DT phorbol/NN myristate/NN acetate/NN effect/NN is/VBZ blocked/VBN to/TO some/DT extent/NN only/RB by/IN cycloheximide/NN ./. 
The/DT calcium/NN ionophore-induced/JJ c-myc/NN suppression/NN ,/, however/RB ,/, strictly/RB requires/VBZ de/FW novo/FW protein/NN synthesis/NN ./. 
Therefore/RB ,/, two/CD different/JJ negative/JJ regulatory/JJ pathways/NNS are/VBP involved/VBN in/IN c-myc/NN regulation/NN :/: one/CD which/WDT is/VBZ independent/JJ and/CC one/CD which/WDT depends/VBZ on/IN de/FW novo/FW protein/NN synthesis/NN ./. 
The/DT latter/JJ one/CD appears/VBZ to/TO be/VB mediated/VBN by/IN a/DT rapidly/RB calcium-dependent/JJ induced/VBN gene/NN product/NN ./. 
UI/LS -/: 91124866/CD 
TI/LS -/: Oestrogen/NN receptor/NN (/( ER/NN )/) analysis/NN in/IN B-cell/NN chronic/JJ lymphocytic/JJ leukemia/NN :/: correlation/NN of/IN biochemical/JJ and/CC immunocytochemical/JJ methods/NNS ./. 
AB/LS -/: Oestrogen/NN receptors/NNS (/( ER/NN )/) are/VBP present/JJ in/IN neoplastic/JJ lymphoid/JJ cells/NNS and/CC have/VBP been/VBN considered/VBN a/DT physiological/JJ marker/NN of/IN growth/NN rate/NN or/CC differentiation/NN ./. 
Tamoxifen/NN ,/, an/DT oestrogen/NN antagonist/NN ,/, has/VBZ been/VBN given/VBN in/IN some/DT patients/NNS with/IN CLL/NN and/CC Hodgkin/NN 's/POS disease/NN ,/, with/IN dramatic/JJ response/NN in/IN single/JJ cases/NNS ./. 
Until/IN now/NN ,/, ER/NN status/NN has/VBZ been/VBN assessed/VBN using/VBG a/DT steroid/NN binding/NN assay/NN (/( SBA/NN )/) which/WDT has/VBZ many/JJ inherent/JJ problems/NNS ./. 
Recently/RB ,/, the/DT development/NN of/IN monoclonal/JJ antibodies/NNS directed/VBN against/IN ER/NN has/VBZ been/VBN applied/VBN to/TO the/DT study/NN of/IN breast/NN carcinomas/NNS and/CC results/NNS obtained/VBN show/VBP good/JJ correlation/NN with/IN the/DT quantitative/JJ SBA/NN ./. 
We/PRP studied/VBD 49/CD cases/NNS of/IN B-cell/NN chronic/JJ lymphocytic/JJ leukemia/NN (/( CLL/NN )/) using/VBG immunostaining/NN of/IN cytospin/NN preparations/NNS ./. 
In/IN 30/CD of/IN these/DT cases/NNS ER/NN enzyme/NN immunoassay/NN (/( ER-EIA/NN )/) was/VBD also/RB performed/VBN ./. 
Cultured/VBN MCF-7/NN cells/NNS ,/, derived/VBN from/IN a/DT pleural/JJ effusion/NN of/IN a/DT breast/NN cancer/NN patient/NN ,/, known/VBN to/TO contain/VB high/JJ levels/NNS of/IN ER/NN were/VBD used/VBN as/IN a/DT positive/JJ control/NN (/( 40-48/CD %/NN ER/NN positive/JJ cells/NNS by/IN immunocytochemistry/NN ;/: 200/CD fmol/mg/NN protein/NN by/IN EIA/NN )/) ./. 
All/DT of/IN the/DT CLL/NN cases/NNS except/IN two/CD (/( 96/CD %/NN )/) were/VBD negative/JJ for/IN ER/NN (/( less/JJR than/IN 1/CD %/NN staining/NN ;/: less/JJR than/IN 4/CD fmol/mg/NN protein/NN )/) ./. 
The/DT two/CD positive/JJ cases/NNS expressed/VBD granular/JJ ER/NN staining/NN over/IN the/DT nucleus/NN (/( 9.2/CD and/CC 12.1/CD %/NN positive/JJ cells/NNS )/) and/CC were/VBD positive/JJ by/IN EIA/NN and/CC SBA/NN ./. 
It/PRP is/VBZ concluded/VBN that/IN (/( i/LS )/) patients/NNS with/IN CLL/NN rarely/RB express/VBP ER/NN and/CC (/( ii/LS )/) immunocytochemical/JJ staining/NN of/IN cytospin/NN preparations/NNS is/VBZ a/DT valid/JJ technique/NN for/IN the/DT measurement/NN of/IN ER/NN ./. 
It/PRP is/VBZ of/IN interest/NN that/IN one/CD of/IN the/DT positive/JJ cases/NNS was/VBD diagnosed/VBN as/IN CLL/NNP with/IN Richter/NN 's/POS transformation/NN confirming/VBG earlier/JJR findings/NNS ./. 
UI/LS -/: 91065749/CD 
TI/LS -/: Type-II/JJ estrogen/NN binding/NN sites/NNS in/IN a/DT lymphoblastoid/JJ cell/NN line/NN and/CC growth-inhibitory/JJ effect/NN of/IN estrogen/NN ,/, anti-estrogen/NN and/CC bioflavonoids/NNS ./. 
AB/LS -/: Type-II/JJ estrogen-binding/JJ sites/NNS (/( type-II/JJ EBS/NNS )/) have/VBP been/VBN demonstrated/VBN in/IN the/DT human/JJ lymphoblastoid/JJ cell/NN line/NN IM-9/NN using/VBG a/DT whole-cell/JJ assay/NN with/IN (/( 6,7-3H/NN )/) estradiol/NN (/( 3H-E2/NN )/) as/IN tracer/NN ./. 
Competition/NN analysis/NN showed/VBD that/IN the/DT anti-estrogen/JJ tamoxifen/NN and/CC the/DT flavonoids/NNS quercetin/NN and/CC rutin/NN competed/VBD for/IN (3H)-E2/NN binding/NN to/TO type-II/JJ EBS/NNS ./. 
Growth/NN experiments/NNS demonstrated/VBD that/IN diethylstilbestrol/NN (/( DES/NN )/) tamoxifen/NN (/( TAM/NN )/) ,/, quercetin/NN and/CC rutin/NN exerted/VBD a/DT reversible/JJ dose-dependent/JJ inhibition/NN of/IN cell/NN proliferation/NN in/IN the/DT range/NN of/IN concentrations/NNS between/IN 10/CD nM/NN and/CC 10/CD microM/NN ./. 
The/DT relative/JJ binding/NN affinity/NN of/IN quercetin/NN ,/, rutin/NN ,/, DES/NN and/CC TAM/NNP for/IN type-II/JJ EBS/NNS correlated/VBD well/RB with/IN their/PRP$ potency/NN as/IN cell/NN growth/NN inhibitors/NNS ./. 
Moreover/RB ,/, hesperidin/NN ,/, a/DT flavonoid/NN which/WDT does/VBZ not/RB bind/VB to/TO type-II/JJ EBS/NNS ,/, was/VBD ineffective/JJ in/IN inhibiting/VBG cell/NN growth/NN ./. 
Cell-cycle/JJ analysis/NN showed/VBD that/IN the/DT growth-inhibitory/JJ effect/NN of/IN DES/NN ,/, TAM/NN or/CC quercetin/NN was/VBD due/JJ to/TO a/DT blocking/NN effect/NN in/IN the/DT G0-G1/JJ phases/NNS ./. 
Our/PRP$ results/NNS suggest/VBP that/IN high/JJ estrogen/NN and/CC anti-estrogen/JJ concentrations/NNS and/CC flavonoids/NNS may/MD regulate/VB IM-9/NN cell/NN growth/NN through/IN a/DT common/JJ mechanism/NN involving/VBG a/DT binding/NN interaction/NN with/IN type-II/JJ EBS/NNS ./. 
UI/LS -/: 91132900/CD 
TI/LS -/: [/( Glucocorticoid/NN receptors/NNS in/IN peripheral/JJ blood/NN lymphocytes/NNS of/IN patients/NNS with/IN bronchial/JJ asthma/NN ]/) 
AB/LS -/: Quantitation/NN of/IN glucocorticoid/NN receptors/NNS (/( GCR/NN )/) and/CC the/DT study/NN of/IN their/PRP$ affinity/NN for/IN glucocorticosteroids/NNS (/( GCS/NNS )/) were/VBD made/VBN in/IN peripheral/JJ blood/NN lymphocytes/NNS of/IN bronchial/JJ asthma/NN (/( BA/NN )/) patients/NNS in/IN consideration/NN of/IN GCR/NN treatment/NN and/CC serum/NN levels/NNS of/IN endogenous/JJ cortisol/NN ./. 
It/PRP is/VBZ stated/VBN that/IN GCR/NN of/IN healthy/JJ controls/NNS and/CC GCS-untreated/JJ patients/NNS outnumbered/VBD those/DT of/IN cortisol-dependent/JJ BA/NN patients/NNS on/IN hormone/NN therapy/NN ./. 
Following/VBG discontinuation/NN of/IN glucocorticoid/NN drugs/NNS GCR/NN count/NN in/IN cortisol-dependent/JJ BA/NN tends/VBZ to/TO rise/VB ./. 
Endogenous/JJ cortisol/NN has/VBZ no/DT effect/NN on/IN GCR/NN level/NN estimated/VBN by/IN 3H-triamcinolone/NN acetonide/NN ./. 
UI/LS -/: 90382324/CD 
TI/LS -/: Two/CD glucocorticoid/NN binding/NN sites/NNS on/IN the/DT human/JJ glucocorticoid/NN receptor/NN ./. 
AB/LS -/: Glucocorticoids/NNS are/VBP known/VBN to/TO have/VB a/DT lytic/JJ effect/NN in/IN leukemic/JJ cells/NNS via/IN interactions/NNS with/IN the/DT glucocorticoid/NN receptor/NN (/( GR/NN )/) ./. 
Cortisol/NN and/CC various/JJ synthetic/JJ glucocorticoids/NNS bind/VBP to/TO the/DT GR/NN with/IN one-site/JJ kinetics/NNS ./. 
Cortivazol/NN (/( CVZ/NN )/) is/VBZ a/DT unique/JJ ,/, high/JJ potency/NN synthetic/JJ glucocorticoid/NN ,/, which/WDT has/VBZ a/DT phenylpyrazol/JJ fused/VBN to/TO the/DT A-ring/NN of/IN the/DT steroid/NN nucleus/NN and/CC displays/VBZ binding/NN consistent/JJ with/IN two/CD or/CC more/JJR sites/NNS in/IN the/DT cytosol/NN from/IN CEM/NN C7/NN cells/NNS (/( a/DT human/JJ acute/JJ lymphoblastic/JJ T-cell/NN line/NN )/) ./. 
It/PRP has/VBZ previously/RB been/VBN shown/VBN that/IN the/DT lower/JJR affinity/NN class/NN of/IN sites/NNS are/VBP similar/JJ in/IN affinity/NN and/CC site/NN molarity/NN to/TO those/DT recognized/VBN by/IN dexamethasone/NN ./. 
The/DT higher/JJR affinity/NN sites/NNS bind/VBP CVZ/NN with/IN 20-/CD to/TO 50-fold/RB greater/JJR affinity/NN ,/, consistent/JJ with/IN CVZ/NN 's/POS enhanced/VBN biological/JJ effects/NNS ./. 
In/IN mutant/JJ leukemic/JJ cells/NNS resistant/JJ to/TO the/DT lytic/JJ effects/NNS of/IN dexamethasone/NN ,/, CVZ/NN both/CC lyses/VBZ the/DT cells/NNS and/CC recognizes/VBZ a/DT single/JJ class/NN of/IN sites/NNS similar/JJ to/TO the/DT high/JJ affinity/NN site/NN in/IN CEM/NN C7/NN cells/NNS ./. 
We/PRP have/VBP carried/VBN out/RP experiments/NNS to/TO define/VB the/DT nature/NN of/IN the/DT higher/JJR affinity/NN CVZ/NN binding/NN site/NN ./. 
We/PRP now/RB show/VBP that/IN :/: 1/LS )/) CVZ/NN has/VBZ more/JJR than/IN one/CD binding/VBG site/NN in/IN a/DT second/JJ ,/, independent/JJ ,/, B-cell/NN line/NN ,/, IM-9/NN ;/: 2/LS )/) the/DT antiglucocorticoid/JJ RU/NN 38486/CD is/VBZ able/JJ to/TO block/VB both/CC CVZ/NN 's/POS higher/JJR and/CC lower/JJR affinity/NN sites/NNS ;/: 3/LS )/) all/DT of/IN CVZ/NN 's/POS binding/VBG sites/NNS are/VBP on/IN a/DT protein/NN immunologically/RB indistinguishable/JJ from/IN the/DT human/JJ GR/NN ;/: and/CC 4/LS )/) freshly/RB isolated/VBN clones/NNS of/IN CVZ-resistant/JJ cells/NNS have/VBP lost/VBN all/DT binding/VBG sites/NNS for/IN CVZ/NN ./. 
These/DT data/NNS indicate/VBP that/IN CVZ/NN is/VBZ recognizing/VBG two/CD glucocorticoid/NN binding/NN sites/NNS on/IN the/DT human/JJ GR/NN or/CC a/DT protein/NN very/RB similar/JJ to/TO it/PRP ./. 
UI/LS -/: 90381363/CD 
TI/LS -/: Retroviral/JJ mediated/VBN transfer/NN and/CC expression/NN of/IN exogenous/JJ genes/NNS in/IN primary/JJ lymphoid/JJ cells/NNS :/: assaying/VBG for/IN a/DT viral/JJ transactivator/NN activity/NN in/IN normal/JJ and/CC malignant/JJ cells/NNS ./. 
AB/LS -/: In/IN this/DT report/NN we/PRP describe/VBP the/DT use/NN of/IN recombinant/JJ retroviruses/NNS to/TO characterize/VB the/DT activity/NN of/IN an/DT exogenous/JJ promoter/NN in/IN primary/JJ cells/NNS obtained/VBN from/IN patients/NNS with/IN lymphoproliferative/JJ disorders/NNS ./. 
The/DT infection/NN of/IN a/DT variety/NN of/IN cultured/VBN and/CC primary/JJ lymphoid/JJ cells/NNS with/IN a/DT recombinant/JJ retrovirus/NN containing/VBG a/DT histone/NN promoter-driven/JJ beta-galactosidase/NN gene/NN is/VBZ shown/VBN to/TO result/VB in/IN the/DT expression/NN of/IN beta-galactosidase/NN in/IN 50/CD %/NN to/TO 100/CD %/NN of/IN the/DT cells/NNS ./. 
A/DT similar/JJ infection/NN with/IN a/DT recombinant/JJ retrovirus/NN containing/VBG the/DT beta-galactosidase/NN gene/NN with/IN an/DT adenovirus/NN E2/NN promoter/NN ,/, results/VBZ in/IN beta-galactosidase/NN activity/NN in/IN a/DT limited/JJ number/NN of/IN cultured/VBN and/CC primary/JJ cells/NNS ./. 
Since/IN the/DT adenovirus/NN E2/NN promoter/NN has/VBZ been/VBN well/RB characterized/VBN and/CC is/VBZ known/VBN to/TO be/VB regulated/VBN by/IN transactivators/NNS encoded/VBN by/IN many/JJ viruses/NNS ,/, the/DT activity/NN of/IN this/DT promoter/NN in/IN specific/JJ cell/NN types/NNS is/VBZ discussed/VBN in/IN reference/NN to/TO both/CC the/DT biology/NN of/IN the/DT cell/NN and/CC the/DT possible/JJ presence/NN of/IN as/RB yet/RB undetected/JJ viral/JJ gene/NN products/NNS ./. 
UI/LS -/: 91049522/CD 
TI/LS -/: [/( The/DT effect/NN of/IN 24,25-dihydroxyvitamin/NN D3/NN (/( dioxyvit/NN )/) on/IN Ca/NN metabolism/NN and/CC immune/JJ status/NN during/IN chronic/JJ kidney/NN failure/NN ]/) 
AB/LS -/: Active/JJ metabolite/NN of/IN vitamin/NN D3/NN ,/, 24R,25 (OH)2D3/NN (/( dioxyvit/NN )/) was/VBD used/VBN at/IN a/DT daily/JJ dose/NN of/IN 100/CD micrograms/NNS in/IN treatment/NN of/IN children/NNS affected/VBN with/IN tubulointerstitial/JJ disease/NN of/IN kidney/NN and/CC with/IN chronic/JJ glomerulonephritis/NN under/IN conditions/NNS of/IN kidney/NN insufficiency/NN ./. 
The/DT drug/NN exhibited/VBD distinct/JJ normalizing/NN effect/NN on/IN patterns/NNS of/IN calcium/NN metabolism/NN :/: increase/NN of/IN total/JJ and/CC ionized/VBN Ca2+/NN and/CC of/IN 25-OHD/NN ,/, decrease/NN in/IN concentration/NN of/IN parath/NN hormone/NN and/CC osteocalcine/NN in/IN blood/NN serum/NN as/RB well/RB as/IN on/IN immunological/JJ parameters/NNS :/: restoration/NN of/IN decreased/VBN content/NN of/IN T-/NN and/CC 0-lymphocytes/NNS ./. 
Concentration/NN of/IN receptors/NNS of/IN hormonal/JJ form/NN of/IN 1,25(OH)2D3/NN was/VBD found/VBN to/TO be/VB minimal/JJ in/IN lymphocytes/NNS under/IN conditions/NNS of/IN chronic/JJ kidney/NN insufficiency/NN ,/, while/IN their/PRP$ expression/NN ,/, after/IN the/DT dioxyvit/NN action/NN ,/, was/VBD detected/VBN only/RB in/IN patients/NNS with/IN glomerulonephritis/NN ./. 
Specific/JJ calcitropic/JJ effect/NN of/IN dioxyvit/NN with/IN simultaneous/JJ correction/NN of/IN vitamin/NN D/NN deficiency/NN were/VBD apparently/RB responsible/JJ for/IN high/JJ efficacy/NN of/IN the/DT drug/NN in/IN treatment/NN of/IN calcium/NN metabolism/NN and/CC immunity/NN impairments/NNS in/IN children/NNS with/IN renal/JJ deteriorations/NNS at/IN the/DT step/NN of/IN chronic/JJ kidney/NN insufficiency/NN ./. 
UI/LS -/: 91013631/CD 
TI/LS -/: [/( The/DT role/NN of/IN glucocorticoid/NN receptors/NNS and/CC HLA/NN antigens/NNS in/IN the/DT pathogenesis/NN of/IN Cushing/NN 's/POS syndrome/NN ]/) 
AB/LS -/: Lymphocytic/JJ levels/NNS of/IN glucocorticoid/NN receptors/NNS were/VBD evaluated/VBN in/IN 114/CD patients/NNS suffering/VBG from/IN Icenko-Cushing/NN 's/POS syndrome/NN ./. 
Incidence/NN of/IN HLA/NN antigens/NNS was/VBD determined/VBN in/IN 94/CD of/IN them/PRP ./. 
A/DT significant/JJ rise/NN of/IN A10/NN and/CC B27/NN antigen/NN incidence/NN compared/VBN to/TO that/DT in/IN normal/JJ subjects/NNS allows/VBZ these/DT antigens/NNS to/TO be/VB considered/VBN genetic/JJ markers/NNS of/IN Icenko-Cushing/NN 's/POS syndrome/NN ./. 
The/DT levels/NNS of/IN glucocorticoid/NN receptors/NNS in/IN lymphocytes/NNS of/IN the/DT patients/NNS are/VBP lower/JJR than/IN in/IN normal/JJ subjects/NNS both/CC in/IN the/DT active/JJ stage/NN of/IN the/DT disease/NN and/CC following/VBG bilateral/JJ total/JJ adrenalectomy/NN ./. 
The/DT patients/NNS carrying/VBG B27/NN antigen/NN had/VBD lymphocytic/JJ receptor/NN concentrations/NNS under/IN the/DT levels/NNS of/IN such/JJ in/IN patients/NNS free/JJ of/IN the/DT antigen/JJ carriage/NN ./. 
Antigen/NN B27/NN seems/VBZ to/TO be/VB a/DT cause/NN of/IN lower/JJR levels/NNS of/IN glucocorticoid/NN receptors/NNS in/IN blood/NN lymphocytes/NNS ./. 
UI/LS -/: 90242285/CD 
TI/LS -/: Effects/NNS of/IN 1/CD alpha/NN ,/, 25-dihydroxyvitamin/NN D3/NN on/IN the/DT human/JJ chronic/JJ myelogenous/JJ leukemia/NN cell/NN line/NN RWLeu-4/NN ./. 
AB/LS -/: The/DT effects/NNS of/IN 1/CD alpha/NN ,/, 25-dihydroxyvitamin/NN D3/NN (/( VD3/NN )/) on/IN proliferation/NN ,/, differentiation/NN ,/, and/CC macromolecular/JJ synthesis/NN in/IN the/DT new/JJ Philadelphia/NN chromosome-positive/JJ chronic/JJ myelogenous/JJ leukemia/NN cell/NN line/NN ,/, RWLeu-4/NN ,/, were/VBD investigated/VBN ./. 
Binding/NN of/IN [3H]VD3/NN was/VBD saturable/JJ ,/, with/IN approximately/RB 2000-3000/CD sites/cell/NNS ,/, and/CC half-maximal/JJ binding/NN occurring/VBG at/IN 0.21-0.33/CD nM/NN ./. 
Treatment/NN of/IN RWLeu-4/NN cells/NNS with/IN VD3/NN induced/VBD 24R-hydroxylase/NN activity/NN ,/, a/DT marker/NN of/IN vitamin/NN D3/NN responsiveness/NN in/IN many/JJ tissues/NNS ./. 
Exposure/NN of/IN RWLeu-4/NN cells/NNS to/TO VD3/NN also/RB inhibited/VBD proliferation/NN and/CC DNA/NN synthesis/NN with/IN a/DT 50/CD %/NN effective/JJ dose/NN of/IN 3.5-10/CD nM/NN within/IN 72/CD h/NN ;/: in/IN addition/NN ,/, protein/NN and/CC RNA/NN synthesis/NN were/VBD inhibited/VBN by/IN VD3/NN treatment/NN ./. 
Exposure/NN of/IN RWLeu-4/NN cells/NNS to/TO 5/CD nM/NN VD3/NN for/IN 72/CD h/NN caused/VBD 50/CD %/NN of/IN the/DT cells/NNS to/TO differentiate/VB into/IN macrophage/monocyte/JJ type/NN cells/NNS as/IN judged/VBN by/IN nitroblue/JJ tetrazolium/NN staining/NN and/CC adherence/NN to/TO plastic/NN ./. 
Progressive/JJ expression/NN of/IN cell/NN surface/NN maturation-specific/JJ antigens/NNS of/IN the/DT monocyte/macrophage/JJ lineage/NN was/VBD induced/VBN by/IN treatment/NN of/IN RWLeu-4/NN cells/NNS with/IN VD3/NN for/IN 24/CD to/TO 72/CD h/NN at/IN doses/NNS that/WDT inhibited/VBD cellular/JJ proliferation/NN ./. 
c-myc/NN RNA/NN ,/, which/WDT is/VBZ constitutively/RB expressed/VBN in/IN RWLeu-4/NN cells/NNS ,/, increased/VBD after/IN 0.5/CD h/NN of/IN treatment/NN with/IN 50/CD nM/NN VD3/NN and/CC then/RB rapidly/RB decreased/VBD to/TO barely/RB detectable/JJ levels/NNS after/IN 4/CD h/NN of/IN treatment/NN ./. 
Finally/RB ,/, the/DT in/FW vitro/FW tyrosine/NN kinase/NN activity/NN associated/VBN with/IN the/DT p210bcr-abl/NN oncogene/NN product/NN was/VBD decreased/VBN approximately/RB 50/CD %/NN by/IN VD3/NN treatment/NN ./. 
Because/IN of/IN the/DT presence/NN of/IN a/DT functional/JJ receptor-effector/JJ system/NN for/IN VD3/NN and/CC multiple/JJ biological/JJ responses/NNS to/TO the/DT hormone/NN ,/, these/DT cells/NNS provide/VBP a/DT unique/JJ model/NN system/NN with/IN which/WDT to/TO probe/VB the/DT specific/JJ effects/NNS of/IN VD3/NN on/IN cell/NN growth/NN and/CC differentiation/NN in/IN chronic/JJ myelogenous/JJ leukemia/NN ./. 
UI/LS -/: 90208323/CD 
TI/LS -/: A/DT new/JJ member/NN of/IN the/DT leucine/NN zipper/NN class/NN of/IN proteins/NNS that/WDT binds/VBZ to/TO the/DT HLA/NN DR/NN alpha/NN promoter/NN ./. 
AB/LS -/: Several/JJ mutants/NNS derived/VBN from/IN transformed/VBN human/JJ B/NN cell/NN lines/NNS are/VBP defective/JJ in/IN expressing/VBG major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN II/CD genes/NNS ./. 
The/DT failure/NN to/TO express/VB a/DT class/NN II/CD gene/NN in/IN at/IN least/JJS one/CD such/JJ mutant/JJ line/NN has/VBZ been/VBN mapped/VBN to/TO the/DT MHC/NN class/NN II/CD X/NN box/NN ,/, a/DT conserved/VBN transcriptional/JJ element/NN in/IN the/DT promoter/NN region/NN ./. 
A/DT complementary/JJ DNA/NN encoding/VBG a/DT DNA-binding/JJ protein/NN (/( human/JJ X/NN box/NN binding/NN protein/NN ,/, hXBP-1/NN )/) whose/WP$ target/NN is/VBZ the/DT human/JJ DR/NN alpha/NN X/NN box/NN and/CC the/DT 3'/JJ flanking/JJ region/NN has/VBZ now/RB been/VBN cloned/VBN ./. 
This/DT complementary/JJ DNA/NN encoded/VBD a/DT protein/NN with/IN structural/JJ similarities/NNS to/TO the/DT c-jun/NN proto-oncogene/NN product/NN ,/, and/CC its/PRP$ target/NN sequence/NN was/VBD closely/RB related/JJ to/TO the/DT palindromic/JJ target/NN sequence/NN of/IN c-jun/NN ./. 
Mutation/NN of/IN the/DT hXBP-1/NN DNA/NN target/NN sequence/NN decreased/VBD DR/NN alpha/NN promoter/NN activity/NN in/FW vivo/FW ./. 
These/DT studies/NNS suggest/VBP that/IN the/DT hXBP-1/NN protein/NN acts/VBZ as/IN a/DT transcription/NN factor/NN in/IN B/NN cells/NNS ./. 
UI/LS -/: 90171176/CD 
TI/LS -/: Pseudohypoaldosteronism/NN in/IN eight/CD families/NNS :/: different/JJ forms/NNS of/IN inheritance/NN are/VBP evidence/NN for/IN various/JJ genetic/JJ defects/NNS ./. 
AB/LS -/: Pseudohypoaldosteronism/NN is/VBZ a/DT rare/JJ hereditary/JJ disorder/NN presenting/VBG in/IN early/JJ infancy/NN with/IN renal/JJ salt/NN loss/NN leading/VBG to/TO hyponatremia/NN and/CC hyperkalemia/NN despite/IN high/JJ levels/NNS of/IN plasma/NN aldosterone/NN ./. 
The/DT patients/NNS are/VBP insensitive/JJ to/TO mineralocorticoids/NNS ;/: however/RB ,/, sodium/NN supplementation/NN is/VBZ able/JJ to/TO correct/VB electrolyte/NN abnormalities/NNS ./. 
Absent/JJ or/CC greatly/RB diminished/VBN type/NN I/CD aldosterone/NN receptors/NNS in/IN peripheral/JJ mononuclear/JJ leucocytes/NNS have/VBP been/VBN recently/RB demonstrated/VBN and/CC explain/VB the/DT lack/NN of/IN response/NN to/TO mineralocorticoids/NNS ./. 
We/PRP have/VBP studied/VBN the/DT mode/NN of/IN inheritance/NN in/IN eight/CD families/NNS with/IN a/DT total/NN of/IN nine/CD patients/NNS ./. 
There/EX was/VBD evidence/NN for/IN an/DT autosomal/JJ recessive/JJ form/NN of/IN inheritance/NN in/IN four/CD families/NNS ,/, while/IN the/DT other/JJ four/CD families/NNS appeared/VBD to/TO have/VB an/DT autosomal/JJ dominant/JJ mode/NN of/IN transmission/NN ./. 
In/IN three/CD families/NNS the/DT autosomal/JJ recessive/JJ form/NN was/VBD characterized/VBN by/IN normal/JJ receptor/NN as/RB well/RB as/IN hormone/NN data/NNS in/IN both/DT parents/NNS ,/, while/IN in/IN one/CD family/NN receptor/NN levels/NNS in/IN both/DT parents/NNS were/VBD greatly/RB reduced/VBN ,/, but/CC hormone/NN levels/NNS were/VBD normal/JJ ./. 
In/IN the/DT four/CD families/NNS with/IN an/DT autosomal/JJ dominant/JJ mode/NN of/IN transmission/NN there/RB was/VBD always/RB one/CD parent/NN with/IN reduced/VBN receptor/NN binding/NN in/IN peripheral/JJ mononuclear/JJ leucocytes/NNS and/CC elevated/JJ serum/NN hormone/NN levels/NNS ./. 
These/DT parents/NNS were/VBD entirely/RB asymptomatic/JJ ./. 
In/IN an/DT extended/VBN family/NN we/PRP were/VBD able/JJ to/TO study/VB an/DT aunt/NN and/CC her/PRP$ newborn/JJ daughter/NN ,/, who/WP were/VBD both/DT also/RB biochemically/RB affected/VBN but/CC clinically/RB asymptomatic/JJ ./. 
It/PRP ,/, therefore/RB ,/, appears/VBZ that/IN this/DT dual/JJ pattern/NN of/IN genetic/JJ transmission/NN may/MD indicate/VB differing/VBG genetic/JJ defects/NNS which/WDT cause/VBP the/DT same/JJ clinical/JJ picture/NN of/IN pseudohypoaldosteronism/NN ./. 
UI/LS -/: 90161003/CD 
TI/LS -/: Perceived/VBN social/JJ support/NN and/CC tumor/NN estrogen/progesterone/JJ receptor/NN status/NN as/IN predictors/NNS of/IN natural/JJ killer/NN cell/NN activity/NN in/IN breast/NN cancer/NN patients/NNS ./. 
AB/LS -/: This/DT report/NN is/VBZ concerned/VBN with/IN the/DT prediction/NN of/IN natural/JJ killer/NN (/( NK/NN )/) cell/NN activity/NN in/IN 61/CD Stage/NN I/CD and/CC II/CD breast/NN cancer/NN patients/NNS ,/, between/IN the/DT ages/NNS of/IN 25/CD and/CC 70/CD ,/, who/WP were/VBD accrued/VBN to/TO this/DT project/NN ./. 
All/DT baseline/NN interview/NN and/CC testing/NN data/NNS were/VBD obtained/VBN either/CC just/RB before/IN patients/NNS were/VBD discharged/VBN from/IN the/DT hospital/NN ,/, or/CC at/IN their/PRP$ first/JJ outpatient/JJ visit/NN ,/, within/IN two/CD weeks/NNS of/IN discharge/NN ./. 
A/DT major/JJ interest/NN of/IN this/DT project/NN is/VBZ the/DT predictive/JJ value/NN of/IN perceived/VBN social/JJ support/NN ,/, as/IN a/DT potential/JJ "/`` stress/NN "/'' buffer/NN ,/, related/VBN to/TO NK/NN activity/NN ./. 
In/IN the/DT main/JJ model/NN reported/VBN here/RB ,/, we/PRP found/VBD that/IN a/DT significant/JJ amount/NN of/IN NK/NN activity/NN variance/NN could/MD be/VB explained/VBN by/IN five/CD variables/NNS ./. 
Higher/JJR NK/NN activity/NN could/MD be/VB predicted/VBN by/IN the/DT perception/NN of/IN high/JJ quality/NN emotional/JJ support/NN from/IN a/DT spouse/NN or/CC intimate/JJ other/JJ ,/, perceived/VBN social/JJ support/NN from/IN the/DT patient/NN 's/POS physician/NN ,/, estrogen/NN receptor-negative/JJ tumor/NN status/NN ,/, having/VBG an/DT excisional/JJ biopsy/NN as/IN surgical/JJ treatment/NN ,/, and/CC actively/RB seeking/VBG social/JJ support/NN as/IN a/DT major/JJ coping/NN strategy/NN (/( R2/NN =/JJ 0.33/CD ,/, F/NN (/( 5/CD ,/, 55/CD )/) =/JJ 5.5/CD ,/, p/NN less/JJR than/IN 0.0004/CD )/) ./. 
Findings/NNS are/VBP discussed/VBN in/IN terms/NNS of/IN host/NN interaction/NN with/IN tumor/NN endocrine/JJ status/NN ,/, and/CC the/DT role/NN that/WDT social/JJ support/NN might/MD play/VB in/IN modulating/VBG such/JJ activity/NN ./. 
UI/LS -/: 91215472/CD 
TI/LS -/: [/( Estrogen/NN receptor/NN content/NN of/IN peripheral/JJ blood/NN lymphocytes/NNS in/IN patients/NNS with/IN systemic/JJ lupus/NN erythematosus/NN ]/) 
AB/LS -/: ER/NN content/NN in/IN lymphocytes/NNS of/IN peripheral/JJ blood/NN from/IN 27/CD SLE/NN patients/NNS and/CC 20/CD healthy/JJ controls/NNS were/VBD determined/VBN by/IN dextran-coated/JJ charcoal/NN assay/NN ./. 
ER/NN content/NN in/IN lymphocytes/NNS of/IN each/DT sample/NN was/VBD expressed/VBN by/IN both/CC fmol/mg/NN of/IN lymphocyte/NN cytosolic/JJ protein/NN and/CC fmol/micrograms/NN of/IN lymphocyte/NN DNA/NN ./. 
The/DT results/NNS showed/VBD that/IN there/EX was/VBD no/DT significant/JJ difference/NN between/IN the/DT ER/NN content/NN of/IN lymphocytes/NNS from/IN the/DT controls/NNS and/CC that/DT from/IN patients/NNS with/IN SLE/NN ./. 
But/CC the/DT logarithmic/JJ mean/NN of/IN ER/NN content/NN in/IN lymphocytes/NNS ,/, expressed/VBN by/IN fmol/mg/NN of/IN cytosolic/JJ protein/NN ,/, in/IN 14/CD patients/NNS with/IN active/JJ SLE/NN (/( 0.9356/CD +/-/CC 0.31/CD )/) was/VBD significantly/RB higher/JJR than/IN that/DT in/IN 13/CD patients/NNS with/IN inactive/JJ SLE/NN (/( 0.2979/CD +/-/CC 0.23/CD ,/, P/NN less/JJR than/IN 0.001/CD )/) and/CC in/IN the/DT controls/NNS (/( 0.6204/CD +/-/CC 0.52/CD ,/, P/NN less/JJR than/IN 0.001/CD )/) ./. 
The/DT normal/JJ upper/JJ limit/NN of/IN ER/NN content/NN in/IN lymphocytes/NNS ,/, expressed/VBN by/IN fmol/micrograms/NN of/IN DNA/NN ,/, was/VBD 0.136/CD ./. 
The/DT elevated/JJ rate/NN of/IN ER/NN content/NN in/IN lymphocytes/NNS in/IN 14/CD active/JJ SLE/NN (/( 92.9/CD %/NN )/) was/VBD also/RB higher/JJR than/IN that/DT in/IN quieiescent/JJ patients/NNS (/( 23.1/CD %/NN ,/, P/NN less/JJR than/IN 0.001/CD )/) and/CC in/IN the/DT controls/NNS (/( 10/CD %/NN ,/, P/NN less/JJR than/IN 0.001/CD )/) ./. 
Moreover/RB ,/, the/DT elevated/JJ level/NN of/IN ER/NN content/NN was/VBD found/VBN to/TO be/VB related/JJ to/TO the/DT positive/JJ antidsDNA/JJ|NN antibody/NN and/CC hypocomplementemia/NN ./. 
UI/LS -/: 91099657/CD 
TI/LS -/: An/DT in/FW vitro/FW globin/NN gene/NN switching/NN model/NN based/VBN on/IN differentiated/VBN embryonic/JJ stem/NN cells/NNS ./. 
AB/LS -/: We/PRP used/VBD mouse/NN embryonic/JJ stem/NN (/( ES/NN )/) cells/NNS to/TO study/VB globin/NN gene/NN expression/NN and/CC switching/NN in/FW vitro/FW ./. 
We/PRP show/VBP that/IN ES-derived/JJ embryoid/JJ bodies/NNS express/VBP the/DT full/JJ complement/NN of/IN mouse/NN embryonic/JJ globin/NN genes/NNS in/IN the/DT correct/JJ temporal/JJ order/NN and/CC that/IN on/IN further/JJ differentiation/NN ,/, a/DT switch/NN occurs/VBZ to/TO the/DT fetal/adult/JJ genes/NNS ./. 
In/IN addition/NN ,/, the/DT erythroid-specific/JJ transcription/NN factor/NN NF-E1/NN was/VBD shown/VBN to/TO be/VB expressed/VBN coordinately/RB with/IN that/DT of/IN globin/NN in/IN embryoid/JJ bodies/NNS ./. 
We/PRP conclude/VBP from/IN these/DT experiments/NNS that/IN the/DT ES/NN cell/NN system/NN provides/VBZ a/DT good/JJ model/NN to/TO study/VB hematopoietic/JJ development/NN ./. 
When/WRB the/DT human/JJ epsilon-/NN or/CC beta-globin/NN genes/NNS driven/VBN by/IN the/DT dominant/JJ control/JJ region/NN (/( DCR/NN )/) are/VBP introduced/VBN into/IN this/DT system/NN ,/, the/DT human/JJ epsilon-globin/NN gene/NN ,/, in/IN contrast/NN to/TO the/DT beta-globin/NN gene/NN ,/, is/VBZ not/RB deregulated/VBN by/IN the/DT presence/NN of/IN the/DT DCR/NN and/CC is/VBZ expressed/VBN strictly/RB as/IN an/DT embryonic/JJ gene/NN ./. 
We/PRP conclude/VBP from/IN this/DT that/IN the/DT epsilon-globin/NN gene/NN is/VBZ not/RB regulated/VBN by/IN competition/NN with/IN other/JJ genes/NNS in/IN the/DT human/JJ beta-globin/NN locus/NN ./. 
UI/LS -/: 91043047/CD 
TI/LS -/: Cloning/NN of/IN a/DT mitogen-inducible/JJ gene/NN encoding/VBG a/DT kappa/NN B/NN DNA-binding/JJ protein/NN with/IN homology/NN to/TO the/DT rel/NN oncogene/NN and/CC to/TO cell-cycle/JJ motifs/NNS ./. 
AB/LS -/: We/PRP have/VBP cloned/VBN and/CC characterized/VBN a/DT mitogen-inducible/JJ gene/NN isolated/VBN from/IN human/JJ T/NN cells/NNS that/WDT predicts/VBZ a/DT protein/NN of/IN 968/CD amino/NN acids/NNS ./. 
The/DT amino-terminal/JJ domain/NN has/VBZ regions/NNS homologous/JJ to/TO the/DT oncogene/NN rel/NN and/CC to/TO the/DT developmentally/RB important/JJ gene/NN dorsal/NN of/IN Drosophila/FW ./. 
The/DT carboxy-terminal/JJ domain/NN contains/VBZ repeat/NN structures/NNS found/VBN in/IN a/DT variety/NN of/IN proteins/NNS that/WDT are/VBP involved/VBN in/IN cell-cycle/JJ control/NN of/IN yeast/NN and/CC in/IN tissue/NN differentiation/NN in/IN Drosophila/FW and/CC Ceanorhabditis/FW elegans/FW ,/, as/RB well/RB as/IN in/IN the/DT putative/JJ human/JJ oncogene/NN bcl-3/NN and/CC in/IN the/DT ankyrin/NN protein/NN ./. 
A/DT truncated/JJ form/NN of/IN the/DT product/NN of/IN this/DT gene/NN translated/VBN in/FW vitro/FW is/VBZ a/DT DNA-binding/NN protein/NN which/WDT interacts/VBZ specifically/RB with/IN the/DT kappa/NN B/NN binding/NN site/NN found/VBN in/IN many/JJ inducible/JJ genes/NNS ,/, including/VBG the/DT enhancer/NN in/IN human/JJ immunodeficiency/NN virus/NN ./. 
This/DT gene/NN is/VBZ yet/RB another/DT in/IN a/DT growing/VBG list/NN of/IN important/JJ regulatory/JJ molecules/NNS whose/WP$ expression/NN is/VBZ transcriptionally/RB induced/VBN upon/IN cellular/JJ activation/NN ./. 
UI/LS -/: 91050279/CD 
TI/LS -/: Extrarenal/JJ receptor-effector-mechanisms/NNS for/IN aldosterone/NN :/: the/DT sequence/NN of/IN effects/NNS on/IN the/DT cellular/JJ electrolyte/NN transport/NN in/IN human/JJ lymphocytes/NNS and/CC their/PRP$ implications/NNS for/IN disorders/NNS of/IN the/DT water/NN and/CC electrolyte/NN balances/NNS ./. 
AB/LS -/: High/JJ affinity/NN aldosterone/NN binding/NN sites/NNS have/VBP not/RB only/RB been/VBN described/VBN in/IN the/DT classic/JJ target/NN tissues/NNS such/JJ as/IN the/DT renal/JJ tubules/NNS ,/, but/CC also/RB in/IN non-classic/JJ target/NN tissues/NNS such/JJ as/IN the/DT hippocampus/NN ,/, mammary/JJ gland/NN ,/, endothelial/JJ cells/NNS and/CC ,/, recently/RB ,/, human/JJ mononuclear/JJ leukocytes/NNS ./. 
An/DT in/FW vitro/FW effect/NN of/IN aldosterone/NN on/IN intracellular/JJ sodium/NN ,/, potassium/NN and/CC calcium/NN concentrations/NNS and/CC cell/NN volume/NN was/VBD shown/VBN in/IN human/JJ mononuclear/JJ leukocytes/NNS ./. 
In/IN the/DT absence/NN of/IN aldosterone/NN ,/, the/DT intracellular/JJ Na+/NN ,/, K+/NN and/CC Ca2+/NN concentrations/NNS and/CC the/DT cell/NN volume/NN decreased/VBD significantly/RB ,/, but/CC remained/VBD constant/JJ when/WRB aldosterone/NN (/( 1.4/CD nmol/l/NN )/) was/VBD added/VBN to/TO the/DT incubation/NN medium/NN ./. 
These/DT effects/NNS of/IN aldosterone/NN were/VBD blocked/VBN by/IN the/DT aldosterone/NN antagonist/NN canrenone/NN (/( 140/CD nmol/l/NN )/) ./. 
The/DT sodium/proton/JJ exchanger/NN of/IN the/DT cell/NN membrane/NN could/MD be/VB identified/VBN as/IN the/DT primary/JJ target/NN of/IN the/DT aldosterone/NN action/NN ,/, possibly/RB non-genomically/RB mediated/VBN through/IN membrane/NN receptors/NNS ./. 
The/DT clinical/JJ significance/NN of/IN this/DT model/NN was/VBD underlined/VBN by/IN the/DT demonstration/NN of/IN absent/JJ or/CC a/DT decreased/VBN number/NN of/IN mineralocorticoid/NN receptors/NNS and/CC the/DT lack/NN of/IN electrolyte/NN response/NN to/TO aldosterone/NN in/IN human/JJ mononuclear/JJ leukocytes/NNS of/IN patients/NNS with/IN pseudohypoaldosteronism/NN and/CC aldosteronism/NN ./. 
Additionally/RB ,/, an/DT abnormal/JJ effector/NN mechanism/NN could/MD be/VB demonstrated/VBN in/IN human/JJ mononuclear/JJ leukocytes/NNS from/IN essential/JJ hypertensives/NNS ./. 
These/DT studies/NNS are/VBP the/DT first/JJ to/TO demonstrate/VB the/DT significance/NN of/IN extrarenal/JJ ,/, nonepithelial/JJ mineralocorticoid/NN receptors/NNS and/CC the/DT related/JJ effector/NN mechanism/NN in/IN different/JJ disorders/NNS of/IN the/DT water/NN and/CC electrolyte/NN balance/NN in/IN man/NN ./. 
UI/LS -/: 91037456/CD 
TI/LS -/: Immunohistochemical/JJ study/NN of/IN steroid/NN hormones/NNS and/CC an/DT estrogen/NN binding/NN assay/NN in/IN malignant/JJ soft/JJ tissue/NN tumors/NNS ./. 
AB/LS -/: Immunohistochemically/RB ,/, the/DT immunoreaction/NN against/IN 5/CD steroid/NN hormone/NN anti-sera/NNS (/( estradiol/NN ,/, estriol/NN ,/, cortisol/NN ,/, progesterone/NN and/CC testosterone/NN )/) was/VBD examined/VBN in/IN 39/CD cases/NNS with/IN the/DT malignant/JJ soft/JJ tissue/NN tumors/NNS (/( fibrosarcoma/NN :/: 8/CD ,/, malignant/JJ fibrous/JJ histiocytoma/NN :/: 6/CD ,/, rhabdomyosarcoma/NN :/: 10/CD ,/, leiomyosarcoma/NN :/: 10/CD ,/, liposarcoma/NN :/: 5/CD )/) ./. 
Seventeen/CD cases/NNS revealed/VBD distinct/JJ immunostaining/NN against/IN at/IN least/JJS 1/CD of/IN the/DT 5/CD steroid/NN hormones/NNS ./. 
Immunostained/VBN tumor/NN cells/NNS were/VBD more/RBR frequently/RB distributed/VBN in/IN the/DT area/NN where/WRB tumor/NN cell/NN infiltration/NN was/VBD more/RBR invasive/JJ ./. 
The/DT majority/NN of/IN the/DT positive/JJ cases/NNS occurred/VBD in/IN female/JJ cases/NNS ./. 
Furthermore/RB ,/, the/DT existence/NN of/IN estrogen/NN receptor/NN (/( estrogen/NN binding/NN activity/NN )/) was/VBD examined/VBN histochemically/RB in/IN 39/CD cases/NNS and/CC it/PRP was/VBD detected/VBN in/IN 8/CD ./. 
We/PRP concluded/VBD that/IN steroid/NN hormones/NNS might/MD be/VB closely/RB related/JJ to/TO tumor/NN cell/NN infiltration/NN of/IN some/DT malignant/JJ soft/JJ tissue/NN tumors/NNS ./. 
UI/LS -/: 90287178/CD 
TI/LS -/: Involvement/NN of/IN cyclic/JJ AMP-dependent/JJ protein/NN kinases/NNS in/IN the/DT signal/NN transduction/NN pathway/NN for/IN interleukin-1/NN ./. 
AB/LS -/: Expression/NN of/IN a/DT highly/RB specific/JJ protein/NN inhibitor/NN for/IN cyclic/JJ AMP-dependent/JJ protein/NN kinases/NNS in/IN interleukin-1/NN (/( IL-1/NN )/) -responsive/JJ cells/NNS blocked/VBD IL-1-induced/JJ gene/NN transcription/NN that/WDT was/VBD driven/VBN by/IN the/DT kappa/NN immunoglobulin/NN enhancer/NN or/CC the/DT human/JJ immunodeficiency/NN virus/NN long/JJ terminal/JJ repeat/NN ./. 
This/DT inhibitor/NN did/VBD not/RB affect/VB protein/NN kinase/NN C-mediated/JJ gene/NN transcription/NN ,/, suggesting/VBG that/IN cyclic/JJ AMP-dependent/JJ protein/NN kinases/NNS are/VBP involved/VBN in/IN the/DT signal/NN transduction/NN pathway/NN for/IN IL-1/NN in/IN a/DT number/NN of/IN responsive/JJ cell/NN types/NNS ./. 
UI/LS -/: 90244395/CD 
TI/LS -/: The/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) ORI1yt/NN enhancer/NN is/VBZ not/RB B-cell/NN specific/JJ and/CC does/VBZ not/RB respond/VB synergistically/RB to/TO the/DT EBV/NN transcription/NN factors/NNS R/NN and/CC Z/NN ./. 
AB/LS -/: The/DT Epstein-Barr/JJ virus/NN DR/NN promoter/NN is/VBZ located/JJ upstream/RB of/IN the/DT PstI/NN repeats/NNS ,/, and/CC in/IN addition/NN to/TO the/DT TATA/NN box/NN ,/, it/PRP contains/VBZ an/DT upstream/JJ region/NN (/( positions/NNS -69/CD to/TO -220/CD )/) responsive/JJ to/TO EB1/NN (Z)/NN (/( the/DT BZLF1-encoded/JJ transcription/NN factor/NN )/) and/CC an/DT enhancer/NN with/IN two/CD functionally/RB distinct/JJ domains/NNS ,/, A/NN and/CC B/NN ./. 
Domain/NN B/NN has/VBZ been/VBN described/VBN as/IN a/DT B-cell-specific/JJ EB1-responsive/JJ element/NN (/( P.M.Lieberman/NNP ,/, J.M.Hardwick/NNP ,/, and/CC S.D.Hayward/NNP ,/, J.Virol.63/NNP :/: 3040-3050/CD ,/, 1989/CD )/) activated/VBN synergistically/RB by/IN EB1/NN and/CC R/NN ,/, an/DT EBV/NN early/JJ product/NN encoded/VBN by/IN the/DT open/JJ reading/NN frame/NN BRLF1/NN (/( M.A./NNP Cox/NNP ,/, J.Leahy/NNP ,/, and/CC J.M.Hardwick/NNP ,/, J.Virol.64/NNP :/: 313-321/CD ,/, 1990/CD )/) ./. 
We/PRP show/VBP here/RB that/IN domain/NN B/NN is/VBZ an/DT R-responsive/JJ element/NN in/IN HeLa/NN cells/NNS and/CC is/VBZ therefore/RB not/RB an/DT EB1-responsive/JJ B-cell-specific/JJ element/NN ./. 
However/RB ,/, there/EX is/VBZ an/DT EB1-binding/JJ site/NN (/( ZRE-B/NN )/) located/JJ within/IN the/DT R-responsive/JJ enhancer/NN region/NN ./. 
ZRE-B/NN can/MD be/VB deleted/VBN without/IN affecting/VBG the/DT R-dependent/JJ enhancer/NN activity/NN ./. 
Moreover/RB ,/, there/EX is/VBZ no/DT cooperation/NN or/CC synergy/NN between/IN R/NN and/CC EB1/NN when/WRB activating/VBG the/DT B/NN domain/NN (/( ZRE-B/NN plus/CC the/DT R-responsive/JJ element/NN )/) positioned/JJ as/IN an/DT enhancer/NN ./. 
ZRE-B/NN is/VBZ therefore/RB not/RB part/NN of/IN the/DT R- inducible/JJ enhancer/NN ./. 
We/PRP have/VBP tested/VBN several/JJ subregions/NNS of/IN the/DT DR/NN enhancer/NN B/NN domain/NN ,/, either/CC alone/RB or/CC in/IN combination/NN ,/, for/IN their/PRP$ capacity/NN to/TO transmit/VB the/DT R-activating/JJ signal/NN to/TO the/DT rabbit/NN beta-globin/NN promoter/NN ./. 
We/PRP found/VBD that/IN the/DT R-responsive/JJ element/NN is/VBZ composed/VBN of/IN four/CD protoenhancers/NNS that/WDT span/VBP the/DT whole/JJ B/NN domain/NN ./. 
These/DT protoenhancers/NNS alone/RB are/VBP weakly/JJ or/CC not/RB responsive/JJ to/TO R/NN ./. 
One/CD of/IN the/DT protoenhancers/NNS contains/VBZ the/DT overlapping/VBG palindromes/NNS 5'-TTGTCCcgtGGACAAaTGTCC-3'/NN ./. 
However/RB ,/, one/CD palindrome/NN ,/, either/CC alone/RB or/CC duplicated/JJ ,/, or/CC the/DT overlapping/VBG palindromes/NNS did/VBD not/RB respond/VB to/TO R/NN ./. 
UI/LS -/: 90360678/CD 
TI/LS -/: Nuclear/JJ 3,5,3'-triiodothyronine/NN receptors/NNS (/( T3R/NNS )/) of/IN circulating/VBG human/JJ lymphocytes/NNS in/IN hyper-/JJ and/CC hypothyroidism/NN and/CC nonthyroidal/JJ diseases/NNS ./. 
AB/LS -/: The/DT clinical/JJ implications/NNS of/IN nuclear/JJ T3R/NN alterations/NNS of/IN circulating/VBG lymphocytes/NNS in/IN hyperthyroidism/NN ,/, hypothyroidism/NN and/CC nonthyroidal/JJ diseases/NNS were/VBD investigated/VBN ./. 
Nuclear/JJ T3R/NN in/IN lymphocytes/NNS was/VBD determined/VBN by/IN radio-ligand/JJ binding/NN analysis/NN ./. 
The/DT results/NNS showed/VBD that/IN in/IN hyper-/JJ and/CC hypothyroid/JJ patients/NNS the/DT nuclear/JJ affinity/NN (/( Ka/NN )/) for/IN T3/NN was/VBD similar/JJ to/TO that/DT of/IN normal/JJ subjects/NNS ./. 
In/IN hyperthyroidism/NN nuclear/JJ T3/NN maximal/JJ binding/NN capacity/NN (/( MBC/NN )/) was/VBD unaltered/JJ ,/, whereas/IN in/IN hypothyroidism/NN the/DT MBC/NN was/VBD significantly/RB increased/VBN ./. 
In/IN the/DT patients/NNS with/IN diabetes/NN mellitus/NN ,/, chronic/JJ renal/JJ failure/NN and/CC hepatic/JJ cirrhosis/NN ,/, the/DT nuclear/JJ T3R/NN MBC/NN of/IN lymphocytes/NNS was/VBD about/RB 1.5-1.6/CD times/NNS of/IN the/DT normal/JJ controls/NNS ./. 
It/PRP was/VBD concluded/VBN that/IN there/EX existed/VBD hormonal/JJ regulation/NN of/IN nuclear/JJ T3R/NN ,/, and/CC up-regulation/NN was/VBD seen/VBN in/IN hypothyroidism/NN and/CC low/JJ T3/NN syndrome/NN ./. 
UI/LS -/: 90255794/CD 
TI/LS -/: Lymphocyte/NN cell/NN lines/NNS from/IN vitamin/NN D-dependent/JJ rickets/NN type/NN II/CD show/VBP functional/JJ defects/NNS in/IN the/DT 1/CD alpha,25-dihydroxyvitamin/NN D3/NN receptor/NN ./. 
AB/LS -/: Lymphocyte/NN cell/NN lines/NNS were/VBD established/VBN from/IN five/CD patients/NNS with/IN vitamin/NN D-dependent/JJ rickets/NN ,/, type/NN II/CD (/( VDDR-II/NN )/) ./. 
These/DT lines/NNS were/VBD established/VBN by/IN infection/NN with/IN human/JJ T-lymphotrophic/JJ virus/NN type/NN I/CD (/( HTLV-I/NN )/) ./. 
Binding/NN of/IN [3H]1/NN alpha,25-dihydroxyvitamin/NN D3/NN (/( 1,25(OH)2D3/NN )/) to/TO its/PRP$ receptor/NN in/IN these/DT cell/NN lines/NNS was/VBD compared/VBN to/TO binding/NN studies/NNS using/VBG a/DT T-lymphocyte/NN cell/NN line/NN (/( S-LB1/NN )/) from/IN a/DT normal/JJ individual/NN ./. 
The/DT 1,25(OH)2D3/NN receptor/NN of/IN S-LB1/NN was/VBD comparable/JJ to/TO the/DT well-characterized/JJ chick/NN intestinal/JJ 1,25(OH)2D3/NN receptor/NN in/IN terms/NNS of/IN its/PRP$ ligand/NN binding/NN affinity/NN and/CC capacity/NN ,/, its/PRP$ mobility/NN on/IN 5-20/CD %/NN sucrose/NN gradients/NNS ,/, and/CC its/PRP$ adsorption/NN to/TO and/CC elution/NN properties/NNS from/IN DNA-cellulose/NN ./. 
Three/CD cell/NN lines/NNS established/VBN from/IN patients/NNS with/IN VDDR-II/NN (/( Rh-VDR/NN ,/, Sh-VDR/NN ,/, and/CC Ab-VDR/NN )/) showed/VBD no/DT specific/JJ binding/NN of/IN 1,25(OH)2D3/NN to/TO a/DT receptor/NN and/CC treatment/NN of/IN the/DT cultured/VBN cells/NNS with/IN 1,25(OH)2D3/NN did/VBD not/RB stimulate/VB production/NN of/IN 24,25-dihydroxy-vitamin/NN D3/NN (/( 24,25(OH)2D3/NN )/) ,/, a/DT response/NN which/WDT is/VBZ diagnostic/JJ of/IN the/DT presence/NN of/IN a/DT functional/JJ 1,25(OH)2D3/NN receptor/NN ./. 
In/IN a/DT fourth/JJ cell/NN line/NN ,/, A1-VDR/NN ,/, the/DT receptor/NN for/IN 1,25(OH)2D3/NN had/VBD a/DT low/JJ binding/NN capacity/NN and/CC 25(OH)D3-24-hydroxylase/NN activity/NN was/VBD not/RB detectable/JJ ./. 
Induction/NN of/IN 24,25-(OH)2D3/NN synthesis/NN by/IN 1,25(OH)2D3/NN was/VBD observed/VBN in/IN the/DT fifth/JJ cell/NN line/NN ,/, designated/VBN Ro-VDR/NN ,/, although/IN the/DT sensitivity/NN to/TO hormone/NN treatment/NN was/VBD lower/JJR than/IN in/IN the/DT control/JJ cell/NN line/NN from/IN a/DT normal/JJ donor/NN ./. 
The/DT capacity/NN of/IN the/DT receptor/NN for/IN 1,25(OH)2D3/NN was/VBD low/JJ in/IN Ro-VDR/NN ./. 
In/IN all/DT cell/NN lines/NNS where/WRB 1,25(OH)2D3/NN binding/NN to/TO a/DT receptor/NN was/VBD detectable/JJ ,/, the/DT receptor/NN had/VBD the/DT typical/JJ sedimentation/NN coefficient/NN of/IN 3.7/CD S/NN on/IN sucrose/NN density/NN gradient/NN analysis/NN ./. 
Binding/NN and/CC elution/NN properties/NNS to/TO DNA-cellulose/NN ,/, however/RB ,/, differed/VBD from/IN normal/JJ in/IN both/CC Ro-VDR/NN and/CC A1-VDR/NN cells/NNS where/WRB elution/NN from/IN DNA-cellulose/NN occurred/VBD at/IN a/DT lower/JJR salt/NN concentration/NN than/IN is/VBZ typical/JJ of/IN the/DT 1,25(OH)2D3/NN receptor/NN ./. 
While/IN Ro-VDR/NN cells/NNS showed/VBD typical/JJ nuclear/JJ localization/NN of/IN the/DT unoccupied/JJ 1,25(OH)2D3/NN receptor/NN ,/, neither/CC the/DT unoccupied/JJ nor/CC the/DT occupied/JJ receptor/NN from/IN A1-VDR/NN cells/NNS was/VBD completely/RB localized/JJ in/IN the/DT nucleus/NN ./. 
In/IN a/DT series/NN of/IN functional/JJ studies/NNS we/PRP found/VBD that/IN modulation/NN of/IN the/DT level/NN of/IN the/DT mRNAs/NNS coding/VBG for/IN both/CC the/DT c-myc/NN oncogene/NN and/CC the/DT growth/NN factor/NN known/VBN as/IN granulocyte-monocyte/JJ colony/NN stimulating/NN activity/NN by/IN 1,25(OH)2D3/NN correlated/VBD with/IN the/DT 1,25(OH)2D3/NN receptor/NN status/NN of/IN these/DT cells/NNS ./. 
Use/NN of/IN these/DT cell/NN lines/NNS will/MD facilitate/VB further/JJ study/NN of/IN the/DT molecular/JJ defect/NN (/( s/NNS )/) in/IN the/DT receptor/NN for/IN 1,25(OH)2D3/NN in/IN vitamin/NN D-dependent/JJ rickets/NN type/NN II/CD and/CC will/MD allow/VB a/DT correlation/NN with/IN impairment/NN of/IN cellular/JJ functions/NNS ./. 
UI/LS -/: 90153985/CD 
TI/LS -/: Transcriptional/JJ and/CC post-transcriptional/JJ regulation/NN of/IN c-jun/NN expression/NN during/IN monocytic/JJ differentiation/NN of/IN human/JJ myeloid/JJ leukemic/JJ cells/NNS ./. 
AB/LS -/: AP-1/NN ,/, the/DT polypeptide/NN product/NN of/IN c-jun/NN ,/, recognizes/VBZ and/CC binds/VBZ to/TO specific/JJ DNA/NN sequences/NNS and/CC stimulates/VBZ transcription/NN of/IN genes/NNS responsive/JJ to/TO certain/JJ growth/NN factors/NNS and/CC phorbol/NN esters/NNS such/JJ as/IN 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) ./. 
We/PRP studied/VBD the/DT effects/NNS of/IN TPA/NN on/IN the/DT regulation/NN of/IN c-jun/NN gene/NN expression/NN in/IN HL-60/NN cells/NNS during/IN monocytic/JJ differentiation/NN ./. 
Low/JJ levels/NNS of/IN c-jun/NN transcripts/NNS were/VBD detectable/JJ in/IN untreated/JJ HL-60/NN leukemic/JJ cells/NNS ,/, increased/VBD significantly/RB by/IN 6/CD h/NN ,/, and/CC reached/VBD near/IN maximal/JJ levels/NNS by/IN 24/CD h/NN of/IN exposure/NN to/TO 32/CD nM/NN TPA/NN ./. 
Similar/JJ kinetics/NNS of/IN c-jun/NN induction/NN by/IN TPA/NN were/VBD observed/VBN in/IN human/JJ U-937/NN and/CC THP-1/NN monocytic/JJ leukemia/NN cells/NNS ./. 
Similar/JJ findings/NNS were/VBD obtained/VBN with/IN bryostatin/NN 1/CD (/( 10/CD nM/NN )/) ,/, another/DT activator/NN of/IN protein/NN kinase/NN C/NN and/CC inducer/NN of/IN monocytic/JJ differentiation/NN ./. 
Furthermore/RB ,/, 1,25-dihydroxyvitamin/NN D3/NN (/( 0.5/CD microM/NN )/) ,/, a/DT structurally/RB distinct/JJ agent/NN which/WDT also/RB induces/VBZ HL-60/NN monocytic/JJ differentiation/NN ,/, increased/VBD c-jun/NN expression/NN ./. 
TPA/NN treatment/NN of/IN HL-60/NN cells/NNS in/IN the/DT presence/NN of/IN cycloheximide/NN was/VBD associated/VBN with/IN superinduction/NN of/IN c-jun/NN transcripts/NNS ./. 
Run-on/JJ analysis/NN demonstrated/VBD detectable/JJ levels/NNS of/IN c-jun/NN gene/NN transcription/NN in/IN untreated/JJ HL-60/NN cells/NNS ,/, and/CC that/IN exposure/NN to/TO TPA/NN increases/VBZ this/DT rate/NN 3.3-fold/RB ./. 
Treatment/NN of/IN HL-60/NN cells/NNS with/IN both/CC TPA/NN and/CC cycloheximide/NN had/VBD no/DT effect/NN on/IN the/DT rates/NNS of/IN c-jun/NN transcription/NN ./. 
The/DT half-life/NN of/IN c-jun/NN RNA/NN as/IN determined/VBN by/IN treating/VBG HL-60/NN cells/NNS with/IN TPA/NN and/CC actinomycin/NN D/NN was/VBD 30/CD min/NN ./. 
In/IN contrast/NN ,/, the/DT half-life/NN of/IN c-jun/NN RNA/NN in/NN TPA-treated/JJ HL-60/NN cells/NNS exposed/VBN to/TO cycloheximide/NN and/CC actinomycin/NN D/NN was/VBD greater/JJR than/IN 2/CD h/NN ./. 
These/DT findings/NNS suggested/VBD that/IN the/DT increase/NN in/IN c-jun/NN RNA/NN observed/VBN during/IN TPA-induced/JJ monocytic/JJ differentiation/NN is/VBZ mediated/VBN by/IN both/CC transcriptional/JJ and/CC post-transcriptional/JJ mechanisms/NNS ./. 
UI/LS -/: 92213636/CD 
TI/LS -/: [/( Hormonal/JJ interactions/NNS and/CC glucocorticoid/NN receptors/NNS in/IN patients/NNS with/IN the/DT nephrotic/JJ syndrome/NN ]/) 
AB/LS -/: As/RB many/JJ as/IN 27/CD children/NNS aged/JJ 6/CD to/TO 15/CD years/NNS with/IN morphologically/RB verified/VBN nephropathies/NNS were/VBD examined/VBN ./. 
Four/CD variants/NNS of/IN changes/NNS in/IN the/DT thyroid/NN status/NN ,/, characteristic/JJ of/IN children/NNS with/IN different/JJ variants/NNS of/IN nephrotic/JJ syndrome/NN were/VBD distinguished/VBN :/: 1/LS )/) biochemical/JJ signs/NNS of/IN primary/JJ hypothyroidism/NN ,/, 2/LS )/) biochemical/JJ signs/NNS of/IN secondary/JJ hypothyroidism/NN ,/, 3/LS )/) low/JJ content/NN of/IN T3/NN ,/, 4/LS )/) dysfunction/NN of/IN the/DT hypophyseal/NN and/CC thyroid/NN system/NN ./. 
It/PRP is/VBZ shown/VBN that/IN the/DT low/JJ level/NN of/IN steroid/NN receptors/NNS ,/, thyroid/NN hormones/NNS that/IN the/DT low/JJ level/NN of/IN steroid/NN receptors/NNS ,/, thyroid/NN hormones/NNS (/( T3/NN and/CC T4/NN )/) and/CC cortisol/NN is/VBZ typical/JJ of/IN children/NNS with/IN the/DT signs/NNS of/IN renal/JJ dysplasia/NN ./. 
It/PRP is/VBZ assumed/VBN that/IN superaddition/NN under/IN such/JJ conditions/NNS of/IN immune/JJ glomerulopathy/NN (/( glomerulonephritis/NN and/CC nephrotic/JJ syndrome/NN )/) gives/VBZ rise/NN to/TO the/DT resistance/NN to/TO the/DT treatment/NN with/IN glucocorticoids/NNS ./. 
UI/LS -/: 91092268/CD 
TI/LS -/: Lymphoid/JJ specific/JJ gene/NN expression/NN of/IN the/DT adenovirus/NN early/JJ region/NN 3/CD promoter/NN is/VBZ mediated/VBN by/IN NF-kappa/NN B/NN binding/NN motifs/NNS ./. 
AB/LS -/: A/DT primary/JJ site/NN of/IN infection/NN by/IN human/JJ adenoviruses/NNS is/VBZ lymphoid/JJ cells/NNS ./. 
However/RB ,/, analysis/NN of/IN the/DT viral/JJ control/NN elements/NNS and/CC the/DT cellular/JJ factors/NNS that/WDT regulate/VBP adenoviral/JJ gene/NN expression/NN in/IN lymphocytes/NNS has/VBZ not/RB been/VBN reported/VBN ./. 
The/DT adenovirus/NN early/JJ region/NN 3/CD (/( ES/NN )/) gene/NN products/NNS are/VBP involved/VBN in/IN the/DT maintenance/NN of/IN viral/JJ persistence/NN by/IN complexing/VBG with/IN the/DT class/NN I/CD MHC/NN antigens/NNS ,/, thus/RB preventing/VBG their/PRP$ cell/NN surface/NN expression/NN with/IN a/DT resultant/JJ decrease/NN in/IN host/NN immunologic/JJ destruction/NN ./. 
To/TO determine/VB whether/IN different/JJ cellular/JJ factors/NNS were/VBD involved/VBN in/IN E3/NN regulation/NN in/IN lymphocytes/NNS as/IN compared/VBN with/IN HeLa/NN cells/NNS ,/, both/CC DNA/NN binding/NN and/CC transfection/NN analysis/NN with/IN the/DT E3/NN promoter/NN in/IN both/DT cell/NN types/NNS were/VBD performed/VBN ./. 
These/DT studies/NNS detected/VBD two/CD novel/JJ domains/NNS referred/VBN to/TO as/RB L1/NN and/CC L2/NN with/IN a/DT variety/NN of/IN lymphoid/JJ but/CC not/RB HeLa/NN extracts/NNS ./. 
Each/DT of/IN these/DT domains/NNS possessed/VBD strong/JJ homology/NN to/TO motifs/NNS previously/RB found/VBN to/TO bind/VB the/DT cellular/JJ factor/NN NF-kappa/NN B/NN ./. 
Transfections/NNS of/IN E3/NN constructs/NNS linked/VBN to/TO the/DT chloramphenicol/NN acetyltransferase/NN gene/NN revealed/VBD that/IN mutagenesis/NN of/IN the/DT distal/JJ NF-kappa/NN B/NN motif/NN (/( L2/NN )/) had/VBD minimal/JJ effects/NNS on/IN promoter/NN expression/NN in/IN HeLa/NN cells/NNS ,/, but/CC resulted/VBD in/IN dramatic/JJ decreases/NNS in/IN expression/NN by/IN lymphoid/JJ cells/NNS ./. 
In/IN contrast/NN ,/, mutagenesis/NN of/IN proximal/JJ NF-kappa/NN B/NN motif/NN (/( L1/NN )/) had/VBD minimal/JJ effects/NNS on/IN gene/NN expression/NN in/IN both/CC HeLa/NN cells/NNS and/CC lymphoid/JJ cells/NNS but/CC resulted/VBD in/IN a/DT small/JJ ,/, but/CC reproducible/JJ ,/, increase/NN in/IN gene/NN expression/NN in/IN lymphoid/JJ cells/NNS when/WRB coupled/VBN to/TO the/DT L2/NN mutation/NN ./. 
Reversing/VBG the/DT position/NN and/CC subsequent/JJ mutagenesis/NN of/IN the/DT L1/NN and/CC L2/NN domains/NNS indicated/VBD that/IN the/DT primary/JJ sequence/NN of/IN these/DT motifs/NNS rather/RB than/IN their/PRP$ position/NN in/IN the/DT E3/NN promoter/NN was/VBD critical/JJ for/IN regulating/VBG gene/NN expression/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 91034184/CD 
TI/LS -/: Characterization/NN of/IN defensin/NN resistance/NN phenotypes/NNS associated/VBN with/IN mutations/NNS in/IN the/DT phoP/NN virulence/NN regulon/NN of/IN Salmonella/FW typhimurium/FW ./. 
AB/LS -/: The/DT defensin/NN sensitivities/NNS of/IN Salmonella/FW typhimurium/FW strains/NNS with/IN mutations/NNS in/IN the/DT phoP/phoQ/NN two-component/JJ virulence/NN regulon/NN were/VBD tested/VBN by/IN using/VBG purified/VBN defensins/NNS NP-1/NN and/CC NP-2/NN ./. 
Strains/NNS with/IN mutations/NNS in/IN either/DT gene/NN of/IN the/DT regulatory/JJ pair/NN (/( phoP/NN [/( transcriptional/JJ activator/NN ]/) or/CC phoQ/JJ [/( membrane/NN sensor/NN kinase/NN ]/) )/) had/VBD increased/VBN sensitivities/NNS to/TO defensin/NN ./. 
The/DT predicted/VBN periplasmic/JJ domain/NN of/IN the/DT PhoQ/NN protein/NN contained/VBD a/DT markedly/RB anionic/JJ domain/NN that/WDT could/MD interact/VB with/IN cationic/JJ proteins/NNS and/CC that/WDT could/MD be/VB responsible/JJ for/IN resistance/NN to/TO defensin/NN ./. 
Because/IN insertion/NN mutations/NNS in/IN phoP/NN are/VBP polar/JJ on/IN phoQ/NN ,/, we/PRP constructed/VBD strains/NNS that/WDT expressed/VBD the/DT PhoQ/NN protein/NN in/IN the/DT absence/NN of/IN PhoP/NN to/TO test/VB whether/IN resistance/NN to/TO defensin/NN requires/VBZ only/RB the/DT phoQ/NN gene/NN product/NN ./. 
We/PRP found/VBD that/IN resistance/NN to/TO defensin/NN requires/VBZ the/DT function/NN of/IN both/DT components/NNS of/IN this/DT regulatory/JJ system/NN ,/, because/IN strains/NNS expressing/VBG PhoQ/NN without/IN PhoP/NN were/VBD still/RB markedly/RB sensitive/JJ to/TO defensins/NNS ./. 
This/DT implied/VBD that/IN a/DT pag/NN (/( phoP-activated/JJ gene/NN )/) product/NN is/VBZ responsible/JJ for/IN defensin/NN resistance/NN ./. 
We/PRP also/RB tested/VBD for/IN the/DT ability/NN of/IN defensins/NNS NP-1/NN ,/, NP-5/NN ,/, and/CC HNP-1/NNP to/TO activate/VB pag/NN expression/NN and/CC found/VBD that/IN these/DT peptides/NNS have/VBP no/DT effect/NN ./. 
Defensin/NN resistance/NN is/VBZ not/RB the/DT only/JJ virulence/NN characteristic/NN controlled/VBN by/IN the/DT PhoP-PhoQ/JJ regulon/NN because/IN mutations/NNS in/IN pagC/NN ,/, as/RB well/RB as/IN ones/NNS in/IN the/DT phoP/NN locus/NN that/WDT resulted/VBD in/IN constitutive/JJ pag/NN activation/NN (/( phenotype/NN PhoPc/NN )/) ,/, had/VBD no/DT effect/NN on/IN defensin/NN resistance/NN ,/, even/RB though/IN they/PRP rendered/VBD the/DT organism/NN avirulent/JJ and/CC deficient/JJ in/IN survival/NN within/IN macrophages/NNS ./. 
The/DT virulence/NN defect/NN conferred/VBN by/IN mutations/NNS in/IN the/DT phoP-phoQ/JJ two-component/NN regulatory/JJ system/NN is/VBZ not/RB completely/RB explained/VBN by/IN alterations/NNS in/IN resistance/NN to/TO cationic/JJ proteins/NNS and/CC involves/VBZ the/DT control/NN of/IN other/JJ proteins/NNS necessary/JJ for/IN S./FW typhimurium/FW survival/NN within/IN macrophages/NNS ./. 
UI/LS -/: 91045897/CD 
TI/LS -/: Stimulation/NN of/IN a/DT human/JJ T-cell/NN clone/NN with/IN anti-CD3/JJ or/CC tumor/NN necrosis/NN factor/NN induces/VBZ NF-kappa/NN B/NN translocation/NN but/CC not/RB human/JJ immunodeficiency/NN virus/NN 1/CD enhancer-dependent/JJ transcription/NN ./. 
AB/LS -/: The/DT expression/NN of/IN transiently/RB transfected/VBN expression/NN vectors/NNS under/IN the/DT control/NN of/IN the/DT long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) of/IN the/DT human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) or/CC its/PRP$ enhancer/NN sequence/NN and/CC the/DT translocation/NN of/IN the/DT HIV/NN enhancer-binding/JJ protein/NN NF-kappa/NN B/NN were/VBD analyzed/VBN in/IN two/CD human/JJ T-cell/NN clones/NNS stimulated/VBN through/IN their/PRP$ T-cell/NN receptor/NN complex/NN or/CC by/IN tumor/NN necrosis/NN factor/NN or/CC phorbol/NN 12-myristate/NN 13-acetate/NN ./. 
We/PRP found/VBD a/DT dissociation/NN of/IN NF-kappa/NN B/NN translocation/NN from/IN transactivation/NN of/IN either/CC the/DT HIV/NN LTR/NN or/CC the/DT HIV/NN enhancer/NN ./. 
Interleukin/NN 2/CD induced/VBD proliferation/NN but/CC not/RB NF-kappa/NN B/NN translocation/NN or/CC LTR/NN transactivation/NN ./. 
Phorbol/NN ester/NN or/CC specific/JJ antigen/NN recognition/NN induced/VBD HIV/NN LTR/NN transactivation/NN ,/, whereas/IN stimulation/NN with/IN tumor/NN necrosis/NN factor/NN or/CC antibody/NN to/TO CD3/NN did/VBD not/RB ./. 
The/DT two/CD latter/JJ signals/NNS were/VBD nevertheless/RB able/JJ to/TO induce/VB NF-kappa/NN B/NN translocation/NN with/IN a/DT pattern/NN in/IN the/DT band-shift/JJ assay/NN indistinguishable/JJ from/IN that/DT observed/VBN using/VBG phorbol/NN ester/NN ./. 
Our/PRP$ finding/NN that/IN induction/NN of/IN NF-kappa/NN B/NN by/IN tumor/NN necrosis/NN factor/NN or/CC antibody/NN to/TO CD3/NN is/VBZ not/RB sufficient/JJ to/TO induce/VB HIV/NN enhancer-dependent/JJ transcription/NN in/IN cloned/VBN T/NN cells/NNS contrasts/VBZ with/IN results/NNS obtained/VBN in/IN most/JJS lymphoblastoid/JJ T-cell/NN lines/NNS and/CC indicates/VBZ that/IN normal/JJ T/NN lymphocytes/NNS differ/VBP from/IN tumoral/JJ T/NN cells/NNS in/IN terms/NNS of/IN requirements/NNS for/IN HIV/NN LTR/NN activation/NN ./. 
Furthermore/RB ,/, our/PRP$ results/NNS suggest/VBP that/IN events/NNS linked/VBN to/TO T-cell/NN activation/NN ,/, in/IN addition/NN to/TO NF-kappa/NN B/NN translocation/NN per/FW se/FW ,/, induce/VBP functional/JJ interactions/NNS of/IN the/DT NF-kappa/NN B/NN complex/NN with/IN the/DT HIV/NN enhancer/NN ./. 
UI/LS -/: 91028334/CD 
TI/LS -/: Decreased/VBN concentration/NN of/IN 1,25-dihydroxyvitamin/NN D3/NN receptors/NNS in/IN peripheral/JJ mononuclear/JJ cells/NNS of/IN patients/NNS with/IN X-linked/JJ hypophosphatemic/JJ rickets/NN :/: effect/NN of/IN phosphate/NN supplementation/NN ./. 
AB/LS -/: Abnormal/JJ renal/JJ tubular/JJ phosphate/NN transport/NN is/VBZ considered/VBN to/TO be/VB the/DT primary/JJ defect/NN in/IN X-linked/JJ hypophosphatemic/JJ rickets/NN (/( XLH/NN )/) ./. 
However/RB ,/, the/DT resistance/NN to/TO vitamin/NN D/NN treatment/NN in/IN XLH/NN can/MD not/RB be/VB explained/VBN by/IN hypophosphatemia/NN alone/RB ./. 
Since/IN most/JJS of/IN the/DT actions/NNS of/IN vitamin/NN D/NN are/VBP mediated/VBN by/IN its/PRP$ receptors/NNS (/( VDR/NN )/) ,/, abnormalities/NNS of/IN VDR/NN have/VBP been/VBN postulated/VBN in/IN XLH/NN ./. 
In/IN order/NN to/TO investigate/VB this/DT possibility/NN ,/, we/PRP measured/VBD the/DT concentration/NN of/IN VDR/NN in/IN PHA-activated/JJ peripheral/JJ mononuclear/JJ cells/NNS from/IN 10/CD XLH/NN patients/NNS ./. 
Patients/NNS without/IN phosphate/NN supplementation/NN showed/VBD significantly/RB lower/JJR concentration/NN (/( 21.7/CD +/-/CC 5.1/CD fmol/mg/NN protein/NN ,/, mean/NN +/-/CC SEM/NN )/) compared/VBN to/TO the/DT normal/JJ controls/NNS (/( 60.7/CD +/-/CC 4.0/CD )/) ./. 
On/IN the/DT contrary/JJ ,/, there/EX was/VBD no/DT significant/JJ difference/NN between/IN the/DT phosphate-supplemented/JJ patients/NNS (/( 58.3/CD +/-/CC 2.7/CD )/) and/CC controls/NNS ./. 
There/EX was/VBD a/DT significant/JJ positive/JJ correlation/NN between/IN VDR/NN concentration/NN and/CC serum/NN phosphate/NN (/( P/NN less/JJR than/IN 0.05/CD )/) ./. 
In/IN two/CD patients/NNS ,/, VDR/NN was/VBD increased/VBN after/IN daily/JJ phosphate/NN supplementation/NN was/VBD started/VBN ./. 
These/DT results/NNS indicate/VBP that/IN a/DT decreased/VBN concentration/NN of/IN VDR/NN secondary/JJ to/TO persistent/JJ hypophosphatemia/NN is/VBZ one/CD of/IN the/DT causes/NNS of/IN vitamin/NN D/NN resistance/NN in/IN XLH/NN ./. 
UI/LS -/: 90319091/CD 
TI/LS -/: Two/CD distinct/JJ forms/NNS of/IN active/JJ transcription/NN factor/NN CREB/NN (/( cAMP/NN response/NN element/NN binding/NN protein/NN )/) ./. 
AB/LS -/: Mammalian/JJ cells/NNS express/VBP two/CD distinct/JJ forms/NNS of/IN transcription/NN factor/NN CREB/NN (/( cAMP/NN response/NN element/NN binding/NN protein/NN )/) that/WDT are/VBP apparently/RB the/DT products/NNS of/IN alternative/JJ splicing/NN of/IN the/DT CREB/NN gene/NN transcript/NN ./. 
The/DT two/CD proteins/NNS differ/VBP by/IN a/DT 14-amino/NN acid/NN serine-rich/JJ insertion/NN present/JJ in/IN one/CD of/IN the/DT CREB/NN isoforms/NNS ./. 
We/PRP show/VBP that/IN both/DT CREB/NN isoforms/NNS are/VBP expressed/VBN in/IN many/JJ cell/NN types/NNS and/CC mammalian/JJ species/NNS ./. 
Both/DT encode/VBP proteins/NNS that/WDT bind/VBP specifically/RB to/TO a/DT cAMP/NN response/NN element/NN in/FW vitro/FW ./. 
As/IN expected/VBN for/IN proteins/NNS of/IN this/DT class/NN ,/, the/DT CREB/NN proteins/NNS bind/VBP DNA/NN as/IN dimers/NNS ./. 
Both/DT proteins/NNS impart/VBP cAMP-regulated/JJ transcriptional/JJ activity/NN to/TO a/DT heterologous/JJ DNA-binding/JJ domain/NN ,/, showing/VBG that/IN cAMP/NN directly/RB modulates/VBZ the/DT transcriptional/JJ stimulatory/JJ activity/NN of/IN CREB/NN ./. 
The/DT presence/NN of/IN multiple/JJ CREB/NN isoforms/NNS with/IN identical/JJ DNA-binding/JJ specificities/NNS but/CC differences/NNS in/IN the/DT presumed/JJ regulatory/JJ domain/NN raises/VBZ the/DT possibility/NN that/IN CREB/NN proteins/NNS may/MD be/VB able/JJ to/TO integrate/VB distinct/JJ regulatory/JJ signals/NNS at/IN the/DT level/NN of/IN gene/NN transcription/NN ./. 
UI/LS -/: 90244434/CD 
TI/LS -/: Human/JJ immunodeficiency/NN virus/NN vpr/NN product/NN is/VBZ a/DT virion-associated/JJ regulatory/JJ protein/NN ./. 
AB/LS -/: The/DT vpr/NN product/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) acts/VBZ in/IN trans/NN to/TO accelerate/VB virus/NN replication/NN and/CC cytopathic/JJ effect/NN in/IN T/NN cells/NNS ./. 
Here/RB it/PRP is/VBZ shown/VBN that/IN the/DT HIV-1/NN viral/JJ particle/NN contains/VBZ multiple/JJ copies/NNS of/IN the/DT vpr/NN protein/NN ./. 
The/DT vpr/NN product/NN is/VBZ the/DT first/JJ regulatory/JJ protein/NN of/IN HIV-1/NN to/TO be/VB found/VBN in/IN the/DT virus/NN particle/NN ./. 
This/DT observation/NN raises/VBZ the/DT possibility/NN that/IN vpr/NN acts/VBZ to/TO facilitate/VB the/DT early/JJ steps/NNS of/IN infection/NN before/IN de/FW novo/FW viral/JJ protein/NN synthesis/NN occurs/VBZ ./. 
UI/LS -/: 90337320/CD 
TI/LS -/: A/DT novel/JJ B-cell/NN lineage-specific/JJ transcription/NN factor/NN present/JJ at/IN early/JJ but/CC not/RB late/JJ stages/NNS of/IN differentiation/NN ./. 
AB/LS -/: A/DT novel/JJ B-cell-specific/JJ transcription/NN factor/NN ,/, BSAP/NN ,/, was/VBD identified/VBN as/IN a/DT mammalian/JJ homolog/NN of/IN the/DT sea/NN urchin/NN protein/NN TSAP/NN ,/, which/WDT interacts/VBZ with/IN the/DT promoters/NNS of/IN four/CD tissue-specific/JJ late/JJ histone/NN H2A-2/NN and/CC H2B-2/NN genes/NNS ./. 
As/IN shown/VBN by/IN mobility-shift/JJ ,/, methylation/NN interference/NN ,/, and/CC mutational/JJ analyses/NNS ,/, the/DT mammalian/JJ protein/NN BSAP/NN recognizes/VBZ all/DT four/CD sea/NN urchin/NN binding/NN sites/NNS in/IN a/DT manner/NN indistinguishable/JJ from/IN TSAP/NN ;/: however/RB ,/, the/DT two/CD proteins/NNS differ/VBP in/IN molecular/JJ weight/NN ./. 
BSAP/NN is/VBZ exclusively/RB restricted/JJ to/TO the/DT B-cell/NN lineage/NN of/IN lymphoid/JJ differentiation/NN ./. 
Its/PRP$ expression/NN appears/VBZ to/TO be/VB activated/VBN during/IN pro-B-cell/JJ development/NN ,/, is/VBZ abundant/JJ at/IN the/DT pre-B-/JJ and/CC mature/JJ B-cell/NN stages/NNS ,/, but/CC is/VBZ absent/JJ in/IN terminally/RB differentiated/VBN plasma/NN cells/NNS ./. 
Moreover/RB ,/, BSAP/NN is/VBZ clearly/RB a/DT B-cell-specific/JJ transcription/NN factor/NN ,/, as/IN a/DT wild-type/JJ but/CC not/RB a/DT mutant/JJ TSAP-binding/JJ site/NN of/IN the/DT sea/NN urchin/NN functions/NNS only/RB in/IN transfected/VBN B/NN cells/NNS as/IN an/DT upstream/JJ promoter/NN element/NN ./. 
Competition/NN experiments/NNS did/VBD not/RB reveal/VB any/DT high-affinity/JJ binding/VBG site/NN for/IN BSAP/NN in/IN known/JJ regulatory/JJ regions/NNS of/IN immunoglobulin/NN and/CC class/NN II/CD major/JJ histocompatibility/NN (/( MHC/NN )/) genes/NNS ,/, suggesting/VBG that/IN BSAP/NN is/VBZ a/DT regulator/NN of/IN a/DT different/JJ set/NN of/IN B-lymphoid-specific/JJ genes/NNS ./. 
UI/LS -/: 90169371/CD 
TI/LS -/: Octamer/NN transcription/NN factors/NNS and/CC the/DT cell/NN type-specificity/NN of/IN immunoglobulin/NN gene/NN expression/NN ./. 
AB/LS -/: Antibodies/NNS are/VBP produced/VBN exclusively/RB in/IN B/NN lymphocytes/NNS ./. 
The/DT expression/NN of/IN the/DT antibody-encoding/JJ genes/NNS ,/, the/DT immunoglobulin/NN (/( Ig/NN )/) genes/NNS ,/, is/VBZ also/RB restricted/JJ to/TO B/NN cells/NNS ./. 
The/DT octamer/NN sequence/NN ATGCAAAT/NN is/VBZ present/JJ in/IN the/DT promoter/NN and/CC the/DT enhancer/NN of/IN Ig/NN genes/NNS ,/, and/CC plays/VBZ an/DT important/JJ role/NN in/IN its/PRP$ tissue-specific/JJ expression/NN ./. 
This/DT sequence/NN motif/NN is/VBZ a/DT binding/VBG site/NN for/IN nuclear/JJ proteins/NNS ,/, the/DT so-called/JJ octamer/NN transcription/NN factors/NNS (/( Oct/NN or/CC OTF/NN factors/NNS )/) ./. 
The/DT Oct-1/NN protein/NN is/VBZ present/JJ in/IN all/DT cell/NN types/NNS analyzed/VBN so/RB far/RB ,/, whereas/IN Oct-2A/NN and/CC Oct-2B/NN are/VBP found/VBN mainly/RB in/IN B/NN lymphocytes/NNS ./. 
All/DT three/CD proteins/NNS show/VBP the/DT same/JJ sequence/NN specificity/NN and/CC binding/NN affinity/NN ./. 
It/PRP appears/VBZ that/IN the/DT B/NN cell-specific/JJ expression/NN of/IN Ig/NN genes/NNS is/VBZ mediated/VBN at/IN least/JJS in/IN part/NN by/IN cell/NN type-specific/JJ Oct/NN factors/NNS ,/, and/CC that/IN there/EX are/VBP both/CC quantitative/JJ and/CC qualitative/JJ differences/NNS between/IN Oct-1/NN and/CC Oct-2/NN factors/NNS ./. 
Recently/RB ,/, a/DT number/NN of/IN other/JJ octamer/NN factor/NN variants/NNS were/VBD identified/VBN ./. 
Many/JJ of/IN these/DT may/MD be/VB created/VBN by/IN alternative/JJ splicing/NN of/IN a/DT primary/JJ transcript/NN of/IN one/CD Oct/NN factor/NN gene/NN and/CC may/MD serve/VB a/DT specific/JJ function/NN in/IN the/DT fine/JJ tuning/NN of/IN gene/NN expression/NN ./. 
UI/LS -/: 90151654/CD 
TI/LS -/: A/DT factor/NN known/VBN to/TO bind/VB to/TO endogenous/JJ Ig/NN heavy/JJ chain/NN enhancer/NN only/RB in/IN lymphocytes/NNS is/VBZ a/DT ubiquitously/RB active/JJ transcription/NN factor/NN ./. 
AB/LS -/: The/DT transcriptional/JJ enhancer/NN located/JJ in/IN the/DT first/JJ intron/NN of/IN the/DT immunoglobulin/NN heavy/JJ chain/NN constant/JJ region/NN is/VBZ a/DT major/JJ determinant/NN of/IN B-cell-specific/JJ expression/NN of/IN immunoglobulin/NN genes/NNS ./. 
Like/IN other/JJ enhancers/NNS ,/, the/DT Ig/NN heavy/JJ chain/NN enhancer/NN contains/VBZ several/JJ short/JJ sequence/NN motifs/NNS that/WDT bind/VBP specific/JJ transcription/NN factors/NNS ./. 
Each/DT binding/VBG site/NN contributes/VBZ to/TO the/DT overall/JJ activity/NN of/IN the/DT enhancer/NN ,/, however/RB no/DT single/JJ element/NN seems/VBZ absolutely/RB required/VBN for/IN activity/NN ./. 
For/IN a/DT better/JJR understanding/NN of/IN the/DT Ig/NN heavy/JJ chain/NN enhancer/NN components/NNS ,/, we/PRP have/VBP cloned/VBN and/CC analyzed/VBN individual/JJ sequence/NN elements/NNS ./. 
We/PRP find/VBP that/IN the/DT factor/NN that/WDT binds/VBZ to/TO the/DT E3/NN enhancer/NN motif/NN ,/, CATGTGGC/NN ,/, is/VBZ a/DT ubiquitous/JJ transcription/NN factor/NN ./. 
It/PRP is/VBZ present/JJ in/IN an/DT active/JJ form/NN in/IN both/CC B/NN cells/NNS and/CC non-B/JJ cells/NNS ,/, where/WRB it/PRP can/MD mediate/VB transcriptional/JJ activation/NN in/FW vitro/FW and/CC in/FW vivo/FW ./. 
However/RB ,/, despite/IN its/PRP$ ability/NN to/TO activate/VB transcription/NN of/IN a/DT transfected/VBN reporter/NN gene/NN ,/, the/DT factor/NN is/VBZ apparently/RB unable/JJ to/TO bind/VB to/TO the/DT endogenous/JJ Ig/NN heavy/JJ chain/NN enhancer/NN in/IN non-lymphoid/JJ cells/NNS :/: In/IN previous/JJ experiments/NNS by/IN others/NNS ,/, the/DT characteristic/JJ in/FW vivo/FW footprint/NN of/IN this/DT factor/NN ,/, designated/VBN NF-muE3/NN ,/, was/VBD detected/VBN in/IN B/NN cells/NNS but/CC not/RB in/IN non-B/JJ cells/NNS ./. 
From/IN this/DT and/CC other/JJ findings/NNS the/DT picture/NN emerges/VBZ that/IN there/EX are/VBP at/IN least/JJS three/CD categories/NNS of/IN factors/NNS which/WDT mediate/VBP cell-type-specific/JJ transcription/NN in/IN B/NN lymphocytes/NNS :/: (/( a/LS )/) cell-specific/JJ factors/NNS such/JJ as/IN Oct-2A/NN and/CC Oct-2B/NN that/WDT are/VBP not/RB expressed/VBN in/IN most/JJS other/JJ cell/NN types/NNS :/: (/( b/LS )/) ubiquitous/JJ factors/NNS such/JJ as/IN NF-kappa/NN B/NN that/WDT are/VBP constitutively/RB active/JJ in/IN B/NN cells/NNS but/CC are/VBP sequestered/VBN in/IN an/DT inactive/JJ form/NN in/IN other/JJ cells/NNS ;/: (/( c/LS )/) ubiquitously/RB active/JJ factors/NNS ,/, exemplified/VBN by/IN the/DT one/NN binding/VBG to/TO the/DT E3/NN sequence/NN motif/NN ./. 
This/DT factor/NN is/VBZ present/JJ in/IN an/DT active/JJ form/NN in/IN a/DT variety/NN of/IN cell/NN types/NNS but/CC is/VBZ apparently/RB unable/JJ to/TO bind/VB to/TO the/DT endogenous/JJ Ig/NN heavy/JJ chain/NN enhancer/NN in/IN non-B/JJ cells/NNS ,/, perhaps/RB due/JJ to/TO a/DT non-permissive/JJ chromatin/NN structure/NN of/IN the/DT Ig/NN heavy/JJ chain/NN locus/NN ./. 
UI/LS -/: 92107586/CD 
TI/LS -/: [/( Endocrine/JJ status/NN changes/NNS in/IN children/NNS with/IN bronchial/JJ asthma/NN ]/) 
AB/LS -/: A/DT study/NN was/VBD made/VBN of/IN adrenocortical/JJ function/NN by/IN measuring/VBG blood/NN plasma/NN cortisol/NN concentration/NN and/CC amount/NN of/IN glucocorticoid/NN receptors/NNS in/IN lymphocytes/NNS as/RB well/RB as/IN thyroid/NN function/NN by/IN measuring/VBG blood/NN plasma/NN triidothyronine/NN and/CC thyroxine/JJ concentration/NN in/IN 58/CD bronchial/JJ asthma/NN children/NNS aged/JJ 1/CD to/TO 14/CD years/NNS ./. 
The/DT authors/NNS revealed/VBD alterations/NNS in/IN the/DT functional/JJ activity/NN of/IN the/DT indicated/VBN endocrine/JJ glands/NNS depending/VBG on/IN the/DT intensity/NN of/IN bronchial/JJ patency/NN disorders/NNS and/CC the/DT nature/NN of/IN the/DT therapeutic/JJ measures/NNS carried/VBN out/RP ./. 
UI/LS -/: 91092266/CD 
TI/LS -/: TAR/NN independent/JJ activation/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN in/IN phorbol/NN ester/NN stimulated/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: Multiple/JJ regulatory/JJ elements/NNS in/IN the/DT human/JJ immunodeficiency/NN virus/NN long/JJ terminal/JJ repeat/NN (/( HIV/NN LTR/NN )/) are/VBP required/VBN for/IN activation/NN of/IN HIV/NN gene/NN expression/NN ./. 
Previous/JJ transfection/NN studies/NNS of/IN HIV/NN LTR/NN constructs/NNS linked/VBN to/TO the/DT chloramphenicol/NN acetyltransferase/NN gene/NN indicated/VBD that/IN multiple/JJ regulatory/JJ regions/NNS including/VBG the/DT enhancer/NN ,/, SP1/NN ,/, TATA/NN and/CC TAR/NN regions/NNS were/VBD important/JJ for/IN HIV/NN gene/NN expression/NN ./. 
To/TO characterize/VB these/DT regulatory/JJ elements/NNS further/RBR ,/, mutations/NNS in/IN these/DT regions/NNS were/VBD inserted/VBN into/IN both/CC the/DT 5'/JJ and/CC 3'/JJ HIV/NN LTRs/NNS and/CC infectious/JJ proviral/JJ constructs/NNS were/VBD assembled/VBN ./. 
These/DT constructs/NNS were/VBD transfected/VBN into/IN either/CC HeLa/NN cells/NNS ,/, Jurkat/NN cells/NNS or/CC U937/NN cells/NNS in/IN both/CC the/DT presence/NN and/CC absence/NN of/IN phorbol/NN esters/NNS which/WDT have/VBP previously/RB been/VBN demonstrated/VBN to/TO activate/VB HIV/NN gene/NN expression/NN ./. 
Viral/JJ gene/NN expression/NN was/VBD assayed/VBN by/IN the/DT level/NN of/IN p24/NN gag/NN protein/NN released/VBN from/IN cultures/NNS transfected/VBN with/IN the/DT proviral/JJ constructs/NNS ./. 
Results/NNS in/IN all/DT cell/NN lines/NNS indicated/VBD that/IN mutations/NNS of/IN the/DT SP1/NN ,/, TATA/NN and/CC the/DT TAR/NN loop/NN and/CC stem/NN secondary/JJ structure/NN resulted/VBD in/IN marked/JJ decreases/NNS in/IN gene/NN expression/NN while/IN mutations/NNS of/IN the/DT enhancer/NN motif/NN or/CC TAR/NN primary/JJ sequence/NN resulted/VBD in/IN only/RB slight/JJ decreases/NNS ./. 
However/RB ,/, viruses/NNS containing/VBG mutations/NNS in/IN either/CC the/DT TAR/NN loop/NN sequences/NNS or/CC stem/NN secondary/JJ structure/NN which/WDT were/VBD very/RB defective/JJ for/IN gene/NN expression/NN in/IN untreated/JJ Jurkat/NN cells/NNS ,/, gave/VBD nearly/RB wild-type/JJ levels/NNS of/IN gene/NN expression/NN in/IN phorbol/NN ester-treated/JJ Jurkat/NN cells/NNS but/CC not/RB in/IN phorbol/NN ester-treated/JJ HeLa/NN or/CC U937/NN cells/NNS ./. 
High/JJ level/NN gene/NN expression/NN of/IN these/DT TAR/NN mutant/JJ constructs/NNS in/IN phorbol/NN ester-treated/JJ Jurkat/NN cells/NNS was/VBD eliminated/VBN by/IN second/JJ site/NN mutations/NNS in/IN the/DT enhancer/NN region/NN or/CC by/IN disruption/NN of/IN the/DT tat/NN gene/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 91258741/CD 
TI/LS -/: A/DT case/NN of/IN hypersensitivity/NN to/TO thyroid/NN hormones/NNS with/IN normally/RB functioning/VBG thyroid/NN gland/NN and/CC increased/VBN nuclear/JJ triiodothyronine/NN receptors/NNS ./. 
AB/LS -/: A/DT 52-year-old/JJ male/NN presented/VBD himself/PRP with/IN tachycardia/NN crises/NNS which/WDT appeared/VBD first/RB during/IN childhood/NN ,/, increased/VBD in/IN frequency/NN without/IN goiter/NN or/CC exophthalmos/NNS ./. 
Cardiac/JJ and/CC adrenergic/JJ diseases/NNS were/VBD excluded/VBN ./. 
The/DT thyroid/NN function/NN was/VBD normal/JJ regarding/VBG T4/NN ,/, free/JJ T4/NN and/CC T3/NN ,/, TBG/NN ,/, radioiodine/NN uptake/NN ,/, TSH/NN and/CC T3/NN suppressibility/NN ;/: however/RB the/DT TSH/NN response/NN to/TO TRH/NN was/VBD decreased/VBN ./. 
The/DT lymphocyte/NN nuclear/JJ T3/NN receptor/NN was/VBD found/VBN with/IN an/DT affinity/NN close/JJ to/TO that/DT of/IN normal/JJ volunteers/NNS (/( Ka/NN :/: 1.42/CD x/CC 10(10)/CD M-1/NN vs/CC 1.95/CD +/-/CC 0.35/CD x/CC 10(10)/CD M-1/NN )/) and/CC a/DT binding/NN capacity/NN markedly/RB increased/VBD (/( 9.9/CD vs/CC 3.7/CD +/-/CC 0.4/CD fmol/NN T3/NN //: 100/CD micrograms/NNS DNA/NN )/) ./. 
Pindolol/NN was/VBD inefficient/JJ on/IN the/DT dysrhythmia/NN which/WDT disappeared/VBD with/IN carbimazole/NN and/CC relapsed/VBD after/IN withdrawal/NN of/IN the/DT antithyroid/NN drug/NN ./. 
Under/IN carbimazole/NN ,/, the/DT plasma/NN T4/NN markedly/RB decreased/VBD (/( 27.7/CD +/-/CC 3.6/CD nmol/l/NN )/) but/CC the/DT patient/NN remained/VBD euthyroid/NN ./. 
The/DT clinical/JJ course/NN and/CC the/DT laboratory/NN data/NNS suggest/VBP that/IN the/DT tachycardia/NN crises/NNS are/VBP the/DT consequence/NN of/IN a/DT hypersensitivity/NN of/IN the/DT heart/NN to/TO thyroid/NN hormones/NNS ,/, associated/VBN with/IN an/DT increased/VBN number/NN of/IN T3/NN nuclear/JJ receptor/NN sites/NNS in/IN lymphocytes/NNS ./. 
UI/LS -/: 90375934/CD 
TI/LS -/: Induction/NN of/IN immediate/JJ early/JJ response/NN genes/NNS by/IN macrophage/NN colony-stimulating/JJ factor/NN in/IN normal/JJ human/JJ monocytes/NNS ./. 
AB/LS -/: A/DT group/NN of/IN coordinately/RB induced/VBN protooncogenes/NNS ,/, cytoskeletal/JJ ,/, and/CC extracellular/JJ matrix/NN genes/NNS have/VBP been/VBN termed/VBN immediate/JJ early/JJ response/NN genes/NNS ,/, and/CC their/PRP$ induction/NN has/VBZ been/VBN associated/VBN with/IN growth/NN factor-stimulated/JJ cell/NN proliferation/NN ./. 
We/PRP have/VBP investigated/VBN the/DT induction/NN of/IN these/DT genes/NNS by/IN macrophage-CSF/NN (/( M-CSF/NN )/) in/IN human/JJ monocytes/NNS that/WDT do/VBP not/RB proliferate/VB in/IN response/NN to/TO M-CSF/NN but/CC require/VBP the/DT factor/NN for/IN optimal/JJ cell/NN differentiation/NN ./. 
Normal/JJ human/JJ monocytes/NNS were/VBD isolated/VBN ,/, carefully/RB washed/VBN ,/, and/CC incubated/VBN for/IN 36/CD to/TO 48/CD h/NN in/IN fetal/JJ bovine/NN serum-containing/JJ medium/NN ./. 
At/IN the/DT end/NN of/IN this/DT incubation/NN the/DT resting/VBG cells/NNS were/VBD stimulated/VBN with/IN M-CSF/NN ,/, and/CC RNA/NN was/VBD isolated/VBN for/IN analysis/NN by/IN Northern/JJ blotting/NN ./. 
RNA/NN from/IN control/JJ resting/VBG cells/NNS contained/VBD low/JJ to/TO undetectable/JJ levels/NNS of/IN c-jun/NN ,/, fibronectin/NN receptor/NN ,/, and/CC actin/NN mRNA/NN ./. 
Within/IN 15/CD to/TO 30/CD min/NN of/IN addition/NN of/IN M-CSF/NN ,/, however/RB ,/, there/EX was/VBD a/DT dramatic/JJ coordinate/JJ induction/NN of/IN these/DT genes/NNS ./. 
The/DT c-jun/NN gene/NN expression/NN was/VBD very/RB transient/JJ and/CC was/VBD not/RB detectable/JJ by/IN 60/CD min/NN after/IN M-CSF/NN addition/NN ./. 
In/IN contrast/NN ,/, the/DT expression/NN of/IN actin/NN and/CC fibronectin/NN receptor/NN mRNA/NN was/VBD more/RBR sustained/VBN ,/, and/CC the/DT expression/NN of/IN these/DT genes/NNS remained/VBD elevated/JJ at/IN 24/CD to/TO 48/CD h/NN after/IN M-CSF/NN addition/NN ./. 
We/PRP also/RB observed/VBD the/DT induction/NN of/IN the/DT myelomonocytic/JJ specific/JJ tyrosine/NN kinase/NN hck/NN gene/NN simultaneously/RB with/IN the/DT other/JJ immediate/JJ early/JJ response/NN genes/NNS ./. 
The/DT protein/NN synthesis/NN inhibitor/NN cycloheximide/NN did/VBD not/RB block/VB the/DT induction/NN of/IN any/DT of/IN these/DT genes/NNS ,/, and/CC in/IN fact/NN ,/, super-induced/VBD the/DT expression/NN of/IN c-jun/NN and/CC hck/NN ./. 
Nuclear/JJ run/NN on/IN transcription/NN of/IN the/DT c-jun/NN ,/, hck/NN ,/, and/CC actin/NN genes/NNS ./. 
Therefore/RB ,/, in/IN normal/JJ human/JJ monocytes/NNS M-CSF/NN induces/VBZ immediate/JJ early/JJ response/NN genes/NNS without/IN inducing/VBG cell/NN proliferation/NN ./. 
These/DT genes/NNS may/MD then/RB play/VB a/DT role/NN in/IN altering/VBG the/DT physiologic/JJ status/NN of/IN the/DT cells/NNS in/IN response/NN to/TO CSF/NN ./. 
UI/LS -/: 90317911/CD 
TI/LS -/: Inducible/JJ nuclear/JJ factor/NN binding/NN to/TO the/DT kappa/NN B/NN elements/NNS of/IN the/DT human/JJ immunodeficiency/NN virus/NN enhancer/NN in/IN T/NN cells/NNS can/MD be/VB blocked/VBN by/IN cyclosporin/NN A/NN in/IN a/DT signal-dependent/JJ manner/NN ./. 
AB/LS -/: Cyclosporin/NN A/NN (/( CsA/NN )/) is/VBZ thought/VBN to/TO exert/VB its/PRP$ immunosuppressive/JJ effects/NNS by/IN inhibiting/VBG the/DT expression/NN of/IN a/DT distinct/JJ set/NN of/IN lymphokine/NN genes/NNS which/WDT are/VBP induced/VBN upon/IN T-cell/NN activation/NN ,/, among/IN them/PRP the/DT gene/NN coding/VBG for/IN interleukin-2/NN ./. 
In/IN addition/NN ,/, the/DT activation/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) is/VBZ partially/RB suppressed/VBN ./. 
To/TO better/RBR understand/VB the/DT molecular/JJ mechanisms/NNS underlying/VBG suppression/NN by/IN CsA/NN ,/, we/PRP have/VBP investigated/VBN the/DT effects/NNS of/IN this/DT drug/NN on/IN transcription/NN factors/NNS in/IN T/NN cells/NNS ./. 
Here/RB we/PRP report/VBP that/IN the/DT formation/NN of/IN two/CD distinct/JJ mitogen-inducible/JJ DNA-binding/JJ complexes/NNS ,/, the/DT kappa/NN B/NN complex/NN within/IN the/DT HIV/NN enhancer/NN and/CC the/DT NFAT-1/NN complex/NN within/IN the/DT interleukin-2/NN enhancer/NN ,/, is/VBZ inhibited/VBN in/IN the/DT presence/NN of/IN CsA/NN ./. 
The/DT kappa/NN B-binding/JJ activity/NN with/IN the/DT HIV/NN enhancer/NN is/VBZ inhibited/VBN only/RB if/IN it/PRP is/VBZ activated/VBN via/IN the/DT mitogen/NN phytohemagglutinin/NN whereas/IN phorbol/NN myristate/NN acetate-mediated/JJ activation/NN is/VBZ completely/RB insensitive/JJ to/TO the/DT drug/NN ./. 
This/DT suggests/VBZ a/DT model/NN in/IN which/WDT functionally/RB indistinguishable/JJ kappa/NN B/NN complexes/NNS can/MD be/VB activated/VBN via/IN two/CD separate/JJ pathways/NNS of/IN signal/NN transduction/NN distinguishable/JJ by/IN CsA/NN ./. 
UI/LS -/: 91190842/CD 
TI/LS -/: Purification/NN of/IN TCF-1/NN alpha/NN ,/, a/DT T-cell-specific/JJ transcription/NN factor/NN that/WDT activates/VBZ the/DT T-cell/NN receptor/NN C/NN alpha/NN gene/NN enhancer/NN in/IN a/DT context-dependent/JJ manner/NN ./. 
AB/LS -/: The/DT differentiation/NN of/IN T/NN cells/NNS into/IN functionally/RB diverse/JJ subpopulations/NNS is/VBZ controlled/VBN in/IN part/NN ,/, by/IN transcriptional/JJ activation/NN and/CC silencing/NN ;/: however/RB ,/, little/JJ is/VBZ known/VBN in/IN detail/NN about/IN the/DT proteins/NNS that/WDT influence/VBP this/DT developmental/JJ process/NN ./. 
We/PRP have/VBP purified/VBN a/DT new/JJ T-cell-specific/JJ factor/NN ,/, TCF-1/NN alpha/NN ,/, that/WDT is/VBZ implicated/VBN in/IN the/DT activation/NN of/IN genes/NNS encoding/VBG a/DT major/JJ component/NN of/IN the/DT human/JJ T-cell/NN receptor/NN (/( TCR/NN )/) ./. 
TCF-1/NN alpha/NN ,/, originally/RB identified/VBN and/CC purified/VBN through/IN its/PRP$ binding/VBG sites/NNS on/IN the/DT HIV-1/NN promoter/NN ,/, was/VBD found/VBN to/TO bind/VB to/TO the/DT TCR/NN alpha/NN enhancer/NN and/CC to/TO promoters/NNS for/IN several/JJ genes/NNS expressed/VBN at/IN significantly/RB earlier/JJR stages/NNS of/IN T-cell/NN development/NN than/IN the/DT TCR/NN alpha/NN gene/NN (/( e.g./FW ,/, p56lck/NN and/CC CD3/NN delta/NN )/) ./. 
Sequences/NNS related/JJ to/TO the/DT TCF-1/NN alpha/NN binding/NN motif/NN (/( 5'-GGCACCCTTTGA-3'/NN )/) are/VBP also/RB found/VBN in/IN the/DT human/JJ TCR/NN delta/NN (/( and/CC possibly/RB TCR/NN beta/NN )/) enhancers/NNS ./. 
Southwestern/JJ and/CC gel/NN renaturation/NN experiments/NNS with/IN the/DT use/NN of/IN purified/VBN protein/NN fractions/NNS revealed/VBD that/IN TCF-1/NN alpha/NN activity/NN is/VBZ derived/VBN from/IN a/DT family/NN of/IN 57-/CD to/TO 53-kD/JJ proteins/NNS that/WDT are/VBP abundantly/RB expressed/VBN in/IN mature/JJ and/CC immature/JJ T-cell/NN lines/NNS (/( Jurkat/NN ,/, CCRF-CEM/NN )/) and/CC not/RB in/IN mature/JJ B/NN cells/NNS (/( JY/NN ,/, Namalwa/NN )/) or/CC nonlymphoid/JJ (/( HeLa/NN )/) cell/NN lines/NNS ./. 
A/DT small/JJ 95-bp/JJ fragment/NN of/IN the/DT TCR/NN alpha/NN control/NN region/NN that/WDT contains/VBZ the/DT TCF-1/NN alpha/NN binding/NN site/NN juxtaposed/VBD between/IN a/DT cAMP-response/NN element/NN (/( the/DT CRE/NN or/CC T/NN alpha/NN 1/CD motif/NN )/) and/CC the/DT binding/VBG site/NN for/IN a/DT distinct/JJ lymphoid-specific/JJ protein/NN (/( TCF-2/NN alpha/NN )/) behaved/VBD as/IN a/DT potent/JJ T-cell-specific/JJ enhancer/NN in/FW vivo/FW ./. 
Tandem/JJ copies/NNS of/IN this/DT enhancer/NN functioned/VBD synergistically/RB in/IN mature/JJ (/( Jurkat/NN )/) T-cell/NN lines/NNS as/RB well/RB as/IN resting/VBG and/CC activated/VBN immature/JJ (/( CCRF-CEM/NN )/) T-cell/NN lines/NNS ./. 
Mutation/NN of/IN the/DT TCF-1/NN alpha/NN binding/NN site/NN diminished/VBD enhancer/NN activity/NN and/CC disrupted/VBD the/DT synergism/NN observed/VBN in/FW vivo/FW between/IN tandem/JJ enhancer/NN repeats/NNS ./. 
The/DT TCF-1/NN alpha/NN binding/NN site/NN was/VBD also/RB required/VBN for/IN TCR/NN alpha/NN enhancer/NN activity/NN in/IN transcriptionally/RB active/JJ extracts/NNS from/IN Jurkat/NN but/CC not/RB HeLa/NN cells/NNS ,/, confirming/VBG that/IN TCF-1/NN alpha/NN is/VBZ a/DT T-cell-specific/JJ transcription/NN factor/NN ./. 
Curiously/RB ,/, the/DT TCF-1/NN alpha/NN binding/NN element/NN was/VBD inactive/JJ in/FW vivo/FW when/WRB removed/VBN from/IN its/PRP$ neighboring/JJ elements/NNS on/IN the/DT TCR/NN alpha/NN enhancer/NN and/CC positioned/JJ in/IN one/CD or/CC more/JJR copies/NNS upstream/RB of/IN a/DT heterologous/JJ promoter/NN ./. 
Thus/RB ,/, the/DT transcriptional/JJ activity/NN of/IN TCF-1/NN alpha/NN appears/VBZ to/TO depend/VB on/IN the/DT TCF-2/NN alpha/NN and/CC T/NN alpha/NN 1/CD (/( CREB/NN )/) transcription/NN factors/NNS and/CC the/DT context/NN of/IN its/PRP$ binding/VBG site/NN within/IN the/DT TCR/NN alpha/NN enhancer/NN ./. 
UI/LS -/: 90346297/CD 
TI/LS -/: Tandem/JJ AP-1-binding/JJ sites/NNS within/IN the/DT human/JJ beta-globin/NN dominant/JJ control/NN region/NN function/VBP as/IN an/DT inducible/JJ enhancer/NN in/IN erythroid/JJ cells/NNS ./. 
AB/LS -/: A/DT powerful/JJ enhancer/NN has/VBZ been/VBN mapped/VBN to/TO an/DT 18-bp/JJ DNA/NN segment/NN located/JJ 11/CD kb/NN 5'/JJ to/TO the/DT human/JJ epsilon-globin/NN gene/NN within/IN the/DT dominant/JJ control/NN or/CC locus-activating/JJ region/NN ./. 
This/DT enhancer/NN is/VBZ inducible/JJ in/IN K562/NN human/JJ erythroleukemia/NN cells/NNS ,/, increasing/VBG linked/VBN gamma-globin/NN promoter/luciferase/NN gene/NN expression/NN to/TO 170-fold/RB over/IN an/DT enhancerless/JJ construct/NN ./. 
The/DT enhancer/NN consists/VBZ of/IN tandem/JJ AP-1-binding/JJ sites/NNS ,/, phased/JJ 10/CD bp/NN apart/RB ,/, which/WDT are/VBP both/DT required/VBN for/IN full/JJ activity/NN ./. 
DNA-protein/NN binding/NN assays/NNS with/IN nuclear/JJ extracts/NNS from/IN induced/VBN cells/NNS demonstrate/VBP a/DT high/JJ molecular/JJ weight/NN complex/NN on/IN the/DT enhancer/NN ./. 
The/DT formation/NN of/IN this/DT complex/NN also/RB requires/VBZ both/DT AP-1/NN sites/NNS and/CC correlates/VBZ with/IN maximal/JJ enhancer/NN activity/NN ./. 
Induction/NN of/IN the/DT enhancer/NN may/MD have/VB a/DT role/NN in/IN the/DT increase/NN in/IN globin/NN gene/NN transcription/NN that/WDT characterizes/VBZ erythroid/JJ maturation/NN ./. 
Enhancer/NN activity/NN appears/VBZ to/TO be/VB mediated/VBN by/IN the/DT binding/NN of/IN a/DT complex/NN of/IN proteins/NNS from/IN the/DT jun/NN and/CC fos/NN families/NNS to/TO tandem/JJ AP-1/NN consensus/NN sequences/NNS ./. 
UI/LS -/: 90220600/CD 
TI/LS -/: Identification/NN of/IN a/DT novel/JJ factor/NN that/WDT interacts/VBZ with/IN an/DT immunoglobulin/NN heavy-chain/JJ promoter/NN and/CC stimulates/VBZ transcription/NN in/IN conjunction/NN with/IN the/DT lymphoid/JJ cell-specific/JJ factor/NN OTF2/NN ./. 
AB/LS -/: The/DT tissue-specific/JJ expression/NN of/IN the/DT MOPC/NN 141/CD immunoglobulin/NN heavy-chain/JJ gene/NN was/VBD studied/VBN by/IN using/VBG in/FW vitro/FW transcription/NN ./. 
B-cell-specific/JJ transcription/NN of/IN this/DT gene/NN was/VBD dependent/JJ on/IN the/DT octamer/NN element/NN 5'-ATGCAAAG-3'/NN ,/, located/JJ in/IN the/DT upstream/JJ region/NN of/IN this/DT promoter/NN and/CC in/IN the/DT promoters/NNS of/IN all/DT other/JJ immunoglobulin/NN heavy-/JJ and/CC light-chain/JJ genes/NNS ./. 
The/DT interaction/NN of/IN purified/VBN octamer/NN transcription/NN factors/NNS 1/CD and/CC 2/CD (/( OTF1/NN and/CC OTF2/NN )/) with/IN the/DT MOPC/NN 141/CD promoter/NN was/VBD studied/VBN by/IN using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS and/CC DNase/NN I/CD footprinting/NN ./. 
Purified/VBN OTF1/NN from/IN HeLa/NN cells/NNS and/CC OTF1/NN and/CC OTF2/NN from/IN B/NN cells/NNS bound/VBD to/TO identical/JJ sequences/NNS within/IN the/DT heavy-chain/JJ promoter/NN ./. 
The/DT OTF/NN interactions/NNS we/PRP observed/VBD extended/VBD over/IN the/DT heptamer/NN element/NN 5'-CTCAGGA-3'/NN ,/, and/CC it/PRP seems/VBZ likely/RB that/IN the/DT binding/NN of/IN the/DT purified/VBN factors/NNS involves/VBZ cooperation/NN between/IN octamer/NN and/CC heptamer/NN sites/NNS in/IN this/DT promoter/NN ./. 
In/IN addition/NN to/TO these/DT elements/NNS ,/, we/PRP identified/VBD a/DT second/JJ regulatory/JJ element/NN ,/, the/DT N/NN element/NN with/IN the/DT sequence/NN 5'-GGAACCTCCCCC-3'/NN ./. 
The/DT N/NN element/NN could/MD independently/RB mediate/VB low/JJ levels/NNS of/IN transcription/NN in/IN both/CC B-cell/NN and/CC HeLa-cell/JJ extracts/NNS ,/, and/CC ,/, in/IN conjunction/NN with/IN the/DT octamer/NN element/NN ,/, it/PRP can/MD promote/VB high/JJ levels/NNS of/IN transcription/NN in/IN B-cell/NN extracts/NNS ./. 
The/DT N/NN element/NN bound/VBD a/DT transcription/NN factor/NN ,/, NTF/NN ,/, that/WDT is/VBZ ubiquitous/JJ in/IN cell-type/JJ distribution/NN ,/, and/CC NTF/NN was/VBD distinct/JJ from/IN any/DT of/IN the/DT previously/RB described/VBN proteins/NNS that/WDT bind/VBP to/TO similar/JJ sequences/NNS ./. 
Based/VBN on/IN these/DT results/NNS ,/, we/PRP propose/VBP that/IN NTF/NN and/CC OTF2/NN interactions/NNS (/( both/CC with/IN their/PRP$ cognate/JJ DNA/NN elements/NNS and/CC possibly/RB at/IN the/DT protein-protein/JJ level/NN )/) may/MD be/VB critical/JJ to/TO B-cell-specific/JJ expression/NN and/CC that/IN these/DT interactions/NNS provide/VBP additional/JJ pathways/NNS for/IN regulating/VBG gene/NN expression/NN ./. 
UI/LS -/: 90158596/CD 
TI/LS -/: NF-kappa/NN B/NN as/IN inducible/JJ transcriptional/JJ activator/NN of/IN the/DT granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN gene/NN ./. 
AB/LS -/: The/DT expression/NN of/IN the/DT gene/NN encoding/VBG the/DT granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) is/VBZ induced/VBN upon/IN activation/NN of/IN T/NN cells/NNS with/IN phytohemagglutinin/NN and/CC active/JJ phorbolester/NN and/CC upon/IN expression/NN of/IN tax1/NN ,/, a/DT transactivating/VBG protein/NN of/IN the/DT human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD ./. 
The/DT same/JJ agents/NNS induce/VBP transcription/NN from/IN the/DT interleukin-2/NN receptor/NN alpha-chain/NN and/CC interleukin-2/NN genes/NNS ,/, depending/VBG on/IN promoter/NN elements/NNS that/WDT bind/VBP the/DT inducible/JJ transcription/NN factor/NN NF-kappa/NN B/NN (/( or/CC an/DT NF-kappa/NN B-like/JJ factor/NN )/) ./. 
We/PRP therefore/RB tested/VBD the/DT possibility/NN that/IN the/DT GM-CSF/NN gene/NN is/VBZ also/RB regulated/VBN by/IN a/DT cognate/JJ motif/NN for/IN the/DT NF-kappa/NN B/NN transcription/NN factor/NN ./. 
A/DT recent/JJ functional/JJ analysis/NN by/IN Miyatake/NNP et/FW al./FW (/( S./NNP Miyatake/NNP ,/, M./NNP Seiki/NNP ,/, M./NNP Yoshida/NNP ,/, and/CC K./NNP Arai/NNP ,/, Mol./NNP Cell./NNP Biol./NNP 8/CD :/: 5581-5587/CD ,/, 1988/CD )/) described/VBD a/DT short/JJ promoter/NN region/NN in/IN the/DT GM-CSF/NN gene/NN that/WDT conferred/VBD strong/JJ inducibility/NN by/IN T-cell-activating/JJ signals/NNS and/CC tax1/NN ,/, but/CC no/DT NF-kappa/NN B-binding/NN motifs/NNS were/VBD identified/VBN ./. 
Using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, we/PRP showed/VBD binding/NN of/IN purified/VBN human/JJ NF-kappa/NN B/NN and/CC of/IN the/DT NF-kappa/NN B/NN activated/VBN in/IN Jurkat/NN T/NN cells/NNS to/TO an/DT oligonucleotide/NN comprising/VBG the/DT GM-CSF/NN promoter/NN element/NN responsible/JJ for/IN mediating/VBG responsiveness/NN to/TO T-cell-activating/JJ signals/NNS and/CC tax1/NN ./. 
As/IN shown/VBN by/IN a/DT methylation/NN interference/NN analysis/NN and/CC oligonucleotide/NN competition/NN experiments/NNS ,/, purified/VBN NF-kappa/NN B/NN binds/VBZ at/IN positions/NNS -82/CD to/TO -91/CD (/( GGGAACTACC/NN )/) of/IN the/DT GM-CSF/NN promoter/NN sequence/NN with/IN an/DT affinity/NN similar/JJ to/TO that/DT with/IN which/WDT it/PRP binds/VBZ to/TO the/DT biologically/RB functional/JJ kappa/NN B/NN motif/NN in/IN the/DT beta/NN interferon/NN promoter/NN (/( GGGAAATTCC/NN )/) ./. 
Two/CD kappa/NN B-like/JJ motifs/NNS at/IN positions/NNS -98/CD to/TO -108/CD of/IN the/DT GM-CSF/NN promoter/NN were/VBD also/RB recognized/VBN but/CC with/IN much/JJ lower/JJR affinities/NNS ./. 
Our/PRP$ data/NNS provide/VBP strong/JJ evidence/NN that/IN the/DT expression/NN of/IN the/DT GM-CSF/NN gene/NN following/VBG T-cell/NN activation/NN is/VBZ controlled/VBN by/IN binding/NN of/IN the/DT NF-kappa/NN B/NN transcription/NN factor/NN to/TO a/DT high-affinity/JJ binding/NN site/NN in/IN the/DT GM-CSF/NN promoter/NN ./. 
UI/LS -/: 90254291/CD 
TI/LS -/: Effects/NNS of/IN mitogenic/JJ agents/NNS upon/IN glucocorticoid/NN action/NN in/IN human/JJ tonsillar/NN T-lymphocytes/NNS ./. 
AB/LS -/: The/DT treatment/NN of/IN human/JJ tonsillar/NN T-lymphocytes/NNS with/IN 4-phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) ,/, resulted/VBD in/IN about/RB two/CD fold/JJ increase/NN in/IN glucocorticoid/NN receptor/NN (/( GR/NN )/) number/NN ,/, without/IN any/DT significant/JJ change/NN in/IN the/DT receptor/NN affinity/NN ./. 
This/DT increase/NN disappeared/VBD in/IN the/DT presence/NN of/IN cycloheximide/NN ./. 
Alone/RB ,/, PMA/NN and/CC calcium/NN ionophore/NN A23187/NN did/VBD not/RB affect/VB ,/, but/CC together/RB stimulated/VBD ,/, like/IN phytohaemagglutinin/NN (/( PHA/NN )/) ,/, leucine/NN and/CC ,/, in/IN particular/JJ ,/, thymidine/NN incorporation/NN ./. 
PMA/NN enhanced/VBD slightly/RB the/DT stimulatory/JJ effect/NN of/IN PHA/NN ./. 
Alone/RB ,/, these/DT agents/NNS failed/VBD to/TO alter/VB the/DT suppressive/JJ effect/NN of/IN dexamethasone/NN on/IN thymidine/NN and/CC leucine/NN incorporation/NN ;/: however/RB ,/, PMA-A23187/JJ and/CC PMA-PHA/JJ combinations/NNS appeared/VBD to/TO antagonize/VB the/DT suppression/NN by/IN dexamethasone/NN ./. 
UI/LS -/: 92010096/CD 
TI/LS -/: To/TO be/VB or/CC not/RB to/TO be/VB a/DT responder/NN in/IN T-cell/NN responses/NNS :/: ubiquitous/JJ oligopeptides/NNS in/IN all/DT proteins/NNS ./. 
AB/LS -/: Amino/NN acid/NN sequences/NNS of/IN all/DT proteins/NNS are/VBP essays/NNS written/VBN in/IN the/DT same/JJ language/NN ./. 
Accordingly/RB ,/, the/DT same/JJ set/NN of/IN words/NNS and/CC phrases/NNS (/( oligopeptides/NNS )/) appear/VBP in/IN totally/RB unrelated/JJ proteins/NNS ./. 
The/DT reason/NN that/IN only/RB certain/JJ individuals/NNS of/IN particular/JJ major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) haplotypes/NNS can/MD mount/VB T-cell/NN responses/NNS against/IN a/DT given/JJ antigen/NN of/IN pathogens/NNS is/VBZ found/VBN in/IN the/DT fact/NN that/IN T-cell/NN receptors/NNS are/VBP designed/VBN to/TO recognize/VB 18-20/CD residue-long/JJ peptide/NN fragments/NNS sandwiched/JJ between/IN two/CD alpha-helices/NNS of/IN class/NN I/CD or/CC class/NN II/CD MHC/NN molecules/NNS ./. 
At/IN this/DT range/NN of/IN peptide/NN lengths/NNS ,/, most/JJS would/MD appear/VB as/IN self/NN ,/, while/IN nonselfness/NN of/IN the/DT remainders/NNS are/VBP destined/VBN to/TO be/VB quite/RB ambiguous/JJ ,/, hence/RB creating/VBG responders/NNS and/CC nonresponders/NNS ./. 
UI/LS -/: 91067681/CD 
TI/LS -/: Two/CD distinct/JJ signal/NN transmission/NN pathways/NNS in/IN T/NN lymphocytes/NNS are/VBP inhibited/VBN by/IN complexes/NNS formed/VBN between/IN an/DT immunophilin/NN and/CC either/CC FK506/NN or/CC rapamycin/NN ./. 
AB/LS -/: Proliferation/NN and/CC immunologic/JJ function/NN of/IN T/NN lymphocytes/NNS are/VBP initiated/VBN by/IN signals/NNS from/IN the/DT antigen/NN receptor/NN that/WDT are/VBP inhibited/VBN by/IN the/DT immunosuppressant/JJ FK506/NN but/CC not/RB by/IN its/PRP$ structural/JJ analog/NN ,/, rapamycin/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, interleukin/NN 2/CD (/( IL-2/NN )/) -induced/JJ signals/NNS are/VBP blocked/VBN by/IN rapamycin/NN but/CC not/RB by/IN FK506/NN ./. 
Remarkably/RB ,/, these/DT two/CD drugs/NNS inhibit/VBP each/DT other/JJ 's/POS actions/NNS ,/, raising/VBG the/DT possibility/NN that/IN both/DT act/VBP by/IN means/NNS of/IN a/DT common/JJ immunophilin/NN (/( immunosuppressant/JJ binding/NN protein/NN )/) ./. 
We/PRP find/VBP that/IN the/DT dissociation/NN constant/NN of/IN rapamycin/NN to/TO the/DT FK506/NN binding/NN protein/NN FKBP/NN (/( Kd/NN =/JJ 0.2/CD nM/NN )/) is/VBZ close/JJ to/TO the/DT dissociation/NN constant/NN of/IN FK506/NN to/TO FKBP/NN (/( Kd/NN =/JJ 0.4/CD nM/NN )/) and/CC to/TO their/PRP$ effective/JJ biologic/JJ inhibitory/JJ concentrations/NNS ./. 
However/RB ,/, an/DT excess/NN of/IN rapamycin/NN is/VBZ needed/VBN to/TO revert/VB FK506-mediated/JJ inhibition/NN of/IN IL-2/NN production/NN ,/, apoptosis/NN ,/, and/CC transcriptional/JJ activation/NN of/IN NF-AT/NN ,/, a/DT T-cell-specific/JJ transcription/NN factor/NN necessary/JJ for/IN IL-2/NN gene/NN activation/NN ./. 
Similarly/RB ,/, an/DT excess/NN of/IN FK506/NN is/VBZ needed/VBN to/TO revert/VB rapamycin-mediated/JJ inhibition/NN of/IN IL-2-induced/JJ proliferation/NN ./. 
The/DT drug/NN concentrations/NNS required/VBN for/IN antagonism/NN may/MD be/VB explained/VBN by/IN the/DT relative/JJ affinity/NN of/IN the/DT drugs/NNS to/TO ,/, and/CC by/IN the/DT abundance/NN of/IN ,/, the/DT immunophilin/NN FKBP/NN ./. 
FKBP/NN has/VBZ been/VBN shown/VBN to/TO catalyze/VB the/DT interconversion/NN of/IN the/DT cis-/JJ and/CC trans-rotamers/NNS of/IN the/DT peptidyl-prolyl/JJ amide/NN bond/NN of/IN peptide/NN substrates/NNS ;/: here/RB we/PRP show/VBP that/IN rapamycin/NN ,/, like/IN FK506/NN ,/, is/VBZ a/DT potent/JJ inhibitor/NN of/IN the/DT rotamase/NN activity/NN of/IN FKBP/NN (/( Ki/NN =/JJ 0.2/CD nM/NN )/) ./. 
Neither/CC FKBP/NN binding/NN nor/CC inhibition/NN of/IN rotamase/NN activity/NN of/IN FKBP/NN alone/RB is/VBZ sufficient/JJ to/TO explain/VB the/DT biologic/JJ actions/NNS of/IN these/DT drugs/NNS ./. 
Rather/RB ,/, these/DT findings/NNS suggest/VBP that/IN immunophilin/NN bound/VBN to/TO FK506/NN interferes/VBZ with/IN antigen/NN receptor-induced/JJ signals/NNS ,/, while/IN rapamycin/NN bound/VBN to/TO the/DT immunophilin/NN interferes/VBZ with/IN IL-2-induced/JJ signals/NNS ./. 
UI/LS -/: 91035625/CD 
TI/LS -/: Adherence-dependent/JJ increase/NN in/IN human/JJ monocyte/NN PDGF(B)/NN mRNA/NN is/VBZ associated/VBN with/IN increases/NNS in/IN c-fos/NN ,/, c-jun/NN ,/, and/CC EGR2/NN mRNA/NN ./. 
AB/LS -/: Adherence/NN is/VBZ an/DT important/JJ initial/JJ step/NN in/IN the/DT transition/NN of/IN a/DT circulating/VBG monocyte/NN to/TO a/DT tissue/NN macrophage/NN ./. 
This/DT differentiation/NN is/VBZ accompanied/VBN by/IN an/DT augmented/JJ capacity/NN to/TO generate/VB growth/NN factors/NNS ./. 
We/PRP hypothesized/VBD that/IN adherence/NN itself/PRP might/MD be/VB an/DT important/JJ trigger/NN for/IN a/DT sequence/NN of/IN gene/NN activation/NN culminating/VBG in/IN cells/NNS with/IN increased/VBN mRNA/NN encoding/VBG profibrotic/JJ growth/NN factors/NNS such/JJ as/IN platelet-derived/JJ growth/NN factor/NN B/NN subunit/NN (/( PDGF[B]/NN )/) and/CC transforming/VBG growth/NN factor-beta/NN (/( TGF-beta/NN )/) ./. 
After/IN in/FW vitro/FW adherence/NN ,/, human/JJ monocytes/NNS had/VBD a/DT biphasic/JJ increase/NN in/IN PDGF(B)/NN mRNA/NN with/IN peaks/NNS at/IN 6/CD h/NN and/CC 13/CD d/NN ./. 
No/DT increase/NN in/IN TGF-beta/NN mRNA/NN was/VBD observed/VBN ./. 
The/DT 6-h/JJ increase/NN in/IN PDGF(B)/NN mRNA/NN was/VBD adherence/NN dependent/JJ ,/, and/CC in/IN addition/NN ,/, was/VBD abrogated/VBN when/WRB the/DT cytoskeletal/JJ integrity/NN was/VBD compromised/VBN by/IN cytochalasin/NN D/NN ./. 
The/DT 6-h/JJ increase/NN in/IN PDGF(B)/NN mRNA/NN was/VBD unaltered/JJ by/IN adherence/NN in/IN the/DT presence/NN of/IN the/DT monocyte/NN stimulus/NN lipopolysaccharide/NN ./. 
Adherence/NN to/TO either/CC fibronectin/NN or/CC collagen-coated/JJ plastic/NN had/VBD little/JJ consistent/JJ effect/NN on/IN PDGF(B)/NN mRNA/NN accumulation/NN ./. 
The/DT increased/VBN PDGF(B)/NN mRNA/NN observed/VBN in/IN adherent/JJ monocytes/NNS was/VBD accompanied/VBN by/IN increases/NNS in/IN mRNAs/NNS of/IN the/DT early/JJ growth/NN response/NN genes/NNS c-fos/NN (/( maximal/JJ at/IN 20/CD min/NN )/) ,/, c-jun/NN ,/, and/CC EGR2/NN (/( maximal/JJ at/IN 6-24/CD h/NN )/) ./. 
The/DT increase/NN in/IN c-jun/NN and/CC EGR2/NN ,/, but/CC not/RB c-fos/NN ,/, mRNA/NN was/VBD also/RB abrogated/VBN by/IN cytochalasin/NN D/NN ./. 
These/DT observations/NNS suggest/VBP that/IN adherence/NN results/VBZ in/IN increases/NNS of/IN c-fos/NN ,/, c-jun/NN ,/, EGR2/NN ,/, and/CC PDGF(B)/NN mRNA/NN ./. 
In/IN addition/NN ,/, the/DT increases/NNS in/IN c-jun/NN ,/, EGR2/NN ,/, and/CC PDGF(B)/NN may/MD depend/VB on/IN cytoskeletal/JJ rearrangement/NN ./. 
Modulation/NN of/IN these/DT events/NNS at/IN the/DT time/NN of/IN adherence/NN offers/VBZ a/DT mechanism/NN by/IN which/WDT differential/JJ priming/NN of/IN the/DT cells/NNS may/MD be/VB accomplished/VBN ./. 
UI/LS -/: 91065527/CD 
TI/LS -/: Single/JJ cell/NN assay/NN of/IN a/DT transcription/NN factor/NN reveals/VBZ a/DT threshold/NN in/IN transcription/NN activated/VBN by/IN signals/NNS emanating/VBG from/IN the/DT T-cell/NN antigen/NN receptor/NN ./. 
AB/LS -/: Stimulation/NN of/IN T/NN lymphocytes/NNS through/IN their/PRP$ antigen/NN receptor/NN leads/VBZ to/TO the/DT appearance/NN of/IN several/JJ transcription/NN factors/NNS ,/, including/VBG NF-AT/NN and/CC NF-kappa/NN B/NN ,/, which/WDT are/VBP involved/VBN in/IN regulating/VBG genes/NNS required/VBN for/IN immunologic/JJ activation/NN ./. 
To/TO investigate/VB the/DT activity/NN of/IN a/DT single/JJ transcription/NN factor/NN in/IN individual/JJ viable/JJ cells/NNS ,/, we/PRP have/VBP applied/VBN an/DT assay/NN that/WDT uses/VBZ the/DT fluorescence-activated/JJ cell/NN sorter/NN to/TO quantitate/VB beta-galactosidase/NN (/( beta-gal/NN )/) ./. 
We/PRP have/VBP analyzed/VBN the/DT distribution/NN of/IN NF-AT/NN transcriptional/JJ activity/NN among/IN T/NN cells/NNS undergoing/VBG activation/NN by/IN using/VBG a/DT construct/NN in/IN which/WDT three/CD tandem/JJ copies/NNS of/IN the/DT NF-AT-binding/NN site/NN directs/VBZ transcription/NN of/IN the/DT lacZ/NN gene/NN ./. 
Unexpectedly/RB ,/, stimulation/NN of/IN cloned/VBN stably/RB transfected/VBN Jurkat/NN T/NN cells/NNS leads/VBZ to/TO a/DT bimodal/JJ pattern/NN of/IN beta-gal/NN expression/NN in/IN which/WDT some/DT cells/NNS express/VBP no/DT beta-gal/NN and/CC others/NNS express/VBP high/JJ levels/NNS ./. 
This/DT expression/NN pattern/NN can/MD not/RB be/VB accounted/VBN for/IN by/IN cell-cycle/JJ position/NN or/CC heritable/JJ variation/NN ./. 
Further/JJ results/NNS ,/, in/IN which/WDT beta-gal/NN activity/NN is/VBZ correlated/VBN with/IN NF-AT-binding/NN activity/NN ,/, indicate/VBP that/IN the/DT concentration/NN of/IN NF-AT/NN must/MD exceed/VB a/DT critical/JJ threshold/NN before/IN transcription/NN initiates/VBZ ./. 
This/DT threshold/NN likely/RB reflects/VBZ the/DT NF-AT/NN concentration-dependent/JJ assembly/NN of/IN transcription/NN complexes/NNS at/IN the/DT promoter/NN ./. 
Similar/JJ constructs/NNS controlled/VBN by/IN NF-kappa/NN B/NN or/CC the/DT entire/JJ interleukin-2/NN enhancer/NN show/VBP bimodal/JJ expression/NN patterns/NNS during/IN induction/NN ,/, suggesting/VBG that/IN thresholds/NNS set/VBN by/IN the/DT concentration/NN of/IN transcription/NN factors/NNS may/MD be/VB a/DT common/JJ property/NN of/IN inducible/JJ genes/NNS ./. 
UI/LS -/: 90317873/CD 
TI/LS -/: The/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) BMRF1/NN promoter/NN for/IN early/JJ antigen/NN (/( EA-D/NN )/) is/VBZ regulated/VBN by/IN the/DT EBV/NN transactivators/NNS ,/, BRLF1/NN and/CC BZLF1/NN ,/, in/IN a/DT cell-specific/JJ manner/NN ./. 
AB/LS -/: The/DT Epstein-Barr/JJ virus/NN early/JJ antigen/NN diffuse/NN component/NN (/( EA-D/NN )/) is/VBZ essential/JJ for/IN Epstein-Barr/JJ virus/NN DNA/NN polymerase/NN activity/NN ,/, and/CC its/PRP$ activity/NN is/VBZ suppressed/VBN during/IN latent/JJ infection/NN ./. 
We/PRP investigated/VBD the/DT regulation/NN of/IN the/DT promoter/NN (/( BMRF1/NN )/) for/IN this/DT early/JJ gene/NN by/IN studying/VBG its/PRP$ responsiveness/NN in/FW vitro/FW to/TO two/CD immediate-early/JJ viral/JJ transactivators/NNS ,/, BZLF1/NN (/( Z/NN )/) and/CC BRLF1/NN (/( R/NN )/) ,/, focusing/VBG on/IN the/DT differences/NNS in/IN response/NN in/IN lymphoid/JJ cells/NNS and/CC epithelial/JJ cells/NNS ./. 
In/IN lymphoid/JJ cells/NNS ,/, Z/NN or/CC R/NN alone/RB produced/VBD only/RB small/JJ increases/NNS in/IN EA-D/NN promoter/NN activity/NN ,/, whereas/IN both/DT transactivators/NNS together/RB produced/VBD a/DT large/JJ stimulatory/JJ effect/NN ./. 
In/IN epithelial/JJ cells/NNS ,/, the/DT Z/NN transactivator/NN alone/RB produced/VBD maximal/JJ stimulation/NN of/IN the/DT EA-D/NN promoter/NN ;/: the/DT effect/NN of/IN R/NN and/CC Z/NN together/RB was/VBD no/DT greater/JJR than/IN that/DT of/IN Z/NN alone/RB ./. 
Deletional/JJ analysis/NN and/CC site-directed/JJ mutagenesis/NN of/IN the/DT EA-D/NN promoter/NN demonstrated/VBD that/IN in/IN epithelial/JJ cells/NNS the/DT potential/JJ AP-1/NN binding/NN site/NN plays/VBZ an/DT essential/JJ role/NN in/IN Z/NN responsiveness/NN ,/, although/IN sequences/NNS further/RB upstream/JJ are/VBP also/RB important/JJ ./. 
In/IN lymphoid/JJ cells/NNS ,/, only/RB the/DT upstream/JJ sequences/NNS are/VBP required/VBN for/IN transactivation/NN by/IN the/DT Z/R/NN combination/NN ,/, and/CC the/DT AP-1/NN site/NN is/VBZ dispensable/JJ ./. 
These/DT data/NNS suggest/VBP that/IN EA-D/NN (/( BMRF1/NN )/) promoter/NN regulation/NN by/IN Z/NN and/CC R/NN is/VBZ cell/NN type/NN specific/JJ and/CC appears/VBZ to/TO involve/VB different/JJ mechanisms/NNS in/IN each/DT cell/NN type/NN ./. 
UI/LS -/: 90319127/CD 
TI/LS -/: Complementary/JJ DNA/NN encoding/VBG the/DT human/JJ T-cell/NN FK506-binding/JJ protein/NN ,/, a/DT peptidylprolyl/JJ cis-trans/JJ isomerase/NN distinct/JJ from/IN cyclophilin/NN ./. 
AB/LS -/: The/DT recently/RB discovered/VBN macrolide/NN FK506/NN has/VBZ been/VBN demonstrated/VBN to/TO have/VB potent/JJ immunosuppressive/JJ activity/NN at/IN concentrations/NNS 100-fold/RB lower/JJR than/IN cyclosporin/NN A/NN ,/, a/DT cyclic/JJ undecapeptide/NN that/WDT is/VBZ used/VBN to/TO prevent/VB rejection/NN after/IN transplantation/NN of/IN bone/NN marrow/NN and/CC organs/NNS ,/, such/JJ as/IN kidney/NN ,/, heart/NN ,/, and/CC liver/NN ./. 
After/IN the/DT recent/JJ discovery/NN that/IN the/DT cyclosporin/NN A-binding/NN protein/NN cyclophilin/NN is/VBZ identical/JJ to/TO peptidylprolyl/JJ cis-trans/JJ isomerase/NN ,/, a/DT cellular/JJ binding/NN protein/NN for/IN FK506/NN was/VBD found/VBN to/TO be/VB distinct/JJ from/IN cyclophilin/NN but/CC to/TO have/VB the/DT same/JJ enzymatic/JJ activity/NN ./. 
In/IN this/DT study/NN ,/, we/PRP isolated/VBD a/DT cDNA/NN coding/VBG for/IN FK506-binding/JJ protein/NN (/( FKBP/NN )/) from/IN human/JJ peripheral/JJ blood/NN T/NN cells/NNS by/IN using/VBG mixed/JJ 20-mer/JJ oligonucleotide/NN probes/NNS synthesized/VBN on/IN the/DT basis/NN of/IN the/DT sequence/NN ,/, Glu-Asp-Gly-Lys-Lys-Phe-Asp/NN ,/, reported/VBN for/IN bovine/JJ FKBP/NN ./. 
The/DT DNA/NN isolated/VBN contained/VBD an/DT open/JJ reading/NN frame/NN encoding/VBG 108/CD amino/NN acid/NN residues/NNS ./. 
The/DT first/JJ 40/CD residues/NNS of/IN the/DT deduced/VBN amino/NN acid/NN sequence/NN were/VBD identical/JJ to/TO those/DT of/IN the/DT reported/VBN amino-terminal/JJ sequence/NN of/IN bovine/JJ FKBP/NN ,/, indicating/VBG that/IN the/DT DNA/NN sequence/NN isolated/VBN represents/VBZ the/DT gene/NN coding/VBG for/IN FKBP/NN ./. 
Computer-assisted/JJ analysis/NN of/IN the/DT deduced/VBN amino/NN acid/NN sequence/NN indicates/VBZ that/IN FKBP/NN exhibits/VBZ no/DT internal/JJ homology/NN and/CC does/VBZ not/RB have/VB significant/JJ sequence/NN similarity/NN to/TO any/DT other/JJ amino/NN acid/NN sequences/NNS of/IN known/JJ proteins/NNS ,/, including/VBG cyclophilin/NN ./. 
This/DT result/NN suggests/VBZ that/IN two/CD catalytically/RB similar/JJ proteins/NNS ,/, cyclophilin/NN and/CC FKBP/NN ,/, evolved/VBD independently/RB ./. 
In/IN Northern/NN blot/NN analysis/NN ,/, mRNA/NN species/NNS of/IN approximately/RB 1.8/CD kilobases/NNS that/WDT hybridized/VBD with/IN human/JJ FKBP/NN cDNA/NN were/VBD detected/VBN in/IN poly(A)+/JJ RNAs/NNS from/IN brain/NN ,/, lung/NN ,/, liver/NN ,/, and/CC placental/JJ cells/NNS and/CC leukocytes/NNS ./. 
Induction/NN of/IN Jurkat/NN leukemic/JJ T/NN cells/NNS with/IN phorbol/NN 12-myristate/NN 13-acetate/NN and/CC ionomycin/NN did/VBD not/RB affect/VB the/DT level/NN of/IN FKBP/NN mRNA/NN ./. 
Southern/NN blot/NN analysis/NN of/IN human/JJ genomic/JJ DNA/NN digested/VBN with/IN different/JJ restriction/NN enzymes/NNS suggests/VBZ the/DT existence/NN of/IN only/RB a/DT few/JJ copies/NNS of/IN the/DT DNA/NN sequence/NN encoding/VBG FKBP/NN ./. 
This/DT is/VBZ in/IN contrast/NN to/TO the/DT result/NN that/IN as/RB many/JJ as/IN 20/CD copies/NNS of/IN the/DT cyclophilin/NN gene/NN and/CC possible/JJ pseudogenes/NNS may/MD be/VB present/JJ in/IN the/DT mammalian/JJ genome/NN ./. 
UI/LS -/: 90258907/CD 
TI/LS -/: Involvement/NN of/IN a/DT second/JJ lymphoid-specific/JJ enhancer/NN element/NN in/IN the/DT regulation/NN of/IN immunoglobulin/NN heavy-chain/NN gene/NN expression/NN ./. 
AB/LS -/: To/TO determine/VB whether/IN enhancer/NN elements/NNS in/IN addition/NN to/TO the/DT highly/RB conserved/VBN octamer/NN (/( OCTA/NN )/) -nucleotide/JJ motif/NN are/VBP important/JJ for/IN lymphoid-specific/JJ expression/NN of/IN the/DT immunoglobulin/NN heavy-chain/NN (/( IgH/NN )/) gene/NN ,/, we/PRP have/VBP investigated/VBN the/DT effect/NN of/IN mutating/VBG the/DT binding/VBG site/NN for/IN a/DT putative/JJ additional/JJ lymphoid-specific/JJ transcription/NN factor/NN ,/, designated/VBN NF-microB/NN ,/, in/IN the/DT murine/JJ IgH/NN enhancer/NN ./. 
We/PRP demonstrate/VBP that/IN the/DT NF-microB-binding/JJ site/NN plays/VBZ a/DT critical/JJ role/NN in/IN the/DT IgH/NN enhancer/NN ,/, because/IN mutation/NN of/IN the/DT microB/NN DNA/NN motif/NN decreased/VBD transcriptional/JJ activity/NN of/IN the/DT IgH/NN enhancer/NN in/IN cells/NNS of/IN the/DT B-cell/NN lineage/NN but/CC not/RB in/IN nonlymphoid/JJ cells/NNS ./. 
This/DT effect/NN was/VBD comparable/JJ to/TO or/CC even/RB stronger/JJR than/IN the/DT effect/NN of/IN a/DT mutation/NN in/IN the/DT OCTA/NN site/NN ./. 
Moreover/RB ,/, combined/JJ mutation/NN of/IN both/CC microB/NN and/CC OCTA/NN sites/NNS further/RBR reduced/VBD enhancer/NN activity/NN in/IN lymphoid/JJ cells/NNS ./. 
Interestingly/RB ,/, alteration/NN of/IN either/CC the/DT microB/NN or/CC E3/NN site/NN in/IN a/DT 70-base-pair/JJ fragment/NN of/IN the/DT IgH/NN enhancer/NN that/WDT lacks/VBZ the/DT binding/VBG site/NN for/IN OCTA/NN abolished/VBD enhancer/NN activity/NN in/IN lymphoid/JJ cells/NNS completely/RB ./. 
Nevertheless/RB ,/, a/DT multimer/NN of/IN the/DT microB/NN motif/NN alone/RB showed/VBD no/DT enhancer/NN activity/NN ./. 
DNase/NN footprinting/NN analysis/NN corroborated/VBD the/DT functional/JJ data/NNS showing/VBG that/IN a/DT lymphoid-specific/JJ protein/NN binds/VBZ to/TO the/DT microB/NN DNA/NN motif/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN the/DT microB/NN element/NN is/VBZ a/DT new/JJ crucial/JJ element/NN important/JJ for/IN lymphoid-specific/JJ expression/NN of/IN the/DT IgH/NN gene/NN but/CC that/IN interaction/NN with/IN another/DT enhancer/NN element/NN is/VBZ essential/JJ for/IN its/PRP$ activity/NN ./. 
UI/LS -/: 90298081/CD 
TI/LS -/: Stimulation/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 2/CD (/( HIV-2/NN )/) gene/NN expression/NN by/IN the/DT cytomegalovirus/NN and/CC HIV-2/NN transactivator/NN gene/NN ./. 
AB/LS -/: Human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) often/RB causes/VBZ latent/JJ infection/NN ./. 
Transactivation/NN by/IN some/DT DNA/NN viruses/NNS has/VBZ been/VBN implicated/VBN in/IN inducing/VBG HIV-1/NN replication/NN and/CC pathogenesis/NN ./. 
The/DT transactivator/NN (/( IE-2/NN )/) gene/NN of/IN the/DT human/JJ cytomegalovirus/NN (/( CMV/NN )/) can/MD enhance/VB HIV-2/NN as/RB well/RB as/IN HIV-1/NN gene/NN expression/NN in/FW vitro/FW ./. 
This/DT inducer/NN can/MD act/VB in/IN concert/NN with/IN the/DT HIV-2/NN tat/NN gene/NN and/CC T-cell/NN activation/NN in/IN enhancing/VBG gene/NN expression/NN in/IN human/JJ CD4+/JJ lymphocytes/NNS ./. 
While/IN the/DT HIV-2/NN and/CC HIV-1/NN tat/NN genes/NNS and/CC T-cell/NN activators/NNS apparently/RB employ/VBP independent/JJ modes/NNS of/IN action/NN ,/, the/DT CMV/NN transactivator/NN in/IN combination/NN with/IN the/DT HIV-2/NN tat/NN or/CC T-cell/NN activators/NNS may/MD employ/VB a/DT gene/NN activation/NN pathway/NN with/IN some/DT common/JJ and/CC some/DT distinct/JJ components/NNS ./. 
Both/CC HIV-2/NN and/CC CMV/NN transactivators/NNS enhance/VBP HIV-2/NN gene/NN expression/NN by/IN transcriptional/JJ activation/NN involving/VBG transcript/NN initiation/NN as/RB well/RB as/IN elongation/NN ,/, with/IN CMV/NN transactivator/NN affecting/VBG elongation/NN more/JJR than/IN the/DT initiation/NN ./. 
A/DT significant/JJ proportion/NN of/IN transcripts/NNS appear/VBP to/TO terminate/VB prematurely/RB in/IN the/DT absence/NN of/IN transactivators/NNS ./. 
Deletion/NN mutation/NN analysis/NN of/IN the/DT HIV-2/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) suggests/VBZ that/IN the/DT element/NN that/WDT responds/VBZ to/TO CMV/NN transactivation/NN in/IN human/JJ CD4+/JJ lymphocytes/NNS is/VBZ either/CC a/DT diffuse/JJ one/CD or/CC located/JJ downstream/RB of/IN the/DT HIV-2/NN enhancer/NN element/NN ./. 
UI/LS -/: 90244306/CD 
TI/LS -/: Quantitative/JJ immunohistochemical/JJ analysis/NN of/IN mononuclear/JJ infiltrates/NNS in/IN breast/NN carcinomas/NNS --/: correlation/NN with/IN tumour/JJ differentiation/NN ./. 
AB/LS -/: Inflammatory/JJ infiltrates/NNS were/VBD analysed/VBN in/IN tissue/NN sections/NNS of/IN 76/CD breast/NN carcinomas/NNS by/IN counting/VBG the/DT percentage/NN of/IN macrophages/NNS ,/, IgA+/JJ and/CC IgG+/JJ plasma/NN cells/NNS ,/, T/NN cells/NNS with/IN their/PRP$ subpopulations/NNS ,/, and/CC natural/JJ killer/NN cells/NNS ,/, and/CC by/IN measuring/VBG postcapillary/JJ venules/NNS (/( PCVs/NNS ,/, found/VBN in/IN 12/CD cases/NNS )/) within/IN the/DT infiltrates/NNS ./. 
These/DT parameters/NNS were/VBD correlated/VBN with/IN nuclear/JJ grade/NN and/CC biochemically/RB determined/VBN hormone/NN receptor/NN status/NN ,/, known/JJ markers/NNS of/IN tumour/NN differentiation/NN ./. 
A/DT direct/JJ correlation/NN was/VBD found/VBN between/IN the/DT extent/NN of/IN inflammation/NN and/CC nuclear/JJ grade/NN (/( P/NN less/JJR than/IN 0.0001/CD )/) ,/, and/CC an/DT inverse/JJ correlation/NN between/IN inflammation/NN and/CC oestrogen/NN receptor/NN (/( OR/NN )/) positivity/NN (/( P/NN less/JJR than/IN 0.05/CD )/) as/RB well/RB as/IN inflammation/NN and/CC progesterone/NN receptor/NN (/( PR/NN )/) positivity/NN (/( P/NN less/JJR than/IN 0.05/CD )/) ./. 
The/DT percentage/NN of/IN the/DT OKT8+/JJ suppressor/cytotoxic/JJ T/NN cells/NNS increased/VBD when/WRB the/DT inflammation/NN expanded/VBD from/IN scanty/JJ to/TO moderate/JJ (/( P/NN less/JJR than/IN 0.02/CD )/) ./. 
The/DT diameter/NN of/IN the/DT PCVs/NNS also/RB increased/VBD with/IN increasing/VBG inflammatory/JJ infiltrate/NN (/( P/NN less/JJR than/IN 0.02/CD )/) ./. 
In/IN addition/NN ,/, a/DT direct/JJ correlation/NN exists/VBZ between/IN the/DT diameter/NN of/IN the/DT PCVs/NNS and/CC both/CC the/DT percentage/NN of/IN the/DT OKT8+/JJ T/NN cells/NNS (/( P/NN less/JJR than/IN 0.04/CD )/) and/CC the/DT Leu-7+/JJ natural/JJ killer/NN cells/NNS (/( P/NN less/JJR than/IN 0.03/CD )/) ./. 
UI/LS -/: 90124644/CD 
TI/LS -/: Reactivity/NN of/IN lymphocytes/NNS to/TO a/DT progesterone/NN receptor-specific/JJ monoclonal/JJ antibody/NN ./. 
AB/LS -/: In/IN this/DT study/NN we/PRP present/VBP evidence/NN for/IN reactivity/NN of/IN pregnancy/NN lymphocytes/NNS ,/, but/CC not/RB nonpregnancy/JJ lymphocytes/NNS ,/, with/IN the/DT progesterone/NN receptor-specific/JJ monoclonal/JJ antibody/NN mPRI/NN ./. 
Using/VBG an/DT avidin-biotin/JJ peroxidase/NN detection/NN system/NN ,/, we/PRP found/VBD a/DT nuclear/JJ staining/NN in/IN 14.6/CD +/-/CC 3.7/CD %/NN (/( mean/NN +/-/CC SEM/NN ,/, N/NN =/JJ 27/CD )/) of/IN pregnancy/NN lymphocytes/NNS ,/, while/IN only/RB 0.47/CD +/-/CC 0.33/CD %/NN (/( mean/NN +/-/CC SEM/NN ,/, N/NN =/JJ 15/CD )/) of/IN nonpregnancy/NN lymphocytes/NNS reacted/VBD with/IN the/DT antibody/NN ./. 
To/TO characterize/VB the/DT receptor-bearing/JJ subset/NN ,/, CD8+/JJ and/CC CD4+/JJ cells/NNS were/VBD depleted/VBN by/IN complement-dependent/JJ lysis/NN ./. 
Depletion/NN of/IN CD8+/JJ cells/NNS was/VBD accompanied/VBN by/IN 62/CD +/-/CC 18/CD %/NN loss/NN of/IN progesterone/NN receptor-bearing/JJ cells/NNS ,/, while/IN depletion/NN of/IN CD4+/JJ cells/NNS resulted/VBD in/IN a/DT twofold/JJ increase/NN in/IN the/DT number/NN of/IN positively/RB staining/VBG lymphocytes/NNS ./. 
In/IN nonpregnancy/NN lymphocytes/NNS a/DT 3-day/JJ PHA/NN treatment/NN ,/, as/RB well/RB as/IN allogeneic/JJ stimulation/NN ,/, resulted/VBD in/IN a/DT significant/JJ increase/NN in/IN the/DT number/NN of/IN receptor-containing/JJ cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN pregnancy/NN ,/, but/CC not/RB nonpregnancy/NN ,/, lymphocytes/NNS contain/VBP progesterone/NN binding/NN structures/NNS ,/, and/CC that/IN these/DT are/VBP inducible/JJ by/IN mitogenic/JJ or/CC alloantigenic/JJ stimuli/NNS ./. 
UI/LS -/: 91079583/CD 
TI/LS -/: Activation/NN of/IN human/JJ CD4/NN T/NN lymphocytes/NNS ./. 
Interaction/NN of/IN fibronectin/NN with/IN VLA-5/NN receptor/NN on/IN CD4/NN cells/NNS induces/VBZ the/DT AP-1/NN transcription/NN factor/NN ./. 
AB/LS -/: Fibronectin/NN synergized/VBD with/IN anti-CD3/JJ antibody/NN to/TO promote/VB CD4/NN cell/NN proliferation/NN in/IN a/DT serum-free/JJ culture/NN system/NN whereas/IN no/DT proliferation/NN was/VBD observed/VBN when/WRB CD4/NN cells/NNS were/VBD cultured/VBN with/IN anti-CD3/NN alone/RB or/CC fibronectin/NN alone/RB ./. 
In/IN addition/NN ,/, anti-CD29/JJ (/( integrin/NN beta/NN 1/CD )/) as/RB well/RB as/IN anti-VLA-5/JJ (/( human/JJ fibronectin/NN receptor/NN )/) antibodies/NNS blocked/VBD this/DT CD4/NN cell/NN activation/NN in/IN this/DT system/NN ./. 
Although/IN anti-CD3/NN alone/RB or/CC fibronectin/NN alone/RB can/MD not/RB induce/VB IL-2/NN message/NN by/IN CD4/NN cells/NNS ,/, the/DT combination/NN of/IN anti-CD3/NN plus/CC fibronectin/NN induced/VBD IL-2/NN message/NN by/IN CD4/NN cells/NNS ./. 
In/IN an/DT analysis/NN of/IN the/DT molecular/JJ mechanism/NN by/IN which/WDT IL-2/NN message/NN was/VBD generated/VBN ,/, we/PRP showed/VBD that/IN a/DT fibronectin-VLA-5/NN fibronectin/NN receptor/NN interaction/NN may/MD contribute/VB an/DT independent/JJ signal/NN distinct/JJ from/IN the/DT CD3/NN pathway/NN of/IN activation/NN by/IN the/DT induction/NN of/IN an/DT AP-1/NN transcriptional/JJ factor/NN ./. 
Thus/RB the/DT VLA-5/NN fibronectin/NN receptor/NN on/IN CD4/NN cells/NNS can/MD play/VB a/DT complementary/JJ role/NN in/IN CD3-TCR-mediated/JJ signal/NN transduction/NN through/IN its/PRP$ interaction/NN with/IN fibronectin/NNS ./. 
UI/LS -/: 91164434/CD 
TI/LS -/: Glucocorticoid/NN receptors/NNS on/IN mononuclear/JJ leukocytes/NNS in/IN Alzheimer/NN 's/POS disease/NN ./. 
AB/LS -/: Several/JJ lines/NNS of/IN evidence/NN suggest/VBP disturbances/NNS of/IN the/DT hypothalamic-pituitary-adrenal/JJ (/( HPA/NN )/) system/NN in/IN Alzheimer/NN 's/POS disease/NN (/( AD/NN )/) ./. 
In/IN an/DT exploration/NN of/IN the/DT potential/JJ role/NN of/IN the/DT glucocorticoid/NN receptor/NN (/( GR/NN )/) in/IN AD/NN ,/, GR/NN density/NN and/CC affinity/NN were/VBD assessed/VBN on/IN mononuclear/JJ leukocytes/NNS of/IN 12/CD AD/NN patients/NNS and/CC 12/CD healthy/JJ controls/NNS ./. 
GR/NN binding/NN characteristics/NNS did/VBD not/RB differ/VB between/IN patients/NNS and/CC controls/NNS or/CC between/IN patients/NNS subdivided/VBN according/VBG to/TO diagnosis/NN or/CC associated/VBN clinical/JJ features/NNS ./. 
These/DT data/NNS suggest/VBP that/IN the/DT abnormalities/NNS of/IN the/DT HPA/NN system/NN in/IN AD/NN are/VBP not/RB related/JJ to/TO a/DT GR/NN deficiency/NN ./. 
UI/LS -/: 91100449/CD 
TI/LS -/: Oncogene/NN amplification/NN correlates/VBZ with/IN dense/JJ lymphocyte/NN infiltration/NN in/IN human/JJ breast/NN cancers/NNS :/: a/DT role/NN for/IN hematopoietic/JJ growth/NN factor/NN release/NN by/IN tumor/NN cells/NNS ?/. 
AB/LS -/: One/CD hundred/CD six/CD primary/JJ breast/NN cancer/NN samples/NNS were/VBD analysed/VBN for/IN c-erbB2/NN ,/, int-2/NN ,/, and/CC c-myc/NN gene/NN amplification/NN ./. 
Surgically/RB confirmed/VBN nodal/JJ involvement/NN was/VBD observed/VBN in/IN 42/CD %/NN ./. 
Level/NN of/IN gene/NN amplification/NN was/VBD studied/VBN by/IN Southern/NN and/or/CC slot/NN blot/NN techniques/NNS ./. 
Amplified/VBN c-erbB2/NN gene/NN sequences/NNS were/VBD present/JJ in/IN 21.5/CD %/NN of/IN all/DT samples/NNS ./. 
Int-2/NN was/VBD amplified/VBN in/IN 13.1/CD %/NN and/CC c-myc/NN was/VBD amplified/VBN in/IN 10.3/CD %/NN ./. 
In/IN a/DT non-parametric/JJ test/NN (/( Kruskal-Wallis/NN )/) a/DT strong/JJ negative/JJ association/NN was/VBD found/VBN between/IN high/JJ levels/NNS of/IN c-erbB2/NN amplification/NN and/CC absence/NN of/IN estrogen/NN receptor/NN (/( ER/NN )/) (/( P/NN =/JJ .0009/CD )/) or/CC progesterone/NN receptor/NN (/( PR/NN )/) (/( P/NN =/JJ .011/CD )/) expression/NN ./. 
No/DT correlations/NNS were/VBD found/VBN between/IN all/DT or/CC high/JJ levels/NNS of/IN amplification/NN of/IN each/DT oncogene/NN separately/RB or/CC combined/VBN with/IN T/NN ,/, N/NN ,/, grade/NN ,/, multifocality/NN of/IN tumor/NN ,/, or/CC associated/VBN carcinoma/NN in/FW situ/FW ./. 
There/EX was/VBD a/DT trend/NN approaching/VBG statistical/JJ significance/NN for/IN patients/NNS with/IN c-erbB2/NN amplifications/NNS to/TO have/VB positive/JJ lymph/NN nodes/NNS at/IN surgery/NN (/( P/NN =/JJ 0.09/CD )/) ./. 
A/DT somewhat/RB surprising/JJ finding/NN however/RB was/VBD a/DT very/RB strong/JJ association/NN between/IN oncogene/NN amplification/NN and/CC dense/JJ lymphocyte/NN infiltration/NN of/IN the/DT tumor/NN (/( P/NN =/JJ .05/CD )/) ./. This/DT correlation/NN is/VBZ even/RB stronger/JJR when/WRB only/RB high/JJ levels/NNS of/IN amplification/NN are/VBP considered/VBN ,/, either/CC for/IN each/DT oncogene/NN separately/RB (/( P/NN =/JJ .0048/CD )/) or/CC in/IN combination/NN (/( P/NN =/JJ .0007/CD )/) ./. 
We/PRP propose/VBP that/IN malignant/JJ cell/NN cytokine/NN production/NN may/MD help/VB explain/VB this/DT observation/NN ./. 
UI/LS -/: 91175707/CD 
TI/LS -/: Suppression/NN of/IN signals/NNS required/VBN for/IN activation/NN of/IN transcription/NN factor/NN NF-kappa/NN B/NN in/IN cells/NNS constitutively/RB expressing/VBG the/DT HTLV-I/NN Tax/NN protein/NN ./. 
AB/LS -/: Transient/JJ short-term/JJ expression/NN of/IN the/DT Tax/NN protein/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type-I/NN (/( HTLV-I/NN )/) leads/VBZ to/TO activation/NN of/IN the/DT pleiotropic/JJ transcription/NN factor/NN NF-kappa/NN B/NN ./. 
Consistent/JJ with/IN findings/NNS obtained/VBN with/IN transient/JJ expression/NN assays/NNS ,/, we/PRP observed/VBD marked/JJ accumulation/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN in/IN the/DT nucleus/NN of/IN Namalwa/NN B/NN lymphoid/JJ cells/NNS ,/, which/WDT constitutively/RB express/VBP Tax/NN ./. 
In/IN contrast/NN ,/, NF-kappa/NN B/NN activity/NN was/VBD not/RB detected/VBN in/IN the/DT nucleus/NN following/VBG long-term/JJ expression/NN of/IN Tax/NN in/IN Jurkat/NN T/NN lymphocytes/NNS ./. 
The/DT ability/NN of/IN both/CC mitogens/NNS and/CC cytokines/NNS to/TO activate/VB NF-kappa/NN B/NN was/VBD also/RB blocked/VBN in/IN Jurkat/NN cells/NNS constitutively/RB expressing/VBG Tax/NN ./. 
However/RB ,/, the/DT activation/NN of/IN other/JJ mitogen-inducible/JJ transcription/NN factors/NNS ,/, such/JJ as/IN Fos/NN and/CC Jun/NN ,/, was/VBD unaffected/JJ ./. 
Thus/RB ,/, depending/VBG on/IN the/DT cellular/JJ environment/NN ,/, the/DT short-/JJ and/CC long-term/JJ effects/NNS of/IN Tax/NN expression/NN can/MD be/VB quite/RB different/JJ ./. 
Consequently/RB ,/, one/CD function/NN of/IN Tax/NN in/IN cells/NNS infected/VBN with/IN HTLV-I/NN might/MD involve/VB cell-type-specific/JJ suppression/NN ,/, as/IN opposed/VBN to/TO activation/NN ,/, of/IN distinct/JJ signal/NN pathways/NNS ./. 
The/DT cells/NNS lines/NNS described/VBN here/RB should/MD be/VB useful/JJ for/IN the/DT delineation/NN of/IN signaling/NN pathways/NNS utilized/VBN in/IN the/DT selective/JJ regulation/NN of/IN gene/NN expression/NN ./. 
UI/LS -/: 91041706/CD 
TI/LS -/: Interferon-gamma/NN and/CC the/DT sexual/JJ dimorphism/NN of/IN autoimmunity/NN ./. 
AB/LS -/: The/DT sexual/JJ difference/NN in/IN the/DT incidence/NN of/IN autoimmune/JJ diseases/NNS has/VBZ remained/VBN an/DT enigma/NN for/IN many/JJ years/NNS ./. 
In/IN the/DT examination/NN of/IN the/DT induction/NN of/IN autoimmunity/NN in/IN transgenic/JJ mice/NNS ,/, evidence/NN has/VBZ been/VBN obtained/VBN further/JJ implicating/VBG the/DT lymphokine/NN interferon-gamma/NN in/IN the/DT etiology/NN of/IN autoimmunity/NN ./. 
Sex/NN steroid/NN regulation/NN of/IN the/DT production/NN of/IN this/DT molecule/NN ,/, as/RB well/RB as/IN other/JJ cytokines/NNS ,/, may/MD help/VB explain/VB the/DT gender-specific/JJ differences/NNS in/IN the/DT immune/JJ system/NN ,/, including/VBG autoimmunity/NN ./. 
UI/LS -/: 90302010/CD 
TI/LS -/: Cloning/NN of/IN a/DT transcriptionally/RB active/JJ human/JJ TATA/NN binding/NN factor/NN ./. 
AB/LS -/: Transcription/NN factor/NN IID/NN (/( TFIID/NN )/) binds/VBZ to/TO the/DT TATA/NN box/NN promoter/NN element/NN and/CC regulates/VBZ the/DT expression/NN of/IN most/JJS eukaryotic/JJ genes/NNS transcribed/VBN by/IN RNA/NN polymerase/NN II/CD ./. 
Complementary/JJ DNA/NN (/( cDNA/NN )/) encoding/VBG a/DT human/JJ TFIID/NN protein/NN has/VBZ been/VBN cloned/VBN ./. 
The/DT human/JJ TFIID/NN polypeptide/NN has/VBZ 339/CD amino/NN acids/NNS and/CC a/DT molecular/JJ size/NN of/IN 37,745/CD daltons/NNS ./. 
The/DT carboxyl-terminal/JJ 181/CD amino/NN acids/NNS of/IN the/DT human/JJ TFIID/NN protein/NN shares/VBZ 80/CD %/NN identity/NN with/IN the/DT TFIID/NN protein/NN from/IN Saccharomyces/FW cerevisiae/FW ./. 
The/DT amino/NN terminus/NN contains/VBZ an/DT unusual/JJ repeat/NN of/IN 38/CD consecutive/JJ glutamine/NN residues/NNS and/CC an/DT X-Thr-Pro/NN repeat/NN ./. 
Expression/NN of/IN DNA/NN in/IN reticulocyte/NN lysates/NNS or/CC in/IN Escherichia/FW coli/FW yielded/VBD a/DT protein/NN that/WDT was/VBD competent/JJ for/IN both/CC DNA/NN binding/NN and/CC transcription/NN activation/NN ./. 
UI/LS -/: 91208110/CD 
TI/LS -/: A/DT novel/JJ T-cell/NN trans-activator/NN that/WDT recognizes/VBZ a/DT phorbol/NN ester-inducible/JJ element/NN of/IN the/DT interleukin-2/NN promoter/NN ./. 
AB/LS -/: The/DT interleukin/NN 2/CD (/( IL-2/NN )/) gene/NN promoter/NN is/VBZ recognized/VBN by/IN several/JJ cell-type-specific/JJ and/CC ubiquitous/JJ transcriptional/JJ regulators/NNS that/WDT integrate/VBP information/NN transmitted/VBN by/IN various/JJ signaling/NN systems/NNS leading/VBG to/TO IL-2/NN production/NN and/CC T-cell/NN activation/NN ./. 
Using/VBG a/DT combination/NN of/IN transfection/NN ,/, protein-DNA/JJ binding/NN ,/, and/CC in/FW vitro/FW transcription/NN methods/NNS ,/, we/PRP have/VBP discovered/VBN the/DT novel/JJ T-cell-specific/JJ transcriptional/JJ activator/NN TCF-1/NN (/( for/IN T-Cell/NN Factor-1/NN )/) ,/, which/WDT recognizes/VBZ a/DT T-cell-specific/JJ response/NN element/NN (/( TCE/NN )/) located/JJ within/IN the/DT IL-2/NN promoter/NN ./. 
Although/IN the/DT TCE/NN is/VBZ similar/JJ in/IN sequence/NN to/TO a/DT consensus/NN NF/NN kappa/NN B/NN site/NN ,/, several/JJ criteria/NNS indicate/VBP that/IN TCF-1/NN is/VBZ distinct/JJ from/IN NF/NN kappa/NN B/NN ./. 
However/RB ,/, like/IN NF/NN kappa/NN B/NN ,/, TCF-1/NN activity/NN is/VBZ induced/VBN by/IN phorbol/NN esters/NNS and/CC other/JJ T-cell/NN activators/NNS ./. 
UI/LS -/: 90199680/CD 
TI/LS -/: Risk/NN factors/NNS for/IN breast/NN recurrence/NN in/IN premenopausal/JJ and/CC postmenopausal/JJ patients/NNS with/IN ductal/JJ cancers/NNS treated/VBN by/IN conservation/NN therapy/NN ./. 
AB/LS -/: Risk/NN factors/NNS for/IN local/JJ failure/NN were/VBD evaluated/VBN for/IN 496/CD clinical/JJ Stage/NN I-II/CD patients/NNS with/IN infiltrating/JJ ductal/JJ carcinomas/NNS (/( median/NN follow-up/NN ,/, 71/CD months/NNS )/) treated/VBN by/IN conservative/JJ surgery/NN and/CC radiotherapy/NN ./. 
Monofactorial/JJ analysis/NN identified/VBD the/DT following/JJ factors/NNS to/TO be/VB correlated/VBN with/IN increased/VBN risk/NN :/: moderate/marked/JJ mononuclear/JJ cell/NN reaction/NN (/( MCR/NN )/) ,/, high/JJ histologic/JJ grade/NN (/( G/NN )/) ,/, extensive/JJ intraductal/JJ component/NN (/( EIC/NN )/) ,/, tumor/NN necrosis/NN ,/, macroscopic/JJ multiplicity/NN ,/, estrogen/NN receptor/NN negativity/NN ,/, anatomic/JJ tumor/NN size/NN ,/, age/NN younger/JJR than/IN 40/CD years/NNS ,/, and/CC vascular/JJ invasion/NN ./. 
Only/RB MCR/NN ,/, G/NN ,/, and/CC EIC/NN proved/VBD significant/JJ in/IN Cox/NN multivariate/JJ analysis/NN ./. 
These/DT risk/NN factors/NNS were/VBD highly/RB age/NN dependent/JJ ,/, with/IN EIC/NN markedly/RB more/RBR prevalent/JJ in/IN women/NNS younger/JJR than/IN 50/CD ,/, MCR/NN and/CC G/NN in/IN women/NNS younger/JJR than/IN 40/CD ./. 
Separate/JJ Cox/NN analysis/NN for/IN premenopausal/JJ patients/NNS showed/VBD that/IN MCR/EIC/NN determined/VBD risk/NN independent/JJ of/IN resection/NN margins/NNS :/: tumors/NNS with/IN MCR/NN had/VBD a/DT 28/CD %/NN ,/, and/CC with/IN EIC/NN a/DT 22/CD %/NN probability/NN of/IN recurring/VBG locally/RB by/IN 5/CD years/NNS ./. 
Premenopausal/JJ patients/NNS with/IN neither/DT risk/NN factor/NN had/VBD a/DT very/RB low/JJ failure/NN rate/NN (/( 2.6/CD %/NN at/IN 5/CD years/NNS )/) ,/, regardless/RB of/IN age/NN ./. 
For/IN postmenopausal/JJ patients/NNS risk/NN of/IN breast/NN recurrence/NN was/VBD determined/VBN both/CC by/IN adequacy/NN of/IN resection/NN margins/NNS and/CC grade/NN ,/, with/IN a/DT high/JJ local/JJ failure/NN rate/NN for/IN patients/NNS having/VBG G3/NN tumors/NNS with/IN positive/JJ or/CC indeterminate/JJ margins/NNS (/( 31/CD %/NN at/IN 5/CD years/NNS )/) ./. 
The/DT authors/NNS conclude/VBP that/IN the/DT microscopic/JJ examination/NN is/VBZ the/DT only/JJ useful/JJ tool/NN for/IN assessing/VBG the/DT risk/NN of/IN local/JJ failure/NN ,/, which/WDT is/VBZ quite/RB low/JJ for/IN the/DT majority/NN of/IN patients/NNS treated/VBN with/IN breast/NN conservation/NN ./. 
High-risk/JJ patients/NNS can/MD be/VB recognized/VBN morphologically/RB ./. 
The/DT age/NN dependence/NN of/IN morphologic/JJ risk/NN factors/NNS appears/VBZ to/TO explain/VB the/DT high/JJ local/JJ failure/NN rate/NN seen/VBN in/IN patients/NNS younger/JJR than/IN 40/CD ./. 
UI/LS -/: 90191722/CD 
TI/LS -/: Tax-independent/JJ binding/NN of/IN multiple/JJ cellular/JJ factors/NNS to/TO Tax-response/JJ element/NN DNA/NN of/IN HTLV-I/NN ./. 
AB/LS -/: The/DT human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) promoter/NN contains/VBZ three/CD copies/NNS of/IN imperfect/JJ repeats/NNS of/IN a/DT 21-base/JJ pair/NN sequence/NN designated/VBN here/RB as/IN TRE/NN (/( Tax-response/JJ element/NN )/) that/WDT is/VBZ responsive/JJ to/TO the/DT virally/RB encoded/VBN transactivator/NN protein/NN Tax/NN ./. 
We/PRP have/VBP identified/VBN and/CC separated/VBN four/CD nuclear/JJ proteins/NNS from/IN C81-66-45/NN cells/NNS ,/, an/DT HTLV-I/NN immortalized/JJ Tax-expressing/VBG human/JJ T-lymphocyte/NN line/NN (/( Salahuddin/NNP et/FW al./FW ,/, 1983/CD )/) ,/, that/WDT interact/VBP with/IN the/DT TRE-DNA/NN ,/, none/NN of/IN which/WDT are/VBP identical/JJ with/IN the/DT Tax-protein/NN ./. 
The/DT proteins/NNS identified/VBN have/VBP molecular/JJ weights/NNS of/IN about/RB 32/CD ,/, 36/CD to/TO 42/CD ,/, 50/CD and/CC 110/CD kD/NN ./. 
Four/CD different/JJ methods/NNS were/VBD used/VBN to/TO identify/VB the/DT proteins/NNS ./. 
First/RB ,/, from/IN different/JJ cell/NN lines/NNS three/CD or/CC all/DT four/CD of/IN the/DT nuclear/JJ proteins/NNS were/VBD specifically/RB cross-linked/VBN by/IN UV/NN irradiation/NN to/TO the/DT radioactively/RB labeled/VBN TRE-DNA/NN fragment/NN ./. 
Second/RB ,/, TRE-DNA/NN binding/NN proteins/NNS sedimented/VBD through/IN a/DT glycerol/NN density/NN gradient/NN at/IN rates/NNS corresponding/VBG to/TO proteins/NNS of/IN native/JJ molecular/JJ weights/NNS of/IN 35/CD to/TO 50/CD kD/NN and/CC 110/CD kD/NN ./. 
Third/RB ,/, only/RB the/DT 50/CD kD/NN protein/NN was/VBD retained/VBN on/IN a/DT biotinylated/VBN DNA-streptavidin/NN matrix/NN when/WRB the/DT DNA/NN fragment/NN contained/VBD the/DT TRE-DNA/NN ./. 
Fourth/RB ,/, extensive/JJ purification/NN by/IN several/JJ cycles/NNS of/IN TRE-DNA/JJ affinity/NN chromatography/NN resulted/VBD in/IN the/DT 32/CD ,/, 36/CD to/TO 42/CD and/CC 110/CD kD/NN proteins/NNS and/CC to/TO less/JJR extent/NN the/DT 50/CD kD/NN factor/NN ./. 
Two/CD abundant/JJ proteins/NNS of/IN 75/CD and/CC 80/CD kD/NN were/VBD competed/VBN out/RP by/IN poly[d(I-C)]/NN in/IN all/DT reactions/NNS ./. 
The/DT cAMP-response/JJ element/NN CRE/NN ,/, TGACGTCA/NN ,/, present/JJ in/IN the/DT 21/CD base-pair/NN sequence/NN ,/, appears/VBZ to/TO be/VB essential/JJ for/IN specific/JJ protein-TRE-DNA/JJ interactions/NNS because/IN mutation/NN of/IN the/DT two/CD G/NN 's/NNS destroys/VBZ this/DT complex/NN ./. 
This/DT result/NN suggests/VBZ that/IN the/DT cAMP/NN response/NN element/NN binding/NN protein/NN ,/, CREB/NN ,/, is/VBZ involved/VBN in/IN the/DT protein-TRE-DNA/JJ complex/NN and/CC in/IN mediating/VBG the/DT Tax/NN response/NN ./. 
UI/LS -/: 90140708/CD 
TI/LS -/: Two/CD distinct/JJ transcription/NN factors/NNS that/WDT bind/VBP the/DT immunoglobulin/NN enhancer/NN microE5/kappa/NN 2/CD motif/NN ./. 
AB/LS -/: Activity/NN of/IN the/DT immunoglobulin/NN heavy/JJ and/CC kappa/NN light/JJ chain/NN gene/NN enhancers/NNS depends/VBZ on/IN a/DT complex/JJ interplay/NN of/IN ubiquitous/JJ and/CC developmentally/RB regulated/VBN proteins/NNS ./. 
Two/CD complementary/JJ DNAs/NNS were/VBD isolated/VBN that/WDT encode/VBP proteins/NNS ,/, denoted/VBN ITF-1/NN and/CC ITF-2/NN ,/, that/WDT are/VBP expressed/VBN in/IN a/DT variety/NN of/IN cell/NN types/NNS and/CC bind/VBP the/DT microE5/kappa/NN 2/CD motif/NN found/VBN in/IN both/CC heavy/JJ and/CC kappa/NN light/JJ chain/NN enhancers/NNS ./. 
The/DT complementary/JJ DNAs/NNS are/VBP the/DT products/NNS of/IN distinct/JJ genes/NNS ,/, yet/CC both/CC ITF-1/NN and/CC ITF-2/NN are/VBP structurally/RB and/CC functionally/RB similar/JJ ./. 
The/DT two/CD proteins/NNS interact/VBP with/IN one/CD another/DT through/IN their/PRP$ putative/JJ helix-loop-helix/JJ motifs/NNS and/CC each/DT possesses/VBZ a/DT distinct/JJ domain/NN that/WDT dictates/VBZ transcription/NN activation/NN ./. 
UI/LS -/: 92077236/CD 
TI/LS -/: Elevated/JJ glucocorticoid/NN receptor/NN concentrations/NNS before/IN and/CC after/IN glucocorticoid/NN therapy/NN in/IN peripheral/JJ mononuclear/JJ leukocytes/NNS of/IN patients/NNS with/IN atopic/JJ dermatitis/NN ./. 
AB/LS -/: The/DT number/NN and/CC affinity/NN of/IN glucocorticoid/NN binding/NN sites/NNS in/IN peripheral/JJ mononuclear/JJ leukocytes/NNS of/IN patients/NNS with/IN atopic/JJ dermatitis/NN (/( AD/NN )/) and/CC healthy/JJ controls/NNS were/VBD determined/VBN under/IN baseline/NN conditions/NNS and/CC after/IN a/DT defined/VBN oral/JJ glucocorticoid/NN treatment/NN ./. 
Patients/NNS with/IN AD/NN (/( n/NN =/JJ 15/CD )/) exhibited/VBD significantly/RB more/JJR glucocorticoid/NN receptors/NNS (/( GR/NN )/) per/IN cell/NN than/IN the/DT control/NN group/NN (/( n/NN =/JJ 22/CD )/) ,/, while/IN the/DT GR/NN affinity/NN did/VBD not/RB differ/VB ./. 
Methylprednisolone/NN treatment/NN resulted/VBD in/IN a/DT significant/JJ reduction/NN of/IN the/DT GR/NN sites/NNS per/IN cell/NN in/IN the/DT steroid-treated/JJ control/NN group/NN (/( n/NN =/JJ 10/CD )/) in/IN contrast/NN to/TO the/DT patients/NNS ./. 
The/DT dissociation/NN constant/NN was/VBD not/RB affected/VBN by/IN methylprednisolone/JJ treatment/NN in/IN either/DT group/NN ./. 
In/IN view/NN of/IN the/DT therapeutic/JJ efficiency/NN of/IN glucocorticoids/NNS in/IN AD/NN and/CC findings/NNS of/IN abnormal/JJ cAMP/NN and/CC cAMP-phosphodiesterase/NN activity/NN ,/, the/DT elevated/JJ GR/NN concentrations/NNS in/IN AD/NN lend/VBP support/NN to/TO the/DT hypothesis/NN of/IN a/DT compensatory/JJ GR/NN upregulation/NN due/JJ to/TO an/DT insufficient/JJ action/NN of/IN endogenous/JJ cortisol/NN or/CC to/TO altered/JJ cAMP-induced/JJ GR/NN expression/NN ./. 
UI/LS -/: 91092267/CD 
TI/LS -/: The/DT actions/NNS of/IN cyclosporin/NN A/NN and/CC FK506/NN suggest/VBP a/DT novel/JJ step/NN in/IN the/DT activation/NN of/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: Cyclosporin/NN A/NN and/CC FK506/NN are/VBP immunosuppressive/JJ compounds/NNS that/WDT have/VBP similar/JJ inhibitory/JJ effects/NNS on/IN the/DT expression/NN of/IN several/JJ lymphokines/NNS produced/VBN by/IN T/NN lymphocytes/NNS ./. 
Despite/IN their/PRP$ similar/JJ effects/NNS the/DT drugs/NNS bind/VBP to/TO two/CD different/JJ cytosolic/JJ protein/NN ,/, cyclophilin/NN and/CC FKBP/NN respectively/RB ,/, which/WDT raises/VBZ the/DT possibility/NN that/IN they/PRP have/VBP different/JJ modes/NNS of/IN action/NN ./. 
Using/VBG constructs/NNS in/IN which/WDT mRNA/NN production/NN controlled/VBN by/IN a/DT specific/JJ transcription/NN factor/NN could/MD be/VB readily/RB measured/VBN we/PRP found/VBD that/IN both/CC cyclosporin/NN A/NN and/CC FK506/NN completely/RB inhibited/VBD transcription/NN activated/VBN by/IN NF-AT/NN ,/, NFIL2/NN A/NN ,/, NFIL2/NN B/NN and/CC partially/RB inhibited/VBD transcription/NN activated/VBN by/IN NF/NN kappa/NN B/NN ./. 
Cyclosporin/NN A/NN and/CC FK506/NN inhibited/VBD only/RB transcriptional/JJ activation/NN that/WDT was/VBD dependent/JJ on/IN Ca2+/NN mobilization/NN ./. 
However/RB ,/, cyclosporin/NN A/NN and/CC FK506/NN did/VBD not/RB inhibit/VB Ca2+/NN mobilization/NN dependent/JJ expression/NN of/IN c-fos/NN mRNA/NN indicating/VBG that/IN only/RB a/DT subset/NN of/IN signalling/NN pathways/NNS regulated/VBN by/IN Ca2+/NN is/VBZ sensitive/JJ to/TO these/DT drugs/NNS ./. 
Furthermore/RB ,/, we/PRP did/VBD not/RB observe/VB any/DT qualitative/JJ differences/NNS between/IN the/DT effect/NN of/IN cyclosporin/NN A/NN and/CC FK506/NN on/IN six/CD different/JJ transcription/NN factors/NNS which/WDT suggests/VBZ that/IN these/DT drugs/NNS may/MD interfere/VB with/IN the/DT activity/NN of/IN a/DT novel/JJ Ca2+/NN dependent/JJ step/NN that/WDT regulates/VBZ several/JJ transcription/NN factors/NNS ./. 
UI/LS -/: 90376447/CD 
TI/LS -/: The/DT internal/JJ methionine/NN codons/NNS of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN II/CD rex/NN gene/NN are/VBP not/RB required/VBN for/IN p24rex/NN production/NN or/CC virus/NN replication/NN and/CC transformation/NN ./. 
AB/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN types/NNS I/CD (/( HTLV-I/NN )/) and/CC II/CD (/( HTLV-II/NN )/) have/VBP two/CD nonstructural/JJ trans-acting/JJ regulatory/JJ genes/NNS ,/, tax/NN and/CC rex/NN ,/, located/JJ in/IN the/DT 3'/JJ region/NN of/IN the/DT viral/JJ genome/NN ./. 
The/DT tax/NN gene/NN product/NN (/( HTLV-I/NN p40tax/NN and/CC HTLV-II/NN p37tax/NN )/) is/VBZ the/DT transcriptional/JJ activator/NN of/IN the/DT viral/JJ long/JJ terminal/JJ repeat/NN ./. 
The/DT rex/NN gene/NN encodes/VBZ two/CD protein/NN products/NNS ,/, p27rex/p21rex/NN and/CC p26rex/p24rex/NN in/IN HTLV-I/NN and/CC HTLV-II/NN ,/, respectively/RB ./. 
Rex/NN acts/VBZ posttranscriptionally/RB to/TO facilitate/VB accumulation/NN of/IN full-length/JJ gag/pol/NN and/CC singly/RB spliced/VBN env/NN mRNA/NN in/IN the/DT cytoplasm/NN of/IN HTLV-infected/JJ cells/NNS ./. 
Previous/JJ studies/NNS showed/VBD that/IN the/DT first/JJ ATG/NN of/IN the/DT rex/NN gene/NN is/VBZ critical/JJ for/IN Rex/NN production/NN and/CC function/NN ./. 
The/DT importance/NN of/IN the/DT internal/JJ ATGs/NNS to/TO Rex/NN function/NN is/VBZ not/RB known/VBN ./. 
However/RB ,/, in/FW vitro/FW mutagenesis/NN of/IN the/DT HTLV-I/NN rex/NN gene/NN has/VBZ provided/VBN indirect/JJ evidence/NN which/WDT suggests/VBZ that/IN p21rex/NN ,/, and/CC by/IN analogy/NN HTLV-II/NN p24rex/NN ,/, results/VBZ from/IN initiation/NN at/IN an/DT internal/JJ AUG/NN of/IN the/DT tax/rex/NN mRNA/NN ./. 
By/IN using/VBG an/DT infectious/JJ molecular/JJ clone/NN of/IN HTLV-II/NN ,/, we/PRP investigated/VBD the/DT importance/NN of/IN the/DT internal/JJ ATGs/NNS of/IN the/DT rex/NN gene/NN on/IN Rex/NN protein/NN production/NN and/CC function/NN ./. 
Our/PRP$ results/NNS indicate/VBP that/IN p24rex/NN of/IN HTLV-II/NN is/VBZ not/RB initiated/VBN at/IN an/DT internal/JJ AUG/NN and/CC that/IN the/DT internal/JJ methionine/NN codons/NNS are/VBP not/RB crucial/JJ to/TO the/DT function/NN of/IN the/DT rex/NN gene/NN and/CC ,/, ultimately/RB ,/, the/DT transforming/NN properties/NNS of/IN the/DT virus/NN ./. 
UI/LS -/: 91016834/CD 
TI/LS -/: Astrocytes/NNS and/CC glioblastoma/NN cells/NNS express/VBP novel/JJ octamer-DNA/NN binding/NN proteins/NNS distinct/JJ from/IN the/DT ubiquitous/JJ Oct-1/NN and/CC B/NN cell/NN type/NN Oct-2/NN proteins/NNS ./. 
AB/LS -/: The/DT '/`` octamer/NN '/'' sequence/NN ,/, ATGCAAAT/NN or/CC its/PRP$ complement/NN ATTTGCAT/NN ,/, is/VBZ a/DT key/JJ element/NN for/IN the/DT transcriptional/JJ regulation/NN of/IN immunoglobulin/NN genes/NNS in/IN B-lymphocytes/NNS as/RB well/RB as/IN a/DT number/NN of/IN housekeeping/JJ genes/NNS in/IN all/DT cell/NN types/NNS ./. 
In/IN lymphocytes/NNS ,/, the/DT octamer-binding/JJ protein/NN Oct-2A/NN and/CC variants/NNS thereof/RB are/VBP thought/VBN to/TO contribute/VB to/TO the/DT B-cell/NN specific/JJ gene/NN expression/NN ,/, while/IN the/DT ubiquitous/JJ protein/NN Oct-1/NN seems/VBZ to/TO control/VB general/JJ octamer/NN site-dependent/JJ transcription/NN ./. 
Various/JJ other/JJ genes/NNS ,/, for/IN example/NN interleukin-1/NN and/CC MHC/NN class/NN II/CD genes/NNS ,/, contain/VBP an/DT octamer/NN sequence/NN in/IN the/DT promoter/NN and/CC are/VBP expressed/VBN in/IN cells/NNS of/IN both/CC the/DT immune/JJ and/CC nervous/JJ systems/NNS ./. 
This/DT prompted/VBD us/PRP to/TO analyze/VB the/DT octamer-binding/JJ proteins/NNS in/IN the/DT latter/JJ cells/NNS ./. 
Using/VBG the/DT electrophoretic/JJ mobility/NN shift/NN assay/NN ,/, at/IN least/JJS six/CD novel/JJ octamer/NN binding/NN proteins/NNS were/VBD detected/VBN in/IN nuclear/JJ extracts/NNS of/IN cultured/VBN mouse/NN astrocytes/NNS ./. 
These/DT proteins/NNS are/VBP differentially/RB expressed/VBN in/IN human/JJ glioblastoma/NN and/CC neuroblastoma/NN cell/NN lines/NNS ./. 
The/DT nervous/JJ system-derived/JJ (/( N-Oct/NN )/) proteins/NNS bound/VBD to/TO the/DT octamer/NN DNA/NN sequence/NN in/IN a/DT manner/NN which/WDT is/VBZ indistinguishable/JJ from/IN the/DT Oct-1/NN and/CC Oct-2A/NN proteins/NNS ./. 
The/DT relationship/NN of/IN the/DT N-Oct/NN proteins/NNS to/TO Oct-1/NN and/CC Oct-2A/NN was/VBD analyzed/VBN by/IN proteolytic/JJ clipping/JJ bandshift/NN assays/NNS and/CC by/IN their/PRP$ reactivity/NN towards/IN antisera/NNS raised/VBN against/IN recombinant/JJ Oct-1/NN and/CC Oct-2A/NN proteins/NNS ./. 
On/IN the/DT basis/NN of/IN these/DT assays/NNS ,/, all/DT N-Oct-factors/NNS were/VBD found/VBN to/TO be/VB distinct/JJ from/IN the/DT ubiquitous/JJ Oct-1/NN and/CC the/DT lymphoid-specific/JJ Oct-2A/NN proteins/NNS ./. 
In/IN melanoma/NN cells/NNS that/WDT contain/VBP the/DT N-Oct-3/NN factor/NN ,/, a/DT transfected/VBN lymphocyte-specific/JJ promoter/NN was/VBD neither/CC activated/VBN nor/CC was/VBD it/PRP repressed/VBN upon/IN contransfection/NN with/IN an/DT Oct-2A/NN expression/NN vector/NN ./. 
We/PRP therefore/RB speculate/VBP that/IN N-Oct-3/NN and/CC other/JJ N-Oct/NN factors/NNS have/VBP a/DT specific/JJ role/NN in/IN gene/NN expression/NN in/IN cells/NNS of/IN the/DT nervous/JJ system/NN ./. 
UI/LS -/: 90351381/CD 
TI/LS -/: Detection/NN in/IN non-erythroid/JJ cells/NNS of/IN a/DT factor/NN with/IN the/DT binding/NN characteristics/NNS of/IN the/DT erythroid/JJ cell/NN transcription/NN factor/NN EF1/NN ./. 
AB/LS -/: The/DT erythroid/JJ transcription/NN factor/NN erythroid/JJ factor-1/NN (/( EF1/NN )/) plays/VBZ a/DT critical/JJ role/NN in/IN the/DT transcription/NN of/IN erythroid-specific/JJ genes/NNS ./. 
Here/RB we/PRP report/VBP the/DT presence/NN of/IN a/DT factor/NN with/IN the/DT mobility/NN and/CC sequence-specific/JJ DNA-binding/JJ characteristics/NNS of/IN EF1/NN at/IN low/JJ abundance/NN in/IN a/DT wide/JJ variety/NN of/IN non-erythroid/JJ cell/NN types/NNS ./. 
This/DT is/VBZ the/DT first/JJ report/NN of/IN an/DT EF1-like/JJ activity/NN in/IN non-erythroid/JJ cells/NNS and/CC indicates/VBZ that/IN this/DT factor/NN may/MD play/VB a/DT role/NN in/IN the/DT regulation/NN of/IN genes/NNS expressed/VBN in/IN such/JJ cells/NNS ./. 
UI/LS -/: 90290483/CD 
TI/LS -/: Protein/NN kinase/NN inhibitor/NN H-7/NN blocks/VBZ accumulation/NN of/IN unspliced/JJ mRNA/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) ./. 
AB/LS -/: Rex/NN ,/, the/DT post-transcriptional/JJ regulator/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) ,/, is/VBZ known/VBN to/TO induce/VB accumulation/NN of/IN the/DT unspliced/JJ viral/JJ gag-pol/NN mRNA/NN ./. 
Rex/NN is/VBZ a/DT phosphoprotein/NN found/VBN in/IN the/DT cell/NN nucleolus/NN ,/, whose/WP$ function/NN may/MD be/VB regulated/VBN by/IN its/PRP$ localization/NN and/CC phosphorylation/NN ./. 
We/PRP have/VBP examined/VBN the/DT role/NN of/IN phosphorylation/NN on/IN Rex/NN function/NN by/IN using/VBG a/DT protein/NN kinase/NN inhibitor/NN ,/, H-7/NN [/( 1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine/NN ]/) ./. 
Treatment/NN of/IN an/DT HTLV-I/NN infected/JJ human/JJ T-cell/NN line/NN with/IN H-7/NN blocked/VBD specifically/RB accumulation/NN of/IN the/DT unspliced/JJ gag-pol/NN mRNA/NN ,/, resulting/VBG in/IN the/DT decreased/VBN Gag/NN protein/NN synthesis/NN that/WDT corresponds/VBZ with/IN the/DT decreased/VBN in/FW vivo/FW phosphorylation/NN of/IN Rex/NN ./. 
In/IN contrast/NN ,/, other/JJ viral/JJ and/CC cellular/JJ products/NNS have/VBP not/RB been/VBN influenced/VBN by/IN the/DT level/NN of/IN H-7/NN used/VBN ./. 
Therefore/RB ,/, the/DT phosphorylation/NN of/IN Rex/NN is/VBZ required/VBN for/IN the/DT viral/JJ RNA/NN partition/NN of/IN HTLV-I/NN ./. 
UI/LS -/: 90292959/CD 
TI/LS -/: Increased/VBN glucocorticoid/NN responsiveness/NN of/IN CD4+/JJ T-cell/NN clonal/JJ lines/NNS grown/VBN in/IN serum-free/JJ media/NNS ./. 
AB/LS -/: CEM-C7/NN ,/, a/DT human/JJ leukemic/JJ CD4+/JJ T-lymphocyte/NN cell/NN line/NN and/CC three/CD of/IN its/PRP$ subclones/NNS ,/, CEM-4R4/NN ,/, CEM-3R43/NN ,/, and/CC ICR-27/NN ,/, previously/RB cultured/VBN in/IN a/DT medium/NN supplemented/VBN with/IN 5/CD to/TO 10/CD %/NN fetal/JJ bovine/JJ serum/NN ,/, have/VBP been/VBN adapted/VBN to/TO serum-free/JJ media/NNS ./. 
The/DT best/JJS medium/NN of/IN those/DT tested/VBN was/VBD RPMI/NN 1640/CD supplemented/VBN with/IN 5/CD micrograms/ml/NNS each/DT transferrin/NN and/CC insulin/NN +/CC 5/CD ng/ml/NN sodium/NN selenite/NN +/-/CC 0.1/CD %/NN bovine/JJ serum/NN albumin/NN ./. 
While/IN growing/VBG either/CC with/IN or/CC without/IN albumin/NN ,/, the/DT several/JJ clonal/JJ lines/NNS of/IN CEM/NN cells/NNS displayed/VBD growth/NN similar/JJ to/TO serum-supplemented/JJ cultures/NNS ./. 
Cell/NN proliferation/NN of/IN CEM-C7/NN cells/NNS cultured/VBN in/IN both/DT serum-free/JJ media/NNS has/VBZ been/VBN sustained/JJ for/IN 3/CD mo./NN 
with/IN culture/NN doubling/VBG times/NNS of/IN about/RB 25/CD h/NN for/IN both/CC serum-supplemented/JJ and/CC serum-free/JJ cultures/NNS (/( viability/NN greater/JJR than/IN or/CC equal/JJ to/TO 90/CD %/NN )/) ./. 
Cell/NN morphology/NN remained/VBD essentially/RB the/DT same/JJ in/IN serum-free/JJ or/CC serum/NN containing/NN media/NNS ./. 
The/DT expression/NN of/IN CD4/NN ,/, a/DT marker/NN for/IN T-derived/JJ lymphoid/JJ cells/NNS ,/, was/VBD not/RB significantly/RB different/JJ in/IN serum-free/JJ medium/NN ./. 
When/WRB grown/VBN in/IN serum-free/JJ medium/NN ,/, CEM-C7/NN cells/NNS exhibited/VBD increased/VBN steroid/NN responsiveness/NN as/IN evidenced/VBN by/IN increased/VBN glucocorticoid/NN receptor/NN binding/NN sites/NNS ,/, increased/VBN induction/NN of/IN glutamine/NN synthetase/NN ,/, and/CC cell/NN lysis/NN at/IN lower/JJR concentrations/NNS of/IN steroid/NN ./. 
Receptor/NN mutant/NN subclones/NNS of/IN CEM-C7/NN ,/, which/WDT are/VBP proven/VBN to/TO be/VB completely/RB unresponsive/JJ to/TO micromolar/JJ concentrations/NNS of/IN dexamethasone/NN when/WRB grown/VBN in/IN serum-supplemented/JJ medium/NN ,/, become/VBP partially/RB sensitive/JJ to/TO the/DT hormone/NN after/IN growth/NN in/IN defined/VBN medium/NN ./. 
The/DT increased/VBN sensitivity/NN of/IN CEM-C7/NN cells/NNS and/CC its/PRP$ subclones/NNS to/TO dexamethasone/NN in/IN serum-free/JJ medium/NN returned/VBD to/TO previous/JJ levels/NNS when/WRB these/DT cells/NNS were/VBD recultured/VBN in/IN serum-containing/JJ medium/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN substances/NNS in/IN serum/NN influence/VBP steroid/NN effects/NNS on/IN these/DT cells/NNS and/CC that/IN the/DT molecular/JJ details/NNS of/IN glucocorticoid/NN hormone/NN action/NN may/MD be/VB pursued/VBN more/RBR precisely/RB in/IN a/DT clearly/RB defined/VBN culture/NN medium/NN ./. 
UI/LS -/: 90381807/CD 
TI/LS -/: [/( Glucocorticoid/NN receptors/NNS on/IN human/JJ peripheral/JJ mononuclear/JJ and/CC polymorphonuclear/JJ leucocytes/NNS :/: changes/NNS in/IN patients/NNS with/IN yang-deficiency/NN ]/) 
AB/LS -/: It/PRP was/VBD found/VBN that/IN ,/, in/IN former/JJ works/NNS ,/, the/DT glucocorticoid/NN receptors/NNS (/( GCR/NN )/) on/IN peripheral/JJ mixed/JJ leucocytes/NNS in/IN patients/NNS with/IN Yang-deficiency/NN were/VBD decreased/VBN ./. 
In/IN this/DT work/NN ,/, the/DT mixed/JJ leucocytes/NNS were/VBD further/RB separated/VBN into/IN mononuclear/JJ (/( MNL/NN )/) and/CC polymorphonuclear/NN (/( PML/NN )/) leucocytes/NNS ,/, and/CC GCR/NN were/VBD determined/VBN in/IN each/DT part/NN of/IN leucocytes/NNS ./. 
GCR/NN on/IN MNL/NN and/CC PML/NN in/IN 6/CD Yang/NN deficient/JJ patients/NNS were/VBD 3473/CD +/-/CC 413/CD and/CC 4433/CD +/-/CC 651/CD sites/cell/NNS respectively/RB ,/, statistically/RB significant/JJ from/IN the/DT normal/JJ control/JJ group/NN (/( 4462/CD +/-/CC 962/CD and/CC 5622/CD +/-/CC 782/CD sites/cell/NNS respectively/RB ,/, P/NN less/JJR than/IN 0.05/CD )/) ./. 
GCR/NN on/IN MNL/NN ,/, PML/NN and/CC mixed/JJ leucocytes/NNS in/IN 5/CD patients/NNS were/VBD determined/VBN simultaneously/RB ,/, and/CC all/DT lowered/VBD from/IN the/DT control/JJ group/NN ./. 
The/DT results/NNS were/VBD 3369/CD +/-/CC 370/CD ,/, 4986/CD +/-/CC 419/CD and/CC 4524/CD +/-/CC 852/CD sites/cell/NNS respectively/RB ,/, with/IN the/DT lowest/JJS GCR/NN on/IN MNL/NN and/CC highest/JJS on/IN PML/NN ./. 
UI/LS -/: 90158614/CD 
TI/LS -/: The/DT ubiquitous/JJ octamer-binding/JJ protein/NN (/( s/NNS )/) is/VBZ sufficient/JJ for/IN transcription/NN of/IN immunoglobulin/NN genes/NNS ./. 
AB/LS -/: All/DT immunoglobulin/NN genes/NNS contain/VBP a/DT conserved/VBN octanucleotide/NN promoter/NN element/NN ,/, ATGCAAAT/NN ,/, which/WDT has/VBZ been/VBN shown/VBN to/TO be/VB required/VBN for/IN their/PRP$ normal/JJ B-cell-specific/JJ transcription/NN ./. 
Proteins/NNS that/WDT bind/VBP this/DT octamer/NN have/VBP been/VBN purified/VBN ,/, and/CC cDNAs/NNS encoding/VBG octamer-binding/JJ proteins/NNS have/VBP been/VBN cloned/VBN ./. 
Some/DT of/IN these/DT proteins/NNS (/( referred/VBN to/TO as/IN OTF-2/NN )/) are/VBP lymphoid/JJ specific/JJ ,/, whereas/IN at/IN least/JJS one/CD other/JJ ,/, and/CC possibly/RB more/JJR (/( referred/VBN to/TO as/IN OTF-1/NN )/) ,/, is/VBZ found/VBN ubiquitously/RB in/IN all/DT cell/NN types/NNS ./. 
The/DT exact/JJ role/NN of/IN these/DT different/JJ proteins/NNS in/IN directing/VBG the/DT tissue-specific/JJ expression/NN of/IN immunoglobulin/NN genes/NNS is/VBZ unclear/JJ ./. 
We/PRP have/VBP identified/VBN two/CD human/JJ pre-B-cell/NN lines/NNS that/WDT contain/VBP extremely/RB low/JJ levels/NNS of/IN OTF-2/NN yet/CC still/RB express/VBP high/JJ levels/NNS of/IN steady-state/JJ immunoglobulin/NN heavy-chain/JJ mRNA/NN in/FW vivo/FW and/CC efficiently/RB transcribe/VBP an/DT immunoglobulin/NN gene/NN in/FW vitro/FW ./. 
Addition/NN of/IN a/DT highly/RB enriched/JJ preparation/NN of/IN OTF-1/NN made/VBN from/IN one/CD of/IN these/DT pre-B/NN cells/NNS or/CC from/IN HeLa/NN cells/NNS specifically/RB stimulated/VBD in/FW vitro/FW transcription/NN of/IN an/DT immunoglobulin/NN gene/NN ./. 
Furthermore/RB ,/, OFT-1/NN appeared/VBD to/TO have/VB approximately/RB the/DT same/JJ transactivation/NN ability/NN as/IN OTF-2/NN when/WRB normalized/VBN for/IN binding/NN activity/NN ./. 
These/DT results/NNS suggest/VBP that/IN OTF-1/NN ,/, without/IN OTF-2/NN ,/, is/VBZ sufficient/JJ for/IN transcription/NN of/IN immunoglobulin/NN genes/NNS and/CC that/IN OTF-2/NN alone/RB is/VBZ not/RB responsible/JJ for/IN the/DT B-cell-specific/JJ regulation/NN of/IN immunoglobulin/NN gene/NN expression/NN ./. 
UI/LS -/: 90205027/CD 
TI/LS -/: Effects/NNS of/IN aldosterone/NN on/IN intralymphocytic/JJ sodium/NN and/CC potassium/NN in/IN patients/NNS with/IN essential/JJ hypertension/NN ./. 
AB/LS -/: In/FW vitro/FW binding/NN of/IN aldosterone/NN to/TO mineralocorticoid/NN receptors/NNS on/IN human/JJ mononuclear/JJ leukocytes/NNS (/( HML/NNS )/) and/CC its/PRP$ effects/NNS on/IN the/DT intracellular/JJ sodium/NN and/CC potassium/NN concentrations/NNS of/IN HML/NNS have/VBP already/RB been/VBN described/VBN ./. 
In/IN the/DT present/JJ paper/NN this/DT easily/RB accessible/JJ human/JJ cell/NN model/NN was/VBD investigated/VBN in/IN 13/CD patients/NNS with/IN essential/JJ hypertension/NN ./. 
In/IN only/RB four/CD patients/NNS sodium/NN in/RP HML/NNS without/IN incubation/NN was/VBD elevated/JJ compared/VBN with/IN the/DT range/NN for/IN normal/JJ persons/NNS ./. 
A/DT decrease/NN of/IN intracellular/JJ sodium/NN or/CC potassium/NN occurred/VBD during/IN incubation/NN without/IN aldosterone/NN (/( P/NN less/JJR than/IN 0.02/CD )/) ./. 
The/DT addition/NN of/IN 1.4/CD nM/NN aldosterone/NN did/VBD not/RB prevent/VB this/DT loss/NN of/IN electrolytes/NNS as/IN observed/VBN in/IN normal/JJ persons/NNS ./. 
Plasma/NN renin/NN activity/NN and/CC aldosterone/NN were/VBD not/RB correlated/VBN with/IN the/DT electrolyte/NN response/NN and/CC were/VBD within/IN the/DT normal/JJ limits/NNS ./. 
The/DT number/NN of/IN mineralocorticoid/NN receptors/cell/NN were/VBD within/IN or/CC close/JJ to/TO the/DT normal/JJ range/NN (/( n/NN =/JJ 9/CD )/) ./. 
The/DT independence/NN of/IN intracellular/JJ electrolytes/NNS from/IN aldosterone/NN despite/IN a/DT normal/JJ number/NN of/IN mineralocorticoid/NN receptors/NNS may/MD reflect/VB an/DT impairment/NN of/IN the/DT mineralocorticoid/NN effector/NN mechanism/NN in/IN the/DT HML/NNS of/IN patients/NNS with/IN essential/JJ hypertension/NN ./. 
UI/LS -/: 91296472/CD 
TI/LS -/: [/( Differential/JJ diagnostic/JJ value/NN of/IN receptors/NNS of/IN 1,25-dihydroxyvitamin/NN D3/NN (/( calcitriol/NN )/) determination/NN in/IN lymphocytes/NNS of/IN children/NNS with/IN rickets/NN and/CC rickets-like/JJ diseases/NNS ]/) 
AB/LS -/: The/DT authors/NNS provide/VBP the/DT results/NNS of/IN studying/VBG 1,25-dihydroxyvitamin/NN D3/NN (/( calcitriol/NN )/) in/IN lymphocytes/NNS of/IN children/NNS with/IN rickets/NN and/CC rickets-like/JJ diseases/NNS ./. 
It/PRP is/VBZ proposed/VBN that/IN the/DT character/NN of/IN their/PRP$ expression/NN under/IN the/DT influence/NN of/IN vitamin/NN D/NN may/MD be/VB used/VBN with/IN differential/JJ diagnostic/JJ purposes/NNS in/IN view/NN ./. 
UI/LS -/: 91048014/CD 
TI/LS -/: Regulation/NN of/IN gene/NN expression/NN with/IN double-stranded/JJ phosphorothioate/NN oligonucleotides/NNS ./. 
AB/LS -/: Alteration/NN of/IN gene/NN transcription/NN by/IN inhibition/NN of/IN specific/JJ transcriptional/JJ regulatory/JJ proteins/NNS is/VBZ necessary/JJ for/IN determining/VBG how/WRB these/DT factors/NNS participate/VBP in/IN cellular/JJ differentiation/NN ./. 
The/DT functions/NNS of/IN these/DT proteins/NNS can/MD be/VB antagonized/VBN by/IN several/JJ methods/NNS ,/, each/DT with/IN specific/JJ limitations/NNS ./. 
Inhibition/NN of/IN sequence-specific/JJ DNA-binding/JJ proteins/NNS was/VBD achieved/VBN with/IN double-stranded/JJ (/( ds/JJ )/) phosphorothioate/NN oligonucleotides/NNS that/WDT contained/VBD octamer/NN or/CC kappa/NN B/NN consensus/NN sequences/NNS ./. 
The/DT phosphorothioate/NN oligonucleotides/NNS specifically/RB bound/VBD either/CC octamer/NN transcription/NN factor/NN or/CC nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN ./. 
The/DT modified/VBN oligonucleotides/NNS accumulated/VBD in/IN cells/NNS more/RBR effectively/RB than/IN standard/JJ ds/JJ oligonucleotides/NNS and/CC modulated/VBD gene/NN expression/NN in/IN a/DT specific/JJ manner/NN ./. 
Octamer-dependent/JJ activation/NN of/IN a/DT reporter/NN plasmid/NN or/CC NF-kappa/NN B-dependent/JJ activation/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) enhancer/NN was/VBD inhibited/VBN when/WRB the/DT appropriate/JJ phosphorothioate/NN oligonucleotide/NN was/VBD added/VBN to/TO a/DT transiently/RB transfected/VBN B/NN cell/NN line/NN ./. 
Addition/NN of/IN phosphorothioate/NN oligonucleotides/NNS that/WDT contained/VBD the/DT octamer/NN consensus/NN to/TO Jurkat/NN T/NN leukemia/NN cells/NNS inhibited/VBD interleukin-2/NN (/( IL-2/NN )/) secretion/NN to/TO a/DT degree/NN similar/JJ to/TO that/DT observed/VBN with/IN a/DT mutated/VBN octamer/NN site/NN in/IN the/DT IL-2/NN enhancer/NN ./. 
The/DT ds/JJ phosphorothioate/NN oligonucleotides/NNS probably/RB compete/VBP for/IN binding/NN of/IN specific/JJ transcription/NN factors/NNS and/CC may/MD provide/VB anti-viral/JJ ,/, immunosuppressive/JJ ,/, or/CC other/JJ therapeutic/JJ effects/NNS ./. 
UI/LS -/: 91098724/CD 
TI/LS -/: [/( Effect/NN of/IN the/DT regimen/NN of/IN kidney-tonifying/JJ and/CC qi-invigorating/JJ on/IN aging/NN changes/NNS of/IN glucocorticoid/NN receptor/NN ]/) 
AB/LS -/: The/DT plasma/NN cortisol/NN concentration/NN and/CC the/DT sites/NNS of/IN glucocorticoid/NN receptor/NN (/( GCR/NN )/) in/IN the/DT peripheral/JJ lymphocytes/NNS were/VBD measured/VBN in/IN 32/CD healthy/JJ aged/JJ persons/NNS and/CC 13/CD young/JJ adults/NNS ./. 
In/IN animal/JJ experiment/NN ,/, GCR/NN of/IN spleen/NN lymphocytic/JJ cell/NN was/VBD also/RB measured/VBN in/IN 18/CD aged/JJ rats/NNS and/CC 9/CD young/JJ rats/NNS ./. 
The/DT results/NNS showed/VBD that/IN GCR/NN was/VBD significantly/RB lower/JJR in/IN the/DT aged/JJ persons/NNS or/CC rats/NNS than/IN that/DT in/IN the/DT young/JJ while/IN the/DT plasma/NN cortisol/NN level/NN did/VBD n't/RB change/VB with/IN aging/NN ./. 
So/RB we/PRP think/VBP that/IN GCR/NN is/VBZ more/RBR sensitive/JJ than/IN the/DT plasma/NN cortisol/NN level/NN to/TO reflect/VB the/DT aging/NN change/NN of/IN the/DT adrenal/JJ cortex/NN function/NN ./. 
After/IN the/DT treatment/NN with/IN the/DT regimen/NN of/IN Kidney-tonifying/JJ and/CC Qi-invigorating/JJ ,/, the/DT GCR/NN of/IN the/DT aged/JJ persons/NNS and/CC rats/NNS was/VBD enhanced/VBN ,/, and/CC in/IN this/DT way/NN ,/, the/DT function/NN of/IN the/DT aged/JJ adrenal/JJ cortex/NN was/VBD improved/VBN ./. 
UI/LS -/: 90381353/CD 
TI/LS -/: Interferon/NN affects/VBZ nuclear/JJ proteins/NNS in/IN cells/NNS of/IN clinically/RB sensitive/JJ chronic/JJ myelogenous/JJ leukemia/NN patients/NNS ./. 
AB/LS -/: Cytoplasmic/JJ protein/NN extracts/NNS from/IN chronic/JJ myelogenous/JJ leukemia/NN (/( CML/NN )/) cells/NNS contained/VBD an/DT activity/NN that/WDT altered/VBD the/DT electrophoretic/JJ mobility/NN of/IN complexes/NNS formed/VBN between/IN nuclear/JJ proteins/NNS and/CC the/DT transcriptional/JJ enhancers/NNS of/IN interferon/NN (/( IFN/NN )/) -inducible/JJ genes/NNS ./. 
Exposure/NN of/IN CML/NN cells/NNS to/TO IFN-alpha/NN diminished/VBD the/DT effect/NN of/IN the/DT CML/NN cytoplasmic/JJ proteins/NNS on/IN these/DT nuclear/JJ protein-DNA/JJ complexes/NNS ./. 
The/DT presence/NN of/IN clinical/JJ responsiveness/NN to/TO IFN-alpha/NN correlated/VBD with/IN the/DT sensitivity/NN to/TO the/DT IFN-induced/JJ change/NN in/IN the/DT electrophoretic/JJ mobility/NN of/IN nuclear/JJ protein-DNA/JJ complexes/NNS ./. 
These/DT data/NNS suggest/VBP that/IN the/DT action/NN of/IN IFN-alpha/NN in/IN CML/NN may/MD be/VB linked/VBN to/TO a/DT pathway/NN that/WDT can/MD result/VB in/IN posttranslational/JJ modification/NN of/IN nuclear/JJ proteins/NNS ./. 
UI/LS -/: 90279073/CD 
TI/LS -/: Epstein-Barr/JJ virus/NN nuclear/JJ antigen/NN 2/CD transactivates/VBZ latent/JJ membrane/NN protein/NN LMP1/NN ./. 
AB/LS -/: Several/JJ lines/NNS of/IN evidence/NN are/VBP compatible/JJ with/IN the/DT hypothesis/NN that/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) nuclear/JJ antigen/NN 2/CD (/( EBNA-2/NN )/) or/CC leader/NN protein/NN (/( EBNA-LP/NN )/) affects/VBZ expression/NN of/IN the/DT EBV/NN latent/JJ infection/NN membrane/NN protein/NN LMP1/NN ./. 
We/PRP now/RB demonstrate/VBP the/DT following/NN ./. 
(/( i/LS )/) Acute/JJ transfection/NN and/CC expression/NN of/IN EBNA-2/NN under/IN control/NN of/IN simian/JJ virus/NN 40/CD or/CC Moloney/NN murine/JJ leukemia/NN virus/NN promoters/NNS resulted/VBD in/IN increased/VBN LMP1/NN expression/NN in/IN P3HR-1-infected/JJ Burkitt/NN 's/POS lymphoma/NN cells/NNS and/CC the/DT P3HR-1/NN or/CC Daudi/NN cell/NN line/NN ./. 
(/( ii/LS )/) Transfection/NN and/CC expression/NN of/IN EBNA-LP/NN alone/RB had/VBD no/DT effect/NN on/IN LMP1/NN expression/NN and/CC did/VBD not/RB act/VB synergistically/RB with/IN EBNA-2/NN to/TO affect/VB LMP1/NN expression/NN ./. 
(/( iii/LS )/) LMP1/NN expression/NN in/IN Daudi/NN and/CC P3HR-1-infected/JJ cells/NNS was/VBD controlled/VBN at/IN the/DT mRNA/NN level/NN ,/, and/CC EBNA-2/NN expression/NN in/IN Daudi/NN cells/NNS increased/VBD LMP1/NN mRNA/NN ./. 
(/( iv/LS )/) No/DT other/JJ EBV/NN genes/NNS were/VBD required/VBN for/IN EBNA-2/NN transactivation/NN of/IN LMP1/NN since/IN cotransfection/NN of/IN recombinant/JJ EBNA-2/NN expression/NN vectors/NNS and/CC genomic/JJ LMP1/NN DNA/NN fragments/NNS enhanced/VBD LMP1/NN expression/NN in/IN the/DT EBV-negative/JJ B-lymphoma/NN cell/NN lines/NNS BJAB/NN ,/, Louckes/NN ,/, and/CC BL30/NN ./. 
(/( v/LS )/) An/DT EBNA-2-responsive/JJ element/NN was/VBD found/VBN within/IN the/DT -512/CD to/TO +40/CD LMP1/NN DNA/NN since/IN this/DT DNA/NN linked/VBN to/TO a/DT chloramphenicol/NN acetyltransferase/NN reporter/NN gene/NN was/VBD transactivated/VBN by/IN cotransfection/NN with/IN an/DT EBNA-2/NN expression/NN vector/NN ./. 
(/( vi/LS )/) The/DT EBV/NN type/NN 2/CD EBNA-2/NN transactivated/VBD LMP1/NN as/RB well/RB as/IN the/DT EBV/NN type/NN 1/CD EBNA-2/NN ./. 
(/( vii/LS )/) Two/CD deletions/NNS within/IN the/DT EBNA-2/NN gene/NN which/WDT rendered/VBD EBV/NN transformation/NN incompetent/JJ did/VBD not/RB transactivate/VB LMP1/NN ,/, whereas/IN a/DT transformation-competent/JJ EBNA-2/NN deletion/NN mutant/NN did/VBD transactivate/VB LMP1/NN ./. 
LMP1/NN is/VBZ a/DT potent/JJ effector/NN of/IN B-lymphocyte/NN activation/NN and/CC can/MD act/VB synergistically/RB with/IN EBNA-2/NN to/TO induce/VB cellular/JJ CD23/NN gene/NN expression/NN ./. 
Thus/RB ,/, EBNA-2/NN transactivation/NN of/IN LMP1/NN amplifies/VBZ the/DT biological/JJ impact/NN of/IN EBNA-2/NN and/CC underscores/VBZ its/PRP$ central/JJ role/NN in/IN EBV-induced/JJ growth/NN transformation/NN ./. 
UI/LS -/: 90278097/CD 
TI/LS -/: The/DT expression/NN of/IN c-fos/NN ,/, c-jun/NN ,/, and/CC c-myc/NN genes/NNS is/VBZ regulated/VBN by/IN heat/NN shock/NN in/IN human/JJ lymphoid/JJ cells/NNS ./. 
AB/LS -/: The/DT effect/NN of/IN heat/NN shock/NN on/IN the/DT expression/NN of/IN the/DT nuclear/JJ protooncogenes/NNS c-fos/NN ,/, c-jun/NN ,/, and/CC c-myc/NN was/VBD studied/VBN in/IN human/JJ lymphoid/JJ cells/NNS ./. 
Heat/NN shock/NN caused/VBD an/DT increase/NN in/IN c-fos/NN and/CC c-jun/NN mRNA/NN levels/NNS and/CC a/DT decrease/NN in/IN c-myc/NN mRNA/NN levels/NNS in/IN pre-B/JJ (/( Hyon/NN )/) and/CC T/NN (/( DND-41/NN )/) cell/NN lines/NNS as/RB well/RB as/IN in/IN freshly/RB isolated/VBN normal/JJ human/JJ thymocytes/NNS ./. 
The/DT changes/NNS in/IN the/DT mRNA/NN levels/NNS of/IN these/DT protooncogenes/NNS in/IN Hyon/NN cells/NNS were/VBD most/RBS pronounced/JJ at/IN 42/CD and/CC 43/CD degrees/NNS C/NN ;/: kinetic/JJ analysis/NN demonstrated/VBD that/IN the/DT changes/NNS could/MD be/VB detected/VBN within/IN 30/CD min/NN of/IN heat/NN shock/NN ./. 
Altered/JJ transcription/NN of/IN c-fos/NN and/CC c-myc/NN genes/NNS was/VBD the/DT primary/JJ effect/NN of/IN heat/NN shock/NN ./. 
Secondarily/RB ,/, heat/NN shock/NN of/IN Hyon/NN cells/NNS stabilized/VBD the/DT c-myc/NN mRNA/NN level/NN by/IN increasing/VBG its/PRP$ half-life/NN from/IN 24/CD to/TO 45/CD min/NN ./. 
The/DT overall/JJ effect/NN of/IN heat/NN shock/NN on/IN c-myc/NN mRNA/NN level/NN ,/, however/RB ,/, was/VBD a/DT marked/JJ inhibition/NN of/IN its/PRP$ transcription/NN ./. 
These/DT results/NNS demonstrate/VBP that/IN the/DT transcription/NN of/IN nuclear/JJ protooncogenes/NNS is/VBZ regulated/VBN by/IN heat/NN shock/NN indicating/VBG a/DT role/NN for/IN nuclear/JJ protooncogenes/NNS in/IN the/DT stress/NN response/NN of/IN lymphoid/JJ cells/NNS ./. 
UI/LS -/: 90244394/CD 
TI/LS -/: Mapping/NN of/IN B-cell/NN epitopes/NNS of/IN the/DT human/JJ hepatitis/NN B/NN virus/NN X/NN protein/NN ./. 
AB/LS -/: The/DT immune/JJ response/NN to/TO the/DT X/NN protein/NN of/IN human/JJ hepatitis/NN B/NN virus/NN (/( HBV/NN )/) was/VBD studied/VBN by/IN epitope/NN mapping/NN by/IN using/VBG a/DT set/NN of/IN MS2-HBx/NN fusion/NN proteins/NNS and/CC synthetic/JJ peptides/NNS ./. 
Antibodies/NNS in/IN sera/NN of/IN patients/NNS with/IN acute/JJ and/CC chronic/JJ HBV/NN infection/NN showed/VBD a/DT multispecific/JJ immune/JJ response/NN ./. 
Each/DT serum/NN contained/VBD antibodies/NNS to/TO a/DT different/JJ set/NN of/IN epitopes/NNS ,/, which/WDT taken/VBN together/RB cover/VBP most/JJS of/IN the/DT HBx/NN sequence/NN ./. 
Some/DT of/IN the/DT epitopes/NNS were/VBD detectable/JJ only/RB by/IN immunoblotting/VBG with/IN fusion/NN proteins/NNS ;/: others/NNS were/VBD detectable/JJ only/RB by/IN an/DT enzyme-linked/JJ immunosorbent/JJ assay/NN (/( ELISA/NN )/) with/IN synthetic/JJ peptides/NNS ./. 
The/DT carboxy-terminal/JJ half/NN of/IN the/DT HBx/NN protein/NN was/VBD preferentially/RB recognized/VBN by/IN antibodies/NNS from/IN patients/NNS with/IN chronic/JJ hepatitis/NN and/CC contained/VBD a/DT short/JJ immunodominant/JJ antigenic/JJ region/NN with/IN at/IN least/JJS two/CD major/JJ nonoverlapping/JJ epitopes/NNS ./. 
Anti-HBx/JJ antibody/NN titers/NNS as/IN revealed/VBN by/IN peptide/NN ELISAs/NNS were/VBD highest/JJS and/CC most/RBS frequent/JJ in/IN patients/NNS with/IN chronic/JJ hepatitis/NN and/CC usually/RB low/JJ in/IN acutely/RB infected/JJ patients/NNS and/CC asymptomatic/JJ carriers/NNS ./. 
The/DT data/NNS demonstrate/VBP a/DT remarkable/JJ qualitative/JJ and/CC quantitative/JJ heterogeneity/NN of/IN the/DT humoral/JJ HBx/NN immune/JJ response/NN which/WDT can/MD be/VB monitored/VBN by/IN HBx-specific/JJ peptide/NN ELISAs/NNS ./. 
Such/JJ tests/NNS may/MD become/VB useful/JJ diagnostic/JJ tools/NNS ./. 
UI/LS -/: 90327113/CD 
TI/LS -/: [/( The/DT inhibitory/JJ effect/NN of/IN hydrocortisone/NN on/IN the/DT chemotactic/JJ migration/NN of/IN human/JJ leukocytes/NNS ]/) 
AB/LS -/: Random/JJ migration/NN (/( RM/NN )/) and/CC chemotactic/JJ migration/NN (/( ChtM/NN )/) of/IN human/JJ leukocytes/NNS to/TO yeast/NN activated/JJ serum/NN were/VBD studied/VBN with/IN the/DT modified/VBN Boyden/NN chamber/NN method/NN ./. 
Both/CC RM/NN and/CC ChtM/NN showed/VBD circadian/JJ rhythm/NN ./. 
Leukocytes/NNS migrated/VBD most/RBS rapidly/RB at/IN night/NN ./. 
The/DT difference/NN between/IN the/DT peak/NN (/( 0/CD :/: 00/CD )/) and/CC trough/NN values/NNS (/( 8/CD :/: 00/CD )/) of/IN RM/NN and/CC ChtM/NN was/VBD significant/JJ statistically/RB (/( P/NN less/JJR than/IN 0.01/CD )/) ./. 
ChtM/NN was/VBD inhibited/VBN by/IN hydrocortisone/NN (/( F/NN )/) of/IN physiological/JJ concentration/NN (/( 10/CD (/( -9/CD )/) -10/CD (/( -7/CD )/) mol/L/NN )/) which/WDT was/VBD dose-dependent/JJ and/CC completely/RB antagonized/VBN by/IN the/DT competitive/JJ antagonist/NN ,/, RU38486/NN ./. 
The/DT inhibitory/JJ effect/NN was/VBD much/RB more/RBR evident/JJ with/IN higher/JJR dose/NN (/( more/JJR than/IN 10/CD (/( -5/CD )/) mol/L/NN )/) and/CC it/PRP was/VBD also/RB reversed/VBN by/IN RU38486/NN ,/, but/CC only/RB partially/RB ./. 
It/PRP is/VBZ suggested/VBN that/IN glucocorticoids/NNS (/( GC/NN )/) may/MD be/VB a/DT physiological/JJ regulator/NN of/IN the/DT activity/NN of/IN leukocytes/NNS and/CC its/PRP$ inhibitory/JJ action/NN on/IN ChtM/NN may/MD be/VB involved/VBN in/IN antiinflammatory/JJ mechanisms/NNS of/IN GC/NN of/IN pharmacological/JJ doses/NNS ./. 
The/DT action/NN of/IN physiological/JJ and/CC pharmacological/JJ concentration/NN of/IN GC/NN may/MD be/VB mediated/VBN by/IN low/JJ affinity/NN specific/JJ binding/VBG sites/NNS of/IN glucocorticoid/NN receptors/NNS ./. 
UI/LS -/: 90277507/CD 
TI/LS -/: Heterogeneity/NN of/IN antigen/NN molecules/NNS recognized/VBN by/IN anti-tax1/JJ monoclonal/JJ antibody/NN Lt-4/NN in/IN cell/NN lines/NNS bearing/VBG human/JJ T/NN cell/NN leukemia/NN virus/NN type/NN I/CD and/CC related/JJ retroviruses/NNS ./. 
AB/LS -/: Using/VBG a/DT monoclonal/JJ antibody/NN ,/, Lt-4/NN ,/, directed/VBN against/IN human/JJ T/NN cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) trans-activator/NN (/( tax1/NN )/) antigen/NN ,/, we/PRP examined/VBD the/DT expression/NN of/IN tax1/NN and/CC related/JJ antigens/NNS in/IN a/DT variety/NN of/IN T/NN cell/NN lines/NNS bearing/VBG HTLV-I/NN and/CC related/JJ retroviruses/NNS ,/, simian/JJ T/NN cell/NN leukemia/NN virus/NN type/NN I/CD (/( STLV-I/NN )/) and/CC HTLV-II/NN ,/, by/IN immunofluorescence/NN and/CC immunoblot/NN assays/NNS ./. 
Lt-4/NN reacted/VBD with/IN all/DT HTLV-I-bearing/JJ cell/NN lines/NNS tested/VBN and/CC five/CD out/IN of/IN eight/CD simian/JJ cell/NN lines/NNS bearing/VBG STLV-I/NN ,/, but/CC not/RB with/IN an/DT HTLV-II-bearing/JJ cell/NN line/NN ./. 
Lt-4/NN detected/VBD 40/CD kd/NN tax1/NN antigen/NN molecules/NNS in/IN most/JJS HTLV-I/JJ -bearing/JJ cell/NN lines/NNS except/IN one/CD cell/NN line/NN that/WDT expressed/VBD 39/CD kd/NN tax1/NN antigen/NN ./. 
In/IN the/DT STLV-I-bearing/JJ T/NN cell/NN lines/NNS ,/, tax1-related/JJ antigen/NN molecules/NNS detected/VBN by/IN Lt-4/NN were/VBD heterogeneous/JJ ,/, having/VBG molecular/JJ weights/NNS in/IN the/DT range/NN of/IN 36-41/CD kd/NN ./. 
UI/LS -/: 90147621/CD 
TI/LS -/: Characterization/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD enhancer-binding/JJ proteins/NNS from/IN the/DT human/JJ T-cell/NN line/NN Jurkat/NN ./. 
AB/LS -/: The/DT transcription/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) is/VBZ under/IN the/DT control/NN of/IN cellular/JJ proteins/NNS that/WDT bind/VBP to/TO the/DT viral/JJ long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) ./. 
Among/IN the/DT protein-binding/JJ regions/NNS of/IN the/DT HIV-1/NN LTR/NN is/VBZ the/DT transcription-enhancer/JJ region/NN ./. 
We/PRP show/VBP that/IN at/IN least/JJS one/CD inducible/JJ ,/, C1/NN ,/, and/CC one/CD constitutive/JJ ,/, C2/NN ,/, protein/NN can/MD bind/VB to/TO the/DT HIV/NN enhancer/NN in/IN Jurkat/NN cells/NNS ./. 
The/DT two/CD proteins/NNS differ/VBP in/IN their/PRP$ surface/NN charge/NN ,/, since/IN they/PRP are/VBP separable/JJ by/IN anion-exchange/JJ chromatography/NN ./. 
Bivalent/JJ cations/NNS such/JJ as/IN Mg2+/NN and/CC Zn2+/NN differentially/RB affect/VBP their/PRP$ binding/NN to/TO oligonucleotides/NNS which/WDT contain/VBP the/DT HIV-enhancer/NN domain/NN ./. 
Both/CC C1/NN and/CC C2/NN proteins/NNS also/RB bind/VBP to/TO a/DT similar/JJ sequence/NN found/VBN in/IN the/DT interleukin-2-receptor/NN alpha-subunit/NN enhancer/NN ./. 
The/DT inducible/JJ C1/NN protein/NN was/VBD partially/RB purified/VBN by/IN three/CD chromatographic/JJ steps/NNS and/CC characterized/VBN by/IN u.v./NN cross-linking/NN as/IN a/DT 47/CD kDa/NN protein/NN ./. 
UI/LS -/: 91079526/CD 
TI/LS -/: Differences/NNS in/IN transcriptional/JJ enhancers/NNS of/IN HIV-1/NN and/CC HIV-2/NN ./. 
Response/NN to/TO T/NN cell/NN activation/NN signals/NNS ./. 
AB/LS -/: T/NN cell/NN activation/NN results/VBZ in/IN high/JJ levels/NNS of/IN HIV/NN replication/NN and/CC is/VBZ thought/VBN to/TO be/VB one/CD mechanism/NN leading/VBG to/TO the/DT conversion/NN from/IN latent/JJ to/TO active/JJ viral/JJ infection/NN ./. 
In/IN HIV-1/NN ,/, the/DT sequences/NNS that/WDT respond/VBP to/TO these/DT signaling/NN events/NNS are/VBP found/VBN in/IN the/DT long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) and/CC comprise/VBP the/DT transcriptional/JJ enhancer/NN ,/, which/WDT contains/VBZ two/CD conserved/VBN binding/VBG sites/NNS for/IN the/DT nuclear/JJ factor/NN kappa/NN B/NN (/( NF/NN kappa/NN B/NN )/) ./. 
The/DT corresponding/JJ region/NN in/IN the/DT second/JJ AIDS/NN retrovirus/NN ,/, HIV-2/NN ,/, contains/VBZ a/DT conserved/VBN and/CC a/DT divergent/JJ NF/NN kappa/NN B/NN binding/NN site/NN ./. 
We/PRP demonstrate/VBP that/IN the/DT HIV-1/NN LTR/NN responds/VBZ better/JJR than/IN the/DT HIV-2/NN LTR/NN to/TO T/NN cell/NN activation/NN signals/NNS ./. 
These/DT qualitative/JJ differences/NNS in/IN the/DT response/NN to/TO T/NN cell/NN activation/NN are/VBP reproduced/VBN not/RB only/RB when/WRB HIV-1/NN or/CC HIV-2/NN enhancers/NNS are/VBP placed/VBN upstream/RB of/IN a/DT heterologous/JJ promoter/NN but/CC also/RB when/WRB these/DT enhancers/NNS are/VBP switched/VBN between/IN their/PRP$ respective/JJ LTR/NN ./. 
In/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, NF/NN kappa/NN B/NN binds/VBZ to/TO both/CC conserved/VBN sites/NNS in/IN the/DT HIV-1/NN transcriptional/JJ enhancer/NN and/CC only/RB to/TO the/DT single/JJ conserved/VBN site/NN in/IN the/DT HIV-2/NN transcriptional/JJ enhancer/NN ./. 
Instead/RB of/IN NF/NN kappa/NN B/NN ,/, the/DT activator/NN protein/NN 3/CD binds/VBZ to/TO the/DT divergent/JJ site/NN in/IN HIV-2/NN ./. 
In/IN conclusion/NN ,/, HIV-1/NN and/CC HIV-2/NN are/VBP differentially/RB regulated/VBN by/IN T/NN cell/NN activation/NN signals/NNS ,/, and/CC this/DT difference/NN may/MD account/VB for/IN the/DT longer/JJR period/NN of/IN viral/JJ latency/NN observed/VBN with/IN HIV-2/NN than/IN with/IN HIV-1/NN infection/NN ./. 
UI/LS -/: 91036996/CD 
TI/LS -/: NF-X2/NN that/WDT binds/VBZ to/TO the/DT DRA/NN X2-box/NN is/VBZ activator/NN protein/NN 1/CD ./. 
Expression/NN cloning/NN of/IN c-Jun/NN ./. 
AB/LS -/: Human/JJ class/NN II/CD MHC/NN Ag/NN are/VBP a/DT family/NN of/IN cell/NN surface/NN glycoproteins/NNS ./. 
Their/PRP$ constitutive/JJ expression/NN is/VBZ limited/JJ to/TO B/NN lymphocytes/NNS and/CC thymic/JJ epithelial/JJ cells/NNS ./. 
In/IN many/JJ other/JJ cells/NNS their/PRP$ expression/NN can/MD be/VB induced/VBN by/IN IFN-gamma/NN ./. 
Conserved/VBN upstream/JJ promoter/NN sequences/NNS regulate/VBP this/DT tissue-specific/JJ expression/NN of/IN class/NN II/CD genes/NNS ./. 
In/IN the/DT DRA/NN promoter/NN ,/, one/CD of/IN these/DT cis-acting/JJ regulatory/JJ motifs/NNS is/VBZ the/DT X2-box/NN to/TO which/WDT nuclear/JJ factor/NN X2/NN (/( NF-X2/NN )/) binds/VBZ ./. 
Here/RB ,/, we/PRP present/VBP the/DT isolation/NN and/CC characterization/NN of/IN the/DT full-length/JJ cDNA/NN clone/NN encoding/VBG NF-X2/NN ./. 
This/DT cDNA/NN clone/NN was/VBD isolated/VBN by/IN expression/NN cDNA/NN cloning/NN ,/, and/CC encodes/VBZ the/DT human/JJ c-Jun/NN protein/NN ,/, which/WDT together/RB with/IN c-Fos/NN forms/VBZ the/DT heterodimeric/JJ activator/NN protein-1/NN transcription/NN complex/NN ./. 
Whereas/IN c-Fos/c-Jun/NN heterodimers/NNS do/VBP not/RB exist/VB in/IN B/NN cells/NNS ,/, they/PRP form/VBP and/CC bind/VBP to/TO the/DT X2-box/NN in/IN class/NN II/CD nonexpressing/JJ cells/NNS ./. 
Thus/RB ,/, c-Fos/c-Jun/NN heterodimers/NNS might/MD contribute/VB to/TO the/DT repression/NN of/IN DRA/NN gene/NN expression/NN ./. 
UI/LS -/: 91098050/CD 
TI/LS -/: Synthesis/NN of/IN 4,19-disubstituted/JJ derivatives/NNS of/IN DOC/NN ./. 
Radioreceptor/NN assay/NN of/IN some/DT corticosteroid/NN derivatives/NNS in/IN human/JJ mononuclear/JJ leukocytes/NNS ./. 
AB/LS -/: Several/JJ new/JJ 4,19-substituted/JJ steroids/NNS and/CC previously/RB synthesized/VBN corticosteroids/NNS were/VBD assayed/VBN for/IN affinity/NN to/TO type/NN 1/CD receptors/NNS in/IN human/JJ mononuclear/JJ leukocytes/NNS ./. 
11/CD beta,19-epoxy-4,21-dihydroxypregn-4-ene-3,20-dione/NN (/( 2/CD )/) was/VBD hydrogenated/VBN with/IN Pd-C/NN to/TO yield/VB a/DT mixture/NN of/IN all/DT four/CD dihydro/NN derivatives/NNS 5/CD ,/, accompanied/VBN by/IN 4,21-diacetoxy-11/NN beta,19-epoxy-3-hydroxypregnan-20-one/NN (/( 6/CD )/) and/CC 21-acetoxy-11/NN beta,19-epoxy-4-hydroxypregnane-3,20-dione/NN (/( 7/CD )/) ./. 
With/IN hot/JJ acetic/JJ +/CC p-toluenesulfonic/JJ acid/NN 5/CD underwent/VBD rearrangement/NN to/TO 21-acetoxy-11/NN beta,19-epoxypregn-5-ene-4,20-dione/NN (/( 8/CD )/) Pd-C/NN hydrogenation/NN of/IN 3,21-diacetoxy-5/NN beta,19-cyclopregna-2,9(11)-diene-4,20-dione/NN (/( 10/CD )/) gave/VBD 3,21-diacetoxy-5/NN beta,19-cyclopregn-5-ene-4,20-dione/NN (/( 11/CD )/) and/CC the/DT 9,11-dihydro/NN derivative/NN of/IN the/DT latter/JJ ./. 
Treatment/NN of/IN 10/CD with/IN warm/JJ HCl/NN furnished/JJ 19-chloro-4,21-dihydroxypregna-4,9(11)-diene-3,20-dione/NN (13)/CD ./. 
Pd-C/NN hydrogenation/NN of/IN its/PRP$ diacetate/NN 14/CD afforded/VBD the/DT 4,5-dihydro/NN derivative/NN 18, 19-chloro-21-acetoxypregn-9(11)-en-20-one/NN (/( 15/CD )/) ,/, its/PRP$ 4-acetoxy/NN derivative/NN 16/CD and/CC the/DT 3,4-diacetoxy/NN derivative/NN 17/CD ./. 
When/WRB tested/VBN in/IN a/DT radioreceptor/NN assay/NN in/IN human/JJ mononuclear/JJ leukocytes/NNS the/DT synthesized/VBN compounds/NNS showed/VBD only/RB low/JJ relative/JJ binding/NN affinities/NNS (/( RBA/NNS )/) to/TO type/NN 1/CD receptor/NN ,/, the/DT highest/JJS being/VBG 0.72/CD %/NN for/IN 13/CD (/( aldosterone/NN =/JJ 100/CD %/NN )/) ./. 
For/IN comparison/NN ,/, other/JJ RBA/NNS in/IN this/DT system/NN were/VBD :/: 19-noraldosterone/NN ,/, 20/CD %/NN ;/: 18-deoxyaldosterone/NN ,/, 5.8/CD %/NN ;/: 18-deoxy-19-noraldosterone/NN ,/, 4.7/CD %/NN ;/: 18,21-anhydroaldosterone/NN ,/, 0.37/CD %/NN ;/: 17-isoaldosterone/NN ,/, 7.6/CD %/NN and/CC apoaldosterone/NN ,/, 4.3/CD %/NN 
UI/LS -/: 90368794/CD 
TI/LS -/: Cell/NN type/NN specificity/NN and/CC activation/NN requirements/NNS for/IN NFAT-1/NN (/( nuclear/JJ factor/NN of/IN activated/VBN T-cells/NNS )/) transcriptional/JJ activity/NN determined/VBN by/IN a/DT new/JJ method/NN using/VBG transgenic/JJ mice/NNS to/TO assay/VB transcriptional/JJ activity/NN of/IN an/DT individual/JJ nuclear/JJ factor/NN ./. 
AB/LS -/: Nuclear/JJ factor/NN of/IN activated/VBN T-cells/NNS (/( NFAT-1/NN )/) is/VBZ a/DT transcription/NN factor/NN which/WDT is/VBZ considered/VBN to/TO be/VB an/DT important/JJ regulator/NN in/IN early/JJ T-cell/NN activation/NN ./. 
We/PRP have/VBP developed/VBN a/DT system/NN to/TO monitor/VB the/DT transcriptional/JJ activity/NN of/IN NFAT-1/NN at/IN the/DT single/JJ cell/NN level/NN in/IN whole/JJ animals/NNS ./. 
The/DT system/NN is/VBZ based/VBN on/IN the/DT use/NN of/IN an/DT oligomerized/JJ NFAT-1/NN binding/NN motif/NN that/WDT directs/VBZ transcription/NN of/IN SV40/NN T-antigen/NN in/IN transgenic/JJ mice/NNS ./. 
This/DT report/NN represents/VBZ the/DT first/JJ demonstration/NN that/IN a/DT multimerized/JJ short/JJ binding/VBG motif/NN can/MD function/VB appropriately/RB in/IN transgenic/JJ mice/NNS ./. 
NFAT-1/NN activity/NN had/VBD previously/RB been/VBN thought/VBN to/TO be/VB confined/VBN to/TO activated/VBN T-lymphocytes/NNS upon/IN release/NN of/IN intracellular/JJ calcium/NN ./. 
By/IN targeting/VBG NFAT-1-dependent/JJ gene/NN expression/NN in/IN transgenic/JJ mice/NNS we/PRP discovered/VBD new/JJ sites/NNS of/IN NFAT-1/NN activity/NN ./. 
Besides/IN in/IN T-lymphocytes/NNS NFAT-1/NN activity/NN could/MD also/RB be/VB induced/VBN in/IN T-lymphocyte-depleted/JJ spleen/NN cells/NNS and/CC purified/VBN B-lymphocytes/NNS and/CC requires/VBZ agents/NNS that/WDT both/CC release/VBP intracellular/JJ calcium/NN and/CC activate/VBP protein/NN kinase/NN C/NN ./. 
A/DT difference/NN in/IN the/DT time/NN course/NN of/IN appearance/NN of/IN NFAT-1/NN activity/NN between/IN T-lymphocytes/NNS and/CC non-T-lymphocytes/NNS was/VBD revealed/VBN ./. 
Constitutive/JJ expression/NN was/VBD observed/VBN in/IN a/DT small/JJ population/NN of/IN cells/NNS in/IN the/DT dermis/NN and/CC some/DT mice/NNS have/VBP developed/VBN skin/NN lesions/NNS ./. 
Interestingly/RB ,/, the/DT tissue/NN pattern/NN of/IN expression/NN of/IN the/DT NFAT-1/NN activity/NN resembles/VBZ the/DT expression/NN pattern/NN described/VBN for/IN HIV-LTR/tat/NN transgenic/JJ mice/NNS (/( Vogel/NNP ,/, J./NNP ,/, Hinrichs/NNP ,/, S./NNP H./NNP ,/, Reynolds/NNP ,/, R./NNP K./NNP ,/, Luciw/NNP ,/, P./NNP A./NNP ,/, and/CC Jay/NNP ,/, G./NNP (/( 1988/CD )/) Nature/NNP 335/CD ,/, 606-611/CD )/) ./. 
This/DT similarity/NN in/IN expression/NN and/CC the/DT fact/NN that/IN NFAT-1/NN has/VBZ been/VBN shown/VBN to/TO bind/VB functional/JJ sequences/NNS in/IN HIV-LTR/NN suggest/VBP a/DT role/NN for/IN NFAT-1/NN in/IN dermal/JJ activation/NN of/IN the/DT HIV-LTR/NN ./. 
UI/LS -/: 90279052/CD 
TI/LS -/: A/DT novel/JJ T-cell/NN protein/NN which/WDT recognizes/VBZ a/DT palindromic/JJ sequence/NN in/IN the/DT negative/JJ regulatory/JJ element/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN long/JJ terminal/JJ repeat/NN ./. 
AB/LS -/: Two/CD major/JJ protein-binding/JJ sites/NNS within/IN the/DT negative/JJ regulatory/JJ element/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD long/JJ terminal/JJ repeat/NN have/VBP been/VBN identified/VBN ./. 
One/CD (/( site/NN B/NN )/) contained/VBD a/DT palindromic/JJ sequence/NN with/IN homology/NN to/TO steroid/thyroid/NN hormone/NN response/NN elements/NNS but/CC was/VBD distinct/JJ from/IN previously/RB described/VBN binding/VBG sites/NNS of/IN this/DT class/NN ./. 
A/DT novel/JJ T-cell/NN protein/NN recognized/VBD the/DT palindromic/JJ sequence/NN within/IN site/NN B/NN and/CC also/RB bound/VBD estrogen-/NN or/CC thyroid/NN hormone-response/NN elements/NNS with/IN lower/JJR affinity/NN ./. 
A/DT 7-base-pair/JJ mutation/NN in/IN the/DT site/NN B/NN palindrome/NN ,/, which/WDT destroyed/VBD protein/NN binding/NN ,/, resulted/VBD in/IN increased/VBN expression/NN from/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD long/JJ terminal/JJ repeat/NN in/IN T/NN cells/NNS ./. 
UI/LS -/: 91025498/CD 
TI/LS -/: Progesterone/NN suppression/NN of/IN pregnancy/NN lymphocytes/NNS is/VBZ not/RB mediated/VBN by/IN glucocorticoid/NN effect/NN ./. 
AB/LS -/: This/DT study/NN investigated/VBD whether/IN the/DT suppressive/JJ effect/NN of/IN progesterone/NN on/IN pregnancy/NN lymphocytes/NNS is/VBZ mediated/VBN by/IN specific/JJ progesterone/NN receptors/NNS ./. 
The/DT effects/NNS of/IN a/DT competitive/JJ progesterone/NN antagonist/NN (/( RU486/NN )/) and/CC a/DT specific/JJ glucocorticoid/NN receptor/NN blocker/NN (/( RU43044/NN )/) were/VBD tested/VBN on/IN the/DT release/NN of/IN a/DT blocking/NN factor/NN by/IN progesterone-treated/JJ pregnancy/NN lymphocytes/NNS ./. 
RU/NN 486/CD tested/VBN at/IN an/DT equal/JJ concentration/NN as/IN progesterone/NN significantly/RB inhibited/VBD the/DT production/NN of/IN the/DT blocking/NN factor/NN ,/, while/IN RU/NN 43044/CD was/VBD without/IN effect/NN ./. 
These/DT data/NNS suggest/VBP that/IN in/IN pregnancy/NN ,/, lymphocyte/NN progesterone/NN acts/VBZ on/IN specific/JJ progesterone/NN receptors/NNS and/CC glucocorticoid/NN binding/NN sites/NNS are/VBP not/RB involved/VBN ./. 
UI/LS -/: 90335211/CD 
TI/LS -/: The/DT 56-59-kilodalton/JJ protein/NN identified/VBN in/IN untransformed/JJ steroid/NN receptor/NN complexes/NNS is/VBZ a/DT unique/JJ protein/NN that/WDT exists/VBZ in/IN cytosol/NN in/IN a/DT complex/NN with/IN both/CC the/DT 70-/CD and/CC 90-kilodalton/JJ heat/NN shock/NN proteins/NNS ./. 
AB/LS -/: It/PRP has/VBZ previously/RB been/VBN shown/VBN that/IN 9S/NN ,/, untransformed/JJ progestin/NN ,/, estrogen/NN ,/, androgen/NN ,/, and/CC glucocorticoid/NN receptor/NN complexes/NNS in/IN rabbit/NN uterine/NN and/CC liver/NN cytosols/NNS contain/VBP a/DT 59-kDa/JJ protein/NN [/( Tai/NNP ,/, P.K./NNP ,/, Maeda/NNP ,/, Y./NNP ,/, Nakao/NNP ,/, K./NNP ,/, Wakim/NNP ,/, N.G./NNP ,/, Duhring/NNP ,/, J.L./NNP ,/, &/CC Faber/NNP ,/, L.E./NNP (/( 1986/CD )/) Biochemistry/NNP 25/CD ,/, 5269-5275/CD ]/) ./. 
In/IN this/DT work/NN we/PRP show/VBP that/IN the/DT monoclonal/JJ antibody/NN KN/NN 382/EC1/NN raised/VBN against/IN the/DT rabbit/NN 59-kDa/JJ protein/NN reacts/VBZ with/IN 9S/NN ,/, untransformed/JJ glucocorticoid/NN receptor/NN complexes/NNS in/IN cytosol/NN prepared/VBN from/IN human/JJ IM-9/NN lymphocytes/NNS but/CC not/RB with/IN 4S/NN salt-transformed/JJ receptors/NNS ./. 
The/DT human/JJ protein/NN recognized/VBN by/IN the/DT EC1/NN antibody/NN is/VBZ a/DT 56-kDa/JJ protein/NN (/( p56/NN )/) of/IN moderate/JJ abundance/NN located/JJ predominantly/RB in/IN the/DT cytoplasm/NN by/IN indirect/JJ immunofluorescence/NN ./. 
There/EX are/VBP at/IN least/JJS six/CD isomorphs/NNS of/IN p56/NN by/IN two-dimensional/JJ gel/NN analysis/NN ./. 
N-Terminal/JJ sequencing/NN (/( 20/CD amino/NN acids/NNS )/) shows/VBZ that/IN p56/NN is/VBZ a/DT unique/JJ human/JJ protein/NN ./. 
When/WRB p56/NN is/VBZ immunoadsorbed/VBN from/IN IM-9/NN cell/NN cytosol/NN ,/, both/CC the/DT 70-/CD and/CC 90-kDa/JJ heat/NN shock/NN proteins/NNS are/VBP coadsorbed/VBN in/IN an/DT immune-specific/JJ manner/NN ./. 
Neither/DT heat/NN shock/NN protein/NN reacts/VBZ directly/RB with/IN the/DT EC1/NN antibody/NN ./. 
We/PRP conclude/VBP that/IN p56/NN exists/VBZ in/IN cytosol/NN in/IN a/DT higher/JJR order/NN complex/NN containing/VBG hsp70/NN and/CC hsp90/NN ,/, both/DT of/IN which/WDT in/IN turn/NN have/VBP been/VBN found/VBN to/TO be/VB associated/VBN with/IN untransformed/JJ steroid/NN receptors/NNS ./. 
UI/LS -/: 90299137/CD 
TI/LS -/: Sequence-specific/JJ DNA/NN binding/NN of/IN the/DT proto-oncoprotein/NN ets-1/NN defines/VBZ a/DT transcriptional/JJ activator/NN sequence/NN within/IN the/DT long/JJ terminal/JJ repeat/NN of/IN the/DT Moloney/NN murine/JJ sarcoma/NN virus/NN ./. 
AB/LS -/: The/DT ets/NN proto-oncogene/NN family/NN is/VBZ a/DT group/NN of/IN sequence-related/JJ genes/NNS whose/WP$ normal/JJ cellular/JJ function/NN is/VBZ unknown/JJ ./. 
In/IN a/DT study/NN of/IN cellular/JJ proteins/NNS involved/VBN in/IN the/DT transcriptional/JJ regulation/NN of/IN murine/JJ retroviruses/NNS in/IN T/NN lymphocytes/NNS ,/, we/PRP have/VBP discovered/VBN that/IN a/DT member/NN of/IN the/DT ets/NN gene/NN family/NN encodes/VBZ a/DT sequence-specific/JJ DNA-binding/JJ protein/NN ./. 
A/DT mouse/NN ets-1/NN cDNA/NN clone/NN was/VBD obtained/VBN by/IN screening/VBG a/DT mouse/NN thymus/NN cDNA/NN expression/NN library/NN with/IN a/DT double-stranded/JJ oligonucleotide/NN probe/NN representing/VBG 20/CD bp/NN of/IN the/DT Moloney/NN murine/JJ sarcoma/NN virus/NN (/( MSV/NN )/) long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) ./. 
The/DT cDNA/NN sequence/NN has/VBZ an/DT 813-bp/JJ open/JJ reading/NN frame/NN (/( ORF/NN )/) whose/WP$ predicted/VBN amino/NN acid/NN sequence/NN is/VBZ 97.6/CD %/NN identical/JJ to/TO the/DT 272/CD carboxy-terminal/JJ amino/NN acids/NNS of/IN the/DT human/JJ ets-1/NN protein/NN ./. 
The/DT ORF/NN was/VBD expressed/VBN in/IN bacteria/NNS ,/, and/CC the/DT 30-kD/JJ protein/NN product/NN was/VBD shown/VBN to/TO bind/VB DNA/NN in/IN a/DT sequence-specific/JJ manner/NN by/IN mobility-shift/JJ assays/NNS ,/, Southwestern/NN blot/NN analysis/NN ,/, and/CC methylation/NN interference/NN ./. 
A/DT mutant/JJ LTR/NN containing/VBG four/CD base/NN pair/NN substitutions/NNS in/IN the/DT ets-1/NN binding/NN site/NN was/VBD constructed/VBN and/CC was/VBD shown/VBN to/TO have/VB reduced/VBN binding/NN in/FW vitro/FW ./. 
Transcriptional/JJ efficiency/NN of/IN the/DT MSV/NN LTR/NN promoter/NN containing/VBG this/DT disrupted/VBN ets-1/NN binding/NN site/NN was/VBD compared/VBN to/TO the/DT activity/NN of/IN a/DT wild-type/JJ promoter/NN in/IN mouse/NN T/NN lymphocytes/NNS in/IN culture/NN ,/, and/CC 15-/CD to/TO 20-fold/JJ reduction/NN in/IN expression/NN of/IN a/DT reporter/NN gene/NN was/VBD observed/VBN ./. 
We/PRP propose/VBP that/IN ets-1/NN functions/VBZ as/IN a/DT transcriptional/JJ activator/NN of/IN mammalian/JJ type-C/JJ retroviruses/NNS and/CC speculate/VBP that/IN ets-related/JJ genes/NNS constitute/VBP a/DT new/JJ group/NN of/IN eukaryotic/JJ DNA-binding/JJ proteins/NNS ./. 
UI/LS -/: 90247097/CD 
TI/LS -/: Type/NN II/CD estrogen/NN binding/NN sites/NNS in/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS :/: variations/NNS during/IN the/DT menstrual/JJ cycle/NN ./. 
AB/LS -/: We/PRP have/VBP previously/RB reported/VBN that/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NNS )/) contain/VBP type/NN II/CD estrogen/NN binding/NN sites/NNS (/( type/NN II/CD EBS/NNS )/) ./. 
In/IN this/DT study/NN ,/, the/DT fluctuations/NNS of/IN type/NN II/CD EBS/NNS during/IN the/DT menstrual/JJ cycle/NN were/VBD analyzed/VBN in/IN 6/CD normally/RB menstruating/VBG women/NNS ./. 
Approximately/RB 3/CD times/NNS higher/JJR levels/NNS of/IN type/NN II/CD EBS/NNS were/VBD found/VBN in/IN the/DT periovulatory/JJ period/NN with/IN respect/NN to/TO both/CC follicular/JJ and/CC luteal/JJ phases/NNS ./. 
In/IN postmenopausal/JJ women/NNS the/DT mean/NN type/NN II/CD EBS/NNS levels/NNS were/VBD similar/JJ to/TO those/DT observed/VBN in/IN the/DT follicular/JJ phase/NN of/IN the/DT cycle/NN ./. 
However/RB ,/, in/IN 3/CD postmenopausal/JJ patients/NNS a/DT short/JJ course/NN of/IN estrogen/NN or/CC tamoxifen/NN resulted/VBD in/IN a/DT marked/JJ increase/NN of/IN type/NN II/CD EBS/NNS levels/NNS ./. 
Tamoxifen/NN was/VBD also/RB found/VBN to/TO compete/VB with/IN 17/CD beta-estradiol/NN for/IN type/NN II/CD EBS/NNS in/IN PBMC/NNS ,/, although/IN to/TO a/DT lesser/JJR extent/NN than/IN diethylstilbestrol/NN ./. 
UI/LS -/: 90311515/CD 
TI/LS -/: Mononuclear/JJ leukocyte/NN glucocorticoid/NN receptor/NN binding/NN characteristics/NNS and/CC down-regulation/NN in/IN major/JJ depression/NN ./. 
AB/LS -/: Some/DT patients/NNS with/IN major/JJ depressive/JJ disorder/NN (/( MDD/NN )/) have/VBP elevated/JJ plasma/NN cortisol/NN concentrations/NNS and/CC show/VBP failure/NN to/TO suppress/VB cortisol/NN secretion/NN upon/IN administration/NN of/IN dexamethasone/NN (/( DEX/NN )/) ,/, yet/CC they/PRP do/VBP not/RB have/VB Cushingoid/JJ features/NNS ./. 
To/TO study/VB whether/IN this/DT represents/VBZ glucocorticoid/NN (/( GC/NN )/) resistance/NN ,/, [3H]-DEX-binding/JJ assays/NNS were/VBD used/VBN to/TO measure/VB ,/, in/FW vitro/FW ,/, the/DT GC/NN receptor/NN affinity/NN (/( 1/Kd/NN )/) and/CC number/NN (/( Bmax/NN )/) in/IN mononuclear/JJ leukocytes/NNS of/IN 11/CD MDD/NN patients/NNS and/CC 15/CD control/JJ subjects/NNS ./. 
No/DT receptor/NN abnormalities/NNS were/VBD detected/VBN in/IN the/DT MDD/NN group/NN ;/: thus/RB any/DT cellular/JJ defect/NN leading/VBG to/TO a/DT lack/NN of/IN responsiveness/NN to/TO GC/NN in/IN the/DT MDD/NN patients/NNS ,/, if/IN present/JJ ,/, probably/RB lies/VBZ beyond/IN the/DT initial/JJ receptor/NN binding/NN ./. 
DEX/NN (/( 1.0/CD mg/NN orally/RB )/) was/VBD administered/VBN to/TO study/VB in/FW vivo/FW GC/NN receptor/NN down-regulation/NN ./. 
Compared/VBN to/TO the/DT control/JJ group/NN ,/, fewer/JJR depressed/JJ subjects/NNS down-regulated/VBD Bmax/NN after/IN DEX/NN ./. 
By/IN paired/JJ t-test/NN ,/, Bmax/NN decreased/VBD significantly/RB in/IN the/DT control/JJ group/NN but/CC not/RB in/IN the/DT depressed/JJ group/NN ./. 
Receptor/NN number/NN on/IN the/DT control/JJ day/NN did/VBD not/RB correlate/VB significantly/RB with/IN the/DT degree/NN of/IN receptor/NN down-regulation/NN ,/, severity/NN of/IN depression/NN or/CC cortisol/NN concentrations/NNS across/IN all/PDT the/DT subjects/NNS ./. 
These/DT results/NNS do/VBP not/RB lend/VB support/NN to/TO previous/JJ reports/NNS suggesting/VBG that/IN GC/NN resistance/NN in/IN MDD/NN results/VBZ from/IN a/DT GC/NN receptor-binding/JJ abnormality/NN ,/, and/CC they/PRP emphasize/VBP the/DT importance/NN of/IN considering/VBG receptor/NN studies/NNS in/IN the/DT context/NN of/IN GC-mediated/JJ cell/NN processes/NNS in/IN order/NN to/TO identify/VB the/DT exact/JJ cellular/JJ defect/NN (/( s/NNS )/) leading/VBG to/TO GC/NN resistance/NN ./. 
UI/LS -/: 98038598/CD 
TI/LS -/: Ras-related/JJ GTP-binding/JJ proteins/NNS and/CC leukocyte/NN signal/NN transduction/NN ./. 
AB/LS -/: Many/JJ aspects/NNS of/IN leukocyte/NN function/NN are/VBP regulated/VBN by/IN both/CC heterotrimeric/JJ and/CC Ras-related/JJ GTP-binding/JJ proteins/NNS ,/, but/CC there/EX is/VBZ little/JJ definite/JJ information/NN about/IN their/PRP$ roles/NNS in/IN the/DT specialized/JJ processes/NNS utilized/VBN by/IN leukocytes/NNS for/IN cell/NN killing/NN ./. 
Recent/JJ progress/NN in/IN understanding/VBG the/DT regulation/NN of/IN the/DT phagocyte/NN NADPH/NN oxidase/NN by/IN the/DT Rac/NN GTP-binding/JJ proteins/NNS provides/VBZ a/DT basis/NN for/IN defining/VBG the/DT operational/JJ characteristics/NNS of/IN one/CD such/JJ phagocyte/NN system/NN ./. 
It/PRP is/VBZ clear/JJ from/IN various/JJ studies/NNS that/IN the/DT activity/NN of/IN the/DT NADPH/NN oxidase/NN can/MD be/VB modulated/VBN through/IN the/DT regulation/NN of/IN the/DT GTP-GDP/JJ state/NN of/IN Rac/NN ./. 
Proteins/NNS exist/VBP in/IN leukocytes/NNS able/JJ to/TO modify/VB GTP-binding/JJ protein/NN function/NN in/IN this/DT manner/NN ,/, and/CC their/PRP$ activity/NN may/MD be/VB regulated/VBN by/IN signals/NNS generated/VBN on/IN phagocyte/NN stimulation/NN ./. 
Proteins/NNS of/IN the/DT Ras/NN superfamily/NN are/VBP likely/JJ to/TO be/VB involved/VBN in/IN a/DT variety/NN of/IN normal/JJ phagocyte/NN functions/NNS through/IN their/PRP$ ability/NN to/TO modulate/VB the/DT assembly/NN of/IN actin/NN filaments/NNS ,/, direct/JJ vesicle/NN trafficking/NN and/CC fusion/NN ,/, and/CC so/RB forth/RB ./. 
UI/LS -/: 96114389/CD 
TI/LS -/: BSAP/NN :/: a/DT key/JJ regulator/NN of/IN B-cell/NN development/NN and/CC differentiation/NN ./. 
AB/LS -/: B-cell-specific/JJ activator/NN protein/NN (/( BSAP/NN )/) is/VBZ a/DT recently/RB identified/VBN member/NN of/IN the/DT Pax-gene/NN family/NN of/IN transcription/NN factors/NNS ;/: in/IN the/DT lymphoid/JJ system/NN ,/, BSAP/NN is/VBZ produced/VBN only/RB in/IN B/NN cells/NNS ./. 
Here/RB ,/, Markus/NNP Neurath/NNP ,/, Eckhard/NNP Stuber/NNP and/CC Warren/NNP Strober/NNP describe/VBP the/DT molecular/JJ structure/NN of/IN BSAP/NN and/CC focus/VBP on/IN the/DT ability/NN of/IN this/DT protein/NN to/TO regulate/VB the/DT expression/NN of/IN B-cell-specific/JJ genes/NNS ./. 
They/PRP propose/VBP that/IN BSAP/NN is/VBZ a/DT key/JJ protein/NN of/IN B/NN cells/NNS and/CC that/IN it/PRP not/RB only/RB influence/VBP B-cell/NN development/NN but/CC also/RB influences/VBZ the/DT balance/NN between/IN B-cell/NN proliferation/NN and/CC immunoglobulin/NN secretion/NN at/IN later/JJR stages/NNS of/IN B-cell/NN differentiation/NN ./. 
UI/LS -/: 96074632/CD 
TI/LS -/: Down-regulation/NN of/IN NF-kappa/NN B/NN protein/NN levels/NNS in/IN activated/VBN human/JJ lymphocytes/NNS by/IN 1,25-dihydroxyvitamin/NN D3/NN [/( published/VBN erratum/NN appears/VBZ in/IN Proc/NNP Natl/NNP Acad/NNP Sci/NNP U/NNP S/NNP A/NNP 1996/CD Jan/NNP 9/CD ;/: 93/CD (/( 1/CD )/) :/: 524/CD ]/) 
AB/LS -/: The/DT effect/NN of/IN 1,25-dihydroxyvitamin/NN D3/NN [/( 1,25(OH)2)D3/NN ]/) ,/, a/DT steroid/NN hormone/NN with/IN immunomodulating/NN properties/NNS ,/, on/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) proteins/NNS was/VBD examined/VBN in/IN in/FW vitro/FW activated/VBN normal/JJ human/JJ lymphocytes/NNS by/IN Western/NN blot/NN analysis/NN ./. 
Over/IN a/DT 72-hr/JJ period/NN of/IN activation/NN ,/, the/DT expression/NN of/IN the/DT 50-kDa/JJ NF-kappa/NN B/NN ,/, p50/NN ,/, and/CC its/PRP$ precursor/NN ,/, p105/NN ,/, was/VBD increased/VBN progressively/RB ./. 
When/WRB cells/NNS were/VBD activated/VBN in/IN the/DT presence/NN of/IN 1,25(OH)2D3/NN ,/, the/DT levels/NNS of/IN the/DT mature/JJ protein/NN as/RB well/RB as/IN its/PRP$ precursor/NN were/VBD decreased/VBN ./. 
The/DT effect/NN of/IN the/DT hormone/NN on/IN the/DT levels/NNS of/IN p50/NN was/VBD demonstrable/JJ in/IN the/DT cytosolic/JJ and/CC nuclear/JJ compartments/NNS ;/: it/PRP required/VBD between/IN 4/CD and/CC 8/CD hr/NN and/CC was/VBD specific/JJ ,/, as/IN 25-hydroxyvitamin/NN D3/NN and/CC 24,25-dihydroxyvitamin/NN D3/NN were/VBD ineffective/JJ ./. 
Besides/IN p50/NN ,/, 1,25(OH)2D3/NN decreased/VBD the/DT levels/NNS of/IN another/DT NF-kappa/NN B/NN protein/NN ,/, namely/RB c-rel/NN ./. 
In/IN addition/NN ,/, 1,25(OH)2D3/NN decreased/VBD the/DT abundance/NN of/IN a/DT specific/JJ DNA-protein/NN complex/NN formed/VBN upon/IN incubation/NN of/IN nuclear/JJ extracts/NNS from/IN activated/VBN lymphocytes/NNS with/IN a/DT labeled/VBN NF-kappa/NN B/NN DNA/NN binding/NN motif/NN ./. 
Further/RB ,/, 1,25(OH)2D3/NN inhibited/VBD the/DT transcriptional/JJ activity/NN of/IN NF-kappa/NN B/NN in/IN Jurkat/NN cells/NNS transiently/RB transfected/VBN with/IN a/DT construct/NN containing/VBG four/CD tandem/JJ repeats/NNS of/IN the/DT NF-kappa/NN B/NN binding/NN sequence/NN of/IN the/DT immunoglobulin/NN kappa/NN light/JJ chain/NN gene/NN linked/VBN to/TO the/DT chloramphenicol/NN acetyltransferase/NN reporter/NN gene/NN ./. 
These/DT observations/NNS demonstrate/VBP directly/RB that/IN there/EX is/VBZ de/FW novo/FW synthesis/NN of/IN NF-kappa/NN B/NN during/IN human/JJ lymphocyte/NN activation/NN and/CC suggest/VBP that/IN this/DT process/NN is/VBZ hormonally/RB regulated/VBN ./. 
UI/LS -/: 96068726/CD 
TI/LS -/: The/DT myeloid/JJ zinc/NN finger/NN gene/NN ,/, MZF-1/NN ,/, regulates/VBZ the/DT CD34/NN promoter/NN in/FW vitro/FW ./. 
AB/LS -/: MZF-1/NN is/VBZ a/DT C2H2/NN zinc/NN finger/NN gene/NN encoding/VBG a/DT putative/JJ transcriptional/JJ regulator/NN of/IN myeloid/JJ differentiation/NN ./. 
The/DT MZF-1/NN protein/NN contains/VBZ 13/CD C2H2/NN zinc/NN fingers/NNS arranged/VBN in/IN bipartite/JJ DNA/NN binding/NN domains/NNS containing/VBG zinc/NN fingers/NNS through/IN 4/CD and/CC ,/, in/IN the/DT carboxy-terminus/NN ,/, 5/CD through/IN 13/CD ./. 
We/PRP previously/RB identified/VBD the/DT DNA/NN consensus/NN binding/NN site/NN recognized/VBN by/IN the/DT two/CD DNA/NN binding/NN domains/NNS ./. 
To/TO assess/VB the/DT transcription/NN regulatory/JJ function/NN of/IN MZF-1/NN ,/, the/DT full-length/JJ MZF-1/NN coding/NN region/NN was/VBD fused/VBN to/TO the/DT DNA/NN binding/NN domain/NN of/IN the/DT yeast/NN transactivator/NN GAL4/NN ./. 
The/DT expression/NN vector/NN was/VBD cotransfected/VBN with/IN the/DT chloramphenicol/NN acetyl/NN transferase/NN (/( CAT/NN )/) reporter/NN gene/NN regulated/VBN by/IN the/DT thymidine/NN kinase/NN promoter/NN containing/VBG GAL4/NN DNA/NN binding/NN sites/NNS into/IN NIH/NN 3T3/NN ,/, 293/CD ,/, K562/NN ,/, and/CC Jurkat/NN cell/NN lines/NNS ./. 
MZF-1/NN represses/VBZ CAT/NN reporter/NN gene/NN expression/NN via/IN GAL4/NN binding/NN sites/NNS in/IN the/DT nonhematopoietic/JJ cell/NN lines/NNS NIH/NN 3T3/NN and/CC 293/CD ./. 
In/IN contrast/NN ,/, MZF-1/NN activates/VBZ CAT/NN reporter/NN gene/NN expression/NN in/IN the/DT hematopoietic/JJ cell/NN lines/NNS K562/NN and/CC Jurkat/NN ./. 
The/DT MZF-1/NN binding/NN sites/NNS are/VBP present/JJ in/IN the/DT promoters/NNS of/IN several/JJ genes/NNS expressed/VBN during/IN myeloid/JJ differentiation/NN ,/, including/VBG the/DT CD34/NN promoter/NN ./. 
MZF-1/NN transcriptional/JJ regulation/NN of/IN this/DT physiologically/RB relevant/JJ promoter/NN was/VBD assessed/VBN in/IN both/CC hematopoietic/JJ and/CC nonhematopoietic/JJ cell/NN lines/NNS ./. 
Recombinant/JJ MZF-1/NN protein/NN specifically/RB binds/VBZ to/TO the/DT consensus/NN binding/NN sites/NNS in/IN the/DT CD34/NN promoter/NN in/IN mobility/NN shift/NN assays/NNS ./. 
MZF-1/NN expression/NN vectors/NNS were/VBD cotransfected/VBN with/IN the/DT luciferase/NN reporter/NN plasmids/NNS regulated/VBN by/IN the/DT CD34/NN promoter/NN into/IN both/CC nonhematopoietic/JJ and/CC hematopoietic/JJ cell/NN lines/NNS ./. 
As/IN with/IN the/DT heterologous/JJ DNA/NN binding/NN domain/NN ,/, MZF-1/NN represses/VBZ reporter/NN gene/NN expression/NN in/IN nonhematopoietic/JJ cell/NN lines/NNS and/CC activates/VBZ expression/NN in/IN hematopoietic/JJ cell/NN lines/NNS ./. 
Activation/NN of/IN CD34/NN expression/NN in/IN hematopoietic/JJ cell/NN lines/NNS is/VBZ dependent/JJ on/IN the/DT presence/NN of/IN intact/JJ MZF-1/NN binding/NN sites/NNS ./. 
The/DT cell/NN type-specific/JJ regulation/NN of/IN the/DT CD34/NN promoter/NN by/IN MZF-1/NN suggests/VBZ the/DT presence/NN of/IN tissue-specific/JJ regulators/adapters/NNS or/CC differential/JJ MZF-1/NN modifications/NNS that/WDT determine/VBP MZF-1/NN transcriptional/JJ regulatory/JJ function/NN ./. 
UI/LS -/: 96038894/CD 
TI/LS -/: The/DT murine/JJ BCL6/NN gene/NN is/VBZ induced/VBN in/IN activated/VBN lymphocytes/NNS as/IN an/DT immediate/JJ early/JJ gene/NN ./. 
AB/LS -/: The/DT chromosomal/JJ translocation/NN involving/VBG 3q27/NN is/VBZ often/RB detected/VBN in/IN human/JJ B-cell/NN lymphomas/NNS ,/, especially/RB diffuse/JJ lymphomas/NNS with/IN a/DT large-cell/JJ component/NN ./. 
The/DT BCL6/NN gene/NN has/VBZ been/VBN isolated/VBN from/IN the/DT chromosomal/JJ breakpoint/NN in/IN these/DT lymphomas/NNS ./. 
Here/RB we/PRP cloned/VBD the/DT murine/JJ BCL6/NN (/( mBCL6/NN )/) cDNA/NN from/IN the/DT muscle/NN cDNA/NN library/NN using/VBG the/DT human/JJ BCL6/NN (/( hBCL6/NN )/) cDNA/NN as/IN a/DT probe/NN ./. 
The/DT predicted/VBN amino/NN acid/NN sequence/NN was/VBD 95/CD %/NN identical/JJ to/TO that/DT of/IN hBCL6/NN ./. 
It/PRP contains/VBZ six/CD repeats/NNS of/IN the/DT Kruppel-like/JJ zinc-finger/JJ motif/NN that/WDT are/VBP completely/RB identical/JJ to/TO those/DT of/IN hBCL6/NN ,/, indicating/VBG that/IN the/DT BCL6/NN gene/NN is/VBZ well/RB conserved/VBN between/IN humans/NNS and/CC mice/NNS ./. 
Expression/NN of/IN the/DT mBCL6/NN gene/NN was/VBD ubiquitously/RB detected/VBN in/IN adult/JJ mouse/NN tissues/NNS including/VBG lymphatic/JJ organs/NNS ./. 
Furthermore/RB ,/, it/PRP was/VBD induced/VBN in/IN lymphocytes/NNS activated/VBN with/IN phorbol/NN ester/NN and/CC Ca2+/NN ionophore/NN within/IN 30/CD min/NN after/IN stimulation/NN ./. 
This/DT induction/NN was/VBD not/RB inhibited/VBN by/IN treatment/NN of/IN the/DT cells/NNS with/IN a/DT protein/NN synthesis/NN inhibitor/NN ,/, cycloheximide/NN ./. 
These/DT results/NNS suggest/VBP that/IN BCL6/NN plays/VBZ a/DT role/NN in/IN activated/VBN lymphocytes/NNS as/IN an/DT immediate/JJ early/JJ gene/NN ./. 
UI/LS -/: 96114497/CD 
TI/LS -/: The/DT role/NN of/IN BSAP/NN (/( Pax-5/NN )/) in/IN B-cell/NN development/NN ./. 
AB/LS -/: The/DT hierarchy/NN of/IN transcriptional/JJ control/NN in/IN B-cell/NN development/NN has/VBZ recently/RB been/VBN analyzed/VBN by/IN targeted/VBN gene/NN inactivation/NN in/IN the/DT mouse/NN ./. 
In/IN this/DT manner/NN ,/, the/DT paired/JJ box/NN containing/VBG gene/NN Pax-5/NN ,/, encoding/VBG the/DT B/NN cell/NN specific/JJ transcription/NN factor/NN BSAP/NN ,/, has/VBZ been/VBN shown/VBN to/TO play/VB a/DT key/JJ role/NN in/IN early/JJ B/NN lymphopoiesis/NN ./. 
Other/JJ experimental/JJ strategies/NNS have/VBP implicated/VBN BSAP/NN in/IN the/DT control/NN of/IN cell/NN proliferation/NN ,/, isotype/NN switching/NN and/CC transcription/NN of/IN the/DT immunoglobulin/NN heavy-chain/NN gene/NN at/IN late/JJ stages/NNS of/IN B-cell/NN differentiation/NN ./. 
UI/LS -/: 96009551/CD 
TI/LS -/: The/DT DNA-binding/JJ properties/NNS of/IN two/CD heat/NN shock/NN factors/NNS ,/, HSF1/NN and/CC HSF3/NN ,/, are/VBP induced/VBN in/IN the/DT avian/JJ erythroblast/NN cell/NN line/NN HD6/NN ./. 
AB/LS -/: Avian/JJ cells/NNS express/VBP three/CD heat/NN shock/NN transcription/NN factor/NN (/( HSF/NN )/) genes/NNS corresponding/VBG to/TO a/DT novel/JJ factor/NN ,/, HSF3/NN ,/, and/CC homologs/NNS of/IN mouse/NN and/CC human/JJ HSF1/NN and/CC HSF2/NN ./. 
Analysis/NN of/IN the/DT biochemical/JJ and/CC cell/NN biological/JJ properties/NNS of/IN these/DT HSFs/NNS reveals/VBZ that/IN HSF3/NN has/VBZ properties/NNS in/IN common/JJ with/IN both/CC HSF1/NN and/CC HSF2/NN and/CC yet/RB has/VBZ features/NNS which/WDT are/VBP distinct/JJ from/IN both/DT ./. 
HSF3/NN is/VBZ constitutively/RB expressed/VBN in/IN the/DT erythroblast/NN cell/NN line/NN HD6/NN ,/, the/DT lymphoblast/NN cell/NN line/NN MSB/NN ,/, and/CC embryo/NN fibroblasts/NNS ,/, and/CC yet/RB its/PRP$ DNA-binding/JJ activity/NN is/VBZ induced/VBN only/RB upon/IN exposure/NN of/IN HD6/NN cells/NNS to/TO heat/NN shock/NN ./. 
Acquisition/NN of/IN HSF3/NN DNA-binding/JJ activity/NN in/IN HD6/NN cells/NNS is/VBZ accompanied/VBN by/IN oligomerization/NN from/IN a/DT non-DNA-binding/JJ dimer/NN to/TO a/DT DNA-binding/JJ trimer/NN ,/, whereas/IN the/DT effect/NN of/IN heat/NN shock/NN on/IN HSF1/NN is/VBZ oligomerization/NN of/IN an/DT inert/JJ monomer/NN to/TO a/DT DNA-binding/JJ trimer/NN ./. 
Induction/NN of/IN HSF3/NN DNA-binding/JJ activity/NN is/VBZ delayed/VBN compared/VBN with/IN that/DT of/IN HSF1/NN ./. 
As/IN occurs/VBZ for/IN HSF1/NN ,/, heat/NN shock/NN leads/VBZ to/TO the/DT translocation/NN of/IN HSF3/NN to/TO the/DT nucleus/NN ./. 
HSF/NN exhibits/VBZ the/DT properties/NNS of/IN a/DT transcriptional/JJ activator/NN ,/, as/IN judged/VBN from/IN the/DT stimulatory/JJ activity/NN of/IN transiently/RB overexpressed/VBN HSF3/NN measured/VBN by/IN using/VBG a/DT heat/NN shock/NN element-containing/JJ reporter/NN construct/NN and/CC as/IN independently/RB assayed/VBN by/IN the/DT activity/NN of/IN a/DT chimeric/JJ GAL4-HSF3/NN protein/NN on/IN a/DT GAL4/NN reporter/NN construct/NN ./. 
These/DT results/NNS reveal/VBP that/IN HSF3/NN is/VBZ negatively/RB regulated/VBN in/IN avian/JJ cells/NNS and/CC acquires/VBZ DNA-binding/JJ activity/NN in/IN certain/JJ cells/NNS upon/IN heat/NN shock/NN ./. 
UI/LS -/: 95403468/CD 
TI/LS -/: Direct/JJ demonstration/NN of/IN NFATp/NN dephosphorylation/NN and/CC nuclear/JJ localization/NN in/IN activated/VBN HT-2/NN cells/NNS using/VBG a/DT specific/JJ NFATp/NN polyclonal/JJ antibody/NN ./. 
AB/LS -/: Nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) regulates/VBZ transcription/NN of/IN a/DT number/NN of/IN cytokine/NN genes/NNS ,/, and/CC NFAT/NN DNA/NN binding/NN activity/NN is/VBZ stimulated/VBN following/VBG T/NN cell/NN activation/NN ./. 
Several/JJ lines/NNS of/IN evidence/NN have/VBP suggested/VBN that/IN NFAT/NN is/VBZ a/DT substrate/NN for/IN calcineurin/NN ,/, a/DT serine/threonine/NN phosphatase/NN ./. 
Using/VBG a/DT polyclonal/JJ antibody/NN to/TO murine/JJ NFATp/NN ,/, Western/NN blot/NN analysis/NN of/IN various/JJ mouse/NN tissues/NNS demonstrated/VBD that/IN the/DT 110-130-kDa/JJ NFATp/NN protein/NN was/VBD highly/RB expressed/VBN in/IN thymus/NN and/CC spleen/NN ./. 
Treatment/NN of/IN immunoprecipitated/VBN NFATp/NN from/IN untreated/JJ HT-2/NN cells/NNS with/IN calcineurin/NN resulted/VBD in/IN the/DT dephosphorylation/NN of/IN NFATp/NN ,/, demonstrating/VBG that/IN NFATp/NN is/VBZ an/DT in/FW vitro/FW substrate/NN for/IN calcineurin/NN ./. 
NFATp/NN immunoprecipitated/VBN from/IN 32P-labeled/JJ HT-2/NN cells/NNS migrated/VBD as/IN an/DT approximately/RB 120-kDa/JJ protein/NN that/WDT was/VBD localized/JJ to/TO the/DT cytosol/NN of/IN the/DT cells/NNS ./. 
Treatment/NN of/IN the/DT cells/NNS with/IN ionomycin/NN resulted/VBD in/IN a/DT decrease/NN in/IN the/DT molecular/JJ weight/NN of/IN NFATp/NN and/CC a/DT loss/NN of/IN 32P/NN ,/, consistent/JJ with/IN NFATp/NN dephosphorylation/NN ./. 
The/DT dephosphorylation/NN of/IN NFATp/NN was/VBD accompanied/VBN by/IN localization/NN of/IN the/DT protein/NN to/TO the/DT nuclear/JJ fraction/NN ./. 
Both/DT of/IN these/DT events/NNS were/VBD blocked/VBN by/IN preincubation/NN of/IN the/DT cells/NNS with/IN FK506/NN ,/, a/DT calcineurin/NN inhibitor/NN ,/, consistent/JJ with/IN the/DT hypothesis/NN that/IN NFATp/NN is/VBZ a/DT calcineurin/NN substrate/NN in/IN cells/NNS ./. 
UI/LS -/: 95378799/CD 
TI/LS -/: Activation/NN and/CC expression/NN of/IN the/DT nuclear/JJ factors/NNS of/IN activated/VBN T/NN cells/NNS ,/, NFATp/NN and/CC NFATc/NN ,/, in/IN human/JJ natural/JJ killer/NN cells/NNS :/: regulation/NN upon/IN CD16/NN ligand/NN binding/NN ./. 
AB/LS -/: The/DT putative/JJ factors/NNS that/WDT couple/VBP the/DT signal/NN transduction/NN from/IN surface/NN receptors/NNS to/TO the/DT activation/NN of/IN cytokine/NN synthesis/NN in/IN natural/JJ killer/NN (/( NK/NN )/) cells/NNS have/VBP not/RB been/VBN elucidated/VBN ./. 
We/PRP report/VBP here/RB that/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFATp/NN )/) ,/, a/DT cyclosporin/NN A/NN (/( CsA/NN )/) -sensitive/JJ factor/NN that/WDT regulates/VBZ the/DT transcription/NN of/IN several/JJ cytokines/NNS ,/, mediates/VBZ CD16-induced/JJ activation/NN of/IN cytokine/NN genes/NNS in/IN human/JJ NK/NN cells/NNS ./. 
CD16/NN (/( Fc/NN gamma/NN RIIIA/NN )/) -induced/JJ expression/NN of/IN cytokine/NN mRNA/NN in/IN NK/NN cells/NNS occurs/VBZ via/IN a/DT CsA-sensitive/JJ and/CC Ca(2+)-dependent/JJ mechanism/NN ./. 
Stimulation/NN of/IN NK/NN cells/NNS with/IN CD16/NN ligands/NNS induces/VBZ NFAT-like/JJ DNA/NN binding/NN activity/NN in/IN the/DT nuclear/JJ extracts/NNS from/IN these/DT cells/NNS ,/, as/IN detected/VBN in/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS ./. 
This/DT occurs/VBZ with/IN fast/JJ kinetics/NNS after/IN stimulation/NN ,/, via/IN a/DT CsA-sensitive/JJ and/CC Ca(2+)-dependent/JJ mechanism/NN that/WDT does/VBZ not/RB require/VB de/FW novo/FW protein/NN synthesis/NN ./. 
NK/NN cell/NN NFAT/NN is/VBZ present/JJ in/IN the/DT cytosol/NN of/IN nonstimulated/JJ cells/NNS ,/, migrates/VBZ to/TO the/DT nucleus/NN upon/IN stimulation/NN ,/, and/CC can/MD associate/VB with/IN AP-1/NN ./. 
Two/CD distinct/JJ molecules/NNS ,/, NFATp/NN and/CC NFATc/NN ,/, have/VBP been/VBN reported/VBN to/TO mediate/VB NFAT/NN activity/NN ./. 
The/DT results/NNS of/IN supershift/NN assays/NNS using/VBG NFATp-/NN and/CC NFATc-specific/JJ antibodies/NNS indicate/VBP that/IN NK/NN cell/NN activation/NN early/RB after/IN CD16/NN ligand/NN binding/NN involves/VBZ primarily/RB ,/, if/IN not/RB exclusively/RB ,/, NFATp/NN ,/, and/CC Western/NN blot/NN analysis/NN shows/VBZ that/IN this/DT has/VBZ the/DT same/JJ electrophoretic/JJ mobility/NN (/( approximately/RB 120/CD kD/NN )/) as/IN that/DT of/IN T/NN lymphocytes/NNS ./. 
NK/NN cells/NNS do/VBP not/RB express/VB NFATc/NN constitutively/RB ,/, but/CC NFATc/NN mRNA/NN accumulation/NN is/VBZ induced/VBN in/IN these/DT cells/NNS within/IN 2/CD h/NN of/IN stimulation/NN with/IN CD16/NN ligands/NNS ./. 
However/RB ,/, supershift/NN assays/NNS using/VBG the/DT available/JJ mAb/NN recognizing/VBG the/DT T/NN cell/NN NFATc/NN revealed/VBD no/DT detectable/JJ NFATc/NN protein/NN in/IN nuclear/JJ and/CC cytoplasmic/JJ extracts/NNS from/IN CD16-/NN or/CC phorbol/NN ester-stimulated/JJ cells/NNS at/IN any/DT time/NN tested/VBN ,/, up/RB to/TO 4/CD h/NN ./. 
These/DT results/NNS provide/VBP the/DT first/JJ direct/JJ evidence/NN that/IN both/DT CsA-sensitive/JJ transcription/NN factors/NNS ,/, NFATp/NN and/CC NFATc/NN ,/, are/VBP expressed/VBN in/IN human/JJ NK/NN cells/NNS ,/, and/CC that/IN their/PRP$ activation/NN and/or/CC expression/NN can/MD be/VB regulated/VBN in/IN primary/JJ cells/NNS by/IN a/DT single/JJ stimulus/NN ,/, that/WDT ,/, in/IN the/DT case/NN of/IN CD16/NN in/IN NK/NN cells/NNS ,/, results/VBZ in/IN early/JJ activation/NN of/IN NFATp/NN and/CC subsequently/RB induced/VBN expression/NN of/IN NFATc/NN mRNA/NN ./. 
UI/LS -/: 95372363/CD 
TI/LS -/: Interleukin/NN 2/CD signaling/NN involves/VBZ the/DT phosphorylation/NN of/IN Stat/NN proteins/NNS ./. 
AB/LS -/: One/CD of/IN the/DT most/RBS important/JJ cytokines/NNS involved/VBN in/IN immune/JJ response/NN regulation/NN is/VBZ interleukin/NN 2/CD (/( IL-2/NN )/) ,/, a/DT potent/JJ activator/NN of/IN the/DT proliferation/NN and/CC function/NN of/IN T/NN lymphocytes/NNS and/CC natural/JJ killer/NN cells/NNS ./. 
The/DT mechanisms/NNS by/IN which/WDT the/DT effects/NNS of/IN IL-2/NN are/VBP propagated/VBN within/IN cells/NNS are/VBP not/RB understood/VBN ./. 
While/IN the/DT binding/NN of/IN IL-2/NN to/TO its/PRP$ receptor/NN was/VBD recently/RB shown/VBN to/TO lead/VB to/TO the/DT activation/NN of/IN two/CD kinases/NNS ,/, Jak-1/NN and/CC Jak-3/CD ,/, subsequent/JJ steps/NNS in/IN the/DT signaling/NN pathway/NN to/TO the/DT nucleus/NN that/WDT lead/VBP to/TO the/DT activation/NN of/IN specific/JJ genes/NNS had/VBD not/RB been/VBN characterized/VBN ./. 
Since/IN many/JJ cytokines/NNS that/WDT activate/VBP Jak/NN kinases/NNS also/RB lead/VBP to/TO the/DT tyrosine/NN phosphorylation/NN and/CC activation/NN of/IN members/NNS of/IN the/DT Stat/NN family/NN of/IN transcription/NN factors/NNS ,/, the/DT ability/NN of/IN IL-2/NN to/TO trigger/VB Stat/NN phosphorylation/NN was/VBD examined/VBN ./. 
Exposure/NN of/IN activated/VBN human/JJ T/NN lymphocytes/NNS or/CC of/IN a/DT natural/JJ killer/NN cell/NN line/NN (/( NKL/NN )/) to/TO IL-2/NN leads/VBZ to/TO the/DT phosphorylation/NN of/IN Stat1/NN alpha/NN ,/, Stat1/NN beta/NN ,/, and/CC Stat3/NN ,/, as/RB well/RB as/IN of/IN two/CD Stat-related/JJ proteins/NNS ,/, p94/NN and/CC p95/NN ./. 
p94/NN and/CC p95/NN share/VBP homology/NN with/IN Stat1/NN at/IN the/DT phosphorylation/NN site/NN and/CC in/IN the/DT Src/NN homology/NN 2/CD (/( SH2/NN )/) domain/NN ,/, but/CC otherwise/RB are/VBP immunologically/RB distinct/JJ from/IN Stat1/NN ./. 
These/DT Stat/NN proteins/NNS were/VBD found/VBN to/TO translocate/VB to/TO the/DT nucleus/NN and/CC to/TO bind/VB to/TO a/DT specific/JJ DNA/NN sequence/NN ./. 
These/DT findings/NNS suggest/VBP a/DT mechanism/NN by/IN which/WDT IL-2/NN binding/VBG to/TO its/PRP$ receptor/NN may/MD activate/VB specific/JJ genes/NNS involved/VBN in/IN immune/JJ cell/NN function/NN ./. 
UI/LS -/: 98029486/CD 
TI/LS -/: Expression/NN of/IN c-fos/NN correlates/VBZ with/IN IFN-alpha/NN responsiveness/NN in/IN Philadelphia/NN chromosome/NN positive/JJ chronic/JJ myelogenous/JJ leukemia/NN ./. 
AB/LS -/: This/DT study/NN evaluates/VBZ (/( i/LS )/) constitutive/JJ levels/NNS of/IN oncogene/NN and/CC p53/NN transcripts/NNS in/IN chronic/JJ phase/NN CML/NN patients/NNS and/CC (/( ii/LS )/) their/PRP$ modulations/NNS subsequent/JJ to/TO in/FW vivo/FW therapy/NN with/IN rIFN-alpha/NN 2c/NN ./. 
Peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( pbmc/NN )/) and/CC bone/NN marrow/NN cells/NNS of/IN 26/CD patients/NNS were/VBD examined/VBN for/IN c-fos/NN ,/, c-myc/NN ,/, p53/NN and/CC the/DT hybrid/NN bcr/abl/NN mRNA/NN levels/NNS ./. 
Results/NNS indicated/VBD that/IN (/( i/LS )/) constitutive/JJ c-fos/NN transcript/NN levels/NNS are/VBP significantly/RB higher/JJR in/IN patients/NNS subsequently/RB responding/VBG to/TO IFN-alpha/NN therapy/NN (/( p/NN </JJR 0.01/CD )/) and/CC positively/RB correlated/VBN with/IN the/DT proportion/NN of/IN lymphocytes/NNS (/( r/NN =/JJ 0.6895/CD ,/, p/NN </JJR 0.01/CD )/) and/CC negatively/RB with/IN the/DT proportion/NN of/IN immature/JJ cells/NNS (/( r/NN =/JJ -0.568/CD ,/, p/NN </JJR 0.01/CD )/) contained/VBN in/IN the/DT pbmc/NN preparations/NNS tested/VBN ,/, (/( ii/LS )/) constitutive/JJ mRNA/NN levels/NNS of/IN the/DT hybrid/NN bcr/abl/NN ,/, c-myc/NN and/CC p53/NN are/VBP positively/RB correlated/VBN with/IN each/DT other/JJ ,/, but/CC failed/VBD to/TO relate/VB to/TO disease/NN parameters/NNS ,/, and/CC (/( iii/LS )/) acute/JJ and/CC chronic/JJ in/FW vivo/FW exposure/NN to/TO IFN-alpha/NN is/VBZ accompanied/VBN by/IN upregulation/NN of/IN c-fos/NN and/CC downregulation/NN of/IN c-myc/NN mRNA/NN levels/NNS in/IN responder/NN patients/NNS ./. 
UI/LS -/: 96191817/CD 
TI/LS -/: Menopause/NN is/VBZ associated/VBN with/IN a/DT significant/JJ increase/NN in/IN blood/NN monocyte/NN number/NN and/CC a/DT relative/JJ decrease/NN in/IN the/DT expression/NN of/IN estrogen/NN receptors/NNS in/IN human/JJ peripheral/JJ monocytes/NNS ./. 
AB/LS -/: PROBLEM/NN :/: The/DT clinical/JJ significance/NN of/IN the/DT differential/JJ expression/NN of/IN estrogen/NN receptor/NN (/( ER/NN )/) in/IN human/JJ monocytes/NNS was/VBD evaluated/VBN ./. 
METHOD/NN :/: Two/CD color/NN flow/NN cytometry/NN analysis/NN was/VBD used/VBN on/IN peripheral/JJ blood/NN samples/NNS of/IN young/JJ and/CC postmenopausal/JJ females/NNS and/CC postmenopausal/JJ females/NNS treated/VBN with/IN estrogen/NN replacement/NN therapy/NN ./. 
In/IN addition/NN ,/, the/DT monocyte/NN and/CC lymphocyte/NN counts/NNS and/CC the/DT blood/NN estrogen/NN levels/NNS of/IN each/DT patient/NN were/VBD determine/VBN ./. 
RESULTS/NNS :/: During/IN menopause/NN there/EX is/VBZ a/DT significant/JJ decrease/NN in/IN the/DT percentage/NN of/IN ER/NN positive/JJ monocytes/NNS ,/, and/CC an/DT increase/NN in/IN blood/NN monocyte/NN number/NN ,/, which/WDT declines/VBZ following/VBG estrogen/NN replacement/NN therapy/NN to/TO values/NNS of/IN the/DT young/JJ ./. 
CONCLUSIONS/NNS :/: These/DT findings/NNS suggest/VBP that/IN estrogen/NN modulates/VBZ the/DT monocyte/NN numbers/NNS and/CC its/PRP$ effects/NNS may/MD be/VB mediated/VBN through/IN the/DT ER/NN in/IN the/DT monocytes/NNS ./. 
UI/LS -/: 96074633/CD 
TI/LS -/: Staphylococcal/JJ enterotoxins/NNS modulate/VBP interleukin/NN 2/CD receptor/NN expression/NN and/CC ligand-induced/JJ tyrosine/NN phosphorylation/NN of/IN the/DT Janus/NN protein-tyrosine/NN kinase/NN 3/CD (/( Jak3/NN )/) and/CC signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( Stat/NN proteins/NNS )/) ./. 
AB/LS -/: Staphylococcal/JJ enterotoxins/NN (/( SE/NNS )/) stimulate/VBP T/NN cells/NNS expressing/VBG the/DT appropriate/JJ variable/JJ region/NN beta/NN chain/NN of/IN (/( V/NN beta/NN )/) T-cell/NN receptors/NNS and/CC have/VBP been/VBN implicated/VBN in/IN the/DT pathogenesis/NN of/IN several/JJ autoimmune/JJ diseases/NNS ./. 
Depending/VBG on/IN costimulatory/JJ signals/NNS ,/, SE/NNS induce/VBP either/CC proliferation/NN or/CC anergy/NN in/IN T/NN cells/NNS ./. 
In/IN addition/NN ,/, SE/NNS can/MD induce/VB an/DT interleukin-2/NN (/( IL-2/NN )/) nonresponsive/JJ state/NN and/CC apoptosis/NN ./. 
Here/RB ,/, we/PRP show/VBP that/IN SE/NNS induce/VBP dynamic/JJ changes/NNS in/IN the/DT expression/NN of/IN and/CC signal/NN transduction/NN through/IN the/DT IL-2/NN receptor/NN (/( IL-2R/NN )/) beta/NN and/CC gamma/NN chains/NNS (/( IL-2R/NN beta/NN and/CC IL-2R/NN gamma/NN )/) in/IN human/JJ antigen-specific/JJ CD4+/JJ T-cell/NN lines/NNS ./. 
Thus/RB ,/, after/IN 4/CD hr/NN of/IN exposure/NN to/TO SEA/NN and/CC SEB/NN ,/, the/DT expression/NN of/IN IL-2R/NN beta/NN was/VBD down-regulated/VBN ,/, IL-2R/NN gamma/NN was/VBD slightly/RB up-regulated/VBN ,/, while/IN IL-2R/NN alpha/NN remained/VBD largely/RB unaffected/JJ ./. 
The/DT changes/NNS in/IN the/DT composition/NN of/IN IL-2Rs/NNS were/VBD accompanied/VBN by/IN inhibition/NN of/IN IL-2-induced/JJ tyrosine/NN phosphorylation/NN of/IN the/DT Janus/NN protein-tyrosine/NN kinase/NN 3/CD (/( Jak3/NN )/) and/CC signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN called/VBN Stat3/NN and/CC Stat5/NN ./. 
In/IN parallel/JJ experiments/NNS ,/, IL-2-driven/JJ proliferation/NN was/VBD inhibited/VBN significantly/RB ./. 
After/IN 16/CD hr/NN of/IN exposure/NN to/TO SE/NNS ,/, the/DT expression/NN of/IN IL-2R/NN beta/NN remained/VBD low/JJ ,/, while/IN that/DT of/IN IL2R/NN alpha/NN and/CC IL2R/NN gamma/NN was/VBD further/RB up-regulated/VBN ,/, and/CC ligand-induced/JJ tyrosine/NN phosphorylation/NN of/IN Jak3/NN and/CC Stat/NN proteins/NNS was/VBD partly/RB normalized/VBN ./. 
Yet/RB ,/, IL-2-driven/JJ proliferation/NN remained/VBD profoundly/RB inhibited/JJ ,/, suggesting/VBG that/IN signaling/NN events/NNS other/JJ than/IN Jak3/Stat/NN activation/NN had/VBD also/RB been/VBN changed/VBN following/VBG SE/NNS stimulation/NN ./. 
In/IN conclusion/NN ,/, our/PRP$ data/NNS suggest/VBP that/IN SE/NNS can/MD modulate/VB IL-2R/NN expression/NN and/CC signal/NN transduction/NN involving/VBG the/DT Jak/Stat/NN pathway/NN in/IN CD4+/JJ T-cell/NN lines/NNS ./. 
UI/LS -/: 96086826/CD 
TI/LS -/: Constitutive/JJ NF-kappa/NN B/NN activation/NN ,/, enhanced/VBN granulopoiesis/NN ,/, and/CC neonatal/JJ lethality/NN in/IN I/NN kappa/NN B/NN alpha-deficient/JJ mice/NNS ./. 
AB/LS -/: Transcription/NN factors/NNS belonging/VBG to/TO the/DT NF-kappa/NN B/NN family/NN are/VBP controlled/VBN by/IN inhibitory/JJ I/NN kappa/NN B/NN proteins/NNS ,/, mainly/RB I/NN kappa/NN B/NN alpha/NN and/CC I/NN kappa/NN B/NN beta/NN ./. 
Apparently/RB normal/JJ at/IN birth/NN ,/, I/NN kappa/NN B/NN alpha-/-/JJ mice/NNS exhibit/VBP severe/JJ runting/NN ,/, skin/NN defects/NNS ,/, and/CC extensive/JJ granulopoiesis/NN postnatally/RB ,/, typically/RB dying/VBG by/IN 8/CD days/NNS ./. 
Hematopoietic/JJ tissues/NNS from/IN these/DT mice/NNS display/VBP elevated/JJ levels/NNS of/IN both/CC nuclear/JJ NF-kappa/NN B/NN and/CC mRNAs/NNS of/IN some/DT ,/, but/CC not/RB all/DT ,/, genes/NNS thought/VBN to/TO be/VB regulated/VBN by/IN NF-kappa/NN B/NN ./. 
NF-kappa/NN B/NN elevation/NN results/VBZ in/IN these/DT phenotypic/JJ abnormalities/NNS because/IN mice/NNS lacking/VBG both/CC I/NN kappa/NN B/NN alpha/NN and/CC the/DT p50/NN subunit/NN of/IN NF-kappa/NN B/NN show/VBP a/DT dramatically/RB delayed/VBN onset/NN of/IN abnormalities/NNS ./. 
In/IN contrast/NN to/TO hematopoietic/JJ cells/NNS ,/, I/NN kappa/NN B/NN alpha-/-/JJ embryonic/JJ fibroblasts/NNS show/VBP minimal/JJ constitutive/JJ NF-kappa/NN B/NN ,/, as/RB well/RB as/IN normal/JJ signal-dependent/JJ NF-kappa/NN B/NN activation/NN that/WDT is/VBZ concomitant/JJ with/IN I/NN kappa/NN B/NN beta/NN degradation/NN ./. 
Our/PRP$ results/NNS indicate/VBP that/IN I/NN kappa/NN b/NN beta/NN ,/, but/CC not/RB I/NN kappa/NN B/NN alpha/NN ,/, is/VBZ required/VBN for/IN the/DT signal-dependent/JJ activation/NN of/IN NF-kappa/NN B/NN in/IN fibroblasts/NNS ./. 
However/RB ,/, I/NN kappa/NN B/NN alpha/NN is/VBZ required/VBN for/IN the/DT postinduction/JJ repression/NN of/IN NF-kappa/NN B/NN in/IN fibroblasts/NNS ./. 
These/DT results/NNS define/VBP distinct/JJ roles/NNS for/IN the/DT two/CD forms/NNS of/IN I/NN kappa/NN B/NN and/CC demonstrate/VBP the/DT necessity/NN for/IN stringent/JJ control/NN of/IN NF-kappa/NN B/NN ./. 
UI/LS -/: 96085174/CD 
TI/LS -/: Interleukin-7/NN can/MD induce/VB the/DT activation/NN of/IN Jak/NN 1/CD ,/, Jak/NN 3/CD and/CC STAT/NN 5/CD proteins/NNS in/IN murine/JJ T/NN cells/NNS ./. 
AB/LS -/: The/DT activation/NN of/IN Janus/NN protein/NN tyrosine/NN kinases/NNS (/( Jak/NN )/) and/CC STAT/NN (/( signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN )/) proteins/NNS has/VBZ recently/RB been/VBN linked/VBN to/TO the/DT signal/NN transduction/NN mechanism/NN of/IN several/JJ cytokines/NNS ./. 
IL-7/NN was/VBD observed/VBN to/TO induce/VB a/DT rapid/JJ and/CC dose-dependent/JJ tyrosine/NN phosphorylation/NN of/IN Jak/NN 1/CD and/CC Jak/NN 3/CD and/CC concomitantly/RB ,/, the/DT tyrosine/NN phosphorylation/NN and/CC DNA/NN binding/NN activity/NN of/IN multiple/JJ STAT/NN proteins/NNS ./. 
The/DT STAT/NN proteins/NNS utilized/VBN by/IN IL-7/NN were/VBD identical/JJ to/TO those/DT induced/VBN by/IN IL-2/NN and/CC could/MD be/VB identified/VBN as/IN various/JJ STAT/NN 5/CD isoforms/NNS ./. 
Moreover/RB ,/, the/DT induction/NN of/IN both/CC Jak/NN 1/CD and/CC 3/CD ,/, and/CC STAT/NN 5/CD activity/NN strongly/RB correlated/VBD with/IN the/DT growth-promoting/JJ effects/NNS of/IN IL-7/NN ,/, suggesting/VBG that/IN this/DT signal/NN transduction/NN mechanism/NN may/MD play/VB a/DT key/JJ role/NN in/IN IL-7-induced/JJ proliferation/NN ./. 
UI/LS -/: 96288304/CD 
TI/LS -/: Cytokine-modulating/JJ activity/NN of/IN tepoxalin/NN ,/, a/DT new/JJ potential/JJ antirheumatic/NN ./. 
AB/LS -/: Tepoxalin/NN is/VBZ a/DT new/JJ dual/JJ cyclooxygenase/5-lipoxygenase/NN anti-inflammatory/JJ compound/NN currently/RB under/IN clinical/JJ investigation/NN ./. 
It/PRP has/VBZ been/VBN shown/VBN to/TO possess/VB anti-inflammatory/JJ activity/NN in/IN a/DT variety/NN of/IN animal/NN models/NNS and/CC more/RBR recently/RB to/TO inhibit/VB IL-2/NN induced/JJ signal/NN transduction/NN ./. 
The/DT current/JJ study/NN was/VBD conducted/VBN to/TO evaluate/VB the/DT cytokine/NN modulating/NN activity/NN of/IN tepoxalin/NN and/CC the/DT role/NN of/IN iron/NN in/IN these/DT effects/NNS ./. 
In/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NN )/) stimulated/VBN with/IN OKT3/PMA/NN ,/, tepoxalin/NN inhibited/VBD lymphocyte/NN proliferation/NN with/IN an/DT IC50/NN of/IN 6/CD microM/NN ./. 
Additionally/RB ,/, it/PRP inhibited/VBD the/DT production/NN of/IN LTB4/NN (/( IC50/NN =/JJ 0.5/CD microM/NN )/) and/CC the/DT cytokines/NNS IL-2/NN ,/, IL-6/NN and/CC TNF/NN alpha/NN (/( IC50/NN =/JJ 10-12/CD microM/NN )/) ./. 
Cytotoxicity/NN was/VBD not/RB demonstrated/VBN at/IN these/DT concentrations/NNS ./. 
Add-back/JJ experiments/NNS with/IN either/CC cytokines/NNS (/( IL-2/NN or/CC IL-6/NN )/) ,/, LTB4/NN or/CC conditioned/JJ media/NNS failed/VBD to/TO restore/VB the/DT proliferative/JJ response/NN in/IN the/DT presence/NN of/IN tepoxalin/NN ./. 
However/RB ,/, the/DT concurrent/JJ addition/NN of/IN iron/NN (/( in/IN the/DT form/NN of/IN ferrous/JJ or/CC ferric/JJ chloride/NN and/CC other/JJ iron/NN salts/NNS )/) reversed/VBD the/DT inhibition/NN of/IN proliferation/NN caused/VBN by/IN tepoxalin/NN ./. 
Tepoxalin/NN also/RB inhibits/VBZ the/DT activation/NN of/IN NF/NN kappa/NN B/NN ,/, a/DT transcription/NN factor/NN which/WDT acts/VBZ on/IN several/JJ cytokine/NN genes/NNS ./. 
Tepoxalin/NN 's/POS effect/NN on/IN NF/NN kappa/NN B/NN is/VBZ also/RB reversed/VBN by/IN the/DT addition/NN of/IN iron/NN salts/NNS ./. 
These/DT data/NNS suggest/VBP that/IN the/DT action/NN of/IN tepoxalin/NN to/TO inhibit/VB proliferation/NN in/IN PBMC/NN may/MD be/VB at/IN least/JJS in/IN part/NN due/JJ to/TO its/PRP$ ability/NN to/TO reduce/VB the/DT amount/NN of/IN available/JJ iron/NN resulting/VBG in/IN decreased/VBN activation/NN of/IN NF/NN kappa/NN B/NN and/CC subsequent/JJ inhibition/NN of/IN cytokine/NN production/NN ./. 
UI/LS -/: 96009559/CD 
TI/LS -/: N-/NN and/CC C-terminal/JJ sequences/NNS control/VBP degradation/NN of/IN MAD3/I/NN kappa/NN B/NN alpha/NN in/IN response/NN to/TO inducers/NNS of/IN NF-kappa/NN B/NN activity/NN ./. 
AB/LS -/: The/DT proteolytic/JJ degradation/NN of/IN the/DT inhibitory/JJ protein/NN MAD3/I/NN kappa/NN B/NN alpha/NN in/IN response/NN to/TO extracellular/JJ stimulation/NN is/VBZ a/DT prerequisite/JJ step/NN in/IN the/DT activation/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN ./. 
Analysis/NN of/IN the/DT expression/NN of/IN human/JJ I/NN kappa/NN B/NN alpha/NN protein/NN in/IN stable/JJ transfectants/NNS of/IN mouse/NN 70Z/3/NN cells/NNS shows/VBZ that/IN ,/, as/IN for/IN the/DT endogenous/JJ murine/JJ protein/NN ,/, exogenous/JJ I/NN kappa/NN B/NN alpha/NN is/VBZ degraded/VBN in/IN response/NN to/TO inducers/NNS of/IN NF-kappa/NN B/NN activity/NN ,/, such/JJ as/IN phorbol/NN myristate/NN acetate/NN or/CC lipopolysaccharide/NN ./. 
In/IN addition/NN ,/, pretreatment/NN of/IN the/DT cells/NNS with/IN the/DT proteasome/JJ inhibitor/NN N-Ac-Leu-Leu-norleucinal/NN inhibits/VBZ this/DT ligand-induced/JJ degradation/NN and/CC ,/, in/IN agreement/NN with/IN previous/JJ studies/NNS ,/, stabilizes/VBZ a/DT hyperphosphorylated/JJ form/NN of/IN the/DT human/JJ I/NN kappa/NN B/NN alpha/NN protein/NN ./. 
By/IN expressing/VBG mutant/JJ forms/NNS of/IN the/DT human/JJ protein/NN in/IN this/DT cell/NN line/NN ,/, we/PRP have/VBP been/VBN able/JJ to/TO delineate/VB the/DT sequences/NNS responsible/JJ for/IN both/CC the/DT ligand-induced/JJ phosphorylation/NN and/CC the/DT degradation/NN of/IN I/NN kappa/NN B/NN alpha/NN ./. 
Our/PRP$ results/NNS show/VBP that/IN deletion/NN of/IN the/DT C/NN terminus/NN of/IN the/DT I/NN kappa/NN B/NN alpha/NN molecule/NN up/RB to/TO amino/NN acid/NN 279/CD abolishes/VBZ constitutive/JJ but/CC not/RB ligand-inducible/JJ phosphorylation/NN and/CC inhibits/VBZ ligand-inducible/JJ degradation/NN ./. 
Further/JJ analysis/NN reveals/VBZ that/IN the/DT inducible/JJ phosphorylation/NN of/IN I/NN kappa/NN B/NN alpha/NN maps/VBZ to/TO two/CD serines/NNS in/IN the/DT N/NN terminus/NN of/IN the/DT protein/NN (/( residues/NNS 32/CD and/CC 36/CD )/) and/CC that/IN the/DT mutation/NN of/IN either/DT residue/NN is/VBZ sufficient/JJ to/TO abolish/VB ligand-induced/JJ degradation/NN ,/, whereas/IN both/DT residues/NNS must/MD be/VB mutated/VBN to/TO abolish/VB inducible/JJ phosphorylation/NN of/IN the/DT protein/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 95403403/CD 
TI/LS -/: Microtubules/NNS mediate/VBP cellular/JJ 25-hydroxyvitamin/NN D3/NN trafficking/NN and/CC the/DT genomic/JJ response/NN to/TO 1,25-dihydroxyvitamin/NN D3/NN in/IN normal/JJ human/JJ monocytes/NNS ./. 
AB/LS -/: The/DT genomic/JJ actions/NNS of/IN 1,25-dihydroxyvitamin/NN D3/NN (/( 1,25(OH)2D3/NN )/) are/VBP mediated/VBN by/IN the/DT intracellular/JJ vitamin/NN D/NN receptor/NN (/( VDR/NN )/) ./. 
Although/IN immunocytochemistry/NN has/VBZ shown/VBN that/IN disruption/NN of/IN microtubular/JJ assembly/NN prevents/VBZ nuclear/JJ access/NN of/IN the/DT sterol-VDR/NN complex/NN ,/, the/DT role/NN of/IN microtubules/NNS in/IN the/DT response/NN to/TO 1,25(OH)2D3/NN has/VBZ not/RB been/VBN studied/VBN in/IN viable/JJ cells/NNS ./. 
Our/PRP$ studies/NNS examined/VBD this/DT interaction/NN in/IN normal/JJ human/JJ monocytes/NNS ./. 
Monocytes/NNS convert/VBP 25(OH)D3/NN to/TO 1,25(OH)2D3/NN and/CC to/TO 24-hydroxylated/JJ metabolites/NNS more/RBR polar/JJ than/IN 1,25(OH)2D3/NN ./. 
Microtubule/NN disruption/NN totally/RB abolished/VBD the/DT ability/NN of/IN exogenous/JJ 1,25(OH)2D3/NN to/TO suppress/VB its/PRP$ own/JJ synthesis/NN and/CC to/TO induce/VB 24-hydroxylase/NN mRNA/NN and/CC activity/NN ,/, without/IN affecting/VBG either/CC total/JJ 1,25(OH)2D3/NN uptake/NN or/CC maximal/JJ 1,25(OH)2D3-VDR/JJ binding/NN ./. 
Thus/RB ,/, intact/JJ microtubules/NNS are/VBP essential/JJ for/IN 1,25(OH)2D3-dependent/JJ modulation/NN of/IN gene/NN transcription/NN ./. 
Interestingly/RB ,/, microtubule/NN disruption/NN also/RB decreased/VBD monocyte/NN 1,25(OH)2D3/NN synthesis/NN ,/, not/RB by/IN decreasing/VBG the/DT Vmax/NN of/IN monocyte/NN mitochondrial/JJ 1/CD alpha-hydroxylase/NN but/CC through/IN an/DT increase/NN in/IN the/DT Km/NN for/IN 25(OH)2D3/NN ./. 
We/PRP examined/VBD 25(OH)D3/NN transport/NN ./. 
Microtubule/NN disruption/NN did/VBD not/RB affect/VB total/JJ cellular/JJ 25(OH)D3/NN uptake/NN but/CC reduced/VBD its/PRP$ intracellular/JJ trafficking/NN to/TO the/DT mitochondria/NN ./. 
Thus/RB ,/, microtubules/NNS participate/VBP in/IN intracellular/JJ 25(OH)D3/NN transport/NN ,/, and/CC their/PRP$ integrity/NN determines/VBZ normal/JJ 1,25(OH)2D3/NN synthesis/NN ./. 
UI/LS -/: 95382761/CD 
TI/LS -/: Relationship/NN between/IN Rap1/NN protein/NN phosphorylation/NN and/CC regulation/NN of/IN Ca2+/NN transport/NN in/IN platelets/NNS :/: a/DT new/JJ approach/NN ./. 
AB/LS -/: Although/IN the/DT interrelationship/NN between/IN the/DT two/CD messengers/NNS Ca2+/NN and/CC cyclic/JJ AMP/NN in/IN platelet/NN function/NN is/VBZ well/RB documented/VBN ,/, its/PRP$ mechanism/NN of/IN action/NN still/RB remains/VBZ to/TO be/VB established/VBN ./. 
We/PRP investigated/VBD here/RB the/DT question/NN of/IN the/DT regulation/NN of/IN platelet/NN Ca(2+)-ATPases/NNS by/IN cyclic/JJ AMP/NN through/IN the/DT phosphorylation/NN of/IN the/DT Rap1/NN protein/NN using/VBG a/DT pathological/JJ model/NN ./. 
We/PRP first/RB found/VBD experimental/JJ conditions/NNS where/WRB Ca(2+)-transport/NN by/IN platelet/NN membrane/NN vesicles/NNS appeared/VBD to/TO be/VB dependent/JJ on/IN the/DT phosphorylation/NN of/IN the/DT Rap1/NN protein/NN ./. 
Then/RB ,/, we/PRP studied/VBD platelets/NNS of/IN patients/NNS with/IN congestive/JJ heart/NN failure/NN for/IN their/PRP$ expression/NN of/IN the/DT potential/JJ 97/CD kDa/NN Ca(2+)-ATPase/NN target/NN of/IN regulation/NN through/IN the/DT Rap1/NN protein/NN as/RB well/RB as/IN the/DT phosphorylation/NN of/IN the/DT Rap1/NN protein/NN using/VBG the/DT catalytic/JJ subunit/NN of/IN the/DT cyclic/JJ AMP-dependent/JJ protein/NN kinase/NN (/( C./JJ Sub./NN )/) ./. 
In/IN the/DT first/JJ patients/NNS studied/VBN ,/, we/PRP found/VBD no/DT significant/JJ modification/NN in/IN the/DT expression/NN of/IN the/DT 97/CD kDa/NN Ca(2+)-ATPase/NN by/IN Western/NN blotting/NN using/VBG the/DT PL/IM/NN 430/CD monoclonal/JJ antibody/NN which/WDT specifically/RB recognized/VBD this/DT isoform/NN ./. 
In/IN contrast/NN ,/, the/DT Rap1/NN protein/NN was/VBD differentially/RB phosphorylated/VBN when/WRB using/VBG 15/CD micrograms/ml/NNS of/IN the/DT C./NN Sub/NN ./. 
These/DT results/NNS allowed/VBD us/PRP to/TO use/VB these/DT pathological/JJ platelets/NNS to/TO study/VB the/DT relationship/NN between/IN the/DT expression/NN of/IN Rap1/NN protein/NN and/CC the/DT regulation/NN of/IN Ca2+/NN transport/NN by/IN selecting/VBG a/DT patient/NN with/IN severe/JJ heart/NN failure/NN ./. 
We/PRP could/MD show/VB a/DT decrease/NN in/IN the/DT expression/NN as/RB well/RB as/IN in/IN the/DT phosphorylation/NN of/IN Rap1/NN protein/NN and/CC demonstrate/VB a/DT lower/JJR effect/NN of/IN C./JJ Sub./NN on/IN Ca2+/NN transport/NN ./. 
Finally/RB ,/, by/IN studying/VBG a/DT further/JJ series/NN of/IN patients/NNS ,/, we/PRP could/MD confirm/VB that/IN the/DT decrease/NN in/IN Rap1/NN protein/NN expression/NN in/IN heart/NN failure/NN ,/, whatever/WDT its/PRP$ extent/NN ,/, was/VBD variable/JJ ,/, and/CC could/MD strictly/RB correlate/VB the/DT expression/NN of/IN Rap1/NN protein/NN with/IN the/DT stimulatory/JJ effect/NN of/IN C./JJ Sub./NN on/IN Ca2+/NN transport/NN ./. 
Besides/IN the/DT evidence/NN for/IN regulation/NN of/IN the/DT expression/NN of/IN the/DT Rap1/NN protein/NN in/IN platelets/NNS from/IN patients/NNS with/IN heart/NN failure/NN ,/, these/DT findings/NNS constitute/VBP a/DT new/JJ approach/NN in/IN favour/NN of/IN the/DT regulation/NN of/IN platelet/NN Ca2+/NN transport/NN through/IN the/DT phosphorylation/NN of/IN the/DT Rap1/NN protein/NN ./. 
UI/LS -/: 95364954/CD 
TI/LS -/: An/DT IRF-1-dependent/JJ pathway/NN of/IN DNA/NN damage-induced/JJ apoptosis/NN in/IN mitogen-activated/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: Lymphocytes/NNS are/VBP particularly/RB susceptible/JJ to/TO DNA/NN damage-induced/JJ apoptosis/NN ,/, a/DT response/NN which/WDT may/MD serve/VB as/IN a/DT form/NN of/IN '/`` altruistic/JJ suicide/NN '/'' to/TO counter/VB their/PRP$ intrinsic/JJ high/JJ potential/NN for/IN mutation/NN and/CC clonal/JJ expansion/NN ./. 
The/DT tumour/NN suppressor/NN p53/NN has/VBZ been/VBN shown/VBN to/TO regulate/VB this/DT type/NN of/IN apoptosis/NN in/IN thymocytes/NNS ,/, but/CC an/DT as/RB yet/RB unknown/JJ ,/, p53-independent/JJ pathway/NN (/( s/NNS )/) appears/VBZ to/TO mediate/VB the/DT same/JJ event/NN in/IN mitogen-activated/JJ mature/JJ T/NN lymphocytes/NNS ./. 
Here/RB we/PRP show/VBP DNA/NN damage-induced/JJ apoptosis/NN in/IN these/DT T/NN lymphocytes/NNS is/VBZ dependent/JJ on/IN the/DT antioncogenic/JJ transcription/NN factor/NN interferon/NN regulatory/JJ factor/NN (/( IRF/NN )/) -1/CD ./. 
Thus/RB two/CD different/JJ anti-onco-genic/JJ transcription/NN factors/NNS ,/, p53/NN and/CC IRF-1/NN ,/, are/VBP required/VBN for/IN distinct/JJ apoptotic/JJ pathways/NNS in/IN T/NN lymphocytes/NNS ./. 
We/PRP also/RB show/VBP that/IN mitogen/NN induction/NN of/IN the/DT interleukin-1/NN beta/NN converting/NN enzyme/NN (/( ICE/NN )/) gene/NN ,/, a/DT mammalian/JJ homologue/NN of/IN the/DT Caenorhabditis/FW elegans/FW cell/NN death/NN gene/NN ced-3/NN ,/, is/VBZ IRF-1-dependent/JJ ./. 
Ectopic/JJ overexpression/NN of/IN IRF-1/NN results/VBZ in/IN the/DT activation/NN of/IN the/DT endogenous/JJ gene/NN for/IN ICE/NN and/CC enhances/VBZ the/DT sensitivity/NN of/IN cells/NNS to/TO radiation-induced/JJ apoptosis/NN ./. 
UI/LS -/: 91017623/CD 
TI/LS -/: Circadian/JJ rhythm/NN of/IN glucocorticoid/NN receptors/NNS in/IN human/JJ peripheral/JJ leukocytes/NNS and/CC their/PRP$ reactivity/NN to/TO glucocorticoids/NNS ./. 
AB/LS -/: 1/LS )/) There/EX exists/VBZ a/DT CR/NN of/IN GR/NN in/IN human/JJ leukocytes/NNS ,/, PMN/NN ,/, and/CC monocytes/NNS with/IN the/DT peak/NN values/NNS from/IN 0400/CD to/TO 0800/CD hr/NN and/CC the/DT trough/NN values/NNS between/IN 2300/CD and/CC 0000/CD hr/NN ./. 
The/DT difference/NN between/IN them/PRP was/VBD significant/JJ statistically/RB ./. 
2/LS )/) The/DT FI/NN of/IN the/DT chemotactic/JJ migration/NN rate/NN of/IN PMN/NN by/IN cortisol/NN also/RB showed/VBD diurnal/JJ changes/NNS which/WDT were/VBD synchronous/JJ with/IN that/DT of/IN GR/NN ./. 
This/DT indicates/VBZ that/IN the/DT CR/NN of/IN GR/NN may/MD be/VB of/IN functional/JJ significance/NN ./. 
3/LS )/) In/IN Cushing/NN 's/POS syndrome/NN ,/, the/DT CR/NN of/IN GR/NN was/VBD normal/JJ in/IN spite/NN of/IN the/DT fact/NN that/IN the/DT CR/NN of/IN plasma/NN cortisol/NN was/VBD disturbed/VBN ./. 
This/DT indicates/VBZ the/DT independency/NN of/IN the/DT CR/NN of/IN GR/NN from/IN that/DT of/IN cortisol/NN ./. 
4/LS )/) In/IN apoplexy/NN caused/VBN by/IN brain/NN ischemia/NN ,/, the/DT CR/NN of/IN GR/NN was/VBD abolished/VBN in/IN patients/NNS with/IN basal/JJ lesions/NNS but/CC preserved/JJ when/WRB the/DT lesions/NNS were/VBD located/JJ in/IN the/DT cerebral/JJ cortex/NN ./. 
These/DT results/NNS strongly/RB suggest/VBP that/IN the/DT main/JJ "/`` circadian/JJ pacemaker/NN "/'' of/IN GR/NN is/VBZ located/JJ in/IN the/DT basal/JJ brain/NN ,/, most/RBS probably/RB in/IN the/DT suprachiasmatic/JJ nuclei/NNS as/IN has/VBZ been/VBN suggested/VBN for/IN rodents/NNS ./. 
UI/LS -/: 98005316/CD 
TI/LS -/: B-lymphoblastoid/JJ cell/NN lines/NNS from/IN multiple/JJ sclerosis/NN patients/NNS and/CC a/DT healthy/JJ control/NN producing/VBG a/DT putative/JJ new/JJ human/JJ retrovirus/NN and/CC Epstein-Barr/JJ virus/NN ./. 
AB/LS -/: On/IN several/JJ occasions/NNS we/PRP have/VBP observed/VBN retrovirus-like/JJ particles/NNS (/( RVLPs/NNS )/) by/IN transmission/NN electron/NN microscopy/NN (/( EM/NN )/) of/IN cultured/VBN T/NN cells/NNS from/IN a/DT patient/NN with/IN MS/NN ./. 
Later/RB we/PRP established/VBD spontaneously/RB formed/VBN B-lymphoblastoid/JJ cell/NN lines/NNS (/( LCLs/NNS )/) from/IN a/DT patient/NN with/IN an/DT MS-like/JJ disease/NN and/CC from/IN another/DT patient/NN with/IN MS/NN who/WP had/VBD a/DT reactivated/VBN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) infection/NN ./. 
Both/DT LCLs/NNS were/VBD found/VBN by/IN EM/NN to/TO produce/VB RVLP/NN and/CC EBV/NN particles/NNS ./. 
Reverse/JJ transcriptase/NN (/( RT/NN )/) assays/NNS were/VBD positive/JJ in/IN purified/VBN viral/JJ material/NN from/IN both/DT LCLs/NNS ./. 
To/TO substantiate/VB these/DT findings/NNS we/PRP initiated/VBD an/DT intensified/VBN culturing/NN procedure/NN and/CC were/VBD able/JJ to/TO establish/VB LCLs/NNS from/IN 5/CD out/RB of/IN 21/CD consecutive/JJ MS/NN patients/NNS and/CC 1/CD out/RB of/IN 13/CD consecutive/JJ healthy/JJ controls/NNS ./. 
All/DT LCLs/NNS were/VBD found/VBN to/TO produce/VB both/CC RVLP/NN and/CC EBV/NN particles/NNS by/IN EM/NN ./. 
Whether/IN the/DT putative/JJ new/JJ retrovirus/NN (/( es/NNS )/) and/CC EBV/NN have/VBP any/DT causal/JJ relationship/NN to/TO MS/NN is/VBZ still/RB not/RB known/VBN ,/, but/CC the/DT findings/NNS support/VBP this/DT possibility/NN ./. 
UI/LS -/: 96140672/CD 
TI/LS -/: Identification/NN of/IN an/DT ionomycin/cyclosporin/NN A-responsive/JJ element/NN within/IN the/DT human/JJ T/NN cell/NN receptor/NN gamma/NN enhancer/NN ./. 
AB/LS -/: Activation/NN through/IN the/DT Ca2+/NN /calcineurin/NN pathway/NN is/VBZ essential/JJ to/TO the/DT transcription/NN of/IN many/JJ cytokine/NN genes/NNS ./. 
The/DT conserved/VBN cis-acting/NN sequence/NN ,/, GGAAAA/NN ,/, and/CC transcription/NN factors/NNS binding/VBG to/TO this/DT sequence/NN are/VBP involved/VBN in/IN the/DT response/NN to/TO increased/VBN intracellular/JJ Ca2+/NN concentrations/NNS ./. 
Here/RB we/PRP report/VBP the/DT identification/NN and/CC importance/NN of/IN the/DT same/JJ sequence/NN in/IN a/DT non-cytokine/JJ gene/NN ,/, the/DT human/JJ T/NN cell/NN receptor/NN gamma/NN (/( TCRG/NN )/) enhancer/NN ./. 
Results/NNS from/IN site-directed/JJ mutations/NNS and/CC electrophoretic/JJ mobility/NN shift/NN assays/NNS strongly/RB suggest/VBP that/IN this/DT sequence/NN mediates/VBZ the/DT ionomycin-induced/JJ activation/NN of/IN the/DT TCRG/NN enhancer/NN ./. 
Our/PRP$ studies/NNS provide/VBP an/DT explanation/NN for/IN a/DT previous/JJ observation/NN that/IN TCRG/NN mRNA/NN levels/NNS ,/, but/CC not/RB mRNA/NN levels/NNS for/IN T/NN cell/NN receptor/NN alpha/NN and/CC -beta/NN ,/, are/VBP increased/VBN by/IN ionomycin/NN treatment/NN ./. 
UI/LS -/: 96074623/CD 
TI/LS -/: Coexpression/NN of/IN NF-kappa/NN B/NN /Rel/NN and/CC Sp1/NN transcription/NN factors/NNS in/IN human/JJ immunodeficiency/NN virus/NN 1-induced/JJ ,/, dendritic/JJ cell-T-cell/NN syncytia/NN ./. 
AB/LS -/: Productive/JJ infection/NN of/IN T/NN cells/NNS with/IN human/JJ immunodeficiency/NN virus/NN 1/CD (/( HIV-1/NN )/) typically/RB requires/VBZ that/IN the/DT T/NN cells/NNS be/VB stimulated/VBN with/IN antigens/NNS or/CC mitogens/NNS ./. 
This/DT requirement/NN has/VBZ been/VBN attributed/VBN to/TO the/DT activation/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN ,/, which/WDT synergizes/VBZ with/IN the/DT constitutive/JJ transcription/NN factor/NN Sp1/NN to/TO drive/VB the/DT HIV-1/NN promoter/NN ./. 
Recently/RB ,/, we/PRP have/VBP found/VBN that/IN vigorous/JJ replication/NN of/IN HIV-1/NN takes/VBZ place/NN in/IN nonactivated/JJ memory/NN T/NN cells/NNS after/IN syncytium/NN formation/NN with/IN dendritic/JJ cells/NNS (/( DCs/NNS )/) ./. 
These/DT syncytia/NNS lack/VBP activated/VBN cells/NNS as/IN determined/VBN by/IN an/DT absence/NN of/IN staining/VBG for/IN Ki-67/NN cell/NN cycle/NN antigen/NN ./. 
The/DT expression/NN and/CC activity/NN of/IN NF-kappa/NN B/NN and/CC Sp1/NN were/VBD ,/, therefore/RB ,/, analyzed/VBN in/IN isolated/VBN T/NN cells/NNS and/CC DCs/NNS from/IN humans/NNS and/CC mice/NNS ./. 
We/PRP have/VBP used/VBN immunolabeling/NN ,/, Western/NN blot/NN analysis/NN ,/, and/CC electrophoretic/JJ mobility/NN shift/NN and/CC supershift/NN assays/NNS ./. 
T/NN cells/NNS lack/VBP active/JJ NF-kappa/NN B/NN but/CC express/VBP Sp1/NN as/IN expected/VBN ./. 
DCs/NNS express/VBP high/JJ levels/NNS of/IN all/DT known/JJ NF-kappa/NN B/NN and/CC Rel/NN proteins/NNS ,/, with/IN activity/NN residing/VBG primarily/RB within/IN RelB/NN ,/, p50/NN ,/, and/CC p65/NN ./. 
However/RB ,/, DCs/NNS lack/VBP Sp1/NN ,/, which/WDT may/MD explain/VB the/DT failure/NN of/IN HIV-1/NN to/TO replicate/VB in/IN purified/VBN DCs/NNS ./. 
Coexpression/NN of/IN NF-kappa/NN B/NN and/CC Sp1/NN occurs/VBZ in/IN the/DT heterologous/JJ DC-T-cell/NN syncytia/NN that/WDT are/VBP induced/VBN by/IN HIV-1/NN ./. 
Therefore/RB ,/, HIV-1-induced/JJ cell/NN fusion/NN brings/VBZ together/RB factors/NNS that/WDT upregulate/VBP virus/NN transcription/NN ./. 
Since/IN DCs/NNS and/CC memory/NN T/NN cells/NNS frequently/RB traffic/VBP together/RB in/FW situ/FW ,/, these/DT unusual/JJ heterologous/JJ syncytia/NN could/MD develop/VB in/IN infected/JJ individuals/NNS and/CC lead/VB to/TO chronic/JJ HIV-1/NN replication/NN without/IN ostensible/JJ immune/JJ stimulation/NN ./. 
UI/LS -/: 96063646/CD 
TI/LS -/: Cupric/JJ ion/NN blocks/VBZ NF/NN kappa/NN B/NN activation/NN through/IN inhibiting/VBG the/DT signal-induced/JJ phosphorylation/NN of/IN I/NN kappa/NN B/NN alpha/NN ./. 
AB/LS -/: A/DT transcription/NN factor/NN NF/NN kappa/NN B/NN ,/, which/WDT regulates/VBZ expression/NN of/IN various/JJ cellular/JJ genes/NNS involved/VBN in/IN immune/JJ responses/NNS and/CC viral/JJ genes/NNS including/VBG HIV/NN ,/, is/VBZ sequestered/VBN in/IN the/DT cytoplasm/NN as/IN a/DT complex/NN with/IN an/DT inhibitory/JJ protein/NN I/NN kappa/NN B/NN ./. 
Various/JJ extracellular/JJ signals/NNS induce/VBP phosphorylation/NN and/CC rapid/JJ degradation/NN of/IN I/NN kappa/NN B/NN alpha/NN to/TO release/VB NF/NN kappa/NN B/NN ./. 
Cu2+/NN was/VBD found/VBN to/TO inhibit/VB the/DT activation/NN of/IN NF/NN kappa/NN B/NN induced/VBN by/IN TNF-alpha/NN ,/, TPA/NN ,/, or/CC H2O2/NN ./. 
Deoxycholate/NN treatment/NN of/IN the/DT cytoplasmic/JJ extract/NN prepared/VBN from/IN cells/NNS stimulated/VBN by/IN TNF-alpha/NN in/IN the/DT presence/NN of/IN Cu2+/NN resulted/VBD in/IN the/DT release/NN of/IN NF/NN kappa/NN B/NN from/IN I/NN kappa/NN B/NN alpha/NN ,/, indicating/VBG that/IN Cu2+/NN interferes/VBZ with/IN the/DT dissociation/NN of/IN the/DT NF/NN kappa/NN B-I/NN kappa/NN B/NN complex/NN ./. 
Neither/CC phosphorylation/NN nor/CC degradation/NN of/IN I/NN kappa/NN B/NN alpha/NN was/VBD observed/VBN upon/IN TNF-alpha/NN stimulation/NN in/IN the/DT presence/NN of/IN Cu2+/NN ./. 
These/DT results/NNS indicate/VBP that/IN Cu2+/NN inhibits/VBZ the/DT release/NN of/IN NF/NN kappa/NN B/NN by/IN blockade/NN of/IN a/DT signal/NN leading/VBG to/TO the/DT phosphorylation/NN of/IN I/NN kappa/NN B/NN alpha/NN ./. 
UI/LS -/: 96038813/CD 
TI/LS -/: Cloning/VBG a/DT cDNA/NN from/IN human/JJ NK/T/NN cells/NNS which/WDT codes/VBZ for/IN a/DT protein/NN with/IN high/JJ proline/NN content/NN ./. 
AB/LS -/: A/DT cDNA/NN clone/NN ,/, B4-2/NN ,/, was/VBD isolated/VBN from/IN a/DT natural/JJ killer/NN (/( NK/NN )/) minus/CC T/NN cell/NN subtractive/JJ library/NN ./. 
The/DT B4-2/NN clone/NN coded/VBD for/IN an/DT mRNA/NN of/IN 2061/CD bp/NN in/IN length/NN ./. 
It/PRP encodes/VBZ a/DT deduced/VBN 327/CD aa/NN protein/NN with/IN a/DT calculated/VBN molecular/JJ mass/NN of/IN 35.2/CD kDa/NN ./. 
Searching/NN of/IN B4-2/NN DNA/NN and/CC protein/NN sequences/NNS against/IN various/JJ databases/NNS revealed/VBD no/DT high/JJ homology/NN to/TO other/JJ sequences/NNS ./. 
However/RB ,/, B4-2/NN has/VBZ an/DT unusually/RB high/JJ proline/NN content/NN (/( 13/CD %/NN )/) ,/, contains/VBZ a/DT putative/JJ nuclear/JJ targeting/NN sequence/NN ,/, and/CC has/VBZ several/JJ SPXX/NN motifs/NNS which/WDT are/VBP frequently/RB found/VBN in/IN gene/NN regulatory/JJ proteins/NNS ./. 
One/CD of/IN the/DT stretches/NNS of/IN prolines/NNS in/IN B4-2/NN closely/RB resembles/VBZ the/DT ligand/NN for/IN proteins/NNS with/IN SH3/NN domains/NNS ./. 
Northern/NN hybridization/NN data/NNS showed/VBD that/IN B4-2/NN is/VBZ not/RB a/DT lymphoid/JJ specific/JJ gene/NN and/CC is/VBZ expressed/VBN in/IN a/DT hepatoma/NN cell/NN line/NN and/CC also/RB weakly/RB transcribed/VBN or/CC absent/JJ in/IN a/DT variety/NN of/IN other/JJ cells/NNS ./. 
A/DT polyclonal/JJ antiserum/NN raised/VBN against/IN recombinant/JJ B4-2/NN recognizes/VBZ a/DT 32-34/CD kDa/NN protein/NN in/IN lymphocytes/NNS ./. 
UI/LS -/: 96127450/CD 
TI/LS -/: Activation/NN of/IN JAK3/NN ,/, but/CC not/RB JAK1/NN ,/, is/VBZ critical/JJ for/IN IL-2-induced/JJ proliferation/NN and/CC STAT5/NN recruitment/NN by/IN a/DT COOH-terminal/JJ region/NN of/IN the/DT IL-2/NN receptor/NN beta-chain/NN ./. 
AB/LS -/: A/DT number/NN of/IN cytokines/NNS and/CC growth/NN factors/NNS use/VBP the/DT JAK-STAT/NN pathway/NN to/TO signal/VB from/IN the/DT cell/NN membrane/NN to/TO the/DT nucleus/NN ./. 
While/IN homodimerizing/VBG cytokine/NN receptors/NNS may/MD transmit/VB signal/NN via/IN a/DT single/JJ form/NN of/IN JAK/NN (/( i.e./FW growth/NN hormone/NN receptors/NNS )/) ,/, several/JJ multicomponent/JJ cytokine/NN receptors/NNS have/VBP been/VBN shown/VBN to/TO require/VB simultaneous/JJ activation/NN of/IN pairs/NNS of/IN different/JJ JAK/NN kinases/NNS (/( i.e./FW interferon/NN receptors/NNS )/) ./. 
Recent/JJ evidence/NN for/IN a/DT preferential/JJ coupling/NN of/IN JAK3/NN to/TO interleukin-2/NN receptor-gamma/NN (/( IL-2R/NN gamma/NN )/) and/CC JAK1/NN to/TO IL-2R/NN beta/NN supports/VBZ the/DT concept/NN of/IN heterotrans-activation/NN of/IN JAK1/NN and/CC JAK3/NN caused/VBN by/IN IL-2-induced/JJ heterodimerization/NN of/IN their/PRP$ receptor/NN partners/NNS ./. 
The/DT present/JJ study/NN verified/VBD the/DT ability/NN of/IN IL-2/NN to/TO cause/VB tyrosine/NN phosphorylation/NN and/CC activation/NN of/IN JAK1/NN and/CC JAK3/NN ,/, but/CC demonstrated/VBD that/IN IL-2/NN stimulated/VBD JAK3/NN to/TO a/DT significantly/RB larger/JJR extent/NN than/IN JAK1/NN in/IN human/JJ T/NN lymphocytes/NNS and/CC the/DT YT/NN cell/NN line/NN ./. 
This/DT conclusion/NN was/VBD based/VBN upon/IN several/JJ independent/JJ criteria/NNS ,/, including/VBG more/RBR vigorous/JJ tyrosine/NN phosphorylation/NN of/IN JAK3/NN ,/, more/RBR marked/JJ enzymatic/JJ activation/NN of/IN JAK3/NN as/RB well/RB as/IN higher/JJR abundance/NN of/IN JAK3/NN in/IN activated/VBN IL-2/NN receptor/NN complexes/NNS ./. 
Furthermore/RB ,/, when/WRB human/JJ IL-2R/NN beta/NN was/VBD stably/RB expressed/VBN in/IN murine/JJ BA/F3/NN cells/NNS ,/, robust/JJ IL-2-induced/JJ proliferation/NN and/CC JAK3/NN activation/NN occurred/VBD without/IN detectable/JJ involvement/NN of/IN either/CC JAK1/NN ,/, JAK2/NN or/CC TYK2/NN ./. 
We/PRP therefore/RB propose/VBP that/IN IL-2/NN receptor/NN signal/NN transduction/NN does/VBZ not/RB depend/VB on/IN equimolar/JJ heterodimerization/NN of/IN JAK1/NN and/CC JAK3/NN following/VBG IL-2-induced/JJ heterodimerization/NN of/IN IL-2R/NN beta/NN and/CC IL-2R/NN gamma/NN ./. 
Nonetheless/RB ,/, a/DT membrane-proximal/JJ region/NN of/IN human/JJ IL-2R/NN beta/NN (/( Asn240-Leu335/NN )/) was/VBD critical/JJ for/IN JAK3/NN activation/NN ,/, and/CC the/DT amount/NN of/IN JAK3/NN present/JJ in/IN activated/VBN IL-2/NN receptor/NN complexes/NNS increased/VBD with/IN time/NN ,/, suggesting/VBG that/IN stabilization/NN of/IN JAK3/NN binding/NN to/TO the/DT receptor/NN complex/NN relies/VBZ on/IN both/CC IL-2R/NN beta/NN and/CC IL-2R/NN gamma/NN ./. 
Moreover/RB ,/, STAT5/NN was/VBD found/VBN to/TO be/VB the/DT predominant/JJ STAT/NN transcription/NN factor/NN used/VBN by/IN IL-2/NN in/IN human/JJ T/NN cells/NNS ,/, and/CC specifically/RB required/VBD a/DT COOH-terminal/JJ region/NN of/IN IL-2R/NN beta/NN (/( Ser386-Val525/NN )/) ,/, while/IN STAT5/NN recruitment/NN was/VBD not/RB correlated/VBN to/TO activation/NN of/IN IL-2R/NN gamma/NN or/CC JAK3/NN ./. 
UI/LS -/: 96001293/CD 
TI/LS -/: Up-regulation/NN of/IN high-affinity/JJ dehydroepiandrosterone/NN binding/NN activity/NN by/IN dehydroepiandrosterone/NN in/IN activated/VBN human/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: Although/IN evidence/NN indicates/VBZ that/IN dehydroepiandrosterone/NN (/( DHEA/NN )/) exerts/VBZ direct/JJ physiological/JJ effects/NNS ,/, its/PRP$ mechanism/NN of/IN action/NN remains/VBZ unknown/JJ ./. 
DHEA/NN binding/NN sites/NNS were/VBD examined/VBN using/VBG a/DT whole-cell/JJ binding/NN assay/NN in/IN a/DT human/JJ T/NN lymphoid/JJ cell/NN line/NN ,/, PEER/NN ,/, revealing/VBG that/IN a/DT single/JJ class/NN of/IN high-affinity/JJ binding/VBG sites/NNS for/IN DHEA/NN (/( dissociation/NN constant/NN =/JJ 7.4/CD +/-/CC 0.53/CD nmol/L/NN ,/, mean/NN +/-/CC SE/NN ,/, n/NN =/JJ 4/CD )/) was/VBD greatly/RB increased/VBN when/WRB treated/VBN with/IN DHEA/NN ,/, phorbol-12-myristate-13-acetate/NN ,/, and/CC the/DT Ca2+/NN ionophore/NN A23187/NN ./. 
Bound/VBN [3H]DHEA/NN was/VBD displaced/JJ sensitively/RB by/IN DHEA/NN and/CC secondarily/RB by/IN dihydrotestosterone/NN ,/, but/CC not/RB effectively/RB by/IN other/JJ steroids/NNS ,/, including/VBG DHEA/NN sulfate/NN ./. 
These/DT results/NNS not/RB only/RB indicate/VBP the/DT existence/NN of/IN a/DT DHEA/NN receptor/NN ,/, but/CC also/RB suggest/VBP that/IN T/NN cells/NNS become/VBP susceptible/JJ to/TO regulation/NN by/IN DHEA/NN during/IN the/DT process/NN of/IN signal-induced/JJ activation/NN ./. 
UI/LS -/: 95394931/CD 
TI/LS -/: Ubiquitin-mediated/JJ processing/NN of/IN NF-kappa/NN B/NN transcriptional/JJ activator/NN precursor/NN p105/NN ./. 
Reconstitution/NN of/IN a/DT cell-free/JJ system/NN and/CC identification/NN of/IN the/DT ubiquitin-carrier/JJ protein/NN ,/, E2/NN ,/, and/CC a/DT novel/JJ ubiquitin-protein/JJ ligase/NN ,/, E3/NN ,/, involved/VBN in/IN conjugation/NN ./. 
AB/LS -/: In/IN most/JJS cases/NNS ,/, the/DT transcriptional/JJ factor/NN NF-kappa/NN B/NN is/VBZ a/DT heterodimer/NN consisting/VBG of/IN two/CD subunits/NNS ,/, p50/NN and/CC p65/NN ,/, which/WDT are/VBP encoded/VBN by/IN two/CD distinct/JJ genes/NNS of/IN the/DT Rel/NN family/NN ./. 
p50/NN is/VBZ translated/VBN as/IN a/DT precursor/NN of/IN 105/CD kDa/NN ./. 
The/DT C-terminal/JJ domain/NN of/IN the/DT precursor/NN is/VBZ rapidly/RB degraded/VBN ,/, forming/VBG the/DT mature/JJ p50/NN subunit/NN consisted/VBN of/IN the/DT N-terminal/JJ region/NN of/IN the/DT molecule/NN ./. 
The/DT mechanism/NN of/IN generation/NN of/IN p50/NN is/VBZ not/RB known/VBN ./. 
It/PRP has/VBZ been/VBN suggested/VBN that/IN the/DT ubiquitin-proteasome/JJ system/NN is/VBZ involved/VBN in/IN the/DT process/NN ;/: however/RB ,/, the/DT specific/JJ enzymes/NNS involved/VBN and/CC the/DT mechanism/NN of/IN limited/JJ proteolysis/NN ,/, in/IN which/WDT half/NN of/IN the/DT molecule/NN is/VBZ spared/VBN ,/, have/VBP been/VBN obscure/JJ ./. 
Palombella/NNP and/CC colleagues/NNS (/( Palombella/NNP ,/, V.J./NNP ,/, Rando/NNP ,/, O.J./NNP ,/, Goldberg/NNP ,/, A.L./NNP ,/, and/CC Maniatis/NNP ,/, T./NNP (/( 1994/CD )/) Cell/NNP 78/CD ,/, 773-785/CD )/) have/VBP shown/VBN that/IN ubiquitin/NN is/VBZ required/VBN for/IN the/DT processing/NN in/IN a/DT cell-free/JJ system/NN of/IN a/DT truncated/VBN ,/, artificially/RB constructed/VBN ,/, 60-kDa/JJ precursor/NN ./. 
They/PRP have/VBP also/RB shown/VBN that/IN proteasome/NN inhibitors/NNS block/VBP the/DT processing/NN both/CC in/FW vitro/FW and/CC in/FW vivo/FW ./. 
In/IN this/DT study/NN ,/, we/PRP demonstrate/VBP reconstitution/NN of/IN a/DT cell-free/JJ processing/NN system/NN and/CC demonstrate/VBP directly/RB that/IN :/: (/( a/LS )/) the/DT ubiquitin-proteasome/JJ system/NN is/VBZ involved/VBN in/IN processing/NN of/IN the/DT intact/JJ p105/NN precursor/NN ,/, (/( b/LS )/) conjugation/NN of/IN ubiquitin/NN to/TO the/DT precursor/NN is/VBZ an/DT essential/JJ intermediate/JJ step/NN in/IN the/DT processing/NN ,/, (/( c/LS )/) the/DT recently/RB discovered/VBN novel/JJ species/NNS of/IN the/DT ubiquitin-carrier/JJ protein/NN ,/, E2-F1/NN ,/, that/WDT is/VBZ involved/VBN in/IN the/DT conjugation/NN and/CC degradation/NN of/IN p53/NN ,/, is/VBZ also/RB required/VBN for/IN the/DT limited/JJ processing/NN of/IN the/DT p105/NN precursor/NN ,/, and/CC (/( d/LS )/) a/DT novel/JJ ,/, approximately/RB 320-kDa/CD species/NNS of/IN ubiquitin-protein/JJ ligase/NN ,/, is/VBZ involved/VBN in/IN the/DT process/NN ./. 
This/DT novel/JJ enzyme/NN is/VBZ distinct/JJ from/IN E6-AP/NN ,/, the/DT p53-conjugating/NN ligase/NN ,/, and/CC from/IN E3/NN alpha/NN ,/, the/DT "/`` N-end/JJ rule/NN "/'' ligase/NN ./. 
UI/LS -/: 95369491/CD 
TI/LS -/: Flutamide/NN in/IN the/DT treatment/NN of/IN hirsutism/NN :/: long-term/JJ clinical/JJ effects/NNS ,/, endocrine/JJ changes/NNS ,/, and/CC androgen/NN receptor/NN behavior/NN ./. 
AB/LS -/: OBJECTIVE/NN :/: To/TO investigate/VB the/DT long-term/JJ effects/NNS of/IN treatment/NN with/IN low/JJ doses/NNS of/IN flutamide/NN on/IN clinical/JJ and/CC hormonal/JJ parameters/NNS ,/, as/RB well/RB as/IN on/IN the/DT androgen/NN receptor/NN status/NN ,/, in/IN hirsute/JJ women/NNS ./. 
DESIGN/NN :/: Eighteen/CD hirsute/JJ patients/NNS with/IN regular/JJ menses/NNS were/VBD studied/VBN basally/RB and/CC during/IN treatment/NN with/IN 125/CD mg/NN flutamide/NN ,/, three/CD times/NNS per/IN day/NN for/IN 12/CD months/NNS ./. 
Barrier/NN or/CC intrauterine/JJ contraception/NN was/VBD used/VBN during/IN the/DT study/NN in/IN sexually/RB active/JJ women/NNS ./. 
Safety/NN parameters/NNS were/VBD assessed/VBN throughout/IN the/DT study/NN ./. 
Hirsutism/NN ,/, graded/VBN by/IN the/DT modified/VBN Ferriman-Gallwey/JJ score/NN ,/, and/CC hormonal/JJ parameters/NNS were/VBD evaluated/VBN basally/RB and/CC at/IN 4-month/JJ intervals/NNS during/IN treatment/NN ./. 
Gonadotropin-releasing/JJ hormone/NN and/CC ACTH/NN stimulation/NN tests/NNS were/VBD performed/VBN before/IN and/CC after/IN 3/CD to/TO 4/CD months/NNS of/IN therapy/NN ./. 
In/IN addition/NN ,/, the/DT concentration/NN of/IN androgen/NN receptors/NNS in/IN mononuclear/JJ leukocytes/NNS was/VBD measured/VBN ,/, in/IN both/CC the/DT follicular/JJ and/CC luteal/JJ phases/NNS of/IN the/DT menstrual/JJ cycle/NN ,/, basally/RB and/CC after/IN 4/CD months/NNS of/IN flutamide/NN treatment/NN ./. 
RESULTS/NNS :/: Flutamide/NN was/VBD well/RB tolerated/VBN in/IN all/DT women/NNS ,/, with/IN the/DT noticeable/JJ exception/NN of/IN one/CD patient/NN who/WP presented/VBD increased/VBN serum/NN transaminase/NN after/IN 8/CD months/NNS of/IN therapy/NN ./. 
Hirsutism/NN markedly/RB improved/VBD in/IN all/DT women/NNS during/IN the/DT treatment/NN (/( Ferriman-Gallwey/JJ score/NN after/IN 1/CD year/NN :/: 4.1/CD +/-/CC 0.5/CD versus/CC 14.1/CD +/-/CC 0.9/CD )/) ./. 
A/DT reduction/NN of/IN serum/NN androgens/NNS was/VBD found/VBN ,/, whereas/IN no/DT change/NN was/VBD observed/VBN in/IN either/CC basal/JJ or/CC GnRH-stimulated/JJ gonadotropins/NNS or/CC in/IN the/DT cortisol/NN and/CC 17/CD alpha-hydroxyprogesterone/NN response/NN to/TO ACTH/NN ./. 
Cycles/NNS remained/VBD ovulatory/JJ ./. 
Before/IN treatment/NN ,/, the/DT number/NN of/IN androgen/NN receptors/NNS was/VBD higher/JJR in/IN the/DT luteal/NN than/IN in/IN the/DT follicular/JJ phase/NN ./. 
This/DT rhythmic/JJ differentiation/NN disappeared/VBD after/IN the/DT patients/NNS had/VBD been/VBN given/VBN the/DT antiandrogen/JJ drug/NN ./. 
CONCLUSIONS/NNS :/: Flutamide/NN is/VBZ effective/JJ in/IN the/DT treatment/NN of/IN hirsutism/NN but/CC requires/VBZ constant/JJ surveillance/NN of/IN liver/NN function/NN ./. 
Androgen/NN receptor/NN blockade/NN might/MD be/VB potentiated/VBN by/IN a/DT reduction/NN of/IN serum/NN androgens/NNS ./. 
Flutamide/NN affects/VBZ androgen/NN receptor/NN behavior/NN during/IN the/DT menstrual/JJ cycle/NN ./. 
The/DT meaning/NN of/IN this/DT finding/NN remains/VBZ to/TO be/VB elucidated/VBN ./. 
UI/LS -/: 90188846/CD 
TI/LS -/: Constitutive/JJ expression/NN of/IN HIV-1/NN tat/NN protein/NN in/IN human/JJ Jurkat/NN T/NN cells/NNS using/VBG a/DT BK/NN virus/NN vector/NN ./. 
AB/LS -/: The/DT production/NN and/CC characterization/NN of/IN Jurkat/NN cell/NN lines/NNS that/WDT constitutively/RB express/VBP functional/JJ human/JJ immune/JJ deficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) tat/NN protein/NN ,/, using/VBG a/DT BK/NN virus/NN plasmid/NN expression/NN vector/NN and/CC HIV-1/NN tat/NN cDNA/NN ,/, is/VBZ described/VBN ./. 
An/DT increased/VBN growth/NN rate/NN of/IN these/DT Jurkat-tat/NN cell/NN lines/NNS as/IN compared/VBN with/IN control/JJ cell/NN lines/NNS was/VBD observed/VBN ./. 
UI/LS -/: 96125073/CD 
TI/LS -/: A/DT PEBP2/NN alpha/AML-1-related/JJ factor/NN increases/VBZ osteocalcin/NN promoter/NN activity/NN through/IN its/PRP$ binding/NN to/TO an/DT osteoblast-specific/JJ cis-acting/JJ element/NN ./. 
AB/LS -/: To/TO identify/VB osteoblast-specific/JJ cis-acting/JJ elements/NNS and/CC trans-acting/JJ factors/NNS ,/, we/PRP initiated/VBD an/DT analysis/NN of/IN the/DT promoter/NN of/IN a/DT mouse/NN osteocalcin/NN gene/NN ,/, an/DT osteoblast-specific/JJ gene/NN ./. 
In/IN this/DT promoter/NN ,/, we/PRP identified/VBD two/CD osteoblast-specific/JJ cis-acting/JJ elements/NNS (/( Ducy/NNP ,/, P./NNP and/CC Karsenty/NNP ,/, G./NNP (/( 1995/CD )/) Mol.Cell.Biol.15/NNP ,/, 1858-1869/CD )/) ./. 
The/DT sequence/NN of/IN one/CD of/IN these/DT elements/NNS ,/, OSE2/NN ,/, is/VBZ identical/JJ to/TO the/DT DNA-binding/JJ site/NN of/IN the/DT PEBP2/NN alpha/AML-1/NN transcription/NN factors/NNS ,/, the/DT mammalian/JJ homologues/NNS of/IN the/DT Drosophila/FW Runt/NN protein/NN ./. 
Here/RB we/PRP show/VBP ,/, using/VBG nuclear/JJ extracts/NNS ,/, recombinant/JJ protein/NN ,/, and/CC a/DT specific/JJ antiserum/NN against/IN AML-1/NN proteins/NNS in/IN DNA-binding/JJ assays/NNS ,/, that/IN one/CD member/NN of/IN this/DT family/NN ,/, AML-1B/NN ,/, binds/VBZ specifically/RB to/TO OSE2/NN and/CC is/VBZ immunologically/RB related/JJ to/TO OSF2/NN ,/, the/DT factor/NN present/JJ in/IN osteoblast/NN nuclear/JJ extracts/NNS that/WDT binds/VBZ to/TO OSE2/NN ./. 
By/IN DNA/NN cotransfection/NN experiments/NNS ,/, we/PRP also/RB demonstrate/VBP that/IN AML-1B/NN can/MD increase/VB the/DT activity/NN of/IN a/DT short/JJ osteocalcin/NN promoter/NN through/IN its/PRP$ binding/NN to/TO OSE2/NN ./. 
Lastly/RB ,/, the/DT different/JJ mobilities/NNS of/IN osteoblast/NN nuclear/JJ extract-DNA/JJ complexes/NNS compared/VBN with/IN T-cell/NN nuclear/JJ extract-DNA/JJ complexes/NNS ,/, along/IN with/IN the/DT inability/NN of/IN OSF2/NN to/TO be/VB upregulated/VBN by/IN retinoic/JJ acid/NN ,/, unlike/IN the/DT other/JJ PEBP2/NN alpha/NN factors/NNS ,/, suggest/VBP that/IN OSF2/NN is/VBZ a/DT new/JJ member/NN of/IN this/DT family/NN of/IN transcription/NN factors/NNS ./. 
Thus/RB ,/, this/DT study/NN demonstrates/VBZ that/IN AML-1B/NN can/MD increase/VB gene/NN expression/NN of/IN an/DT osteoblast-specific/JJ gene/NN through/IN its/PRP$ binding/NN to/TO an/DT osteoblast-specific/JJ cis-acting/JJ element/NN and/CC presents/VBZ evidence/NN that/IN OSF2/NN is/VBZ a/DT member/NN of/IN the/DT PEBP2/NN alpha/AML-1/NN family/NN of/IN transcription/NN factors/NNS ./. 
UI/LS -/: 96069375/CD 
TI/LS -/: Initiation/NN binding/NN repressor/NN ,/, a/DT factor/NN that/WDT binds/VBZ to/TO the/DT transcription/NN initiation/NN site/NN of/IN the/DT histone/NN h5/NN gene/NN ,/, is/VBZ a/DT glycosylated/VBN member/NN of/IN a/DT family/NN of/IN cell/NN growth/NN regulators/NNS [/( corrected/JJ ]/) [/( published/VBN erratum/NN appears/VBZ in/IN Mol/NNP Cell/NNP Biol/NNP 1996/CD Feb/NNP ;/: 16/CD (/( 2/CD )/) :/: 735/CD ]/) 
AB/LS -/: Initiation/NN binding/NN repressor/NN [/( corrected/VBN ]/) (/( IBR/NN )/) is/VBZ a/DT chicken/NN erythrocyte/NN factor/NN (/( apparent/JJ molecular/JJ mass/NN ,/, 70/CD to/TO 73/CD kDa/NN )/) that/WDT binds/VBZ to/TO the/DT sequences/NNS spanning/VBG the/DT transcription/NN initiation/NN site/NN of/IN the/DT histone/NN h5/NN gene/NN ,/, repressing/VBG its/PRP$ transcription/NN ./. 
A/DT variety/NN of/IN other/JJ cells/NNS ,/, including/VBG transformed/VBN erythroid/JJ precursors/NNS ,/, do/VBP not/RB have/VB IBR/NN but/CC a/DT factor/NN referred/VBN to/TO as/IN IBF/NN (/( 68/CD to/TO 70/CD kDa/NN )/) that/WDT recognizes/VBZ the/DT same/JJ IBR/NN sites/NNS ./. 
We/PRP have/VBP cloned/VBN the/DT IBR/NN cDNA/NN and/CC studied/VBN the/DT relationship/NN of/IN IBR/NN and/CC IBF/NN ./. 
IBR/NN is/VBZ a/DT 503-amino-acid-long/JJ acidic/JJ protein/NN which/WDT is/VBZ 99.0/CD %/NN identical/JJ to/TO the/DT recently/RB reported/VBN human/JJ NRF-1/alpha-Pal/NN factor/NN and/CC highly/RB related/JJ to/TO the/DT invertebrate/JJ transcription/NN factors/NNS P3A2/NN and/CC erected/JJ wing/NN gene/NN product/NN (/( EWG/NN )/) ./. 
We/PRP present/VBP evidence/NN that/IN IBR/NN and/CC IBF/NN are/VBP most/RBS likely/RB identical/JJ proteins/NNS ,/, differing/VBG in/IN their/PRP$ degree/NN of/IN glycosylation/NN ./. 
We/PRP have/VBP analyzed/VBN several/JJ molecular/JJ aspects/NNS of/IN IBR/F/NN and/CC shown/VBN that/IN the/DT factor/NN associates/VBZ as/IN stable/JJ homodimers/NNS and/CC that/IN the/DT dimer/NN is/VBZ the/DT relevant/JJ DNA-binding/JJ species/NNS ./. 
The/DT evolutionarily/RB conserved/VBN N-terminal/JJ half/NN of/IN IBR/F/NN harbors/VBZ the/DT DNA-binding/dimerization/JJ domain/NN (/( outer/JJ limits/NNS ,/, 127/CD to/TO 283/CD )/) ,/, one/CD or/CC several/JJ casein/NN kinase/NN II/CD sites/NNS (/( 37/CD to/TO 67/CD )/) ,/, and/CC a/DT bipartite/JJ nuclear/JJ localization/NN signal/NN (/( 89/CD to/TO 106/CD )/) which/WDT appears/VBZ to/TO be/VB necessary/JJ for/IN nuclear/JJ targeting/NN ./. 
Binding/VBG site/NN selection/NN revealed/VBD that/IN the/DT alternating/VBG RCGCRYGCGY/NN consensus/NN constitutes/VBZ high-affinity/JJ IBR/F/NN binding/NN sites/NNS and/CC that/IN the/DT direct-repeat/JJ palindrome/NN TGCGCATGCGCA/NN is/VBZ the/DT optimal/JJ site/NN ./. 
A/DT survey/NN of/IN genes/NNS potentially/RB regulated/VBN by/IN this/DT family/NN of/IN factors/NNS primarily/RB revealed/VBD genes/NNS involved/VBN in/IN growth-related/JJ metabolism/NN ./. 
UI/LS -/: 96070930/CD 
TI/LS -/: Triggering/NN of/IN the/DT human/JJ interleukin-6/NN gene/NN by/IN interferon-gamma/NN and/CC tumor/NN necrosis/NN factor-alpha/NN in/IN monocytic/JJ cells/NNS involves/VBZ cooperation/NN between/IN interferon/NN regulatory/JJ factor-1/NN ,/, NF/NN kappa/NN B/NN ,/, and/CC Sp1/NN transcription/NN factors/NNS ./. 
AB/LS -/: We/PRP investigated/VBD the/DT molecular/JJ basis/NN of/IN the/DT synergistic/JJ induction/NN by/IN interferon-gamma/NN (/( IFN-gamma/NN )/) /tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) of/IN human/JJ interleukin-6/NN (/( IL-6/NN )/) gene/NN in/IN THP-1/NN monocytic/JJ cells/NNS ,/, and/CC compared/VBD it/PRP with/IN the/DT basis/NN of/IN this/DT induction/NN by/IN lipopolysaccharide/NN (/( LPS/NN )/) ./. 
Functional/JJ studies/NNS with/IN IL-6/NN promoter/NN demonstrated/VBD that/IN three/CD regions/NNS are/VBP the/DT targets/NNS of/IN the/DT IFN-gamma/NN and/or/CC TNF-alpha/NN action/NN ,/, whereas/IN only/RB one/CD of/IN these/DT regions/NNS seemed/VBD to/TO be/VB implicated/VBN in/IN LPS/NN activation/NN ./. 
The/DT three/CD regions/NNS concerned/VBN are/VBP :/: 1/LS )/) a/DT region/NN between/IN -73/CD and/CC -36/CD ,/, which/WDT is/VBZ the/DT minimal/JJ element/NN inducible/JJ by/IN LPS/NN or/CC TNF-alpha/NN ;/: 2/LS )/) an/DT element/NN located/JJ between/IN -181/CD and/CC -73/CD ,/, which/WDT appeared/VBD to/TO regulate/VB the/DT response/NN to/TO IFN-gamma/NN and/CC TNF-alpha/NN negatively/RB ;/: and/CC 3/LS )/) a/DT distal/JJ element/NN upstream/JJ of/IN -224/CD ,/, which/WDT was/VBD inducible/JJ by/IN IFN-gamma/NN alone/RB ./. 
LPS/NN signaling/NN was/VBD found/VBN to/TO involve/VB NF/NN kappa/NN B/NN activation/NN by/IN the/DT p50/NN /p65/NN heterodimers/NNS ./. 
Synergistic/JJ induction/NN of/IN the/DT IL-6/NN gene/NN by/IN IFN-gamma/NN and/CC TNF-alpha/NN ,/, in/IN monocytic/JJ cells/NNS ,/, involved/VBD cooperation/NN between/IN the/DT IRF-1/NN and/CC NF/NN kappa/NN B/NN p65/NN homodimers/NNS with/IN concomitant/JJ removal/NN of/IN the/DT negative/JJ effect/NN of/IN the/DT retinoblastoma/NN control/NN element/NN present/JJ in/IN the/DT IL-6/NN promoter/NN ./. 
This/DT removal/NN occurred/VBD by/IN activation/NN of/IN the/DT constitutive/JJ Sp1/NN factor/NN ,/, whose/WP$ increased/VBN binding/NN activity/NN and/CC phosphorylation/NN were/VBD mediated/VBN by/IN IFN-gamma/NN ./. 
UI/LS -/: 96055115/CD 
TI/LS -/: Mutation/NN of/IN Jak3/NN in/IN a/DT patient/NN with/IN SCID/NN :/: essential/JJ role/NN of/IN Jak3/NN in/IN lymphoid/JJ development/NN ./. 
AB/LS -/: Males/NNS with/IN X-linked/JJ severe/JJ combined/JJ immunodeficiency/NN (/( XSCID/NN )/) have/VBP defects/NNS in/IN the/DT common/JJ cytokine/NN receptor/NN gamma/NN chain/NN (/( gamma/NN c/NN )/) gene/NN that/WDT encodes/VBZ a/DT shared/JJ ,/, essential/JJ component/NN of/IN the/DT receptors/NNS of/IN interleukin-2/NN (/( IL-2/NN )/) ,/, IL-4/NN ,/, IL-7/NN ,/, IL-9/NN ,/, and/CC IL-15/NN ./. 
The/DT Janus/NN family/NN tyrosine/NN kinase/NN Jak3/NN is/VBZ the/DT only/JJ signaling/VBG molecule/NN known/VBN to/TO be/VB associated/VBN with/IN gamma/NN c/NN ,/, so/IN it/PRP was/VBD hypothesized/VBN that/IN defects/NNS in/IN Jak3/NN might/MD cause/VB an/DT XSCID-like/JJ phenotype/NN ./. 
A/DT girl/NN with/IN immunological/JJ features/NNS indistinguishable/JJ from/IN those/DT of/IN XSCID/NN was/VBD therefore/RB selected/VBN for/IN analysis/NN ./. 
An/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) -transformed/JJ cell/NN line/NN derived/VBN from/IN her/PRP$ lymphocytes/NNS had/VBD normal/JJ gamma/NN c/NN expression/NN but/CC lacked/VBD Jak3/NN protein/NN and/CC had/VBD greatly/RB diminished/VBN Jak3/NN messenger/NN RNA/NN ./. 
Sequencing/NN revealed/VBD a/DT different/JJ mutation/NN on/IN each/DT allele/NN :/: a/DT single/JJ nucleotide/NN insertion/NN resulting/VBG in/IN a/DT frame/NN shift/NN and/CC premature/JJ termination/NN in/IN the/DT Jak3/NN JH4/NN domain/NN and/CC a/DT nonsense/JJ mutation/NN in/IN the/DT Jak3/NN JH2/NN domain/NN ./. 
The/DT lack/NN of/IN Jak3/NN expression/NN correlated/VBD with/IN impaired/JJ B/NN cell/NN signaling/NN ,/, as/IN demonstrated/VBN by/IN the/DT inability/NN of/IN IL-4/NN to/TO activate/VB Stat6/NN in/IN the/DT EBV-transformed/JJ cell/NN line/NN from/IN the/DT patient/NN ./. These/DT observations/NNS indicate/VBP that/IN the/DT functions/NNS of/IN gamma/NN c/NN are/VBP dependent/JJ on/IN Jak3/NN and/CC that/IN Jak3/NN is/VBZ essential/JJ for/IN lymphoid/JJ development/NN and/CC signaling/NN ./. 
UI/LS -/: 96017245/CD 
TI/LS -/: Constitutive/JJ overexpression/NN of/IN the/DT L-selectin/NN gene/NN in/IN fresh/JJ leukemic/JJ cells/NNS of/IN adult/JJ T-cell/NN leukemia/NN that/WDT can/MD be/VB transactivated/VBN by/IN human/JJ T-cell/NN lymphotropic/JJ virus/NN type/NN 1/CD Tax/NN ./. 
AB/LS -/: L-selectin/NN is/VBZ an/DT adhesion/NN molecule/NN of/IN the/DT selectin/NN family/NN that/WDT mediates/VBZ the/DT initial/JJ step/NN of/IN leukocyte/NN adhesion/NN to/TO vascular/JJ endothelium/NN ./. 
Upon/IN cellular/JJ activation/NN ,/, expression/NN of/IN the/DT L-selectin/NN gene/NN is/VBZ downregulated/VBN at/IN both/CC the/DT protein/NN and/CC mRNA/NN levels/NNS ./. 
To/TO understand/VB the/DT mechanism/NN of/IN leukemic/JJ cell/NN infiltration/NN into/IN organs/NNS ,/, we/PRP studied/VBD the/DT expression/NN and/CC regulation/NN of/IN L-selectin/NN mRNA/NN in/IN fresh/JJ leukemic/JJ cells/NNS of/IN adult/JJ T-cell/NN leukemia/NN (/( ATL/NN )/) patients/NNS and/CC investigated/VBD the/DT response/NN of/IN the/DT L-selectin/NN promoter/NN to/TO human/JJ T-cell/NN lymphotropic/JJ virus/NN type/NN 1/CD (/( HTLV-1/NN )/) Tax/NN ,/, which/WDT is/VBZ a/DT viral/JJ transcriptional/JJ transactivator/NN ./. 
Flow/NN cytometry/NN showed/VBD that/IN L-selectin/NN was/VBD expressed/VBN on/IN fresh/JJ ATL/NN cells/NNS along/IN with/IN other/JJ activation/NN antigens/NNS ./. 
Northern/NN blot/NN analysis/NN showed/VBD that/IN ATL/NN cells/NNS overexpressed/VBD that/DT L-selectin/NN mRNA/NN and/CC that/IN the/DT level/NN was/VBD aberrantly/RB upregulated/VBN after/IN PMA/NN stimulation/NN ./. 
Studies/NNS using/VBG in/FW situ/FW hybridization/NN showed/VBD expression/NN of/IN the/DT L-selectin/NN mRNA/NN in/IN the/DT infiltrating/VBG leukemic/JJ cells/NNS in/IN the/DT liver/NN of/IN two/CD ATL/NN patients/NNS ./. 
Intravenous/JJ injection/NN of/IN a/DT rat/NN T-cell/NN line/NN that/WDT overexpresses/VBZ L-selectin/NN showed/VBD increased/VBN organ/NN infiltration/NN ./. 
The/DT induction/NN of/IN Tax/NN expression/NN in/IN JPX9/NN cells/NNS resulted/VBD in/IN about/RB a/DT twofold/JJ increase/NN in/IN the/DT mRNA/NN expression/NN levels/NNS compared/VBN with/IN the/DT basal/JJ level/NN ./. 
Chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) assay/NN after/IN transient/JJ cotransfection/NN showed/VBD about/RB a/DT fivefold/JJ transactivation/NN of/IN the/DT L-selectin/NN promoter/NN by/IN Tax/NN ./. 
The/DT serum/NN level/NN of/IN the/DT shed/NN form/NN of/IN L-selectin/NN was/VBD significantly/RB increased/VBN in/IN ATL/NN patients/NNS (/( mean/NN +/-/CC SD/NN ,/, 4,215.4/CD +/-/CC 4,111/CD ng/mL/NN )/) compared/VBN with/IN those/DT of/IN asymptomatic/JJ carriers/NNS and/CC healthy/JJ blood/NN donors/NNS (/( mean/NN +/-/CC SD/NN ,/, 1,148.0/CD +/-/CC 269.0/CD ng/mL/NN and/CC 991.9/CD +/-/CC 224/CD ng/mL/NN ,/, respectively/RB )/) ./. 
These/DT results/NNS indicated/VBD that/IN ATL/NN cells/NNS constitutively/RB overexpress/VBP the/DT L-selectin/NN gene/NN that/WDT can/MD be/VB transactivated/VBN by/IN HTLV-1/NN Tax/NN ./. 
The/DT overexpression/NN of/IN L-selectin/NN ,/, as/RB well/RB as/IN of/IN inflammatory/JJ cytokines/NNS ,/, by/IN ATL/NN cells/NNS may/MD provide/VB a/DT basis/NN for/IN ATL/NN cells/NNS to/TO attach/VB the/DT vascular/JJ endothelium/NN ,/, leading/VBG to/TO transmigration/NN and/CC organ/NN infitration/NN ./. 
UI/LS -/: 96157213/CD 
TI/LS -/: Human/JJ herpesvirus/NN 6/CD variant/NN A/NN ,/, but/CC not/RB variant/NN B/NN ,/, infects/VBZ EBV-positive/JJ B/NN lymphoid/JJ cells/NNS ,/, activating/VBG the/DT latent/JJ EBV/NN genome/NN through/IN a/DT BZLF-1-dependent/JJ mechanism/NN ./. 
AB/LS -/: Human/JJ herpesvirus/NN 6/CD ,/, a/DT predominantly/RB T/NN lymphotropic/JJ virus/NN ,/, has/VBZ been/VBN recently/RB shown/VBN to/TO infect/VB some/DT EBV/JJ -positive/JJ B/NN cell/NN lines/NNS ,/, and/CC to/TO induce/VB in/IN them/PRP the/DT activation/NN of/IN the/DT EBV/NN lytic/JJ cycle/NN ./. 
Here/RB we/PRP have/VBP confirmed/VBN and/CC extended/VBN such/JJ observations/NNS ,/, showing/VBG that/IN (/( 1/LS )/) this/DT phenomenon/NN is/VBZ restricted/JJ to/TO the/DT variant/NN A/NN of/IN HHV-6/NN :/: in/IN fact/NN two/CD isolates/NNS belonging/VBG to/TO the/DT HHV-6/NN variant/NN B/NN (/( BA92/NN and/CC Z29/NN )/) were/VBD neither/CC able/JJ to/TO infect/VB any/DT B/NN cell/NN line/NN ,/, independently/RB of/IN the/DT EBV/NN status/NN ,/, nor/CC to/TO induce/VB the/DT EBV/NN genome/NN expression/NN ./. 
The/DT only/JJ exception/NN is/VBZ represented/VBN by/IN the/DT P3HR1/NN cells/NNS ,/, in/IN which/WDT ,/, however/RB ,/, the/DT infection/NN by/IN the/DT variant/NN B/NN does/VBZ not/RB determine/VB induction/NN of/IN EBV/NN antigens/NNS ;/: (/( 2/LS )/) the/DT presence/NN of/IN the/DT EBV/NN genome/NN contributes/VBZ to/TO the/DT susceptibility/NN of/IN the/DT B/NN cell/NN lines/NNS to/TO HHV-6/NN infection/NN ,/, increasing/VBG the/DT binding/VBG sites/NNS and/CC the/DT percentage/NN of/IN infectable/JJ cells/NNS ,/, as/IN detected/VBN by/IN immunoelectron/NN microscopy/NN ;/: and/CC (/( 3/LS )/) HHV-6/NN infected/JJ T/NN cells/NNS ,/, transfected/VBN with/IN plasmids/NNS bearing/VBG the/DT promoter/NN regions/NNS of/IN the/DT EBV/NN early/RB genes/NNS BZLF1/NN and/CC BMRF1/NN ,/, show/VBP a/DT strong/JJ transactivation/NN of/IN these/DT promoters/NNS ./. 
UI/LS -/: 96001288/CD 
TI/LS -/: Evidence/NN for/IN normal/JJ vitamin/NN D/NN receptor/NN messenger/NN ribonucleic/JJ acid/NN and/CC genotype/NN in/IN absorptive/JJ hypercalciuria/NN ./. 
AB/LS -/: Absorptive/JJ hypercalciuria/NN (/( a/DT stone-forming/JJ condition/NN )/) is/VBZ characterized/VBN by/IN gut/NN hyperabsorption/NN of/IN calcium/NN ,/, hypercalciuria/NN ,/, and/CC reduced/VBN bone/NN density/NN ./. 
Inasmuch/RB as/IN these/DT features/NNS implicate/VBP enhanced/VBN calcitriol/NN action/NN in/IN gut/NN and/CC bone/NN ,/, we/PRP analyzed/VBD the/DT vitamin/NN D/NN receptor/NN (/( VDR/NN )/) gene/NN to/TO ascertain/VB whether/IN an/DT abnormality/NN of/IN this/DT gene/NN marks/VBZ patients/NNS with/IN intestinal/JJ hyperabsorption/NN of/IN calcium/NN ./. 
We/PRP have/VBP compared/VBN the/DT frequency/NN of/IN a/DT restriction/NN fragment/NN length/NN polymorphism/NN (/( Bsm/NN I/NN )/) associated/VBN with/IN different/JJ alleles/NNS of/IN the/DT VDR/NN gene/NN in/IN a/DT group/NN of/IN 33/CD well/RB characterized/VBN absorptive/JJ hypercalciuric/NN patients/NNS and/CC a/DT group/NN of/IN 36/CD normal/JJ race-/NN and/CC age-matched/JJ control/JJ subjects/NNS ./. 
There/EX was/VBD no/DT difference/NN between/IN the/DT distribution/NN of/IN the/DT VDR/NN alleles/NNS in/IN the/DT patient/NN population/NN when/WRB compared/VBN with/IN the/DT normal/JJ population/NN ./. 
The/DT coding/VBG region/NN of/IN VDR/NN messenger/NN RNA/NN was/VBD also/RB normal/JJ ,/, as/IN determined/VBN by/IN both/CC DNA/NN sequence/NN analysis/NN and/CC chemical/JJ mismatch/NN cleavage/NN analysis/NN of/IN copy/NN DNA/NN from/IN 11/CD index/NN absorptive/JJ hypercalciuric/NN patients/NNS ./. 
On/IN the/DT basis/NN of/IN these/DT results/NNS ,/, we/PRP propose/VBP that/IN the/DT enhanced/VBN intestinal/JJ calcium/NN absorption/NN invariably/RB seen/VBN in/IN absorptive/JJ hypercalciuria/NN and/CC attendant/JJ symptoms/NNS of/IN this/DT disorder/NN are/VBP not/RB attributable/JJ to/TO mutations/NNS of/IN the/DT VDR/NN and/CC are/VBP not/RB linked/VBN to/TO a/DT common/JJ VDR/NN genotype/NN ./. 
UI/LS -/: 95394907/CD 
TI/LS -/: Transcriptional/JJ regulation/NN of/IN the/DT gene/NN encoding/VBG the/DT human/JJ C-type/JJ lectin/NN leukocyte/NN receptor/NN AIM/CD69/NN and/CC functional/JJ characterization/NN of/IN its/PRP$ tumor/NN necrosis/NN factor-alpha-responsive/JJ elements/NNS ./. 
AB/LS -/: The/DT human/JJ activation/NN antigen/NN CD69/NN is/VBZ a/DT member/NN of/IN the/DT C-type/JJ animal/NN lectin/NN superfamily/NN that/WDT functions/VBZ as/IN a/DT signal-transmitting/JJ receptor/NN ./. 
Although/IN the/DT expression/NN of/IN CD69/NN can/MD be/VB induced/VBN in/FW vitro/FW on/IN cells/NNS of/IN most/JJS hematopoietic/JJ lineages/NNS with/IN a/DT wide/JJ variety/NN of/IN stimuli/NNS ,/, in/FW vivo/FW it/PRP is/VBZ mainly/RB expressed/VBN by/IN T-lymphocytes/NNS located/JJ in/IN the/DT inflammatory/JJ infiltrates/NNS of/IN several/JJ human/JJ diseases/NNS ./. 
To/TO elucidate/VB the/DT mechanisms/NNS that/WDT regulate/VBP the/DT constitutive/JJ and/CC inducible/JJ expression/NN of/IN CD69/NN by/IN leukocytes/NNS ,/, we/PRP isolated/VBD the/DT promoter/NN region/NN of/IN the/DT CD69/NN gene/NN and/CC carried/VBD out/RP its/PRP$ functional/JJ characterization/NN ./. 
Sequence/NN analysis/NN of/IN the/DT 5'-flanking/JJ region/NN of/IN the/DT CD69/NN gene/NN revealed/VBD the/DT presence/NN of/IN a/DT potential/JJ TATA/NN element/NN 30/CD base/NN pairs/NNS upstream/JJ of/IN the/DT major/JJ transcription/NN initiation/NN site/NN and/CC several/JJ putative/JJ binding/NN sequences/NNS for/IN inducible/JJ transcription/NN factors/NNS (/( NF-kappa/NN B/NN ,/, Egr-1/NN ,/, AP-1/NN )/) ,/, which/WDT might/MD mediate/VB the/DT inducible/JJ expression/NN of/IN this/DT gene/NN ./. 
Transient/JJ expression/NN of/IN CD69/NN promoter-based/JJ reporter/NN gene/NN constructs/NNS in/IN K562/NN cells/NNS indicated/VBD that/IN the/DT proximal/JJ promoter/NN region/NN spanning/VBG positions/NNS -78/CD to/TO +16/CD contained/VBD the/DT cis-acting/JJ sequences/NNS necessary/JJ for/IN basal/JJ and/CC phorbol/NN 12-myristate/NN 13-acetate-inducible/JJ transcription/NN of/IN the/DT CD69/NN gene/NN ./. 
Removal/NN of/IN the/DT upstream/JJ sequences/NNS located/JJ between/IN positions/NNS -78/CD and/CC -38/CD resulted/VBD in/IN decreased/VBN promoter/NN strength/NN and/CC abolished/VBD the/DT response/NN to/TO phorbol/NN 12-myristate/NN 13-acetate/NN ./. 
We/PRP also/RB found/VBD that/IN tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) is/VBZ capable/JJ of/IN inducing/VBG the/DT surface/NN expression/NN of/IN the/DT CD69/NN molecule/NN as/RB well/RB as/IN the/DT promoter/NN activity/NN of/IN fusion/NN plasmids/NNS that/WDT contain/VBP 5'-flanking/JJ sequences/NNS of/IN the/DT CD69/NN gene/NN ,/, suggesting/VBG that/IN this/DT cytokine/NN may/MD regulate/VB in/FW vivo/FW the/DT expression/NN of/IN CD69/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 95368765/CD 
TI/LS -/: Characterization/NN of/IN 5'/JJ end/NN of/IN human/JJ thromboxane/NN receptor/NN gene/NN ./. 
Organizational/JJ analysis/NN and/CC mapping/NN of/IN protein/NN kinase/NN C/NN --/: responsive/JJ elements/NNS regulating/VBG expression/NN in/IN platelets/NNS ./. 
AB/LS -/: Platelet/NN thromboxane/NN receptors/NNS are/VBP acutely/RB and/CC reversibly/RB upregulated/VBN after/IN acute/JJ myocardial/JJ infarction/NN ./. 
To/TO determine/VB if/IN platelet/NN thromboxane/NN receptors/NNS are/VBP under/IN transcriptional/JJ control/NN ,/, we/PRP isolated/VBD and/CC characterized/VBD human/JJ genomic/JJ DNA/NN clones/NNS containing/VBG the/DT 5'/JJ flanking/JJ region/NN of/IN the/DT thromboxane/NN receptor/NN gene/NN ./. 
The/DT exon-intron/JJ structure/NN of/IN the/DT 5'/JJ portion/NN of/IN the/DT thromboxane/NN receptor/NN gene/NN was/VBD determined/VBN initially/RB by/IN comparing/VBG the/DT nucleotide/NN sequence/NN of/IN the/DT 5'/JJ flanking/JJ genomic/JJ clone/NN with/IN that/DT of/IN a/DT novel/JJ human/JJ uterine/NN thromboxane/NN receptor/NN cDNA/NN that/WDT extended/VBD the/DT mRNA/NN 141/CD bp/NN further/RBR upstream/RB than/IN the/DT previously/RB identified/VBN human/JJ placental/JJ cDNA/NN ./. 
A/DT major/JJ transcription/NN initiation/NN site/NN was/VBD located/JJ in/IN three/CD human/JJ tissues/NNS approximately/RB 560/CD bp/NN upstream/JJ from/IN the/DT translation/NN initiation/NN codon/NN and/CC 380/CD bp/NN upstream/JJ from/IN any/DT previously/RB identified/VBN transcription/NN initiation/NN site/NN ./. 
The/DT thromboxane/NN receptor/NN gene/NN has/VBZ neither/CC a/DT TATA/NN nor/CC a/DT CAAT/NN consensus/NN site/NN ./. 
Promoter/NN function/NN of/IN the/DT 5'/JJ flanking/JJ region/NN of/IN the/DT thromboxane/NN receptor/NN gene/NN was/VBD evaluated/VBN by/IN transfection/NN of/IN thromboxane/NN receptor/NN gene/NN promoter/chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) chimera/NN plasmids/NNS into/IN platelet-like/JJ K562/NN cells/NNS ./. 
Thromboxane/NN receptor/NN promoter/NN activity/NN ,/, as/IN assessed/VBN by/IN CAT/NN expression/NN ,/, was/VBD relatively/RB weak/JJ but/CC was/VBD significantly/RB enhanced/VBN by/IN phorbol/NN ester/NN treatment/NN ./. 
Functional/JJ analysis/NN of/IN 5'/JJ deletion/NN constructs/NNS in/IN transfected/VBN K562/NN cells/NNS and/CC gel/NN mobility/NN shift/NN localized/VBD the/DT major/JJ phorbol/NN ester-responsive/JJ motifs/NNS in/IN the/DT thromboxane/NN receptor/NN gene/NN promoter/NN to/TO a/DT cluster/NN of/IN activator/NN protein-2/NN (/( AP-2/NN )/) binding/NN consensus/NN sites/NNS located/JJ approximately/RB 1.8/CD kb/NN 5'/JJ from/IN the/DT transcription/NN initiation/NN site/NN ./. 
These/DT studies/NNS are/VBP the/DT first/JJ to/TO determine/VB the/DT structure/NN and/CC organization/NN of/IN the/DT 5'/JJ end/NN of/IN the/DT thromboxane/NN receptor/NN gene/NN and/CC demonstrate/VBP that/IN thromboxane/NN receptor/NN gene/NN expression/NN can/MD be/VB regulated/VBN by/IN activation/NN of/IN protein/NN kinase/NN C/NN via/IN induction/NN of/IN an/DT AP-2-like/JJ nuclear/JJ factor/NN binding/VBG to/TO upstream/JJ promoter/NN elements/NNS ./. 
These/DT findings/NNS strongly/RB suggest/VBP that/IN the/DT mechanism/NN for/IN previously/RB described/VBN upregulation/NN of/IN platelet/NN thromboxane/NN receptors/NNS after/IN acute/JJ myocardial/JJ infarction/NN is/VBZ increased/VBN thromboxane/NN receptor/NN gene/NN transcription/NN in/IN platelet-progenitor/JJ cells/NNS ./. 
UI/LS -/: 91172250/CD 
TI/LS -/: Estrogen/NN receptor/NN concentration/NN and/CC social/JJ factors/NNS as/IN predictors/NNS of/IN natural/JJ killer/NN cell/NN activity/NN in/IN early-stage/JJ breast/NN cancer/NN patients/NNS ./. 
Confirmation/NN of/IN a/DT model/NN ./. 
AB/LS -/: Previous/JJ work/NN of/IN ours/PRP has/VBZ demonstrated/VBN that/IN a/DT significant/JJ amount/NN of/IN natural/JJ killer/NN (/( NK/NN )/) activity/NN variance/NN after/IN surgery/NN in/IN stage/NN I/CD and/CC II/CD breast/NN cancer/NN patients/NNS could/MD be/VB accounted/VBN for/IN by/IN both/CC the/DT estrogen/NN receptor/NN (/( ER/NN )/) status/NN of/IN the/DT tumor/NN and/CC by/IN social/JJ factors/NNS ,/, namely/RB ,/, perceived/VBN social/JJ support/NN and/CC seeking/VBG social/JJ support/NN as/IN a/DT general/JJ coping/NN strategy/NN ./. 
As/IN considerable/JJ evidence/NN has/VBZ accumulated/VBN that/IN social/JJ support/NN in/IN both/CC animal/NN and/CC human/JJ populations/NNS may/MD have/VB survival/NN value/NN ,/, we/PRP sought/VBD to/TO test/VB the/DT reliability/NN of/IN this/DT regression/NN model/NN ,/, using/VBG coping/NN and/CC perceived/VBN support/NN factor/NN values/NNS obtained/VBN at/IN 3/CD months/NNS after/IN surgery/NN to/TO account/VB for/IN concurrent/JJ follow-up/JJ NK/NN activity/NN in/IN this/DT serially/RB assessed/VBN group/NN of/IN patients/NNS ./. 
It/PRP was/VBD found/VBN that/IN the/DT most/RBS significant/JJ variable/NN predicting/VBG NK/NN activity/NN at/IN follow-up/NN was/VBD tumor/NN ER/NN concentration/NN ,/, with/IN higher/JJR NK/NN activity/NN associated/VBN with/IN ER-/JJ status/NN ./. 
In/IN addition/NN ,/, seeking/VBG social/JJ support/NN as/IN a/DT coping/NN strategy/NN ,/, as/RB well/RB as/IN the/DT perceived/VBN quality/NN of/IN support/NN ,/, also/RB entered/VBD the/DT model/NN to/TO account/VB for/IN a/DT significant/JJ amount/NN of/IN NK/NN activity/NN variance/NN (/( multivariate/JJ F/NN =/JJ 5.25/CD ,/, p/NN less/JJR than/IN 0.001/CD )/) ./. 
If/IN ,/, as/IN the/DT literature/NN suggests/VBZ ,/, NK/NN activity/NN is/VBZ relevant/JJ to/TO breast/NN cancer/NN control/NN ,/, and/CC since/IN ER-/NN tumors/NNS have/VBP a/DT worse/JJR prognosis/NN ,/, we/PRP suggest/VBP here/RB that/IN perhaps/RB such/JJ tumors/NNS are/VBP resistant/JJ to/TO control/NN by/IN NK/NN cells/NNS because/IN they/PRP lack/VBP the/DT ability/NN to/TO attract/VB an/DT accumulation/NN of/IN effector/NN cells/NNS to/TO the/DT tumor/NN site/NN ,/, or/CC because/IN blocking/NN factors/NNS at/IN the/DT site/NN of/IN the/DT tumor/NN prevent/VBP local/JJ tumor/NN control/NN at/IN the/DT site/NN of/IN action/NN ./. 
The/DT finding/NN related/JJ to/TO social/JJ support/NN also/RB replicates/VBZ results/NNS from/IN an/DT independent/JJ sample/NN of/IN breast/NN cancer/NN patients/NNS ./. 
This/DT finding/NN ,/, taken/VBN together/RB with/IN other/JJ evidence/NN that/IN this/DT social/JJ variable/NN is/VBZ associated/VBN with/IN longer/JJR survival/NN in/IN breast/NN cancer/NN populations/NNS ,/, underscores/VBZ the/DT potential/JJ importance/NN of/IN this/DT social/JJ support/NN variable/NN ./. 
Our/PRP$ findings/NNS also/RB suggest/VBP one/CD possible/JJ immunological/JJ variable/NN involved/JJ ,/, with/IN potential/JJ clinical/JJ significance/NN ,/, for/IN this/DT patient/NN population/NN ./. 
UI/LS -/: 96107207/CD 
TI/LS -/: Solution/NN structure/NN of/IN the/DT sequence-specific/JJ HMG/NN box/NN of/IN the/DT lymphocyte/NN transcriptional/JJ activator/NN Sox-4/NN ./. 
AB/LS -/: Two/CD groups/NNS of/IN HMG/NN box/NN proteins/NNS are/VBP distinguished/VBN ./. 
Proteins/NNS in/IN the/DT first/JJ group/NN contain/VBP multiple/JJ HMG/NN boxes/NNS ,/, are/VBP non-sequence-specific/JJ ,/, and/CC recognize/VBP structural/JJ features/NNS as/IN found/VBN in/IN cruciform/JJ DNA/NN and/CC cross-over/JJ DNA/NN ./. 
The/DT abundant/JJ chromosomal/JJ protein/NN HMG-1/NN belongs/VBZ to/TO this/DT subgroup/NN ./. 
Proteins/NNS in/IN the/DT second/JJ group/NN carry/VBP a/DT single/JJ HMG/NN box/NN with/IN affinity/NN for/IN the/DT minor/JJ groove/NN of/IN the/DT heptamer/NN motif/NN AACAAAG/NN or/CC variations/NNS thereof/RB ./. 
A/DT solution/NN structure/NN for/IN the/DT non-sequence-specific/JJ C-terminal/JJ HMG/NN box/NN of/IN HMG-1/NN has/VBZ recently/RB been/VBN proposed/VBN ./. 
Now/RB ,/, we/PRP report/VBP the/DT solution/NN structure/NN of/IN the/DT sequence-specific/JJ HMG-box/NN of/IN the/DT SRY-related/JJ protein/NN Sox-4/NN ./. 
NMR/NN analysis/NN demonstrated/VBD the/DT presence/NN of/IN three/CD alpha-helices/NNS (/( Val10-Gln22/NN ,/, Glu30-Leu41/NN and/CC Phe50-Tyr65/NN )/) connected/VBN by/IN loop/NN regions/NNS (/( Ser23-Ala49/NN and/CC Leu42-Pro49/NN )/) ./. 
Helices/NNS I/CD and/CC II/CD are/VBP positioned/JJ in/IN an/DT antiparallel/JJ mode/NN and/CC form/VBP one/CD arm/NN of/IN the/DT HMG/NN box/NN ./. 
Helix/NN III/CD is/VBZ less/RBR rigid/JJ ,/, makes/VBZ an/DT average/JJ angle/NN of/IN about/RB 90/CD degrees/NNS with/IN helices/NNS I/CD and/CC II/CD ,/, and/CC constitutes/VBZ the/DT other/JJ arm/NN of/IN the/DT molecule/NN ./. 
As/IN in/IN HMG1B/NN ,/, the/DT overall/JJ structure/NN of/IN the/DT Sox-4/NN HMG/NN box/NN is/VBZ L-shaped/JJ and/CC is/VBZ maintained/VBN by/IN a/DT cluster/NN of/IN conserved/VBN ,/, mainly/RB aromatic/JJ residues/NNS ./. 
UI/LS -/: 96072803/CD 
TI/LS -/: Nuclear/JJ factor-IL6/NN activates/VBZ the/DT human/JJ IL-4/NN promoter/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: Positive/JJ regulatory/JJ element/NN I/NN (/( PRE-I/NN )/) is/VBZ a/DT strong/JJ enhancer/NN element/NN essential/JJ for/IN expression/NN of/IN the/DT human/JJ IL-4/NN gene/NN ./. 
To/TO identify/VB transcription/NN factors/NNS binding/VBG to/TO PRE-I/NN ,/, we/PRP screened/VBD a/DT cDNA/NN expression/NN library/NN from/IN Jurkat/NN T/NN cells/NNS and/CC isolated/VBD a/DT cDNA/NN encoding/NN nuclear/JJ factor/NN (/( NF/NN )/) -IL6/NN (/( also/RB known/VBN as/IN C/EBP/NN beta/NN )/) ./. 
NF-IL6/NN mRNA/NN was/VBD found/VBN in/IN human/JJ Jurkat/NN T/NN cells/NNS and/CC in/IN the/DT mouse/NN Th2/NN clone/NN D10/NN ,/, but/CC not/RB in/IN Th1/NN clone/NN 29/CD ./. 
rNF-IL6/NN expressed/VBN in/IN bacteria/NNS was/VBD shown/VBN to/TO specifically/RB bind/VB to/TO PRE-I/NN ./. 
PRE-I/NN forms/VBZ multiple/JJ DNA-protein/NN complexes/NNS with/IN nuclear/JJ extracts/NNS from/IN Jurkat/NN cells/NNS ./. 
Some/DT of/IN these/DT complexes/NNS were/VBD demonstrated/VBN to/TO contain/VB NF-IL6/NN by/IN using/VBG anti-C/EBP/JJ beta/NN Abs/NNS ./. 
Overexpression/NN of/IN NF-IL6/NN enhanced/VBD expression/NN of/IN the/DT chloramphenicol/NN acetyl/JJ transferase/NN reporter/NN gene/NN linked/VBN to/TO the/DT PRE-I-thymidine/NN kinase/NN or/CC the/DT human/JJ IL-4/NN promoter/NN more/JJR than/IN 10-fold/RB in/IN Jurkat/NN cells/NNS ./. 
Promoter/NN deletion/NN studies/NNS revealed/VBD two/CD additional/JJ NF-IL6/NN binding/NN sites/NNS located/JJ at/IN positions/NNS -44/CD to/TO -36/CD (/( C/EBP/NN proximal/JJ )/) and/CC -87/CD to/TO -79/CD (/( C/EBP/NN medial/JJ )/) ,/, respectively/RB ./. 
Our/PRP$ results/NNS demonstrate/VBP that/IN NF-IL6/NN is/VBZ involved/VBN in/IN transcriptional/JJ activation/NN of/IN the/DT human/JJ IL-4/NN promoter/NN in/IN T/NN cells/NNS ./. 
UI/LS -/: 96070929/CD 
TI/LS -/: Identification/NN of/IN an/DT I/NN kappa/NN B/NN alpha-associated/JJ protein/NN kinase/NN in/IN a/DT human/JJ monocytic/JJ cell/NN line/NN and/CC determination/NN of/IN its/PRP$ phosphorylation/NN sites/NNS on/IN I/NN kappa/NN B/NN alpha/NN ./. 
AB/LS -/: Nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) is/VBZ stored/JJ in/IN the/DT cytoplasm/NN as/IN an/DT inactive/JJ form/NN through/IN interaction/NN with/IN I/NN kappa/NN B/NN ./. 
Stimulation/NN of/IN cells/NNS leads/VBZ to/TO a/DT rapid/JJ phosphorylation/NN of/IN I/NN kappa/NN B/NN alpha/NN ,/, which/WDT is/VBZ presumed/VBN to/TO be/VB important/JJ for/IN the/DT subsequent/JJ degradation/NN ./. 
We/PRP have/VBP recently/RB reported/VBN the/DT establishment/NN of/IN a/DT lipopolysaccharide/NN (/( LPS/NN )/) -dependent/JJ cell-free/JJ activation/NN system/NN of/IN NF-kappa/NN B/NN in/IN association/NN with/IN the/DT induction/NN of/IN I/NN kappa/NN B/NN alpha/NN phosphorylation/NN ./. 
In/IN this/DT study/NN ,/, we/PRP have/VBP identified/VBN a/DT kinase/NN in/IN cell/NN extracts/NNS from/IN the/DT LPS-stimulated/JJ human/JJ monocytic/JJ cell/NN line/NN ,/, THP-1/NN ,/, that/WDT specifically/RB binds/VBZ and/CC phosphorylates/VBZ I/NN kappa/NN B/NN alpha/NN ./. 
LPS/NN stimulation/NN transiently/RB enhanced/VBD the/DT I/NN kappa/NN B/NN alpha-bound/JJ kinase/NN activity/NN in/IN THP-1/NN cells/NNS ./. 
Mutational/JJ analyses/NNS of/IN I/NN kappa/NN B/NN alpha/NN and/CC competition/NN experiments/NNS with/IN the/DT synthetic/JJ peptides/NNS identified/VBD major/JJ phosphorylation/NN sites/NNS by/IN the/DT bound/VBN kinase/NN as/IN Ser/NN and/CC Thr/NN residues/NNS in/IN the/DT C-terminal/JJ acidic/JJ domain/NN of/IN I/NN kappa/NN B/NN alpha/NN ./. 
Moreover/RB ,/, we/PRP show/VBP that/IN the/DT peptide/NN ,/, corresponding/VBG to/TO the/DT C-terminal/JJ acidic/JJ domain/NN of/IN I/NN kappa/NN B/NN alpha/NN ,/, blocked/VBD the/DT LPS-induced/JJ NF-kappa/NN B/NN activation/NN as/RB well/RB as/IN inducible/JJ phosphorylation/NN of/IN endogenous/JJ I/NN kappa/NN B/NN alpha/NN in/IN a/DT cell-free/JJ system/NN using/VBG THP-1/NN cells/NNS ./. 
These/DT results/NNS suggested/VBD that/IN the/DT bound/JJ kinase/NN is/VBZ involved/VBN in/IN the/DT signaling/NN pathway/NN of/IN LPS/NN by/IN inducing/VBG the/DT phosphorylation/NN of/IN the/DT C-terminal/JJ region/NN of/IN I/NN kappa/NN B/NN alpha/NN and/CC subsequent/JJ dissociation/NN of/IN the/DT NF-kappa/NN B.I/NN kappa/NN B/NN alpha/NN complex/NN ./. 
UI/LS -/: 96068922/CD 
TI/LS -/: Bik/NN ,/, a/DT novel/JJ death-inducing/JJ protein/NN shares/VBZ a/DT distinct/JJ sequence/NN motif/NN with/IN Bcl-2/NN family/NN proteins/NNS and/CC interacts/VBZ with/IN viral/JJ and/CC cellular/JJ survival-promoting/JJ proteins/NNS ./. 
AB/LS -/: The/DT survival-promoting/JJ activity/NN of/IN the/DT Bcl-2/NN family/NN of/IN proteins/NNS appears/VBZ to/TO be/VB modulated/VBN by/IN interactions/NNS between/IN various/JJ cellular/JJ proteins/NNS ./. 
We/PRP have/VBP identified/VBN a/DT novel/JJ cellular/JJ protein/NN ,/, Bik/NN ,/, that/WDT interacts/VBZ with/IN the/DT cellular/JJ survival-promoting/JJ proteins/NNS ,/, Bcl-2/NN and/CC Bcl-xL/NN ,/, as/RB well/RB as/IN the/DT viral/JJ survival-promoting/JJ proteins/NNS ,/, Epstein/NN Barr/NN virus-BHRF1/NN and/CC adenovirus/NN E1B-19/NN kDa/NN ./. 
In/IN transient/JJ transfection/NN assays/NNS ,/, Bik/NN promotes/VBZ cell/NN death/NN in/IN a/DT manner/NN similar/JJ to/TO the/DT death-promoting/JJ members/NNS of/IN the/DT Bcl-2/NN family/NN ,/, Bax/NN and/CC Bak/NN ./. 
This/DT death-promoting/JJ activity/NN of/IN Bik/NN can/MD be/VB suppressed/VBN by/IN coexpression/NN of/IN Bcl-2/NN ,/, Bcl-XL/NN ,/, EBV-BHRF1/NN and/CC E1B-19/NN kDa/NN proteins/NNS suggesting/VBG that/IN Bik/NN may/MD be/VB a/DT common/JJ target/NN for/IN both/CC cellular/JJ and/CC viral/JJ anti-apoptotic/JJ proteins/NNS ./. 
While/IN Bik/NN does/VBZ not/RB show/VB overt/JJ homology/NN to/TO the/DT BH1/NN and/CC BH2/NN conserved/JJ domains/NNS characteristic/JJ of/IN the/DT Bcl-2/NN family/NN ,/, it/PRP does/VBZ share/VB a/DT 9/CD amino/NN acid/NN domain/NN (/( BH3/NN )/) with/IN Bax/NN and/CC Bak/NN which/WDT may/MD be/VB a/DT critical/JJ determinant/NN for/IN the/DT death-promoting/JJ activity/NN of/IN these/DT proteins/NNS ./. 
UI/LS -/: 96017239/CD 
TI/LS -/: The/DT human/JJ TCF-1/NN gene/NN encodes/VBZ a/DT nuclear/JJ DNA-binding/JJ protein/NN uniquely/RB expressed/VBN in/IN normal/JJ and/CC neoplastic/JJ T-lineage/JJ lymphocytes/NNS ./. 
AB/LS -/: The/DT TCF-1/NN gene/NN encodes/VBZ a/DT putative/JJ transcription/NN factor/NN with/IN affinity/NN for/IN a/DT sequence/NN motif/NN occurring/VBG in/IN a/DT number/NN of/IN T-cell/NN enhancers/NNS ./. 
TCF-1/NN mRNA/NN was/VBD originally/RB found/VBN to/TO be/VB expressed/VBN in/IN a/DT T/NN cell-specific/JJ fashion/NN within/IN a/DT set/NN of/IN human/JJ and/CC mouse/NN cell/NN lines/NNS ./. 
In/IN contrast/NN ,/, expression/NN reportedly/RB occurs/VBZ in/IN multiple/JJ nonlymphoid/JJ tissues/NNS during/IN murine/JJ embryogenesis/NN ./. 
We/PRP have/VBP now/RB raised/VBN a/DT monoclonal/JJ antibody/NN to/TO document/VB expression/NN and/CC biochemistry/NN of/IN the/DT human/JJ TCF-1/NN protein/NN ./. 
As/IN expected/VBN ,/, the/DT TCF-1/NN protein/NN was/VBD detectable/JJ only/RB in/IN cell/NN lines/NNS of/IN T/NN lineage/NN ./. 
Its/PRP$ expression/NN was/VBD always/RB restricted/JJ to/TO the/DT nucleus/NN ./. 
Immunohistochemistry/NN on/IN a/DT panel/NN of/IN human/JJ tissues/NNS revealed/VBD that/IN the/DT TCF-1/NN protein/NN was/VBD found/VBN exclusively/RB in/IN thymocytes/NNS and/CC in/IN CD3+/JJ T/NN cells/NNS in/IN peripheral/JJ lymphoid/JJ tissues/NNS ./. 
Western/NN blotting/NN yielded/VBD a/DT set/NN of/IN bands/NNS ranging/VBG from/IN 25/CD kD/NN to/TO 55/CD kD/NN ,/, resulting/VBG from/IN extensive/JJ alternative/JJ splicing/NN ./. 
The/DT TCF-1/NN protein/NN was/VBD detectable/JJ in/IN all/DT samples/NNS of/IN a/DT set/NN of/IN 22/CD T-cell/NN malignancies/NNS of/IN various/JJ stages/NNS of/IN maturation/NN ,/, but/CC was/VBD absent/JJ from/IN a/DT large/JJ number/NN of/IN other/JJ hematologic/JJ neoplasms/NNS ./. 
These/DT observations/NNS imply/VBP a/DT T/NN cell-specific/JJ function/NN for/IN TCF-1/NN ,/, a/DT notion/NN corroborated/VBN by/IN recent/JJ observations/NNS on/IN Tcf-1/NN knock-out/JJ mice/NNS ./. 
In/IN addition/NN ,/, these/DT results/NNS indicate/VBP that/IN nuclear/JJ TCF-1/NN expression/NN can/MD serve/VB as/IN a/DT pan-T-lineage/JJ marker/NN in/IN the/DT diagnosis/NN of/IN lymphoid/JJ malignancies/NNS ./. 
UI/LS -/: 96128660/CD 
TI/LS -/: Cross-linking/NN of/IN Fc/NN gamma/NN receptors/NNS activates/VBZ HIV-1/NN long/JJ terminal/JJ repeat-driven/JJ transcription/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: Elevation/NN of/IN the/DT levels/NNS of/IN circulating/VBG immune/JJ complexes/NNS frequently/RB accompanies/VBZ HIV-1/NN infection/NN and/CC is/VBZ a/DT prognostic/JJ indicator/NN of/IN clinical/JJ progression/NN from/IN asymptomatic/JJ infection/NN to/TO AIDS/NN ./. 
Here/RB we/PRP report/VBP that/IN cross-linking/NN of/IN Fc/NN gamma/NN RI/NN or/CC Fc/NN gamma/NN RII/NN by/IN adherent/JJ human/JJ IgG/NN or/CC by/IN specific/JJ anti-Fc/JJ gamma/NN R/NN mAb/NN activates/VBZ HIV-1/NN gene/NN expression/NN in/IN the/DT human/JJ monocytic/JJ cell/NN line/NN BF24/NN and/CC increased/VBN HIV/NN RNA/NN expression/NN in/IN monocytes/NNS from/IN HIV/NN infected/JJ patients/NNS as/IN assayed/VBN by/IN reverse/JJ transcription-PCR/NN ./. 
In/IN THP-1/NN cells/NNS ,/, Fc/NN gamma/NN R/NN cross-linking/NN induced/VBD NF-kappa/NN B/NN ,/, which/WDT is/VBZ known/VBN to/TO bind/VB to/TO the/DT regulatory/JJ region/NN of/IN the/DT long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) of/IN HIV-1/NN and/CC to/TO activate/VB HIV-1/NN transcription/NN ./. Anti-TNF-alpha/JJ antibody/NN but/CC not/RB anti-IL-1/JJ beta/NN antibody/NN strongly/RB inhibited/VBD both/CC the/DT induction/NN of/IN HIV-1-LTR-driven/JJ transcription/NN and/CC the/DT induction/NN of/IN NF-kappa/NN B/NN by/IN Fc/NN gamma/NN R/NN cross-linking/NN ./. 
These/DT results/NNS indicate/VBP that/IN Fc/NN gamma/NN R/NN can/MD mediate/VB a/DT TNF-alpha-dependent/JJ induction/NN of/IN HIV-1/NN gene/NN transcription/NN and/CC suggest/VBP that/IN immune/JJ complexes/NNS may/MD contribute/VB to/TO the/DT pathophysiology/NN of/IN HIV-1/NN infection/NN by/IN augmenting/VBG viral/JJ replication/NN in/IN monocytes/NNS ./. 
UI/LS -/: 96003970/CD 
TI/LS -/: Signalling/NN via/IN CD28/NN of/IN human/JJ naive/JJ neonatal/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: Accessory/JJ molecules/NNS play/VBP a/DT crucial/JJ role/NN in/IN the/DT development/NN of/IN the/DT T/NN cell/NN response/NN to/TO antigenic/JJ challenge/NN ./. 
We/PRP have/VBP examined/VBN the/DT role/NN of/IN CD28/NN in/IN modulating/VBG the/DT '/`` naive/JJ '/'' neonatal/JJ T/NN cell/NN response/NN to/TO anti-CD2-mediated/JJ activation/NN ./. 
To/TO compare/VB the/DT role/NN of/IN CD28/NN ,/, neonatal/JJ and/CC adult/JJ T/NN cells/NNS were/VBD stimulated/VBN with/IN a/DT pair/NN of/IN mitogenic/JJ anti-CD2/JJ antibodies/NNS in/IN the/DT presence/NN or/CC absence/NN of/IN anti-CD28/JJ MoAb/NN ./. 
With/IN anti-CD2/NN alone/RB ,/, neonatal/JJ T/NN cells/NNS proliferated/VBD slightly/RB but/CC produced/VBD no/DT detectable/JJ IL-2/NN ,/, whereas/IN adult/JJ T/NN cells/NNS proliferated/VBD vigorously/RB ,/, with/IN significant/JJ IL-2/NN production/NN ./. 
Costimulation/NN with/IN anti-CD28/JJ MoAb/NN greatly/RB enhanced/VBD the/DT proliferative/JJ response/NN of/IN neonatal/JJ T/NN cells/NNS to/TO levels/NNS equivalent/JJ to/TO those/DT of/IN adult/JJ T/NN cells/NNS ,/, whereas/IN adult/JJ T/NN cells/NNS showed/VBD only/RB slight/JJ increases/NNS ./. 
Although/IN IL-2/NN secretion/NN was/VBD increased/VBN in/IN the/DT presence/NN of/IN anti-CD28/JJ MoAb/NN ,/, neonatal/JJ T/NN cell/NN IL-2/NN production/NN remained/VBD lower/JJR than/IN in/IN adults/NNS ./. 
In/IN contrast/NN ,/, enhancement/NN of/IN IL-2/NN mRNA/NN expression/NN in/IN neonates/NNS was/VBD similar/JJ to/TO adult/JJ levels/NNS ./. 
Anti-CD28/JJ MoAb/NN costimulation/NN increased/VBD NF/NN kappa/NN B/NN levels/NNS in/IN neonates/NNS ,/, albeit/IN to/TO levels/NNS lower/JJR than/IN that/DT of/IN adults/NNS ./. 
The/DT cellular/JJ mechanism/NN governing/VBG the/DT diminished/VBN proliferative/JJ response/NN of/IN neonatal/JJ T/NN lymphocytes/NNS to/TO anti-CD2/NN may/MD therefore/RB be/VB due/JJ to/TO decreased/VBN NF/NN kappa/NN B/NN induction/NN ,/, reduced/VBN IL-2/NN mRNA/NN expression/NN and/CC deficient/JJ IL-2/NN production/NN ./. 
Although/IN anti-CD28/JJ MoAb/NN costimulation/NN enhances/VBZ all/DT of/IN the/DT above/JJ signals/NNS ,/, NF/NN kappa/NN B/NN and/CC IL-2/NN levels/NNS remain/VBP lower/JJR than/IN in/IN adults/NNS ,/, suggesting/VBG the/DT need/NN for/IN further/JJ activation/NN requirements/NNS in/IN the/DT neonate/NN ./. 
UI/LS -/: 95391995/CD 
TI/LS -/: TCL1/NN oncogene/NN activation/NN in/IN preleukemic/JJ T/NN cells/NNS from/IN a/DT case/NN of/IN ataxia-telangiectasia/NN ./. 
AB/LS -/: The/DT TCL1/NN oncogene/NN on/IN human/JJ chromosome/NN 14q32.1/NN is/VBZ involved/VBN in/IN chromosome/NN translocations/NNS [/( t(14;14)(q11;q32.1)/NN and/CC t(7;14)(q35;q32.1)/NN ]/) and/CC inversions/NNS [/( inv14(q11;q32.1)/NN ]/) with/IN TCR/NN alpha/beta/NN loci/NNS in/IN T-cell/NN leukemias/NNS ,/, such/JJ as/IN T-prolymphocytic/JJ (/( T-PLL/NN )/) ./. 
It/PRP is/VBZ also/RB involved/VBN in/IN T-acute/JJ and/CC -chronic/JJ leukemias/NNS arising/VBG in/IN cases/NNS of/IN ataxia-telangiectasia/NN (/( AT/NN )/) ,/, an/DT immunodeficiency/NN syndrome/NN ./. 
Similar/JJ chromosomal/JJ rearrangements/NNS occur/VBP also/RB in/IN the/DT clonally/RB expanded/VBN T/NN cells/NNS in/IN AT/NN patients/NNS before/IN the/DT appearance/NN of/IN the/DT overt/JJ leukemia/NN ./. 
We/PRP have/VBP analyzed/VBN the/DT expression/NN of/IN TCL1/NN mRNA/NN and/CC protein/NN in/IN peripheral/JJ blood/NN lymphocytes/NNS (/( PBLs/NNS )/) from/IN four/CD AT/NN cases/NNS and/CC from/IN healthy/JJ controls/NNS ./. 
We/PRP found/VBD that/IN the/DT TCL1/NN gene/NN was/VBD overexpressed/VBN in/IN the/DT PBLs/NNS of/IN an/DT AT/NN patient/NN with/IN a/DT large/JJ clonal/JJ T-cell/NN population/NN exhibiting/VBG the/DT t(14;14)/NN translocation/NN but/CC not/RB in/IN the/DT lymphocytes/NNS of/IN the/DT other/JJ cases/NNS ./. 
Fluorescence/NN in/FW situ/FW hybridization/NN of/IN the/DT TCL1/NN genomic/JJ locus/NN to/TO lymphocyte/NN metaphases/NNS from/IN the/DT AT/NN patient/NN with/IN the/DT T-cell/NN clonal/JJ expansion/NN showed/VBD that/IN the/DT breakpoint/NN of/IN the/DT t(14;14)/NN translocation/NN lies/VBZ within/IN the/DT TCL1/NN locus/NN and/CC is/VBZ accompanied/VBN by/IN an/DT inverted/VBN duplication/NN of/IN the/DT distal/JJ part/NN of/IN chromosome/NN 14/CD ./. 
These/DT data/NNS indicate/VBP that/IN TCL1/NN is/VBZ activated/VBN in/IN preleukemic/JJ clonal/JJ cells/NNS as/IN a/DT consequence/NN of/IN chromosome/NN translocation/NN involving/NN sequences/NNS from/IN the/DT TCR/NN locus/NN at/IN 14q11/NN ./. 
Deregulation/NN of/IN TCL1/NN is/VBZ the/DT first/JJ event/NN in/IN the/DT initiation/NN of/IN malignancy/NN in/IN these/DT types/NNS of/IN leukemias/NNS and/CC represents/VBZ a/DT potential/JJ tool/NN for/IN clinical/JJ evaluation/NN ./. 
UI/LS -/: 95363941/CD 
TI/LS -/: C/EBP/NN proteins/NNS activate/VBP transcription/NN from/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD long/JJ terminal/JJ repeat/NN in/IN macrophages/monocytes/NNS ./. 
AB/LS -/: Three/CD binding/VBG sites/NNS for/IN C/EBP/NN proteins/NNS are/VBP found/VBN in/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) (/( V.M./NNP Tesmer/NNP ,/, A.Rajadhyaksha/NNP ,/, J.Babin/NNP ,/, and/CC M.Bina/NNP ,/, Proc.Natl.Acad.Sci./NNP USA/NNP 90/CD :/: 7298-7302/CD ,/, 1993/CD )/) ./. 
We/PRP have/VBP determined/VBN the/DT functional/JJ role/NN of/IN C/EBP/NN proteins/NNS and/CC C/EBP/NN sites/NNS in/IN regulating/VBG transcription/NN from/IN the/DT HIV- 1/NN LTR/NN in/IN monocytes/NNS /macrophages/NNS ./. 
Inhibition/NN of/IN endogenous/JJ C/EBP/NN proteins/NNS ,/, using/VBG either/CC an/DT excess/NN of/IN C/EBP/NN binding/NN sites/NNS or/CC a/DT trans- dominant/JJ negative/JJ inhibitor/NN ,/, demonstrated/VBD that/IN C/EBP/NN proteins/NNS are/VBP required/VBN for/IN basal/JJ and/CC activated/VBN levels/NNS of/IN HIV-1/NN LTR/NN transcription/NN in/IN the/DT promonocytic/JJ cell/NN line/NN U937/NN ./. 
Northern/NN (/( RNA/NN )/) blots/NNS and/CC binding/NN assays/NNS showed/VBD that/IN NF-IL6/NN is/VBZ the/DT only/RB known/JJ C/EBP/NN family/NN member/NN which/WDT is/VBZ increased/VBN when/WRB U937/NN cells/NNS are/VBP activated/VBN ./. 
Mutational/JJ analyses/NNS of/IN the/DT HIV-1/NN LTR/NN showed/VBD that/IN one/CD C/EBP/NN site/NN is/VBZ required/VBN for/IN normal/JJ LTR/NN transcription/NN both/CC before/IN and/CC after/IN cellular/JJ activation/NN and/CC that/IN the/DT two/CD 3'/JJ C/EBP/NN sites/NNS are/VBP functionally/RB equivalent/JJ ./. 
However/RB ,/, transcription/NN from/IN crippled/VBN HIV-1/NN LTRs/NNS lacking/VBG C/EBP/NN sites/NNS can/MD still/RB be/VB induced/VBN following/VBG activation/NN of/IN U937/NN cells/NNS ./. 
Several/JJ models/NNS are/VBP suggested/VBN for/IN how/WRB elevated/JJ NF-IL6/NN may/MD participate/VB in/IN an/DT autostimulatory/JJ loop/NN involving/VBG HIV/NN infection/NN ,/, macrophage/NN activation/NN ,/, cytokine/NN expression/NN ,/, and/CC HIV/NN replication/NN ./. 
UI/LS -/: 91175694/CD 
TI/LS -/: Human/JJ immunodeficiency/NN virus/NN type-2/JJ gene/NN expression/NN :/: two/CD enhancers/NNS and/CC their/PRP$ activation/NN by/IN T-cell/NN activators/NNS ./. 
AB/LS -/: The/DT human/JJ immunodeficiency/NN viruses/NNS (/( HIVs/NNS )/) may/MD include/VB a/DT spectrum/NN of/IN retroviruses/NNS with/IN varying/VBG potential/NN to/TO infect/VB their/PRP$ host/NN ,/, undergo/VB long/JJ periods/NNS of/IN latent/JJ infection/NN ,/, and/CC induce/VB pathology/NN ./. 
Since/IN expression/NN of/IN the/DT viruses/NNS is/VBZ in/IN large/JJ part/NN regulated/VBN by/IN the/DT sequence/NN elements/NNS in/IN their/PRP$ long/JJ terminal/JJ repeats/NNS (/( LTRs/NNS )/) ,/, this/DT study/NN was/VBD directed/VBN to/TO an/DT analysis/NN of/IN the/DT regulatory/JJ elements/NNS in/IN the/DT HIV-2/NN LTR/NN ./. 
The/DT HIV-2/NN LTR/NN was/VBD found/VBN to/TO contain/VB two/CD enhancers/NNS ./. 
One/CD of/IN these/DT enhancers/NNS is/VBZ ,/, in/IN part/NN ,/, identical/JJ to/TO the/DT HIV-1/NN enhancer/NN ./. 
This/DT enhancer/NN in/IN HIV-1/NN is/VBZ the/DT T-cell/NN activation/NN response/NN element/NN ;/: in/IN HIV-2/NN ,/, however/RB ,/, it/PRP is/VBZ the/DT second/JJ enhancer/NN that/WDT is/VBZ mainly/RB responsible/JJ for/IN activation/NN in/IN response/NN to/TO T-cell/NN activators/NNS ./. 
The/DT second/JJ enhancer/NN interacts/VBZ with/IN two/CD nuclear/JJ binding/NN proteins/NNS (/( 85/CD kD/NN and/CC 27/CD kD/NN mobility/NN )/) that/WDT appear/VBP to/TO be/VB required/VBN for/IN optimal/JJ enhancer/NN function/NN and/CC activation/NN ./. 
Observations/NNS such/JJ as/IN these/DT encourage/VBP the/DT speculation/NN that/IN there/EX may/MD be/VB subtle/JJ differences/NNS in/IN the/DT regulation/NN of/IN HIV-1/NN and/CC HIV-2/NN expression/NN that/WDT may/MD be/VB relevant/JJ to/TO the/DT possible/JJ longer/JJR latency/NN and/CC reduced/VBN pathogenicity/NN of/IN HIV-2/NN ./. 
UI/LS -/: 96134911/CD 
TI/LS -/: NF-M/NN (/( chicken/NN C/EBP/NN beta/NN )/) induces/VBZ eosinophilic/JJ differentiation/NN and/CC apoptosis/NN in/IN a/DT hematopoietic/JJ progenitor/NN cell/NN line/NN ./. 
AB/LS -/: CAAT/enhancer/NN binding/NN proteins/NNS (/( C/EBPs/NNS )/) are/VBP transcriptional/JJ activators/NNS implicated/VBN in/IN the/DT differentiation/NN processes/NNS of/IN various/JJ cell/NN lineages/NNS ./. 
We/PRP have/VBP shown/VBN earlier/RBR that/IN NF-M/NN ,/, the/DT chicken/NN homolog/NN of/IN C/EBP/NN beta/NN ,/, is/VBZ specifically/RB expressed/VBN in/IN myelomonocytic/JJ and/CC eosinophilic/JJ cells/NNS of/IN the/DT hematopoietic/JJ system/NN ./. 
To/TO investigate/VB the/DT role/NN of/IN NF-M/NN in/IN hematopoietic/JJ cell/NN lineage/NN commitment/NN ,/, we/PRP constructed/VBD a/DT conditional/JJ form/NN of/IN the/DT protein/NN by/IN fusing/VBG it/PRP to/TO the/DT hormone/NN binding/NN domain/NN of/IN the/DT human/JJ estrogen/NN receptor/NN ./. 
This/DT construct/NN was/VBD stably/RB expressed/VBN in/IN a/DT multipotent/JJ progenitor/NN cell/NN line/NN transformed/VBN by/IN the/DT Myb-Ets/NN oncoprotein/NN ./. 
We/PRP report/VBP here/RB that/IN both/CC NF-M-dependent/JJ promoter/NN constructs/NNS and/CC resident/JJ genes/NNS could/MD be/VB activated/VBN by/IN addition/NN of/IN beta-estradiol/NN to/TO the/DT NF-M-estrogen/NN receptor/NN expressing/VBG progenitors/NNS ./. 
At/IN the/DT same/JJ time/NN ,/, we/PRP observed/VBD a/DT down-regulation/NN of/IN progenitor-specific/JJ surface/NN markers/NNS and/CC the/DT up-regulation/NN of/IN differentiation/NN markers/NNS restricted/JJ to/TO the/DT eosinophil/NN and/CC myeloid/JJ lineages/NNS ./. 
In/IN addition/NN to/TO the/DT onset/NN of/IN differentiation/NN ,/, cell/NN death/NN was/VBD induced/VBN with/IN typical/JJ apoptotic/JJ features/NNS ./. 
Our/PRP$ results/NNS suggest/VBP that/IN NF-M/NN plays/VBZ an/DT important/JJ role/NN in/IN commitment/NN along/IN the/DT eosinophil/NN lineage/NN and/CC in/IN the/DT induction/NN of/IN apoptosis/NN ./. 
UI/LS -/: 96079922/CD 
TI/LS -/: Prolactin/NN and/CC interleukin-2/NN receptors/NNS in/IN T/NN lymphocytes/NNS signal/VBP through/IN a/DT MGF-STAT5-like/JJ transcription/NN factor/NN ./. 
AB/LS -/: The/DT cell/NN surface/NN receptors/NNS for/IN PRL/NN and/CC interleukin-2/NN (/( IL-2/NN )/) are/VBP structurally/RB distinct/JJ ,/, but/CC share/VBP regulatory/JJ tasks/NNS in/IN T/NN lymphocytes/NNS ./. 
They/PRP can/MD stimulate/VB proliferation/NN and/CC activate/VB transcription/NN of/IN over-lapping/JJ sets/NNS of/IN genes/NNS of/IN T/NN cells/NNS ./. 
PRL/NN and/CC IL-2/NN receptor/NN activation/NN are/VBP both/DT linked/VBN to/TO the/DT Jak/Stat/NN (/( signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN )/) pathway/NN ./. 
We/PRP investigated/VBD the/DT ability/NN of/IN PRL/NN and/CC IL-2/NN to/TO activate/VB Stat/NN proteins/NNS in/IN different/JJ T/NN cell/NN lines/NNS ./. 
The/DT DNA/NN binding/NN specificities/NNS ,/, the/DT reactivities/NNS toward/IN Stat-specific/JJ antisera/NNS ,/, and/CC the/DT mol/NN wt/NN of/IN IL-2-/NN and/CC PRL-induced/JJ DNA-binding/JJ proteins/NNS in/IN Nb2/NN and/CC C196/NN T/NN cell/NN lines/NNS were/VBD investigated/VBN ./. 
A/DT comparison/NN with/IN the/DT Stat/NN proteins/NNS induced/VBN by/IN interferon-gamma/NN ,/, PRL/NN ,/, and/CC IL-6/NN in/IN T47D/NN mammary/JJ tumor/NN cells/NNS was/VBD made/VBN ./. 
We/PRP found/VBD that/IN these/DT parameters/NNS were/VBD indistinguishable/JJ for/IN one/CD of/IN the/DT PRL-/NN and/CC IL-2-induced/JJ factors/NNS ./. 
A/DT transcription/NN factor/NN closely/RB related/JJ to/TO mammary/JJ gland/NN factor-Stat5/NN is/VBZ rapidly/RB activated/VBN upon/IN interaction/NN of/IN IL-2/NN and/CC PRL/NN with/IN their/PRP$ respective/JJ receptors/NNS ./. 
Activation/NN of/IN a/DT second/JJ protein/NN related/JJ to/TO Stat1/NN was/VBD also/RB observed/VBN ./. 
Our/PRP$ results/NNS emphasize/VBP the/DT role/NN of/IN PRL/NN as/IN a/DT regulator/NN of/IN the/DT immune/JJ response/NN and/CC indicate/VBP that/IN the/DT Stat/NN factors/NNS mammary/JJ gland/NN factor-Stat5/NN and/CC Stat1/NN play/VBP a/DT role/NN in/IN the/DT regulation/NN of/IN gene/NN expression/NN during/IN T/NN cell/NN development/NN ./. 
UI/LS -/: 96074843/CD 
TI/LS -/: ETS1/NN transactivates/VBZ the/DT human/JJ GM-CSF/NN promoter/NN in/IN Jurkat/NN T/NN cells/NNS stimulated/VBN with/IN PMA/NN and/CC ionomycin/NN ./. 
AB/LS -/: Activation/NN of/IN T/NN helper/NN cells/NNS results/VBZ in/IN coordinate/JJ expression/NN of/IN a/DT number/NN of/IN cytokines/NNS involved/VBN in/IN differentiation/NN ,/, proliferation/NN and/CC activation/NN of/IN the/DT haematopoietic/JJ system/NN ./. 
Granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) is/VBZ one/CD such/JJ cytokine/NN whose/WP$ increased/VBN expression/NN results/VBZ partly/RB from/IN increases/NNS in/IN transcription/NN ./. 
Cis-acting/JJ elements/NNS with/IN NF/NN kappa/NN B/NN ,/, AP-1/NN and/CC ETS-like/JJ motifs/NNS have/VBP been/VBN identified/VBN in/IN the/DT promoter/NN region/NN of/IN the/DT GM-CSF/NN gene/NN ,/, which/WDT are/VBP important/JJ for/IN transcriptional/JJ activity/NN following/VBG PMA/NN and/CC ionomycin/NN stimulation/NN ./. 
A/DT number/NN of/IN the/DT ETS/NN family/NN of/IN transcription/NN factors/NNS are/VBP expressed/VBN in/IN T/NN cells/NNS ,/, including/VBG ETS1/NN and/CC ELF1/NN ./. 
Here/RB we/PRP describe/VBP the/DT ability/NN of/IN these/DT factors/NNS to/TO interact/VB with/IN a/DT site/NN (/( GM5/NN )/) ,/, located/JJ within/IN the/DT CLE0/NN element/NN ,/, -47/CD to/TO -40/CD upstream/RB of/IN the/DT GM-CSF/NN transcription/NN initiation/NN site/NN ./. 
Exogenous/JJ ETS1/NN ,/, but/CC not/RB ELF1/NN ,/, can/MD transactivate/VB GM-CSF/NN ,/, through/IN the/DT GM5/NN site/NN ,/, in/IN a/DT PMA/NN /ionomycin/NN dependent/JJ manner/NN ./. 
Other/JJ unidentified/JJ ETS-like/JJ factors/NNS present/JJ in/IN Jurkat/NN cells/NNS are/VBP also/RB capable/JJ of/IN binding/VBG GM5/NN ./. 
Mutation/NN of/IN the/DT core/NN ETS/NN binding/NN site/NN from/IN -GGAA-/NN to/TO -GGAT-/NN prevents/VBZ the/DT binding/NN of/IN ETS-like/JJ factors/NNS with/IN the/DT exception/NN of/IN ETS1/NN ./. 
The/DT GM-CSF/NN promoter/NN ,/, modified/VBN in/IN this/DT way/NN to/TO be/VB ETS1/NN specific/JJ ,/, is/VBZ fully/RB responsive/JJ to/TO PMA/NN /ionomycin/NN induction/NN ,/, in/IN addition/NN to/TO ETS1/NN transactivation/NN in/IN the/DT presence/NN of/IN PMA/NN and/CC ionomycin/NN ./. 
Together/RB these/DT data/NNS suggest/VBP that/IN ETS1/NN may/MD be/VB involved/VBN in/IN mediating/VBG the/DT increased/VBN GM-CSF/NN production/NN associated/VBN with/IN T/NN cell/NN activation/NN ./. 
UI/LS -/: 96379940/CD 
TI/LS -/: Quantitation/NN of/IN beta/NN 1/CD triiodothyronine/NN receptor/NN mRNA/NN in/IN human/JJ tissues/NNS by/IN competitive/JJ reverse/JJ transcription/NN polymerase/NN chain/NN reaction/NN ./. 
AB/LS -/: Thyroid/NN hormones/NNS act/VBP by/IN binding/VBG to/TO nuclear/JJ receptor/NN proteins/NNS ,/, the/DT thyroid/NN hormone/NN receptors/NNS (/( TR/NN )/) alpha/NN and/CC beta/NN ./. 
Data/NNS from/IN cell/NN culture/NN and/CC animal/NN studies/NNS indicate/VBP that/IN TR/NN expression/NN may/MD be/VB regulated/VBN to/TO modulate/VB target/NN organ/NN responsiveness/NN to/TO thyroid/NN hormone/NN ./. 
To/TO investigate/VB whether/IN such/JJ adaptive/JJ changes/NNS in/IN TR/NN expression/NN occur/VBP in/IN humans/NNS ,/, we/PRP determined/VBD the/DT mRNA/NN levels/NNS of/IN the/DT hTR/NN beta/NN 1/CD in/IN various/JJ thyroid/NN states/NNS ./. 
Patients/NNS with/IN overt/JJ hypo-/JJ or/CC hyperthyroidism/NN were/VBD enrolled/VBN in/IN the/DT study/NN ./. 
Total/JJ RNA/NN was/VBD isolated/VBN from/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS and/CC hTR/NN beta/NN 1/CD mRNA/NN levels/NNS determined/VBN by/IN quantitative/JJ competitive/JJ reverse/JJ transcription/NN PCR/NN ./. 
For/IN comparison/NN ,/, hTR/NN beta/NN 1/CD mRNA/NN levels/NNS were/VBD determined/VBN in/IN lymphocytes/NNS and/CC normal/JJ thyroid/NN tissue/NN of/IN euthyroid/NN patients/NNS ./. 
Human/JJ TR/NN beta/NN 1/CD mRNA/NN levels/NNS in/IN lymphocytes/NNS were/VBD 1.8/CD +/-/CC 0.4/CD ,/, 1.9/CD +/-/CC 0.5/CD ,/, 1.1/CD +/-/CC 0.4/CD 10/CD (/( -18/CD )/) mol/microgram/NN RNA/NN in/IN hypo-/JJ ,/, eu-/JJ and/CC hyperthyroid/JJ patients/NNS ,/, respectively/RB ,/, corresponding/VBG to/TO an/DT estimated/VBN 0.5 -2/CD molecules/NNS per/IN cell/NN ./. 
Although/IN the/DT mean/JJ hTR/NN beta/NN 1/CD mRNA/NN levels/NNS were/VBD 40/CD %/NN lower/JJR in/IN hyperthyroid/JJ than/IN in/IN euthyroid/JJ subjects/NNS ,/, this/DT difference/NN did/VBD not/RB reach/VB statistical/JJ significance/NN ./. 
Similar/JJ levels/NNS of/IN hTR/NN beta/NN 1/CD mRNA/NN levels/NNS were/VBD detected/VBN in/IN thyroid/NN gland/NN from/IN euthyroid/JJ patients/NNS ./. 
In/IN summary/NN ,/, we/PRP developed/VBD an/DT assay/NN for/IN the/DT quantitative/JJ determination/NN of/IN hTR/NN beta/NN 1/CD mRNA/NN levels/NNS in/IN small/JJ human/JJ tissue/NN samples/NNS ,/, containing/VBG as/RB little/JJ as/IN 50/CD ng/NN of/IN total/JJ RNA/NN ./. 
Absolute/JJ hTR/NN beta/NN 1/CD mRNA/NN levels/NNS are/VBP very/RB low/JJ with/IN an/DT estimated/VBN one/CD molecule/NN of/IN mRNA/NN being/VBG present/JJ in/IN a/DT mononuclear/JJ blood/NN cell/NN or/CC thyrocyte/NN ./. 
No/DT up-regulation/NN of/IN hTR/NN beta/NN 1/CD was/VBD seen/VBN in/IN hypothyroid/JJ relative/JJ to/TO euthyroid/JJ patients/NNS ./. 
However/RB ,/, there/EX is/VBZ a/DT non-significant/JJ trend/NN towards/IN a/DT down-regulation/NN of/IN hTR/NN beta/NN 1/CD mRNA/NN levels/NNS in/IN hyperthyroid/JJ patients/NNS ./. 
UI/LS -/: 96025857/CD 
TI/LS -/: Multiple/JJ proteins/NNS interact/VBP with/IN the/DT nuclear/JJ inhibitory/JJ protein/NN repressor/NN element/NN in/IN the/DT human/JJ interleukin-3/NN promoter/NN ./. 
AB/LS -/: T/NN cell/NN expression/NN of/IN interleukin/NN 3/CD (/( IL-3/NN )/) is/VBZ directed/VBN by/IN positive/JJ and/CC negative/JJ cis-acting/JJ DNA/NN elements/NNS clustered/JJ within/IN 300/CD base/NN pairs/NNS of/IN the/DT transcriptional/JJ start/NN site/NN ./. 
A/DT strong/JJ repressor/NN element/NN ,/, termed/VBN nuclear/JJ inhibitory/JJ protein/NN (/( NIP/NN )/) ,/, was/VBD previously/RB mapped/VBN to/TO a/DT segment/NN of/IN the/DT IL-3/NN promoter/NN between/IN nucleotides/NNS -271/CD and/CC -250/CD ./. 
Functional/JJ characterization/NN of/IN this/DT element/NN demonstrates/VBZ that/IN it/PRP can/MD mediate/VB repression/NN when/WRB linked/VBN in/IN cis/NN to/TO a/DT heterologous/JJ promoter/NN ./. 
DNA/NN binding/NN experiments/NNS were/VBD carried/VBN out/RP to/TO characterize/VB the/DT repressor/NN activity/NN ./. 
Using/VBG varying/JJ conditions/NNS ,/, three/CD distinct/JJ complexes/NNS were/VBD shown/VBN to/TO interact/VB specifically/RB with/IN the/DT NIP/NN region/NN ,/, although/IN only/RB one/CD correlates/VBZ with/IN repressor/NN activity/NN ./. 
Complex/NN 1/CD results/VBZ from/IN binding/NN of/IN a/DT ubiquitous/JJ polypeptide/NN that/WDT recognizes/VBZ the/DT 3'/JJ portion/NN of/IN this/DT sequence/NN and/CC is/VBZ not/RB required/VBN for/IN repression/NN ./. 
Complex/NN 2/CD corresponds/VBZ to/TO binding/NN of/IN transcription/NN factor/NN (/( upstream/JJ stimulatory/JJ factor/NN )/) to/TO an/DT E-box/NN motif/NN in/IN the/DT 5'/JJ portion/NN of/IN the/DT NIP/NN region/NN ./. 
DNA/NN binding/NN specificity/NN of/IN complex/NN 3/CD overlaps/VBZ with/IN that/DT of/IN upstream/JJ stimulatory/JJ factor/NN but/CC is/VBZ clearly/RB distinct/JJ ./. 
To/TO determine/VB which/WDT of/IN the/DT latter/JJ two/CD complexes/NNS represents/VBZ NIP/NN activity/NN ,/, we/PRP incorporated/VBD small/JJ alterations/NNS into/IN the/DT NIP/NN site/NN of/IN an/DT IL-3/NN promoter-linked/JJ reporter/NN construct/NN and/CC examined/VBD their/PRP$ effects/NNS on/IN NIP-mediated/JJ repression/NN ./. 
Functional/JJ specificity/NN for/IN repression/NN matches/VBZ the/DT DNA/NN binding/NN specificity/NN of/IN complex/NN 3/CD ;/: both/DT repressor/NN activity/NN and/CC complex/NN 3/CD binding/NN require/VBP the/DT consensus/NN sequence/NN CTCACNTNC/NN ./. 
UI/LS -/: 95399778/CD 
TI/LS -/: The/DT hematopoietic/JJ transcription/NN factor/NN PU.1/NN is/VBZ downregulated/VBN in/IN human/JJ multiple/JJ myeloma/NN cell/NN lines/NNS ./. 
AB/LS -/: PU.1/NN is/VBZ a/DT hematopoietic/JJ transcription/NN factor/NN belonging/VBG to/TO the/DT Ets-family/NN ./. 
It/PRP is/VBZ identical/JJ to/TO the/DT Spi-1/NN oncogene/NN ,/, which/WDT is/VBZ implicated/VBN in/IN spleen/NN focus-forming/JJ virus-induced/JJ murine/JJ erythroleukemias/NNS ./. 
PU.1/NN seems/VBZ to/TO be/VB required/VBN for/IN early/JJ development/NN of/IN multiple/JJ hematopoietic/JJ lineages/NNS ,/, but/CC its/PRP$ expression/NN in/IN mature/JJ cells/NNS is/VBZ preferentially/RB observed/VBN in/IN cells/NNS of/IN the/DT B-cell-and/NN monocyte/macrophage-differentiation/NN lineage/NN ./. 
It/PRP binds/VBZ the/DT so-called/JJ Pu/NN box/NN ,/, an/DT important/JJ tissue-specific/JJ regulatory/JJ DNA/NN element/NN present/JJ in/IN a/DT number/NN of/IN genes/NNS expressed/VBN in/IN these/DT cell/NN lineages/NNS ./. 
We/PRP have/VBP analyzed/VBN the/DT expression/NN and/CC activity/NN of/IN PU.1/NN during/IN human/JJ B-cell/NN development/NN using/VBG a/DT panel/NN of/IN B-cell/NN lines/NNS representing/VBG different/JJ stages/NNS of/IN maturation/NN ,/, from/IN early/JJ precursors/NNS to/TO differentiated/VBN plasma/NN cells/NNS ./. 
PU.1/NN mRNA/NN expression/NN and/CC PU.1/NN DNA/NN binding/NN activity/NN ,/, as/IN measured/VBN by/IN Northern/NN blot/NN analysis/NN and/CC electrophoretic/JJ mobility/NN shift/NN assay/NN ,/, respectively/RB ,/, were/VBD evident/JJ in/IN cell/NN lines/NNS representing/VBG pro-B/JJ ,/, pre-B/JJ ,/, and/CC mature/JJ B/NN cells/NNS ./. 
We/PRP could/MD also/RB show/VB Pu/NN box-dependent/JJ transactivation/NN of/IN a/DT reporter/NN gene/NN in/IN transient/JJ transfections/NNS in/IN these/DT cell/NN lines/NNS ./. 
In/IN contrast/NN ,/, in/IN a/DT number/NN of/IN multiple/JJ myeloma/NN cell/NN lines/NNS ,/, representing/VBG differentiated/VBN ,/, plasma/NN cell-like/JJ B/NN cells/NNS ,/, PU.1/NN DNA/NN binding/NN activity/NN ,/, mRNA/NN expression/NN ,/, and/CC Pu/NN box-dependent/JJ transactivation/NN were/VBD absent/JJ or/CC detectable/JJ at/IN a/DT very/RB low/JJ level/NN ./. 
In/IN lymphoblastoid/JJ cell/NN lines/NNS ,/, which/WDT exemplify/VBP an/DT intermediate/JJ stage/NN of/IN B-cell/NN differentiation/NN ,/, a/DT reduced/VBN expression/NN and/CC activity/NN were/VBD observed/VBN ./. 
The/DT findings/NNS in/IN the/DT human/JJ multiple/JJ myeloma/NN cell/NN lines/NNS represent/VBP the/DT first/JJ examples/NNS of/IN B/NN cells/NNS with/IN downregulated/VBN PU.1/NN expression/NN and/CC apparently/RB contradict/VBP observations/NNS in/IN the/DT murine/JJ system/NN in/IN which/WDT PU.1/NN is/VBZ expressed/VBN and/CC active/JJ in/IN plasmacytoma/NN cell/NN lines/NNS ./. 
At/IN present/JJ ,/, it/PRP is/VBZ unclear/JJ whether/IN the/DT lack/NN of/IN PU.1/NN expression/NN and/CC activity/NN in/IN human/JJ multiple/JJ myeloma/NN cell/NN lines/NNS represents/VBZ a/DT malignancy-associated/JJ defect/NN in/IN these/DT cells/NNS or/CC exemplifies/VBZ a/DT normal/JJ developmental/JJ regulation/NN in/IN terminally/RB differentiated/VBN B/NN cells/NNS ./. 
UI/LS -/: 95399771/CD 
TI/LS -/: Regulation/NN of/IN granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN and/CC E-selectin/NN expression/NN in/IN endothelial/JJ cells/NNS by/IN cyclosporin/NN A/NN and/CC the/DT T-cell/NN transcription/NN factor/NN NFAT/NN ./. 
AB/LS -/: Nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) was/VBD originally/RB described/VBN as/IN a/DT T-cell-specific/JJ transcription/NN factor/NN athat/WDT supported/VBD the/DT activation/NN of/IN cytokine/NN gene/NN expression/NN and/CC mediated/VBD the/DT immunoregulatory/JJ effects/NNS of/IN cyclosporin/NN A/NN (/( CsA/NN )/) ./. 
As/IN we/PRP observed/VBD that/IN activated/VBN endothelial/JJ cells/NNS also/RB expressed/VBD NFAT/NN ,/, we/PRP tested/VBD the/DT antiinflammatory/JJ properties/NNS of/IN CsA/NN in/IN endothelial/JJ cells/NNS ./. 
Significantly/RB ,/, CsA/NN completely/RB suppressed/VBD the/DT induction/NN of/IN NFAT/NN in/IN endothelial/JJ cells/NNS and/CC inhibited/VBD the/DT activity/NN of/IN granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) gene/NN regulatory/JJ elements/NNS that/WDT use/VBP NFAT/NN by/IN 60/CD %/NN ./. 
CsA/NN similarly/RB mediated/VBD a/DT reduction/NN of/IN up/RB to/TO 65/CD %/NN in/IN GM-CSF/NN mRNA/NN and/CC protein/NN expression/NN in/IN activated/VBN endothelial/JJ cells/NNS ./. 
CsA/NN also/RB suppressed/VBD E-selectin/NN ,/, but/CC not/RB vascular/JJ cell/NN adhesion/NN molecule-1/NN (/( VCAM-1/NN )/) expression/NN in/IN endothelial/JJ cells/NNS ,/, even/RB though/IN the/DT E-selectin/NN promoter/NN is/VBZ activated/VBN by/IN NF-kappa/NN B/NN rather/RB than/IN NFAT/NN ./. 
Hence/RB ,/, induction/NN of/IN cell/NN surface/NN expression/NN of/IN this/DT leukocyte/NN adhesion/NN molecule/NN by/IN tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) -alpha/NN was/VBD reduced/VBN by/IN 40/CD %/NN in/IN the/DT presence/NN of/IN CsA/NN ,/, and/CC this/DT was/VBD reflected/VBN by/IN a/DT 29/CD %/NN decrease/NN in/IN neutrophil/NN adhesion/NN ./. 
The/DT effects/NNS of/IN CsA/NN on/IN endothelial/JJ cells/NNS were/VBD also/RB detected/VBN at/IN the/DT chromatin/NN structure/NN level/NN ,/, as/IN DNasel/NN hypersensitive/JJ sites/NNS within/IN both/CC the/DT GM-CSF/NN enhancer/NN and/CC the/DT E-selectin/NN promoter/NN were/VBD suppressed/VBN by/IN CsA/NN ./. 
This/DT represents/VBZ the/DT first/JJ report/NN of/IN NFAT/NN in/IN endothelial/JJ cells/NNS and/CC suggests/VBZ mechanisms/NNS by/IN which/WDT CsA/NN could/MD function/VB as/IN an/DT antiinflammatory/JJ agent/NN ./. 
UI/LS -/: 96049646/CD 
TI/LS -/: Costimulation/NN requirement/NN for/IN AP-1/NN and/CC NF-kappa/NN B/NN transcription/NN factor/NN activation/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: The/DT transcriptional/JJ activity/NN of/IN the/DT IL-2/NN promoter/NN requires/VBZ T-cell/NN costimulation/NN delivered/VBN by/IN the/DT TCR/NN and/CC the/DT auxiliary/JJ receptor/NN CD28/NN ./. 
Several/JJ transcription/NN factors/NNS participate/VBP in/IN IL-2/NN promoter/NN activation/NN ,/, among/IN which/WDT are/VBP AP-1-like/JJ factors/NNS and/CC NF-kappa/NN B/NN ./. 
Protein/NN phosphorylation/NN has/VBZ an/DT important/JJ role/NN in/IN the/DT regulation/NN of/IN these/DT two/CD factors/NNS :/: (/( 1/LS )/) it/PRP induces/VBZ the/DT transactivating/NN capacity/NN of/IN the/DT AP-1/NN protein/NN c-Jun/NN ;/: and/CC (/( 2/LS )/) it/PRP is/VBZ involved/VBN in/IN the/DT release/NN of/IN the/DT cytoplasmic/JJ inhibitor/NN ,/, I/NN kappa/NN B/NN ,/, from/IN NF-kappa/NN B/NN ,/, allowing/VBG translocation/NN of/IN the/DT latter/JJ into/IN the/DT nucleus/NN ./. 
We/PRP have/VBP recently/RB shown/VBN that/IN both/DT phosphorylation/NN processes/NNS require/VBP T-cell/NN costimulation/NN ./. 
Furthermore/RB ,/, in/IN activated/VBN T/NN cells/NNS ,/, the/DT kinetics/NNS of/IN the/DT two/CD phosphorylation/NN events/NNS are/VBP essentially/RB similar/JJ ./. 
According/VBG to/TO our/PRP$ results/NNS ,/, however/RB ,/, the/DT kinases/NNS responsible/JJ for/IN the/DT two/CD processes/NNS are/VBP distinct/JJ entities/NNS ./. 
Whereas/IN TPCK/NN inhibits/VBZ phosphorylation/NN of/IN I/NN kappa/NN B/NN and/CC ,/, consequently/RB ,/, activation/NN of/IN NF-kappa/NN B/NN ,/, it/PRP markedly/RB enhances/VBZ the/DT activity/NN of/IN JNK/NN ,/, the/DT MAP/NN kinase-related/JJ kinase/NN that/WDT phosphorylates/VBZ the/DT transactivation/NN domain/NN of/IN c-Jun/NN ./. 
We/PRP ,/, therefore/RB ,/, propose/VBP the/DT activation/NN scheme/NN presented/VBN in/IN FIGURE/NN 3/CD for/IN T-cell/NN costimulation/NN ./. 
Costimulation/NN results/VBZ in/IN the/DT activation/NN of/IN a/DT signaling/NN pathway/NN that/WDT leads/VBZ to/TO the/DT simultaneous/JJ induction/NN of/IN the/DT two/CD transcription/NN factors/NNS ,/, AP-1/NN and/CC NF-kappa/NN B/NN ./. 
Integration/NN of/IN the/DT signals/NNS generated/VBN by/IN TCR/NN and/CC CD28/NN engagement/NN occurs/VBZ along/IN this/DT pathway/NN ,/, which/WDT then/RB bifurcates/VBZ to/TO induce/VB I/NN kappa/NN B/NN phosphorylation/NN and/CC NF-kappa/NN B/NN activation/NN on/IN the/DT one/CD hand/NN ,/, and/CC JNK/NN activation/NN and/CC c-Jun/NN phosphorylation/NN on/IN the/DT other/JJ ./. 
We/PRP are/VBP currently/RB engaged/VBN in/IN defining/VBG where/WRB the/DT two/CD signals/NNS integrate/VBP along/IN the/DT AP-1/NN /NF-kappa/NN B/NN pathway/NN ./. 
UI/LS -/: 96035700/CD 
TI/LS -/: Regulation/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD and/CC cytokine/NN gene/NN expression/NN in/IN myeloid/JJ cells/NNS by/IN NF-kappa/NN B/NN /Rel/NN transcription/NN factors/NNS ./. 
AB/LS -/: CD4+/JJ macrophages/NNS in/IN tissues/NNS such/JJ as/IN lung/NN ,/, skin/NN ,/, and/CC lymph/NN nodes/NNS ,/, promyelocytic/JJ cells/NNS in/IN bone/NN marrow/NN ,/, and/CC peripheral/JJ blood/NN monocytes/NNS serve/VBP as/IN important/JJ targets/NNS and/CC reservoirs/NNS for/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) replication/NN ./. 
HIV-1-infected/JJ myeloid/JJ cells/NNS are/VBP often/RB diminished/VBN in/IN their/PRP$ ability/NN to/TO participate/VB in/IN chemotaxis/NN ,/, phagocytosis/NN ,/, and/CC intracellular/JJ killing/NN ./. 
HIV-1/NN infection/NN of/IN myeloid/JJ cells/NNS can/MD lead/VB to/TO the/DT expression/NN of/IN surface/NN receptors/NNS associated/VBN with/IN cellular/JJ activation/NN and/or/CC differentiation/NN that/WDT increase/VBP the/DT responsiveness/NN of/IN these/DT cells/NNS to/TO cytokines/NNS secreted/VBN by/IN neighboring/VBG cells/NNS as/RB well/RB as/IN to/TO bacteria/NNS or/CC other/JJ pathogens/NNS ./. 
Enhancement/NN of/IN HIV-1/NN replication/NN is/VBZ related/JJ in/IN part/NN to/TO increased/VBN DNA-binding/JJ activity/NN of/IN cellular/JJ transcription/NN factors/NNS such/JJ as/IN NF-kappa/NN B/NN ./. 
NF-kappa/NN B/NN binds/VBZ to/TO the/DT HIV-1/NN enhancer/NN region/NN of/IN the/DT long/JJ terminal/JJ repeat/NN and/CC contributes/VBZ to/TO the/DT inducibility/NN of/IN HIV-1/NN gene/NN expression/NN in/IN response/NN to/TO multiple/JJ activating/VBG agents/NNS ./. 
Phosphorylation/NN and/CC degradation/NN of/IN the/DT cytoplasmic/JJ inhibitor/NN I/NN kappa/NN B/NN alpha/NN are/VBP crucial/JJ regulatory/JJ events/NNS in/IN the/DT activation/NN of/IN NF-kappa/NN B/NN DNA-binding/JJ activity/NN ./. 
Both/CC N-/NN and/CC C-terminal/JJ residues/NNS of/IN I/NN kappa/NN B/NN alpha/NN are/VBP required/VBN for/IN inducer-mediated/JJ degradation/NN ./. 
Chronic/JJ HIV-1/NN infection/NN of/IN myeloid/JJ cells/NNS leads/VBZ to/TO constitutive/JJ NF-kappa/NN B/NN DNA-binding/JJ activity/NN and/CC provides/VBZ an/DT intranuclear/JJ environment/NN capable/JJ of/IN perpetuating/VBG HIV-1/NN replication/NN ./. 
Increased/VBN intracellular/JJ stores/NNS of/IN latent/JJ NF-kappa/NN B/NN may/MD also/RB result/VB in/IN rapid/JJ inducibility/NN of/IN NF-kappa/NN B-dependent/JJ cytokine/NN gene/NN expression/NN ./. 
In/IN response/NN to/TO secondary/JJ pathogenic/JJ infections/NNS or/CC antigenic/JJ challenge/NN ,/, cytokine/NN gene/NN expression/NN is/VBZ rapidly/RB induced/VBN ,/, enhanced/VBN ,/, and/CC sustained/JJ over/RP prolonged/JJ periods/NNS in/IN HIV-1-infected/JJ myeloid/JJ cells/NNS compared/VBN with/IN uninfected/JJ cells/NNS ./. 
Elevated/JJ levels/NNS of/IN several/JJ inflammatory/JJ cytokines/NNS have/VBP been/VBN detected/VBN in/IN the/DT sera/NN of/IN HIV-1-infected/JJ individuals/NNS ./. 
Secretion/NN of/IN myeloid/JJ cell-derived/JJ cytokines/NNS may/MD both/CC increase/VB virus/NN production/NN and/CC contribute/VB to/TO AIDS-associated/JJ disorders/NNS ./. 
UI/LS -/: 90173249/CD 
TI/LS -/: Steroid/NN mediated/JJ lysis/NN of/IN lymphoblasts/NNS requires/VBZ the/DT DNA/NN binding/NN region/NN of/IN the/DT steroid/NN hormone/NN receptor/NN ./. 
AB/LS -/: Glucocorticoids/NNS kill/VBP certain/JJ types/NNS of/IN lymphoblasts/NNS ,/, but/CC the/DT mechanisms/NNS are/VBP unknown/JJ ./. 
It/PRP is/VBZ clear/JJ that/IN sufficient/JJ numbers/NNS of/IN functional/JJ glucocorticoid/NN receptors/NNS are/VBP required/VBN to/TO mediate/VB lysis/NN ,/, but/CC whether/IN they/PRP do/VBP so/RB through/IN the/DT classical/JJ model/NN of/IN steroid/NN hormone/NN activation/NN and/CC modulation/NN of/IN gene/NN expression/NN has/VBZ not/RB been/VBN established/VBN ./. 
In/IN this/DT report/NN we/PRP have/VBP asked/VBN which/WDT region/NN (/( s/NNS )/) of/IN the/DT steroid/NN receptor/NN are/VBP important/JJ for/IN mediating/VBG lysis/NN in/IN leukemic/JJ T/NN lymphoblasts/NNS ./. 
CEM-ICR/NN 27/CD leukemic/JJ lymphoblasts/NNS ,/, a/DT clone/NN of/IN CEM/NN cells/NNS which/WDT lack/VBP functional/JJ glucocorticoid/NN receptors/NNS and/CC therefore/RB are/VBP neither/CC lysed/VBN by/IN dexamethasone/NN nor/CC capable/JJ of/IN showing/VBG glutamine/NN synthetase/NN induction/NN ,/, were/VBD provided/VBN with/IN steroid/NN receptors/NNS by/IN DNA/NN transfections/NNS of/IN various/JJ receptor/NN gene/NN constructs/NNS ./. 
We/PRP measured/VBD steroid/NN mediated/JJ lysis/NN ,/, receptor/NN number/NN and/CC induction/NN of/IN glutamine/NN synthetase/NN in/IN the/DT transfected/VBN cells/NNS ./. 
Our/PRP$ results/NNS provide/VBP evidence/NN that/IN the/DT lysis/NN mechanism/NN in/IN the/DT ICR27/NN lymphoblasts/NNS is/VBZ restored/VBN when/WRB functional/JJ receptor/NN number/NN is/VBZ restored/VBN ./. 
The/DT DNA/NN binding/NN region/NN specifying/VBG high/JJ affinity/NN for/IN GRE/NN sites/NNS is/VBZ required/VBN ./. 
Lysis/NN is/VBZ mediated/VBN by/IN any/DT steroid/NN that/WDT allows/VBZ for/IN activation/NN of/IN the/DT receptor/NN containing/VBG such/JJ a/DT region/NN ./. 
Our/PRP$ data/NNS support/VBP the/DT view/NN that/IN steroid-mediated/JJ cell/NN death/NN occurs/VBZ by/IN a/DT process/NN requiring/VBG direct/JJ interaction/NN of/IN steroid-receptor/JJ complexes/NNS with/IN the/DT genome/NN ./. 
UI/LS -/: 96102041/CD 
TI/LS -/: Functional/JJ characterization/NN of/IN the/DT murine/JJ homolog/NN of/IN the/DT B/NN cell-specific/JJ coactivator/NN BOB.1/OBF.1/NN ./. 
AB/LS -/: B/NN cell-specific/JJ transcriptional/JJ promoter/NN activity/NN mediated/VBN by/IN the/DT octamer/NN motif/NN requires/VBZ the/DT Oct1/NN or/CC Oct2/NN protein/NN and/CC additional/JJ B/NN cell-restricted/JJ cofactors/NNS ./. 
One/CD such/JJ cofactor/NN ,/, BOB.1/OBF.1/NN ,/, was/VBD recently/RB isolated/VBN from/IN human/JJ B/NN cells/NNS ./. 
Here/RB ,/, we/PRP describe/VBP the/DT isolation/NN and/CC detailed/JJ characterization/NN of/IN the/DT murine/JJ homolog/NN ./. 
Full-length/JJ cDNAs/NNS and/CC genomic/JJ clones/NNS were/VBD isolated/VBN ,/, and/CC the/DT gene/NN structure/NN was/VBD determined/VBN ./. Comparison/NN of/IN the/DT deduced/VBN amino/NN acids/NNS shows/VBZ 88/CD %/NN sequence/NN identity/NN between/IN mouse/NN and/CC human/JJ BOB.1/OBF.1/NN ./. 
The/DT NH2-terminal/JJ 126/CD amino/NN acids/NNS of/IN BOB.1/OBF.1/NN are/VBP both/CC essential/JJ and/CC sufficient/JJ for/IN interaction/NN with/IN the/DT POU/NN domains/NNS of/IN either/CC Oct1/NN or/CC Oct2/NN ./. 
This/DT protein-protein/JJ interaction/NN does/VBZ not/RB require/VB the/DT simultaneous/JJ binding/NN of/IN Oct/NN proteins/NNS to/TO DNA/NN ,/, and/CC high/JJ resolution/NN footprinting/NN of/IN the/DT Oct-DNA/NN interaction/NN reveals/VBZ that/IN binding/NN of/IN BOB.1/OBF.1/NN to/TO Oct1/NN or/CC Oct2/NN does/VBZ not/RB alter/VB the/DT interaction/NN with/IN DNA/NN ./. 
BOB.1/OBF.1/NN can/MD efficiently/RB activate/VB octamer-dependent/JJ promoters/NNS in/IN fibroblasts/NNS ;/: however/RB ,/, it/PRP fails/VBZ to/TO stimulate/VB octamer-dependent/JJ enhancer/NN activity/NN ./. 
Fusion/NN of/IN subdomains/NNS of/IN BOB.1/OBF.1/NN with/IN the/DT GAL4/NN DNA/NN binding/NN domain/NN reveals/VBZ that/IN both/CC NH2-/NN and/CC COOH-terminal/JJ domains/NNS of/IN BOB.1/OBF.1/NN contribute/VBP to/TO full/JJ transactivation/NN function/NN ,/, the/DT COOH-terminal/JJ domain/NN is/VBZ more/RBR efficient/JJ in/IN this/DT transactivation/NN assay/NN ./. 
Consistent/JJ with/IN the/DT failure/NN of/IN full-length/JJ BOB.1/OBF.1/NN to/TO stimulate/VB octamer-dependent/JJ enhancer/NN elements/NNS in/IN non/JJ B/NN cells/NNS ,/, the/DT GAL4/NN fusions/NNS likewise/RB only/RB stimulate/VBP from/IN a/DT promoter-proximal/JJ position/NN ./. 
UI/LS -/: 96096469/CD 
TI/LS -/: Anti-immunoglobulin/NN M/NN activates/VBZ nuclear/JJ calcium/NN /calmodulin-dependent/JJ protein/NN kinase/NN II/CD in/IN human/JJ B/NN lymphocytes/NNS ./. 
AB/LS -/: We/PRP and/CC others/NNS have/VBP previously/RB shown/VBN that/IN the/DT nuclear/JJ protein/NN ,/, Ets-1/NN ,/, is/VBZ phosphorylated/VBN in/IN a/DT calcium-dependent/JJ manner/NN after/IN ligation/NN of/IN immunoglobulin/NN (/( Ig/NN )/) M/NN on/IN B/NN lymphocytes/NNS ./. 
As/IN this/DT phosphorylation/NN was/VBD independent/JJ of/IN protein/NN kinase/NN C/NN activity/NN ,/, we/PRP tested/VBD whether/IN a/DT calcium/NN /calmodulin-dependent/JJ protein/NN kinase/NN (/( CaM/NN kinase/NN )/) might/MD phosphorylate/VB the/DT Ets-1/NN protein/NN after/IN elevation/NN of/IN intracellular/JJ free/JJ calcium/NN concentrations/NNS ./. 
The/DT dephosphorylated/JJ form/NN of/IN Ets-1/NN has/VBZ been/VBN shown/VBN to/TO bind/VB to/TO chromatin/NN ,/, suggesting/VBG that/IN the/DT operative/JJ kinase/NN should/MD be/VB detectable/JJ in/IN the/DT nucleus/NN ./. 
We/PRP prepared/VBD nuclear/JJ extracts/NNS from/IN two/CD human/JJ B/NN cell/NN lines/NNS in/IN which/WDT increased/VBN intracellular/JJ free/JJ calcium/NN levels/NNS correlated/VBD with/IN increased/VBN phosphorylation/NN of/IN the/DT Ets-1/NN protein/NN ./. 
Activity/NN of/IN the/DT CaM/NN kinases/NNS was/VBD determined/VBN using/VBG a/DT synthetic/JJ peptide/NN substrate/NN both/CC in/IN the/DT absence/NN and/CC presence/NN of/IN an/DT inhibitor/NN specific/JJ for/IN the/DT CaM/NN kinase/NN family/NN ,/, KN-62/NN ./. 
Stimulation/NN of/IN cells/NNS with/IN anti-IgM/NN led/VBD to/TO increased/VBN activity/NN of/IN a/DT nuclear/JJ kinase/NN that/WDT could/MD phosphorylate/VB the/DT peptide/NN ,/, and/CC this/DT activity/NN was/VBD reduced/VBN by/IN 10/CD microM/NN KN-62/NN ./. 
Kinase/NN activity/NN was/VBD reduced/VBN in/IN lysates/NNS preadsorbed/VBN using/VBG an/DT antibody/NN specific/JJ for/IN CaM/NN kinase/NN II/CD ./. 
Two-dimensional/JJ phosphopeptide/NN maps/NNS of/IN the/DT Ets-1/NN protein/NN from/IN cells/NNS incubated/VBN with/IN ionomycin/NN or/CC anti-IgM/NN contained/VBD two/CD unique/JJ phosphopeptides/NNS that/WDT were/VBD absent/JJ in/IN untreated/JJ cells/NNS ./. 
Incubation/NN of/IN isolated/VBN Ets-1/NN protein/NN with/IN purified/VBN CaM/NN kinase/NN II/CD produced/VBD phosphorylation/NN of/IN peptides/NNS that/WDT migrated/VBD identically/RB to/TO those/DT found/VBN in/IN cells/NNS incubated/VBN with/IN either/CC anti-IgM/NN or/CC ionomycin/NN ./. 
These/DT data/NNS suggest/VBP a/DT model/NN of/IN signal/NN transduction/NN by/IN the/DT antigen/NN receptor/NN on/IN B/NN lymphocytes/NNS in/IN which/WDT increased/VBN intracellular/JJ free/JJ calcium/NN can/MD rapidly/RB activate/VB nuclear/JJ CaM/NN kinase/NN II/CD ,/, potentially/RB resulting/VBG in/IN phosphorylation/NN and/CC regulation/NN of/IN DNA-binding/JJ proteins/NNS ./. 
UI/LS -/: 96096754/CD 
TI/LS -/: Transcriptional/JJ activation/NN and/CC repression/NN ,/, two/CD properties/NNS of/IN the/DT lymphoid-specific/JJ transcription/NN factor/NN Oct-2a/NN ./. 
AB/LS -/: The/DT lymphoid-specific/JJ transcription/NN factor/NN Oct-2a/NN contains/VBZ two/CD transcriptional/JJ activation/NN domains/NNS which/WDT are/VBP located/JJ within/IN the/DT N-terminal/JJ and/CC C-terminal/JJ regions/NNS ./. 
To/TO study/VB their/PRP$ differential/JJ activation/NN properties/NNS ,/, we/PRP linked/VBD the/DT isolated/VBN effector/NN domains/NNS to/TO the/DT GAL4/NN DNA-binding/JJ domain/NN ./. 
We/PRP have/VBP shown/VBN that/IN both/DT activating/VBG regions/NNS of/IN Oct-2a/NN ,/, isolated/VBN from/IN their/PRP$ natural/JJ context/NN ,/, can/MD activate/VB transcription/NN as/IN promoter/NN factors/NNS ./. 
In/IN contrast/NN to/TO the/DT C-terminus/NN ,/, activation/NN by/IN the/DT N-terminal/JJ domain/NN is/VBZ dependent/JJ on/IN a/DT yet/RB unidentified/JJ factor/NN (/( s/NNS )/) binding/VBG to/TO the/DT simian/JJ virus/NN 40/CD enhancer/NN ./. 
The/DT results/NNS obtained/VBN by/IN duplication/NN of/IN activation/NN domains/NNS or/CC their/PRP$ mixed/JJ combination/NN suggest/VBP that/IN the/DT domains/NNS are/VBP functionally/RB independent/JJ ./. 
However/RB ,/, activation/NN from/IN a/DT remote/JJ position/NN could/MD only/RB be/VB achieved/VBN with/IN the/DT C-terminus/NN of/IN Oct-2a/NN in/IN B/NN cells/NNS ./. 
In/IN lymphoid/JJ cells/NNS ,/, higher/JJR activation/NN levels/NNS were/VBD observed/VBN ,/, suggesting/VBG that/IN distinct/JJ B-cell-specific/JJ cofactors/NNS in/IN concert/NN with/IN the/DT effector/NN domains/NNS of/IN Oct-2a/NN might/MD be/VB involved/VBN in/IN mediating/VBG transcription/NN from/IN proximal/JJ and/CC remote/JJ positions/NNS ./. 
Furthermore/RB ,/, we/PRP identified/VBD a/DT repression/NN domain/NN at/IN the/DT N-terminus/NN of/IN Oct-2a/NN ./. 
When/WRB transferred/VBN to/TO a/DT potent/JJ activator/NN ,/, transcriptional/JJ stimulation/NN was/VBD inhibited/VBN efficiently/RB ./. 
These/DT results/NNS underscore/VBP the/DT modular/JJ structure/NN of/IN Oct-2a/NN with/IN separable/JJ domains/NNS for/IN activation/NN and/CC repression/NN and/CC suggest/VBP that/IN Oct-2a/NN might/MD have/VB complex/JJ regulatory/JJ functions/NNS in/FW vivo/FW ./. 
UI/LS -/: 96029754/CD 
TI/LS -/: Nonopsonic/JJ phagocytosis/NN of/IN Pseudomonas/FW aeruginosa/FW by/IN macrophages/NNS and/CC polymorphonuclear/JJ leukocytes/NNS requires/VBZ the/DT presence/NN of/IN the/DT bacterial/JJ flagellum/NN ./. 
AB/LS -/: Whereas/IN the/DT mechanism/NN of/IN nonopsonic/JJ phagocytosis/NN of/IN Pseudomonas/FW aeruginosa/FW has/VBZ been/VBN described/VBN ,/, the/DT bacterial/JJ ligands/NNS required/VBN are/VBP poorly/RB understood/VBN ./. 
To/TO identify/VB the/DT requisite/JJ bacterial/JJ ligands/NNS ,/, studies/NNS with/IN isogenic/JJ mutants/NNS of/IN P./FW aeruginosa/FW PAK/NN lacking/VBG pili/NNS ,/, flagella/NNS ,/, and/CC the/DT RpoN/NN sigma/NN factor/NN were/VBD undertaken/VBN ./. 
The/DT RpoN/NN mutant/NN ,/, lacking/VBG pili/NNS ,/, flagella/NNS ,/, and/CC nonpilus/JJ adhesins/NNS ,/, bound/VBD poorly/RB and/CC was/VBD resistant/JJ to/TO ingestion/NN by/IN both/CC macrophages/NNS and/CC neutrophils/NNS ./. 
Pili/NNS were/VBD not/RB absolutely/RB required/VBN for/IN binding/NN or/CC phagocytosis/NN of/IN P./FW aeruginosa/FW ./. 
The/DT presence/NN of/IN a/DT flagellum/NN was/VBD not/RB required/VBN for/IN binding/NN of/IN P./FW aeruginosa/FW to/TO macrophages/NNS but/CC was/VBD critical/JJ for/IN the/DT subsequent/JJ internalization/NN of/IN the/DT bacterium/NN ,/, suggesting/VBG that/IN this/DT factor/NN or/CC a/DT surface/NN ligand/NN associated/VBN with/IN its/PRP$ assembly/NN was/VBD responsible/JJ for/IN stimulation/NN of/IN nonopsonic/JJ phagocytosis/NN ./. 
UI/LS -/: 96025852/CD 
TI/LS -/: Identification/NN of/IN essential/JJ GATA/NN and/CC Ets/NN binding/NN motifs/NNS within/IN the/DT promoter/NN of/IN the/DT platelet/NN glycoprotein/NN Ib/NN alpha/NN gene/NN ./. 
AB/LS -/: Platelet/NN glycoprotein/NN (/( GP/NN )/) Ib-IX-V/NN is/VBZ a/DT multisubunit/JJ adhesion/NN receptor/NN that/WDT supports/VBZ platelet/NN attachment/NN to/TO thrombogenic/JJ surfaces/NNS at/IN sites/NNS of/IN vascular/JJ injury/NN ./. 
The/DT congenital/JJ absence/NN of/IN the/DT receptor/NN results/VBZ in/IN a/DT bleeding/JJ disorder/NN associated/VBN with/IN "/`` giant/JJ "/'' platelets/NNS ,/, a/DT condition/NN linking/VBG the/DT expression/NN of/IN the/DT complex/NN to/TO platelet/NN morphogenesis/NN ./. 
To/TO understand/VB better/JJR the/DT expression/NN of/IN the/DT GP/NN Ib-IX-V/NN complex/NN ,/, studies/NNS were/VBD undertaken/VBN to/TO define/VB the/DT essential/JJ genetic/JJ elements/NNS supporting/VBG the/DT expression/NN of/IN the/DT alpha-subunit/NN of/IN the/DT complex/NN (/( GP/NN Ib/NN alpha/NN )/) ./. 
GP/NN Ib/NN alpha/NN promoter/NN activity/NN was/VBD evaluated/VBN by/IN transfection/NN of/IN human/JJ erythroleukemia/NN cells/NNS with/IN reporter/NN plasmids/NNS coding/VBG for/IN the/DT enzyme/NN ,/, luciferase/NN ./. 
Studies/NNS were/VBD initiated/VBN with/IN a/DT fragment/NN extending/VBG 2,738/CD nucleotides/NNS 5'/JJ to/TO the/DT transcription/NN start/NN site/NN and/CC lead/VBD to/TO the/DT identification/NN of/IN 253/CD nucleotides/NNS retaining/VBG full/JJ promoter/NN activity/NN in/IN human/JJ erythroleukemia/NN cells/NNS ./. 
In/IN cells/NNS of/IN nonhematopoietic/JJ lineage/NN ,/, human/JJ endothelial/JJ and/CC HeLa/NN cells/NNS ,/, the/DT GP/NN Ib/NN alpha/NN promoter/NN activity/NN was/VBD no/RB greater/JJR than/IN background/NN levels/NNS obtained/VBN with/IN promoterless/JJ constructs/NNS ./. 
Gel/NN shift/NN assays/NNS and/CC site-directed/JJ mutagenesis/NN studies/NNS defined/VBD essential/JJ GATA/NN and/CC Ets/NN binding/NN motifs/NNS 93/CD and/CC 150/CD nucleotides/NNS upstream/JJ of/IN the/DT transcription/NN start/NN site/NN ,/, a/DT finding/NN which/WDT further/RB substantiates/VBZ these/DT elements/NNS as/IN important/JJ determinants/NNS of/IN megakaryocytic/JJ gene/NN expression/NN ./. 
The/DT results/NNS define/VBP essential/JJ cis-acting/JJ elements/NNS responsible/JJ for/IN the/DT expression/NN of/IN GP/NN Ib/NN alpha/NN and/CC provide/VBP insights/NNS into/IN molecular/JJ events/NNS coinciding/VBG with/IN the/DT release/NN of/IN normal/JJ platelets/NNS into/IN the/DT bloodstream/NN ./. 
UI/LS -/: 96062038/CD 
TI/LS -/: CD30/NN ligation/NN induces/VBZ nuclear/JJ factor-kappa/NN B/NN activation/NN in/IN human/JJ T/NN cell/NN lines/NNS ./. 
AB/LS -/: CD30/NN is/VBZ a/DT recently/RB described/VBN member/NN of/IN the/DT tumor/NN necrosis/NN factor/nerve/NN growth/NN factor/NN receptor/NN superfamily/NN ./. 
In/IN this/DT report/NN ,/, we/PRP show/VBP that/IN following/VBG incubation/NN of/IN L540/NN cells/NNS (/( Hodgkin/NN 's/POS disease-derived/JJ ,/, T/NN cell-like/JJ ,/, CD30+/JJ cells/NNS )/) with/IN the/DT agonistic/JJ anti-CD30/JJ monoclonal/JJ antibodies/NNS (/( mAb/NN )/) M44/NN and/CC M67/NN ,/, two/CD nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN DNA/NN binding/NN activities/NNS were/VBD induced/VBN in/IN nuclear/JJ extracts/NNS ,/, as/IN determined/VBN in/IN gel/NN retardation/NN assays/NNS ./. 
The/DT effect/NN of/IN the/DT mAb/NN towards/IN NF-kappa/NN B/NN activation/NN was/VBD rapid/JJ ,/, as/IN it/PRP occurred/VBD within/IN 20/CD min/NN ,/, and/CC was/VBD sustained/JJ for/IN up/RB to/TO 6/CD h/NN ./. 
By/IN comparison/NN ,/, an/DT isotype-matched/JJ antibody/NN had/VBD no/DT effect/NN on/IN NF-kappa/NN B/NN activation/NN ./. 
Moreover/RB ,/, in/IN human/JJ T/NN helper/NN (/( Th/NN )/) clones/NNS functionally/RB characterized/VBN as/IN being/VBG of/IN the/DT type/NN 0/CD ,/, type/NN 1/CD and/CC type/NN 2/CD (/( 28/CD %/NN ,/, </JJR 1/CD %/NN und/CC 93/CD %/NN CD30+/JJ ,/, respectively/RB )/) ,/, the/DT extent/NN of/IN CD30-mediated/JJ NF-kappa/NN B/NN activation/NN correlated/VBD with/IN the/DT proportion/NN of/IN CD30+/JJ cells/NNS ./. 
In/IN all/DT cell/NN lines/NNS investigated/VBN ,/, the/DT NF-kappa/NN B/NN complexes/NNS induced/VBN following/VBG CD30/NN engagement/NN were/VBD shown/VBN to/TO contain/VB p50/NN NF-kappa/NN B1/NN ,/, p65/NN RelA/NN ,/, and/CC possibly/RB other/JJ transcription/NN factors/NNS ./. 
Collectively/RB ,/, our/PRP$ results/NNS demonstrate/VBP that/IN nuclear/JJ translocation/NN and/CC activation/NN of/IN NF-kappa/NN B/NN rank/NN among/IN the/DT short-term/JJ cellular/JJ responses/NNS elicited/VBD following/VBG CD30/NN ligation/NN ./. 
UI/LS -/: 96016217/CD 
TI/LS -/: Pathogenesis/NN of/IN atherosclerosis/NN ./. 
AB/LS -/: The/DT earliest/JJS lesion/NN in/IN the/DT development/NN of/IN an/DT atherosclerotic/JJ plaque/NN is/VBZ the/DT fatty/JJ streak/NN ./. 
This/DT chronic/JJ inflammatory/JJ reaction/NN results/VBZ from/IN a/DT sequence/NN of/IN events/NNS that/WDT begins/VBZ with/IN the/DT trapping/NN of/IN low/JJ density/NN lipoprotein/NN (/( LDL/NN )/) in/IN the/DT subendothelial/JJ space/NN of/IN the/DT artery/NN wall/NN ./. 
The/DT trapped/VBN LDL/NN is/VBZ seeded/VBN with/IN oxidative/JJ species/NNS released/VBN by/IN the/DT overlying/VBG endothelium/NN ,/, and/CC lipid/NN oxidation/NN is/VBZ initiated/VBN within/IN the/DT LDL/NN particle/NN ./. Some/DT of/IN the/DT lipids/NNS that/WDT result/VBP lead/VBP to/TO the/DT activation/NN of/IN NFkB-like/JJ transcription/NN factors/NNS that/WDT cause/VBP the/DT expression/NN of/IN genes/NNS whose/WP$ protein/NN products/NNS mediate/VBP monocyte/NN binding/NN ,/, monocyte/NN chemotaxis/NN into/IN the/DT subendothelial/JJ space/NN ,/, and/CC conversion/NN into/IN macrophages/NNS ./. 
At/IN least/JJS 1/CD major/JJ gene/NN modulates/VBZ the/DT oxidation/NN of/IN LDL/NN lipids/NNS and/or/CC the/DT biologic/JJ response/NN to/TO these/DT lipids/NNS ./. 
The/DT inverse/JJ relation/NN between/IN high/JJ density/NN lipoprotein/NN (/( HDL/NN )/) and/CC atherosclerotic/JJ events/NNS may/MD in/IN part/NN be/VB due/JJ to/TO enzymes/NNS associated/VBN with/IN HDL/NN that/WDT destroy/VBP the/DT biologically/RB active/JJ lipids/NNS generated/VBN in/IN LDL/NN ./. 
UI/LS -/: 97252236/CD 
TI/LS -/: Estrogen/NN and/CC progesterone/NN receptors/NNS in/IN vernal/JJ keratoconjunctivitis/NN ./. 
AB/LS -/: PURPOSE/NN :/: Sex-related/JJ influences/NNS have/VBP been/VBN implicated/VBN in/IN the/DT pathogenesis/NN of/IN vernal/JJ keratoconjunctivitis/NN (/( VKC/NN )/) ,/, an/DT allergic/JJ eosinophilic/JJ disease/NN ./. 
METHODS/NNS :/: The/DT authors/NNS evaluated/VBD tarsal/JJ and/CC bulbar/JJ conjunctival/JJ biopsies/NNS from/IN seven/CD patients/NNS with/IN severe/JJ and/CC symptomatic/JJ VKC/NN for/IN the/DT presence/NN of/IN estrogen/NN and/CC progesterone/NN receptors/NNS by/IN using/VBG monoclonal/JJ antibodies/NNS with/IN a/DT peroxidase-antiperoxidase/JJ technique/NN ./. 
RESULTS/NNS :/: Both/CC the/DT epithelium/NN and/CC subepithelium/NN of/IN the/DT tarsal/JJ and/CC bulbar/JJ conjunctiva/NN of/IN patients/NNS with/IN VKC/NN ,/, but/CC not/RB those/DT of/IN four/CD nonatopic/JJ control/JJ subjects/NNS ,/, showed/VBD intense/JJ positive/JJ staining/NN for/IN estrogen/NN and/CC progesterone/NN receptors/NNS ./. 
Immunofluorescence/NN colocalization/NN of/IN both/CC estrogen/NN and/CC progesterone/NN receptors/NNS with/IN eosinophil/NN cationic/JJ protein/NN showed/VBD that/IN approximately/RB 70/CD %/NN of/IN positive/JJ cells/NNS were/VBD eosinophils/NNS ./. 
CONCLUSIONS/NNS :/: Sexual/JJ hormones/NNS ,/, through/IN their/PRP$ receptors/NNS ,/, may/MD influence/VB the/DT activity/NN of/IN eosinophils/NNS in/IN patients/NNS with/IN VKC/NN ./. 
UI/LS -/: 96091806/CD 
TI/LS -/: CIITA/NN activates/VBZ the/DT expression/NN of/IN MHC/NN class/NN II/CD genes/NNS in/IN mouse/NN T/NN cells/NNS ./. 
AB/LS -/: It/PRP has/VBZ long/RB been/VBN a/DT puzzle/NN that/IN MHC/NN class/NN II/CD molecules/NNS are/VBP expressed/VBN in/IN human/JJ T/NN cells/NNS after/IN activation/NN but/CC not/RB in/IN mouse/NN T/NN cells/NNS ;/: this/DT expression/NN is/VBZ believed/VBN to/TO play/VB a/DT role/NN in/IN the/DT cell/NN mediated/JJ immune/JJ response/NN ./. 
Recently/RB the/DT MHC/NN class/NN II/CD transactivator/NN (/( CIITA/NN )/) has/VBZ been/VBN reported/VBN to/TO be/VB a/DT major/JJ regulatory/JJ factor/NN for/IN both/CC the/DT constitutive/JJ and/CC IFN/NN inducible/JJ expression/NN of/IN MHC/NN class/NN II/CD genes/NNS ./. 
Here/RB we/PRP show/VBP that/IN human/JJ T/NN cells/NNS expressing/VBG MHC/NN class/NN II/CD have/VBP CIITA/NN transcripts/NNS while/IN MHC/NN class/NN II-negative/JJ human/JJ T/NN cells/NNS and/CC mouse/NN T/NN cells/NNS do/VBP not/RB ./. 
The/DT expression/NN of/IN MHC/NN class/NN II/CD genes/NNS in/IN mouse/NN T/NN cells/NNS can/MD be/VB reconstituted/VBN upon/IN transfection/NN with/IN the/DT human/JJ CIITA/NN cDNA/NN ./. 
These/DT data/NNS indicate/VBP that/IN the/DT expression/NN of/IN CIITA/NN explains/VBZ the/DT expression/NN or/CC lack/NN of/IN expression/NN of/IN MHC/NN class/NN II/CD in/IN human/JJ and/CC mouse/NN T/NN cells/NNS respectively/RB ./. 
UI/LS -/: 90110496/CD 
TI/LS -/: Anti-Ro(SSA)/JJ autoantibodies/NNS are/VBP associated/VBN with/IN T/NN cell/NN receptor/NN beta/NN genes/NNS in/IN systemic/JJ lupus/NN erythematosus/NN patients/NNS ./. 
AB/LS -/: Several/JJ of/IN the/DT heterogeneous/JJ clinical/JJ manifestations/NNS of/IN systemic/JJ lupus/NN erythematosus/NN have/VBP been/VBN associated/VBN with/IN specific/JJ autoantibodies/NNS ./. 
Associations/NNS between/IN HLA/NN class/NN II/CD antigens/NNS and/CC autoantibodies/NNS to/TO the/DT ribonucleoproteins/NNS Ro(SSA)/NN and/CC La(SSB)/NN have/VBP been/VBN reported/VBN in/IN these/DT patients/NNS ./. 
Because/IN HLA/NN class/NN II/CD molecules/NNS present/VBP antigen/NN to/TO T/NN cell/NN receptors/NNS (/( TCRs/NNS )/) ,/, we/PRP have/VBP searched/VBN for/IN a/DT TCR/NN gene/NN associated/VBN with/IN the/DT production/NN of/IN anti-Ro(SSA)/JJ antibodies/NNS ./. 
A/DT pair/NN of/IN restriction/NN fragment/NN length/NN polymorphisms/NNS (/( RFLPs/NNS )/) ,/, one/CD of/IN which/WDT hybridizes/VBZ to/TO the/DT TCR/NN constant/JJ region/NN C/NN beta/NN 1/CD and/CC the/DT other/JJ to/TO the/DT C/NN beta/NN 2/CD gene/NN ,/, has/VBZ been/VBN identified/VBN ,/, suggesting/VBG these/DT may/MD be/VB genotypic/JJ markers/NNS for/IN an/DT extended/VBN region/NN of/IN the/DT TCR/NN beta/NN locus/NN ./. 
This/DT RFLP/NN pair/NN occurs/VBZ in/IN 76/CD %/NN of/IN patients/NNS with/IN Ro(SSA)/NN precipitins/NNS ,/, 84/CD %/NN of/IN anti-Ro(SSA)-positive/JJ patients/NNS lacking/VBG La(SSB)/NN precipitins/NNS ,/, but/CC only/RB 41/CD %/NN of/IN the/DT patients/NNS lacking/VBG both/DT precipitins/NNS (/( P/NN =/JJ 0.0004/CD )/) ./. 
This/DT disproportionate/JJ occurrence/NN in/IN a/DT subset/NN of/IN lupus/NN patients/NNS indicates/VBZ that/IN these/DT RFLPs/NNS are/VBP not/RB disease/NN susceptibility/NN markers/NNS ,/, but/CC rather/RB are/VBP important/JJ markers/NNS for/IN TCR/NN genes/NNS whose/WP$ products/NNS are/VBP involved/VBN in/IN the/DT production/NN of/IN anti-Ro(SSA)/JJ antibodies/NNS ./. 
The/DT majority/NN of/IN patients/NNS who/WP have/VBP these/DT RFLPs/NNS and/CC HLA/NN class/NN II/CD antigens/NNS previously/RB associated/VBN with/IN the/DT anti-Ro(SSA)/JJ response/NN make/VBP this/DT antibody/NN ,/, suggesting/VBG that/IN interactions/NNS between/IN products/NNS of/IN these/DT loci/NNS occur/VBP in/IN response/NN to/TO Ro(SSA)/NN ./. 
UI/LS -/: 96102166/CD 
TI/LS -/: Inhibition/NN of/IN NF-AT-dependent/JJ transcription/NN by/IN NF-kappa/NN B/NN :/: implications/NNS for/IN differential/JJ gene/NN expression/NN in/IN T/NN helper/NN cell/NN subsets/NNS ./. 
AB/LS -/: Activation/NN of/IN individual/JJ CD4+/JJ T/NN cells/NNS results/VBZ in/IN differential/JJ lymphokine/NN expression/NN :/: interleukin/NN 2/CD (/( IL-2/NN )/) is/VBZ preferentially/RB produced/VBN by/IN T/NN helper/NN type/NN 1/CD (/( TH1/NN )/) cells/NNS ,/, which/WDT are/VBP involved/VBN in/IN cell-mediated/JJ immune/JJ responses/NNS ,/, whereas/IN IL-4/NN is/VBZ synthesized/VBN by/IN TH2/NN cells/NNS ,/, which/WDT are/VBP essential/JJ for/IN humoral/JJ immunity/NN ./. 
The/DT Ca(2+)-dependent/JJ factor/NN NF-ATp/NN plays/VBZ a/DT key/JJ role/NN in/IN the/DT inducible/JJ transcription/NN of/IN both/DT these/DT lymphokine/NN genes/NNS ./. 
However/RB ,/, while/IN IL2/NN expression/NN requires/VBZ the/DT contribution/NN of/IN Ca(2+)-/NN and/CC protein/NN kinase/NN C-dependent/JJ signals/NNS ,/, we/PRP report/VBP that/IN activation/NN of/IN human/JJ IL4/NN transcription/NN through/IN the/DT Ca(2+)-dependent/JJ pathway/NN is/VBZ diminished/VBN by/IN protein/NN kinase/NN C/NN stimulation/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
This/DT phenomenon/NN is/VBZ due/JJ to/TO mutually/RB exclusive/JJ binding/NN of/IN NF-ATp/NN and/CC NF-kappa/NN B/NN to/TO the/DT P/NN sequence/NN ,/, an/DT element/NN located/JJ 69/CD bp/NN upstream/RB of/IN the/DT IL4/NN transcription/NN initiation/NN site/NN ./. 
Human/JJ IL4/NN promoter-mediated/JJ transcription/NN is/VBZ downregulated/VBN in/IN Jurkat/NN cells/NNS stimulated/VBN with/IN the/DT NF-kappa/NN B-activating/JJ cytokine/NN tumor/NN necrosis/NN factor/NN alpha/NN and/CC suppressed/VBN in/IN RelA-overexpressing/JJ cells/NNS ./. 
In/IN contrast/NN ,/, protein/NN kinase/NN C/NN stimulation/NN or/CC RelA/NN overexpression/NN does/VBZ not/RB affect/VB the/DT activity/NN of/IN a/DT human/JJ IL4/NN promoter/NN containing/VBG a/DT mouse/NN P/NN sequence/NN ,/, which/WDT is/VBZ a/DT higher-affinity/JJ site/NN for/IN NF-ATp/NN and/CC a/DT lower-affinity/JJ site/NN for/IN RelA/NN ./. 
Thus/RB ,/, competition/NN between/IN two/CD general/JJ transcriptional/JJ activators/NNS ,/, RelA/NN and/CC NF-ATp/NN ,/, mediates/VBZ the/DT inhibitory/JJ effect/NN of/IN protein/NN kinase/NN C/NN stimulation/NN on/IN IL4/NN expression/NN and/CC may/MD contribute/VB to/TO differential/JJ gene/NN expression/NN in/IN TH/NN cells/NNS ./. 
UI/LS -/: 96096457/CD 
TI/LS -/: Regulation/NN of/IN the/DT balance/NN of/IN cytokine/NN production/NN and/CC the/DT signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT/NN )/) transcription/NN factor/NN activity/NN by/IN cytokines/NNS and/CC inflammatory/JJ synovial/JJ fluids/NNS ./. 
AB/LS -/: The/DT balance/NN between/IN type/NN 1/CD and/CC 2/CD T/NN helper/NN cell/NN cytokine/NN production/NN plays/VBZ an/DT important/JJ role/NN in/IN several/JJ animal/JJ models/NNS of/IN autoimmunity/NN ,/, and/CC skewed/JJ patterns/NNS of/IN cytokine/NN expression/NN have/VBP been/VBN described/VBN in/IN human/JJ inflammatory/JJ diseases/NNS ./. 
Many/JJ cytokines/NNS activate/VBP signal/NN transducer/NN and/CC activation/NN of/IN transcription/NN (/( STAT/NN )/) transcription/NN factors/NNS ,/, which/WDT ,/, in/IN turn/NN ,/, activate/VBP transcription/NN of/IN inflammatory/JJ effector/NN genes/NNS ./. 
We/PRP used/VBD mononuclear/JJ cell/NN priming/NN cultures/NNS and/CC inflammatory/JJ synovial/JJ fluids/NNS (/( SFs/NNS )/) derived/VBN from/IN arthritis/NN patients/NNS to/TO examine/VB the/DT regulation/NN of/IN cytokine/NN production/NN and/CC STAT/NN activity/NN by/IN an/DT inflammatory/JJ synovial/JJ microenvironment/NN ./. 
Exposure/NN to/TO SFs/NNS during/IN priming/NN resulted/VBD in/IN an/DT 81/CD %/NN inhibition/NN of/IN interferon/NN (/( IFN/NN )/) -gamma/NN ,/, but/CC not/RB interleukin/NN (/( IL/NN )/) 4/CD ,/, production/NN by/IN effector/NN cells/NNS generated/VBN in/IN priming/JJ cultures/NNS ./. 
SF/NN suppression/NN was/VBD mediated/VBN by/IN IL-4/NN and/CC IL-10/NN and/CC inhibition/NN of/IN IL-12/NN expression/NN ,/, and/CC it/PRP was/VBD reversed/VBN in/IN a/DT dominant/JJ fashion/NN by/IN exogenous/JJ IL-12/NN ./. 
SFs/NNS blocked/VBD the/DT sustained/JJ activity/NN of/IN transcription/NN factor/NN Stat1/NN ,/, but/CC not/RB Stat3/NN ,/, during/IN the/DT priming/NN period/NN ,/, and/CC Stat1/NN activity/NN was/VBD differentially/RB regulated/VBN by/IN cytokines/NNS in/IN parallel/NN with/IN their/PRP$ positive/JJ or/CC negative/JJ regulation/NN of/IN IFN-gamma/NN production/NN ./. 
Active/JJ Stat3/NN ,/, but/CC not/RB Stat1/NN ,/, was/VBD detected/VBN in/IN cells/NNS from/IN inflamed/JJ joints/NNS ./. 
These/DT results/NNS suggest/VBP a/DT role/NN for/IN altered/JJ balance/NN of/IN Stat1/NN and/CC Stat3/NN transcriptional/JJ activity/NN in/IN the/DT regulation/NN of/IN T/NN cell/NN differentiation/NN and/CC in/IN the/DT pathogenesis/NN of/IN inflammatory/JJ synovitis/NN ./. 
UI/LS -/: 96062305/CD 
TI/LS -/: Triggering/NN of/IN complement/NN receptors/NNS CR1/NN (/( CD35/NN )/) and/CC CR3/NN (/( CD11b/CD18/NN )/) induces/VBZ nuclear/JJ translocation/NN of/IN NF-kappa/NN B/NN (/( p50/NN /p65/NN )/) in/IN human/JJ monocytes/NNS and/CC enhances/VBZ viral/JJ replication/NN in/IN HIV-infected/JJ monocytic/JJ cells/NNS ./. 
AB/LS -/: Monocyte/macrophages/NNS may/MD harbor/VB HIV/NN in/IN a/DT nonproductive/JJ fashion/NN for/IN prolonged/JJ periods/NNS of/IN time/NN ./. 
Viral/JJ gene/NN expression/NN may/MD be/VB reactivated/VBN by/IN stimulation/NN of/IN the/DT cells/NNS with/IN LPS/NN or/CC cytokines/NNS such/JJ as/IN TNF-alpha/NN in/FW vitro/FW ./. 
The/DT effect/NN of/IN LPS/NN and/CC TNF-alpha/NN is/VBZ mediated/VBN by/IN their/PRP$ ability/NN to/TO induce/VB nuclear/JJ translocation/NN of/IN the/DT DNA-binding/JJ heterodimer/NN NF-kappa/NN B/NN (/( p50/NN /p65/NN )/) ,/, which/WDT binds/VBZ to/TO a/DT specific/JJ sequence/NN in/IN the/DT HIV-long/JJ terminal/JJ repeat/NN ./. 
The/DT present/JJ study/NN demonstrates/VBZ that/IN triggering/NN of/IN complement/NN receptors/NNS CR1/NN (/( CD35/NN )/) and/CC CR3/NN (/( CD11b/CD18/NN )/) enhances/VBZ viral/JJ replication/NN in/IN HIV-infected/JJ human/JJ monocytic/JJ cells/NNS ./. 
Monocytic/JJ cell/NN lines/NNS and/CC normal/JJ peripheral/JJ blood/NN monocytes/NNS were/VBD infected/VBN with/IN HIV-1/NN in/FW vitro/FW and/CC cultured/VBN in/IN the/DT presence/NN or/CC absence/NN of/IN F(ab')2/NN fragments/NNS of/IN monoclonal/JJ anti-CR1/JJ or/CC anti-CR3/JJ Abs/NNS or/CC with/IN C3/NN fragments/NNS ./. 
Stimulation/NN of/IN CR1/NN or/CC CR3/NN induces/VBZ a/DT two-/CD to/TO fourfold/JJ increase/NN in/IN the/DT amount/NN of/IN cell-associated/JJ and/CC released/VBN p24/NN Ag/NN in/IN cell/NN cultures/NNS that/WDT was/VBD equivalent/JJ to/TO that/DT observed/VBN in/IN control/JJ cultures/NNS triggered/VBN with/IN LPS/NN ./. 
We/PRP further/RB observed/VBD that/IN stimulation/NN of/IN CR1/NN or/CC CR3/NN induces/VBZ the/DT nuclear/JJ translocation/NN of/IN NF-kappa/NN B/NN p50/NN /p65/NN in/IN infected/JJ cells/NNS ./. 
Translocation/NN of/IN NF-kappa/NN B/NN p50/NN /p65/NN was/VBD also/RB observed/VBN following/VBG stimulation/NN of/IN CR1/NN or/CC CR3/NN of/IN uninfected/JJ peripheral/JJ blood/NN monocytes/NNS from/IN HIV-seronegative/JJ donors/NNS ./. 
The/DT amount/NN of/IN protein/NN translocated/VBN was/VBD similar/JJ to/TO that/DT observed/VBN when/WRB cells/NNS were/VBD stimulated/VBN with/IN rhTNF-alpha/NN ./. 
TNF-alpha/NN did/VBD not/RB mediate/VB the/DT translocation/NN of/IN NF-kappa/NN B/NN p50/NN /p65/NN induced/VBN by/IN triggering/NN of/IN complement/NN receptors/NNS ./. 
Taken/VBN together/RB ,/, these/DT observations/NNS suggest/VBP that/IN HIV/NN gene/NN expression/NN may/MD be/VB activated/VBN in/IN infected/JJ monocytes/NNS through/IN interaction/NN of/IN the/DT cells/NNS with/IN complement-opsonized/JJ particles/NNS and/CC that/IN enhanced/VBN viral/JJ replication/NN is/VBZ associated/VBN with/IN C3/NN receptor-mediated/JJ nuclear/JJ translocation/NN of/IN the/DT NF-kappa/NN B/NN complex/NN ./. 
UI/LS -/: 96029750/CD 
TI/LS -/: Attenuation/NN of/IN gamma/NN interferon-induced/JJ tyrosine/NN phosphorylation/NN in/IN mononuclear/JJ phagocytes/NNS infected/VBN with/IN Leishmania/FW donovani/FW :/: selective/JJ inhibition/NN of/IN signaling/NN through/IN Janus/NN kinases/NNS and/CC Stat1/NN ./. 
AB/LS -/: The/DT induction/NN of/IN gene/NN transcription/NN in/IN response/NN to/TO gamma/NN interferon/NN is/VBZ impaired/JJ in/IN mononuclear/JJ phagocytes/NNS infected/VBN with/IN Leishmania/FW donovani/FW ,/, and/CC the/DT mechanisms/NNS involved/VBN are/VBP not/RB fully/RB understood/VBN ./. 
The/DT changes/NNS in/IN gene/NN expression/NN brought/VBN about/RP by/IN gamma/NN interferon/NN are/VBP thought/VBN to/TO involve/VB transient/JJ increases/NNS in/IN the/DT activities/NNS of/IN cellular/JJ protein/NN tyrosine/NN kinases/NNS ,/, including/VBG the/DT Janus/NN kinases/NNS Jak1/NN and/CC Jak2/NN ,/, leading/VBG to/TO tyrosine/NN phosphorylation/NN of/IN the/DT transcription/NN factor/NN Stat1/NN ./. 
To/TO investigate/VB the/DT mechanisms/NNS accounting/VBG for/IN the/DT impaired/JJ responses/NNS to/TO gamma/NN interferon/NN ,/, a/DT model/JJ system/NN for/IN examining/VBG overall/JJ changes/NNS in/IN protein/NN tyrosine/NN phosphorylation/NN ,/, activation/NN of/IN Jak1/NN and/CC Jak2/NN and/CC phosphorylation/NN of/IN Stat1/NN was/VBD developed/VBN in/IN phorbol/NN 12-myristate/NN 13-acetate-differentiated/JJ U-937/NN cells/NNS ./. 
Analysis/NN of/IN whole-cell/JJ lysates/NNS by/IN antiphosphotyrosine/NN immunoblotting/NN showed/VBD that/IN incubation/NN with/IN gamma/NN interferon/NN brought/VBD about/RP specific/JJ increases/NNS in/IN phosphotyrosine/NN labeling/NN of/IN several/JJ proteins/NNS ./. 
Increased/VBN labeling/NN of/IN these/DT proteins/NNS occurred/VBD to/TO similar/JJ extents/NNS in/IN control/JJ cells/NNS and/CC in/IN cells/NNS that/WDT had/VBD been/VBN infected/VBN with/IN L./FW donovani/FW for/IN 16/CD h/NN ./. 
Jak1/NN ,/, Jak2/NN ,/, and/CC Stat1/NN were/VBD immunoprecipitated/VBN from/IN control/JJ and/CC interferon-treated/JJ cells/NNS ,/, and/CC tyrosine/NN phosphorylation/NN of/IN these/DT proteins/NNS ,/, detected/VBN by/IN antiphosphotyrosine/NN immunoblotting/NN was/VBD used/VBN to/TO measured/VBN their/PRP$ activation/NN ./. 
Tyrosine/NN phosphorylation/NN of/IN Jak1/NN ,/, Jak2/NN ,/, and/CC Stat1/NN increased/VBD markedly/RB ,/, in/IN a/DT dose-dependent/JJ manner/NN ,/, in/IN U-937/NN cells/NNS incubated/VBN with/IN gamma/NN interferon/NN ./. 
In/IN contrast/NN ,/, in/IN cells/NNS infected/VBN with/IN L./FW donovani/FW ,/, tyrosine/NN phosphorylation/NN of/IN Jak1/NN ,/, Jak2/NN ,/, and/CC Stat1/NN was/VBD markedly/RB impaired/JJ ./. 
This/DT effect/NN was/VBD dependent/JJ upon/IN the/DT duration/NN of/IN exposure/NN to/TO L./FW donovani/FW and/CC was/VBD maximal/JJ and/CC complete/JJ at/IN 16/CD h/NN ./. 
Results/NNS similar/JJ to/TO those/DT observed/VBN with/IN U-937/NN cells/NNS were/VBD also/RB obtained/VBN with/IN human/JJ peripheral/JJ blood/NN monocytes/NNS ./. 
These/DT findings/NNS indicate/VBP that/IN infection/NN of/IN human/JJ mononuclear/JJ phagocytes/NNS with/IN L./FW donovani/FW leads/VBZ to/TO impaired/JJ gamma/NN interferon-mediated/JJ tyrosine/NN phosphorylation/NN and/CC selective/JJ effects/NNS on/IN the/DT Jak-Stat1/NN pathway/NN ./. 
Unresponsiveness/NN to/TO gamma/NN interferon/NN for/IN activation/NN of/IN this/DT pathway/NN may/MD explain/VB impaired/JJ transcriptional/JJ responses/NNS in/IN leishmania-infected/JJ cells/NNS ./. 
UI/LS -/: 96025779/CD 
TI/LS -/: Mutually/RB exclusive/JJ interaction/NN of/IN a/DT novel/JJ matrix/NN attachment/NN region/NN binding/NN protein/NN and/CC the/DT NF-muNR/NN enhancer/NN repressor/NN ./. 
Implications/NNS for/IN regulation/NN of/IN immunoglobulin/NN heavy/JJ chain/NN expression/NN ./. 
AB/LS -/: The/DT immunoglobulin/NN heavy/NN chain/NN (/( IgH/NN )/) intronic/JJ enhancer/NN stimulates/VBZ transcription/NN from/IN functional/JJ promoters/NNS in/IN B/NN lymphocytes/NNS but/CC not/RB other/JJ cell/NN types/NNS ./. 
The/DT observation/NN that/IN binding/VBG sites/NNS for/IN the/DT nuclear/JJ factor-mu/NN negative/JJ regulator/NN (/( NF-muNR/NN )/) enhancer/NN repressor/NN overlap/VBP nuclear/JJ matrix/NN attachment/NN regions/NNS (/( MARs/NNS )/) in/IN this/DT enhancer/NN has/VBZ lead/VBN to/TO the/DT hypothesis/NN that/IN the/DT cell/NN type/NN specificity/NN of/IN the/DT enhancer/NN might/MD be/VB controlled/VBN by/IN regulating/VBG nuclear/JJ matrix/NN attachment/NN (/( Scheuermann/NNP ,/, R./NNP H./NNP ,/, and/CC Chen/NNP ,/, U./NNP (/( 1989/CD )/) Genes/NNP &/CC Dev./NNP 3/CD ,/, 1255-1266/CD )/) ./. 
To/TO understand/VB the/DT role/NN of/IN MARs/NNS in/IN IgH/NN enhancer/NN regulation/NN ,/, we/PRP have/VBP identified/VBN a/DT novel/JJ MAR-binding/JJ protein/NN ,/, MAR-BP1/NN ,/, from/IN soluble/JJ nuclear/JJ matrix/NN preparations/NNS based/VBN on/IN its/PRP$ ability/NN to/TO bind/VB to/TO the/DT MARs/NNS associated/VBN with/IN the/DT IgH/NN enhancer/NN ./. 
Purified/VBN MAR-BP1/NN migrates/VBZ as/IN a/DT 33-kDa/JJ protein/NN ,/, and/CC it/PRP can/MD be/VB found/VBN in/IN nuclear/JJ matrix/NN preparations/NNS from/IN a/DT number/NN of/IN different/JJ types/NNS of/IN lymphoid/JJ cell/NN lines/NNS ./. 
Although/IN specific/JJ binding/VBG sites/NNS have/VBP been/VBN difficult/JJ to/TO localize/VB by/IN chemical/JJ or/CC enzymatic/JJ footprinting/NN procedures/NNS ,/, NF-muNR/NN binding/NN sites/NNS are/VBP critical/JJ for/IN efficient/JJ MAR-BP1/NN binding/NN ./. 
Indeed/RB ,/, binding/NN of/IN the/DT IgH/NN enhancer/NN to/TO either/CC intact/JJ nuclear/JJ matrix/NN preparations/NNS or/CC to/TO MAR-BP1/NN is/VBZ mutually/RB exclusive/JJ to/TO NF-muNR/NN binding/NN ./. 
These/DT results/NNS are/VBP consistent/JJ with/IN a/DT model/NN for/IN cell-type/JJ specific/JJ regulation/NN in/IN which/WDT binding/NN of/IN the/DT NF-muNR/NN repressor/NN to/TO the/DT IgH/NN enhancer/NN prevents/VBZ nuclear/JJ matrix/NN attachment/NN in/IN inappropriate/JJ cells/NNS by/IN interfering/VBG with/IN MAR-BP1/enhancer/NN interaction/NN ./. 
UI/LS -/: 96009612/CD 
TI/LS -/: PU.1/NN (/( Spi-1/NN )/) and/CC C/EBP/NN alpha/NN regulate/VBP expression/NN of/IN the/DT granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN receptor/NN alpha/NN gene/NN ./. 
AB/LS -/: Growth/NN factor/NN receptors/NNS play/VBP an/DT important/JJ role/NN in/IN hematopoiesis/NN ./. 
In/IN order/NN to/TO further/RB understand/VB the/DT mechanisms/NNS directing/VBG the/DT expression/NN of/IN these/DT key/JJ regulators/NNS of/IN hematopoiesis/NN ,/, we/PRP initiated/VBD a/DT study/NN investigating/VBG the/DT transcription/NN factors/NNS activating/VBG the/DT expression/NN of/IN the/DT granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) receptor/NN alpha/NN gene/NN ./. 
Here/RB ,/, we/PRP demonstrate/VBP that/IN the/DT human/JJ GM-CSF/NN receptor/NN alpha/NN promoter/NN directs/VBZ reporter/NN gene/NN activity/NN in/IN a/DT tissue-specific/JJ fashion/NN in/IN myelomonocytic/JJ cells/NNS ,/, which/WDT correlates/VBZ with/IN its/PRP$ expression/NN pattern/NN as/IN analyzed/VBN by/IN reverse/NN transcription/NN PCR/NN ./. 
The/DT GM-CSF/NN receptor/NN alpha/NN promoter/NN contains/VBZ an/DT important/JJ functional/JJ site/NN between/IN positions/NNS -53/CD and/CC -41/CD as/IN identified/VBN by/IN deletion/NN analysis/NN of/IN reporter/NN constructs/NNS ./. 
We/PRP show/VBP that/IN the/DT myeloid/JJ and/CC B/NN cell/NN transcription/NN factor/NN PU.1/NN binds/VBZ specifically/RB to/TO this/DT site/NN ./. 
Furthermore/RB ,/, we/PRP demonstrate/VBP that/IN a/DT CCAAT/NN site/NN located/JJ upstream/RB of/IN the/DT PU.1/NN site/NN between/IN positions/NNS -70/CD and/CC -54/CD is/VBZ involved/VBN in/IN positive-negative/JJ regulation/NN of/IN the/DT GM-CSF/NN receptor/NN alpha/NN promoter/NN activity/NN ./. 
C/EBP/NN alpha/NN is/VBZ the/DT major/JJ CCAAT/enhancer-binding/JJ protein/NN (/( C/EBP/NN )/) form/NN binding/VBG to/TO this/DT site/NN in/IN nuclear/JJ extracts/NNS of/IN U937/NN cells/NNS ./. 
Point/NN mutations/NNS of/IN either/CC the/DT PU.1/NN site/NN or/CC the/DT C/EBP/NN site/NN that/WDT abolish/VBP the/DT binding/NN of/IN the/DT respective/JJ factors/NNS result/VBP in/IN a/DT significant/JJ decrease/NN of/IN GM-CSF/NN receptor/NN alpha/NN promoter/NN activity/NN in/IN myelomonocytic/JJ cells/NNS only/RB ./. 
Furthermore/RB ,/, we/PRP demonstrate/VBP that/IN in/IN myeloid/JJ and/CC B/NN cell/NN extracts/VBZ ,/, PU.1/NN forms/VBZ a/DT novel/JJ ,/, specific/JJ ,/, more/RBR slowly/RB migrating/VBG complex/NN (/( PU-SF/NN )/) when/WRB binding/VBG the/DT GM-CSF/NN receptor/NN alpha/NN promoter/NN PU.1/NN site/NN ./. 
This/DT is/VBZ the/DT first/JJ demonstration/NN of/IN a/DT specific/JJ interaction/NN with/IN PU.1/NN on/IN a/DT myeloid/JJ PU.1/NN binding/NN site/NN ./. 
The/DT novel/JJ complex/NN is/VBZ distinct/JJ from/IN that/DT described/VBN previously/RB as/IN binding/VBG to/TO B/NN cell/NN enhancer/NN sites/NNS and/CC can/MD be/VB formed/VBN by/IN addition/NN of/IN PU.1/NN to/TO extracts/NNS from/IN certain/JJ nonmyeloid/JJ cell/NN types/NNS which/WDT do/VBP not/RB express/VB PU.1/NN ,/, including/VBG T/NN cells/NNS and/CC epithelial/JJ cells/NNS ,/, but/CC not/RB from/IN erythroid/JJ cells/NNS ./. 
Furthermore/RB ,/, we/PRP demonstrate/VBP that/IN the/DT PU-SF/NN complex/NN binds/VBZ to/TO PU.1/NN sites/NNS found/VBN on/IN a/DT number/NN of/IN myeloid/JJ promoters/NNS ,/, and/CC its/PRP$ formation/NN requires/VBZ an/DT intact/JJ PU.1/NN site/NN adjacent/JJ to/TO a/DT single-stranded/JJ region/NN ./. 
Expression/NN of/IN PU.1/NN in/IN nonmyeloid/JJ cells/NNS can/MD activate/VB the/DT GM-CSF/NN receptor/NN alpha/NN promoter/NN ./. 
Deletion/NN of/IN the/DT amino-terminal/JJ region/NN of/IN PU.1/NN results/VBZ in/IN a/DT failure/NN to/TO form/VB the/DT PU-SF/NN complex/NN and/CC in/IN a/DT concomitant/JJ loss/NN of/IN transactivation/NN ,/, suggesting/VBG that/IN formation/NN of/IN the/DT PU-SF/NN complex/NN is/VBZ of/IN functional/JJ importance/NN for/IN the/DT activity/NN of/IN the/DT GM-CSF/NN receptor/NN alpha/NN promoter/NN ./. 
Finally/RB ,/, we/PRP demonstrate/VBP that/IN C/EBP/NN alpha/NN can/MD also/RB active/JJ the/DT GM-CSF/NN receptor/NN alpha/NN promoter/NN in/IN nonmyeloid/JJ cells/NNS ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 400/CD WORDS/NNS )/) 
UI/LS -/: 96024587/CD 
TI/LS -/: HMG-I/NN binds/VBZ to/TO GATA/NN motifs/NNS :/: implications/NNS for/IN an/DT HPFH/NN syndrome/NN ./. 
AB/LS -/: We/PRP have/VBP examined/VBN binding/NN of/IN the/DT nuclear/JJ protein/NN HMG-I/NN to/TO the/DT human/JJ gamma-globin/NN promoter/NN ./. 
We/PRP find/VBP that/IN HMG-I/NN binds/VBZ preferentially/RB to/TO the/DT more/JJR 3'/JJ of/IN a/DT pair/NN of/IN GATA/NN motifs/NNS in/IN the/DT gamma-globin/NN promoter/NN ;/: this/DT paired/JJ motif/NN is/VBZ bound/VBN by/IN the/DT erythroid/JJ factor/NN GATA-1/NN ./. 
A/DT naturally/RB occurring/VBG mutation/NN (/( -175/CD T-C/NN )/) in/IN the/DT area/NN bound/VBN by/IN HMG-I/NN results/VBZ in/IN overexpression/NN of/IN gamma-globin/NN in/IN adult/JJ red/JJ blood/NN cells/NNS (/( HPFH/NN )/) and/CC up-regulation/NN of/IN the/DT gamma-globin/NN promoter/NN in/IN in/FW vitro/FW expression/NN assays/NNS ;/: HMG-I/NN does/VBZ not/RB bind/VB to/TO this/DT mutant/JJ sequence/NN ./. 
A/DT survey/NN of/IN GATA/NN motifs/NNS from/IN other/JJ globin/NN cis-elements/NNS demonstrates/VBZ HMG-I/NN binding/NN to/TO most/JJS of/IN them/PRP ./. 
These/DT findings/NNS implicate/VBP HMG-I/NN in/IN the/DT HPFH/NN phenotype/NN ;/: we/PRP speculate/VBP that/IN it/PRP may/MD participate/VB in/IN the/DT formation/NN of/IN multiprotein/JJ complexes/NNS that/WDT regulate/VBP globin/NN gene/NN expression/NN ./. 
UI/LS -/: 95386713/CD 
TI/LS -/: Constitutive/JJ activation/NN of/IN different/JJ Jak/NN tyrosine/NN kinases/NNS in/IN human/JJ T/NN cell/NN leukemia/NN virus/NN type/NN 1/CD (/( HTLV-1/NN )/) tax/NN protein/NN or/CC virus-transformed/JJ cells/NNS ./. 
AB/LS -/: HTLV-1/NN infection/NN causes/VBZ an/DT adult/JJ T/NN cell/NN leukemia/NN in/IN humans/NNS ./. 
The/DT viral/JJ encoded/VBN protein/NN tax/NN ,/, is/VBZ thought/VBN to/TO play/VB an/DT important/JJ role/NN in/IN oncogenesis/NN ./. 
Our/PRP$ previous/JJ data/NNS obtained/VBN from/IN a/DT tax/NN transgenic/JJ mouse/NN model/NN revealed/VBD that/IN tax/NN transforms/VBZ mouse/NN fibroblasts/NNS but/CC not/RB thymocytes/NNS ,/, despite/IN comparable/JJ levels/NNS of/IN tax/NN expression/NN in/IN both/DT tissues/NNS ./. 
Constitutive/JJ tyrosine/NN phosphorylation/NN of/IN a/DT 130-kD/JJ protein/NN (/( s/NNS )/) was/VBD observed/VBN in/IN the/DT tax/NN transformed/JJ fibroblast/NN B/NN line/NN and/CC in/IN HTLV-1/NN transformed/JJ human/JJ lymphoid/JJ lines/NNS ,/, but/CC not/RB in/IN thymocytes/NNS from/IN Thy-tax/NN transgenic/JJ mice/NNS ./. 
Phosphotyrosine/NN immunoprecipitation/NN followed/VBN by/IN Western/NN blot/NN analysis/NN with/IN a/DT set/NN of/IN Jak/NN kinase/NN specific/JJ antibodies/NNS ,/, identified/VBD p130/NN as/IN Jak2/NN in/IN the/DT tax/NN transformed/JJ mouse/NN fibroblastic/JJ cell/NN line/NN and/CC Jak3/NN in/IN HTLV-1/NN transformed/JJ human/JJ T/NN cell/NN lines/NNS ./. 
Phosphorylation/NN of/IN Jak2/NN in/IN tax/NN transformed/JJ cells/NNS resulted/VBD from/IN high/JJ expression/NN of/IN IL-6/NN ./. 
Tyrosine/NN phosphorylation/NN of/IN this/DT protein/NN could/MD also/RB be/VB induced/VBN in/IN Balb/c3T3/NN cells/NNS using/VBG a/DT supernatant/NN from/IN the/DT B/NN line/NN ,/, which/WDT was/VBD associated/VBN with/IN induction/NN of/IN cell/NN proliferation/NN ./. 
Both/CC phosphorylation/NN and/CC proliferation/NN were/VBD inhibited/VBN by/IN IL-6/NN neutralizing/NN antibodies/NNS ./. 
Constitutive/JJ phosphorylation/NN of/IN Jak/NN kinases/NNS may/MD facilitate/VB tumor/NN growth/NN in/IN both/CC HTLV-1/NN infected/JJ human/JJ T/NN cells/NNS and/CC the/DT transgenic/JJ mouse/NN model/NN ./. 
UI/LS -/: 95367587/CD 
TI/LS -/: Regulation/NN of/IN c-jun/NN mRNA/NN expression/NN by/IN hydroxyurea/NN in/IN human/JJ K562/NN cells/NNS during/IN erythroid/JJ differentiation/NN [/( published/VBN erratum/NN appears/VBZ in/IN Biochim/NNP Biophys/NNP Acta/NNP 1995/CD Dec/NNP 27/CD ;/: 1264/CD (/( 3/CD )/) :/: 409/CD ]/) 
AB/LS -/: Hydroxyurea/NN (/( HU/NN )/) is/VBZ an/DT antitumor/JJ agent/NN which/WDT also/RB induces/VBZ hemoglobinization/NN during/IN erythroid/JJ differentiation/NN ./. 
In/IN addition/NN ,/, HU/NN stimulates/VBZ the/DT synthesis/NN of/IN fetal/JJ hemoglobin/NN in/IN sickle/NN cell/NN anemia/NN patients/NNS ./. 
To/TO further/RB understand/VB its/PRP$ mechanism/NN of/IN action/NN ,/, we/PRP investigated/VBD the/DT effects/NNS of/IN HU/NN on/IN regulation/NN of/IN c-jun/NN expression/NN prior/RB to/TO the/DT onset/NN of/IN erythroid/JJ differentiation/NN of/IN K562/NN cells/NNS ./. 
HU/NN induced/VBD a/DT dose-dependent/JJ stimulation/NN of/IN c-jun/NN synthesis/NN ./. 
The/DT levels/NNS of/IN c-jun/NN mRNA/NN was/VBD elevated/VBN 4/CD to/TO 7.5-fold/RB by/IN HU/NN within/IN 2/CD h/NN ./. 
This/DT was/VBD followed/VBN by/IN a/DT gradual/JJ decline/NN to/TO the/DT basal/JJ level/NN by/IN 24/CD h/NN ./. 
Both/CC nuclear/JJ run-on/JJ and/CC actinomycin/NN D/NN pulse/NN experiments/NNS strongly/RB indicate/VBP that/IN HU/NN regulates/VBZ c-jun/NN mRNA/NN expression/NN by/IN increasing/VBG the/DT rate/NN of/IN synthesis/NN as/RB well/RB as/IN stabilizing/VBG the/DT c-jun/NN mRNA/NN ./. 
In/IN addition/NN ,/, the/DT level/NN of/IN jun/NN protein/NN was/VBD elevated/JJ by/IN 2/CD to/TO 5-fold/NN within/IN 4/CD h/NN in/IN HU/NN treated/JJ cells/NNS ./. 
Furthermore/RB ,/, concentrations/NNS of/IN HU/NN below/IN 250/CD microM/NN slightly/RB increased/VBD the/DT 5X/NN AP-1/CAT/NN activity/NN ./. 
These/DT results/NNS strongly/RB suggest/VBP that/IN HU/NN induces/VBZ both/CC transcriptional/JJ and/CC post-transcription/JJ regulation/NN of/IN c-jun/NN during/IN erythroid/JJ differentiation/NN ./. 
UI/LS -/: 92187059/CD 
TI/LS -/: In/FW vivo/FW and/CC in/FW vitro/FW effects/NNS of/IN glucocorticoids/NNS on/IN lymphocyte/NN proliferation/NN in/IN man/NN :/: relationship/NN to/TO glucocorticoid/NN receptors/NNS ./. 
AB/LS -/: Interrelations/NNS between/IN the/DT hypothalamic-pituitary-adrenal/JJ system/NN (/( HPA/NN )/) and/CC the/DT immune/JJ system/NN represent/VBP a/DT well-documented/JJ biological/JJ phenomenon/NN ./. 
While/IN in/FW vitro/FW administration/NN of/IN glucocorticoids/NNS may/MD inhibit/VB concanavalin/NN A/NN (/( Con/NN A/NN )/) -/: and/CC phytohemagglutinin/NN (/( PHA/NN )/) -induced/JJ T-cell/NN proliferation/NN ,/, pokeweed/NN mitogen/NN (/( PWM/NN )/) -driven/JJ B-cell/NN mitogenesis/NN is/VBZ relatively/RB resistant/JJ to/TO glucocorticoids/NNS ./. 
To/TO further/RB explore/VB the/DT link/NN between/IN the/DT HPA/NN and/CC the/DT immune/JJ system/NN in/IN relation/NN to/TO glucocorticoid/NN receptor/NN function/NN ,/, dose-response/JJ curves/NNS were/VBD obtained/VBN for/IN Con/NN A-/NN and/CC PHA/JJ -induced/JJ T-cell/NN mitogenesis/NN ,/, PWM-generated/JJ B-cell/NN mitogenesis/NN and/CC spontaneous/JJ lymphocyte/NN proliferation/NN in/IN 13/CD healthy/JJ controls/NNS ./. 
Glucocorticoid/NN effects/NNS were/VBD assessed/VBN in/FW vivo/FW by/IN depletion/NN of/IN endogenous/JJ glucocorticoids/NNS after/IN oral/JJ administration/NN of/IN 1.5/CD g/NN metyrapone/NN (/( MET/NN )/) and/CC subsequent/JJ glucocorticoid/NN replacement/NN ,/, and/CC in/FW vitro/FW by/IN incubation/NN of/IN the/DT cells/NNS with/IN different/JJ doses/NNS of/IN dexamethasone/NN (/( DEX/NN )/) ./. 
There/EX was/VBD a/DT significant/JJ decrease/NN in/IN PWM-induced/JJ B-cell/NN mitogenesis/NN and/CC a/DT more/RBR pronounced/JJ effect/NN of/IN DEX/NN administered/VBN in/FW vitro/FW on/IN spontaneous/JJ lymphocyte/NN proliferation/NN after/IN MET/NN treatment/NN when/WRB compared/VBN with/IN the/DT DEX/NN plus/CC MET/NN pretreated/JJ condition/NN in/FW vivo/FW ./. 
These/DT data/NNS suggest/VBP that/IN the/DT inhibition/NN of/IN spontaneous/JJ lymphocyte/NN proliferation/NN by/IN glucocorticoids/NNS in/FW vitro/FW is/VBZ related/JJ to/TO glucocorticoid/NN receptor/NN function/NN ./. 
The/DT decrease/NN in/IN PWM-generated/JJ B-cell/NN proliferation/NN following/VBG cortisol/NN depletion/NN by/IN MET/NN may/MD be/VB seen/VBN in/IN connection/NN with/IN impaired/JJ glucocorticoid-mediated/JJ induction/NN of/IN interleukin-1/NN receptor/NN synthesis/NN ./. 
UI/LS -/: 96356325/CD 
TI/LS -/: Transcription/NN specific/JJ differences/NNS visualized/VBN by/IN fluorescence/NN in/FW situ/FW hybridization/NN pattern/NN on/IN interphase/JJ nuclei/NNS of/IN different/JJ cell/NN types/NNS ./. 
AB/LS -/: Application/NN of/IN a/DT "/`` formamide/NN free/JJ "/'' and/CC thus/RB "/`` material/NN preserving/NN "/'' in/FW situ/FW hybridization/NN technique/NN using/VBG the/DT cDNA/NN of/IN the/DT myf3/NN gene/NN revealed/VBD the/DT following/JJ results/NNS :/: Human/JJ rhabdomyosarcoma/NN cells/NNS ,/, characterized/VBN by/IN a/DT high/JJ expression/NN of/IN myf3/NN show/VBP intensive/JJ hybridization/NN signals/NNS in/IN their/PRP$ interphase/NN ./. 
RNase/NN treatment/NN prior/JJ to/TO hybridization/NN considerably/RB reduces/VBZ the/DT size/NN of/IN this/DT signals/NNS ./. 
In/IN comparison/NN ,/, isolated/VBN nuclei/NNS of/IN human/JJ lymphocytes/NNS in/IN which/WDT no/DT need/NN for/IN the/DT expression/NN of/IN this/DT gene/NN exists/VBZ ,/, show/VBP barely/RB hybridization/NN signals/NNS ./. 
Correspondingly/RB ,/, RNase/NN treatment/NN had/VBD no/DT effect/NN on/IN hybridization/NN pattern/NN at/IN all/DT ./. 
In/IN conclusion/NN an/DT increased/VBN transcription/NN efficiency/NN of/IN a/DT cell/NN type/NN specific/JJ gene/NN is/VBZ accompanied/VBN by/IN a/DT higher/JJR hybridization/NN accessibility/NN in/IN the/DT corresponding/JJ cell/NN nuclei/NNS ./. 
UI/LS -/: 96079009/CD 
TI/LS -/: Oncogenicity/NN of/IN human/JJ papillomavirus-/NN or/CC adenovirus-transformed/JJ cells/NNS correlates/VBZ with/IN resistance/NN to/TO lysis/NN by/IN natural/JJ killer/NN cells/NNS ./. 
AB/LS -/: The/DT reasons/NNS for/IN the/DT dissimilar/JJ oncogenicities/NNS of/IN human/JJ adenoviruses/NNS and/CC human/JJ papillomaviruses/NNS (/( HPV/NNS )/) in/IN humans/NNS are/VBP unknown/JJ but/CC may/MD relate/VB to/TO differences/NNS in/IN the/DT capacities/NNS of/IN the/DT E1A/NN and/CC E7/NN proteins/NNS to/TO target/VB cells/NNS for/IN rejection/NN by/IN the/DT host/NN natural/JJ killer/NN (/( NK/NN )/) cell/NN response/NN ./. 
As/IN one/CD test/NN of/IN this/DT hypothesis/NN ,/, we/PRP compared/VBD the/DT abilities/NNS of/IN E1A-/NN and/CC E7-expressing/JJ human/JJ fibroblastic/JJ or/CC keratinocyte-derived/JJ human/JJ cells/NNS to/TO be/VB selectively/RB killed/VBN by/IN either/CC unstimulated/JJ or/CC interferon/NN (/( IFN/NN )/) -activated/JJ NK/NN cells/NNS ./. 
Cells/NNS expressing/VBG the/DT E1A/NN oncoprotein/NN were/VBD selectively/RB killed/VBN by/IN unstimulated/JJ NK/NN cells/NNS ,/, while/IN the/DT same/JJ parental/JJ cells/NNS but/CC expressing/VBG the/DT HPV/NNS type/NN 16/CD (/( HPV-16/NN )/) or/CC HPV-18/NN E7/NN oncoprotein/NN were/VBD resistant/JJ to/TO NK/NN cell/NN lysis/NN ./. 
The/DT ability/NN of/IN IFN-activated/JJ NK/NN cells/NNS to/TO selectively/RB kill/VB virally/RB transformed/VBN cells/NNS depends/VBZ on/IN IFN/NN 's/POS ability/NN to/TO induce/VB resistance/NN to/TO NK/NN cell/NN lysis/NN in/IN normal/JJ (/( i.e./FW ,/, non-viral/JJ oncogene-expressing/JJ )/) but/CC not/RB virally/RB transformed/VBN cells/NNS ./. 
E1A/NN blocked/VBD IFN/NN 's/POS induction/NN of/IN cytolytic/JJ resistance/NN ,/, resulting/VBG in/IN the/DT selective/JJ lysis/NN of/IN adenovirus-transformed/JJ cells/NNS by/IN IFN-activated/JJ NK/NN cells/NNS ./. 
The/DT extent/NN of/IN IFN-induced/JJ NK/NN cell/NN killing/NN of/IN E1A-expressing/JJ cells/NNS was/VBD proportional/JJ to/TO the/DT level/NN of/IN E1A/NN expression/NN and/CC correlated/VBN with/IN the/DT ability/NN of/IN E1A/NN to/TO block/VB IFN-stimulated/JJ gene/NN expression/NN in/IN target/NN cells/NNS ./. 
In/IN contrast/NN ,/, E7/NN blocked/VBD neither/CC IFN-stimulated/JJ gene/NN expression/NN nor/CC IFN/NN 's/POS induction/NN of/IN cytolytic/JJ resistance/NN ,/, thereby/RB precluding/VBG the/DT selective/JJ lysis/NN of/IN HPV-transformed/JJ cells/NNS by/IN IFN-activated/JJ NK/NN cells/NNS ./. 
In/IN conclusion/NN ,/, E1A/NN expression/NN marks/VBZ cells/NNS for/IN destruction/NN by/IN the/DT host/NN NK/NN cell/NN response/NN ,/, whereas/IN the/DT E7/NN oncoprotein/NN lacks/VBZ this/DT activity/NN ./. 
UI/LS -/: 96062284/CD 
TI/LS -/: Regulation/NN of/IN IkB/NN alpha/NN phosphorylation/NN by/IN PKC-/NN and/CC Ca(2+)-dependent/JJ signal/NN transduction/NN pathways/NNS ./. 
AB/LS -/: The/DT Ca(2+)-dependent/JJ phosphatase/NN calcineurin/NN ,/, a/DT target/NN of/IN FK506/NN and/CC CsA/NN ,/, synergizes/VBZ with/IN PKC-induced/JJ activation/NN of/IN nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN in/IN T/NN cell/NN lines/NNS ./. 
We/PRP have/VBP investigated/VBN whether/IN this/DT synergy/NN is/VBZ present/JJ in/IN other/JJ cell/NN types/NNS and/CC the/DT mechanism/NN (/( s/NNS )/) by/IN which/WDT these/DT two/CD pathways/NNS lead/VBP to/TO NF-kappa/NN B/NN activation/NN ./. 
While/IN this/DT synergy/NN is/VBZ present/JJ in/IN other/JJ cell/NN types/NNS ,/, in/IN the/DT monocytic/JJ cell/NN line/NN U937/NN calcineurin/NN is/VBZ also/RB sufficient/JJ to/TO activate/VB NF-kappa/NN B/NN ./. 
Having/VBG previously/RB shown/VBN that/IN Ca(2+)-/NN and/CC PKC-/NN dependent/JJ pathways/NNS synergize/VBP by/IN accelerating/VBG the/DT degradation/NN of/IN IkB/NN alpha/NN ,/, we/PRP focused/VBD on/IN the/DT regulation/NN of/IN IkB/NN alpha/NN phosphorylation/NN ./. 
While/IN PKC-dependent/JJ pathways/NNS sequentially/RB result/VBP in/IN the/DT phosphorylation/NN and/CC in/IN an/DT incomplete/JJ degradation/NN of/IN IkB/NN alpha/NN in/IN T/NN cell/NN lines/NNS ,/, co-activation/NN of/IN Ca(2+)-dependent/JJ pathways/NNS accelerates/VBZ the/DT rate/NN of/IN IkB/NN alpha/NN phosphorylation/NN and/CC results/VBZ in/IN its/PRP$ complete/JJ degradation/NN ./. 
Activation/NN of/IN Ca(2+)-dependent/JJ pathways/NNS alone/RB do/VBP not/RB result/VB in/IN the/DT phosphorylation/NN and/or/CC degradation/NN of/IN IkB/NN alpha/NN in/IN Jurkat/NN T/NN or/CC in/IN U937/NN cells/NNS ./. 
Treatment/NN of/IN T/NN cells/NNS with/IN the/DT selective/JJ PKC/NN inhibitor/NN GF109203X/NN abrogates/VBZ the/DT PMA-induced/JJ IkB/NN alpha/NN phosphorylation/degradation/NN irrespective/JJ of/IN activation/NN of/IN Ca(2+)-dependent/JJ pathways/NNS ,/, but/CC not/RB the/DT phosphorylation/NN and/CC degradation/NN of/IN IkB/NN alpha/NN induced/VBN by/IN TNF-alpha/NN ,/, a/DT PKC-independent/JJ stimulus/NN ./. 
Contrary/JJ to/TO the/DT interaction/NN with/IN PKC/NN ,/, Ca(2+)-dependent/JJ pathways/NNS synergize/VBP with/IN TNF-alpha/NN not/RB at/IN the/DT level/NN of/IN IkB/NN alpha/NN phosphorylation/NN ,/, but/CC at/IN the/DT level/NN of/IN its/PRP$ degradation/NN ./. 
These/DT results/NNS indicate/VBP that/IN Ca(2+)-dependent/JJ pathways/NNS ,/, including/VBG the/DT phosphatase/NN calcineurin/NN ,/, participate/VBP in/IN the/DT regulation/NN of/IN NF-kappa/NN B/NN in/IN a/DT cell/NN specific/JJ fashion/NN and/CC synergize/VBP with/IN PKC-dependent/JJ and/CC -independent/JJ pathways/NNS at/IN the/DT level/NN of/IN IkB/NN alpha/NN phosphorylation/NN and/CC degradation/NN ./. 
UI/LS -/: 96054968/CD 
TI/LS -/: Vitamin/NN E/NN therapy/NN of/IN acute/JJ CCl4-induced/JJ hepatic/JJ injury/NN in/IN mice/NNS is/VBZ associated/VBN with/IN inhibition/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN binding/NN ./. 
AB/LS -/: Oxidative/JJ stress/NN ,/, with/IN reactive/JJ oxygen/NN intermediate/NN formation/NN ,/, may/MD represent/VB a/DT common/JJ mechanism/NN by/IN which/WDT liver/NN injury/NN is/VBZ induced/VBN by/IN diverse/JJ etiologies/NNS ./. 
Oxidative/JJ stress/NN enhances/VBZ nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) activity/NN ,/, and/CC NF-kappa/NN B/NN activity/NN has/VBZ been/VBN shown/VBN to/TO enhance/VB the/DT expression/NN of/IN cytotoxic/JJ cytokines/NNS ./. 
Acute/JJ hepatic/JJ injury/NN caused/VBN by/IN reactive/JJ oxygen/NN intermediate/NN production/NN was/VBD induced/VBN by/IN an/DT intraperitoneal/JJ injection/NN of/IN CCl4/NN in/IN mice/NNS ./. 
This/DT injury/NN was/VBD significantly/RB inhibited/VBN by/IN intravenous/JJ pretreatment/NN of/IN the/DT mice/NNS with/IN a/DT water-soluble/JJ emulsion/NN of/IN alpha-tocopherol/NN ./. 
Alpha-tocopherol/NN treatment/NN of/IN the/DT mice/NNS given/VBN the/DT CCl4/NN also/RB reduced/VBD the/DT NF-kappa/NN B/NN binding/NN to/TO levels/NNS approaching/VBG those/DT found/VBN in/IN normal/JJ mice/NNS ./. 
In/FW vitro/FW treatment/NN of/IN a/DT monocyte/macrophage/NN cell/NN line/NN with/IN CCl4/NN led/VBD to/TO enhanced/VBN NF-kappa/NN B/NN binding/NN and/CC an/DT increase/NN in/IN tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) messenger/NN RNA/NN levels/NNS ./. 
Liver/NN specimens/NNS taken/VBN from/IN patients/NNS with/IN acute/JJ fulminant/JJ hepatitis/NN had/VBD markedly/RB increased/VBN NF-kappa/NN B/NN binding/NN activity/NN in/IN comparison/NN with/IN the/DT binding/NN of/IN normal/JJ livers/NNS ./. 
These/DT data/NNS demonstrate/VBP that/IN abolishing/VBG acute/JJ hepatic/JJ injury/NN with/IN alpha-tocopherol/NN ,/, a/DT free/JJ radical/NN scavenger/NN ,/, also/RB eliminated/VBD increased/VBN NF-kappa/NN B/NN binding/NN ./. 
It/PRP is/VBZ tempting/JJ to/TO speculate/VB that/IN enhanced/VBN NF-kappa/NN B/NN expression/NN caused/VBN by/IN free/JJ radical/NN production/oxidative/JJ stress/NN may/MD modulate/VB liver/NN injury/NN ,/, perhaps/RB through/IN an/DT effect/NN on/IN cytotoxic/JJ cytokine/NN synthesis/NN ./. 
UI/LS -/: 96026328/CD 
TI/LS -/: Immunosuppression/NN by/IN glucocorticoids/NNS :/: inhibition/NN of/IN NF-kappa/NN B/NN activity/NN through/IN induction/NN of/IN I/NN kappa/NN B/NN synthesis/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: Glucocorticoids/NNS are/VBP among/IN the/DT most/RBS potent/JJ anti-inflammatory/JJ and/CC immunosuppressive/JJ agents/NNS ./. 
They/PRP inhibit/VBP synthesis/NN of/IN almost/RB all/DT known/JJ cytokines/NNS and/CC of/IN several/JJ cell/NN surface/NN molecules/NNS required/VBN for/IN immune/JJ function/NN ,/, but/CC the/DT mechanism/NN underlying/VBG this/DT activity/NN has/VBZ been/VBN unclear/JJ ./. Here/RB it/PRP is/VBZ shown/VBN that/IN glucocorticoids/NNS are/VBP potent/JJ inhibitors/NNS of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) activation/NN in/IN mice/NNS and/CC cultured/VBN cells/NNS ./. 
This/DT inhibition/NN is/VBZ mediated/VBN by/IN induction/NN of/IN the/DT I/NN kappa/NN B/NN alpha/NN inhibitory/JJ protein/NN ,/, which/WDT traps/VBZ activated/VBN NF-kappa/NN B/NN in/IN inactive/JJ cytoplasmic/JJ complexes/NNS ./. 
Because/IN NF-kappa/NN B/NN activates/VBZ many/JJ immunoregulatory/JJ genes/NNS in/IN response/NN to/TO pro-inflammatory/JJ stimuli/NNS ,/, the/DT inhibition/NN of/IN its/PRP$ activity/NN can/MD be/VB a/DT major/JJ component/NN of/IN the/DT anti-inflammatory/JJ activity/NN of/IN glucocorticoids/NNS ./. 
UI/LS -/: 96009608/CD 
TI/LS -/: Transcriptional/JJ repression/NN of/IN the/DT interleukin-2/NN gene/NN by/IN vitamin/NN D3/NN :/: direct/JJ inhibition/NN of/IN NFATp/NN /AP-1/NN complex/JJ formation/NN by/IN a/DT nuclear/JJ hormone/NN receptor/NN ./. 
AB/LS -/: T-lymphocyte/NN proliferation/NN is/VBZ suppressed/VBN by/IN 1,25-dihydroxyvitamin/NN D3/NN [/( 1,25(OH)2D3/NN ]/) ,/, the/DT active/JJ metabolite/NN of/IN vitamin/NN D3/NN ,/, and/CC is/VBZ associated/VBN with/IN a/DT decrease/NN in/IN interleukin/NN 2/CD (/( IL-2/NN )/) ,/, gamma/NN interferon/NN ,/, and/CC granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN mRNA/NN levels/NNS ./. 
We/PRP report/VBP here/RB that/IN 1,25(OH)2D3-mediated/JJ repression/NN in/IN Jurkat/NN cells/NNS is/VBZ cycloheximide/NN resistant/JJ ,/, suggesting/VBG that/IN it/PRP is/VBZ a/DT direct/JJ transcriptional/JJ repressive/JJ effect/NN on/IN IL-2/NN expression/NN by/IN the/DT vitamin/NN D3/NN receptor/NN (/( VDR/NN )/) ./. 
We/PRP therefore/RB examined/VBD vitamin/NN D3-mediated/JJ repression/NN of/IN activated/VBN IL-2/NN expression/NN by/IN cotransfecting/VBG Jurkat/NN cells/NNS with/IN IL-2/NN promoter/NN /reporter/NN constructs/NNS and/CC a/DT VDR/NN overexpression/NN vector/NN and/CC by/IN DNA/NN binding/NN ./. 
We/PRP delineated/VBD an/DT element/NN conferring/VBG both/CC DNA/NN binding/NN by/IN the/DT receptor/NN in/FW vitro/FW and/CC 1,25(OH)2D3-mediated/JJ repression/NN in/FW vivo/FW to/TO a/DT short/JJ 40-bp/JJ region/NN encompassing/VBG an/DT important/JJ positive/JJ regulatory/JJ element/NN ,/, NF-AT-1/NN ,/, which/WDT is/VBZ bound/VBN by/IN a/DT T-cell-specific/JJ transcription/NN factor/NN ,/, NFATp/NN ,/, as/RB well/RB as/IN by/IN AP-1/NN ./. 
VDR/NN DNA-binding/JJ mutants/NNS were/VBD unable/JJ to/TO either/RB bind/VB to/TO this/DT element/NN in/FW vitro/FW or/CC repress/VB in/FW vivo/FW ;/: the/DT VDR/NN DNA-binding/JJ domain/NN alone/RB ,/, however/RB ,/, bound/VBD the/DT element/NN but/CC also/RB could/MD not/RB repress/VB IL-2/NN expression/NN ./. 
These/DT results/NNS indicate/VBP that/IN DNA/NN binding/NN by/IN VDR/NN is/VBZ necessary/JJ but/CC not/RB sufficient/JJ to/TO mediate/VB IL-2/NN repression/NN ./. 
By/IN combining/VBG partially/RB purified/VBN proteins/NNS in/FW vitro/FW ,/, we/PRP observed/VBD the/DT loss/NN of/IN the/DT bound/VBN NFATp/NN /AP-1-DNA/NN complex/NN upon/IN inclusion/NN of/IN VDR/NN or/CC VDR-retinoid/NN X/NN receptor/NN ./. 
Order/NN of/IN addition/NN and/CC off-rate/JJ experiments/NNS indicate/VBP that/IN the/DT VDR-retinoid/NN X/NN receptor/NN heterodimer/NN blocks/VBZ NFATp/NN /AP-1/NN complex/NN formation/NN and/CC then/RB stably/RB associates/VBZ with/IN the/DT NF-AT-1/NN element/NN ./. 
This/DT direct/JJ inhibition/NN by/IN a/DT nuclear/JJ hormone/NN receptor/NN of/IN transcriptional/JJ activators/NNS of/IN the/DT IL-2/NN gene/NN may/MD provide/VB a/DT mechanistic/JJ explanation/NN of/IN how/WRB vitamin/NN derivatives/NNS can/MD act/VB as/IN potent/JJ immunosuppressive/JJ agents/NNS ./. 
UI/LS -/: 96017769/CD 
TI/LS -/: Tissue-specific/JJ regulation/NN of/IN the/DT rabbit/JJ 15-lipoxygenase/NN gene/NN in/IN erythroid/JJ cells/NNS by/IN a/DT transcriptional/JJ silencer/NN ./. 
AB/LS -/: The/DT 15-lipoxygenase/NN (/( lox/NN )/) gene/NN is/VBZ expressed/VBN in/IN a/DT tissue-specific/JJ manner/NN ,/, predominantly/RB in/IN erythroid/JJ cells/NNS but/CC also/RB in/IN airway/NN epithelial/JJ cells/NNS and/CC eosinophils/NNS ./. 
We/PRP demonstrate/VBP in/IN this/DT report/NN that/IN the/DT 5'/JJ flanking/JJ DNA/NN of/IN the/DT 15-lox/NN gene/NN contains/VBZ sequences/NNS which/WDT down-regulate/VBP its/PRP$ activity/NN in/IN a/DT variety/NN of/IN non-erythroid/JJ cell/NN lines/NNS but/CC not/RB in/IN two/CD erythroid/JJ cell/NN lines/NNS ./. 
The/DT element/NN has/VBZ characteristics/NNS of/IN a/DT transcriptional/JJ '/`` silencer/NN '/'' since/IN it/PRP functions/VBZ in/IN both/DT orientations/NNS ./. 
The/DT main/JJ activity/NN of/IN the/DT silencer/NN has/VBZ been/VBN mapped/VBN to/TO the/DT first/JJ 900/CD bp/NN of/IN 5'/JJ flanking/JJ DNA/NN ,/, which/WDT contains/VBZ nine/CD binding/VBG sites/NNS for/IN a/DT nuclear/JJ factor/NN present/JJ in/IN non-erythroid/JJ cells/NNS but/CC not/RB in/IN erythroid/JJ cells/NNS ./. 
These/DT binding/VBG sites/NNS have/VBP similar/JJ sequences/NNS and/CC multiple/JJ copies/NNS of/IN the/DT binding/VBG sites/NNS confer/VBP tissue-specific/JJ down-regulation/NN when/WRB attached/VBN to/TO a/DT minimal/JJ lox/NN promoter/NN fragment/NN ./. 
The/DT 5'/JJ flanking/JJ DNA/NN also/RB contains/VBZ a/DT cluster/NN of/IN three/CD binding/VBG sites/NNS for/IN the/DT GATA/NN family/NN of/IN transcription/NN factors/NNS ./. 
UI/LS -/: 95386516/CD 
TI/LS -/: Phosphorylation/NN of/IN the/DT transcription/NN factor/NN NFATp/NN inhibits/VBZ its/PRP$ DNA/NN binding/NN activity/NN in/IN cyclosporin/NN A-treated/JJ human/JJ B/NN and/CC T/NN cells/NNS ./. 
AB/LS -/: Cyclosporin/NN A/NN (/( CsA/NN )/) exerts/VBZ its/PRP$ immunosuppressive/JJ effect/NN by/IN inhibiting/VBG the/DT activity/NN of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) ,/, thus/RB preventing/VBG transcriptional/JJ induction/NN of/IN several/JJ cytokine/NN genes/NNS ./. 
This/DT effect/NN is/VBZ thought/VBN to/TO be/VB largely/RB mediated/VBN through/IN inactivation/NN of/IN the/DT phosphatase/NN calcineurin/NN ,/, which/WDT in/IN turn/NN inhibits/VBZ translocation/NN of/IN an/DT NFAT/NN component/NN to/TO the/DT nucleus/NN ./. 
Here/RB we/PRP report/VBP that/IN CsA/NN treatment/NN of/IN Raji/NN B/NN and/CC Jurkat/NN T/NN cell/NN lines/NNS yields/VBZ a/DT phosphorylated/JJ form/NN of/IN NFATp/NN that/WDT is/VBZ inhibited/VBN in/IN DNA-binding/JJ and/CC in/IN its/PRP$ ability/NN to/TO form/VB an/DT NFAT/NN complex/NN with/IN Fos/NN and/CC Jun/NN ./. 
Immunoblot/NN analyses/NNS and/CC metabolic/JJ labeling/NN with/IN [32P]orthophosphate/NN show/VBP that/IN CsA/NN alters/VBZ NFATp/NN migration/NN on/IN SDS-polyacrylamide/NN gel/NN electrophoresis/NN by/IN increasing/VBG its/PRP$ phosphorylation/NN level/NN without/IN affecting/VBG subcellular/JJ distribution/NN ./. 
Dephosphorylation/NN by/IN in/FW vitro/FW treatment/NN with/IN calcineurin/NN or/CC alkaline/NN phosphatase/NN restores/VBZ NFATp/NN DNA/NN binding/NN activity/NN and/CC its/PRP$ ability/NN to/TO reconstitute/VB an/DT NFAT/NN complex/NN with/IN Fos/NN and/CC Jun/NN proteins/NNS ./. 
These/DT data/NNS point/VBP to/TO a/DT new/JJ mechanism/NN for/IN CsA-sensitive/JJ regulation/NN of/IN NFATp/NN in/IN which/WDT dephosphorylation/NN is/VBZ critical/JJ for/IN DNA/NN binding/NN ./. 
UI/LS -/: 95367586/CD 
TI/LS -/: Transcription/NN factors/NNS as/IN targets/NNS for/IN oxidative/JJ signalling/NN during/IN lymphocyte/NN activation/NN ./. 
AB/LS -/: We/PRP previously/RB have/VBP demonstrated/VBN a/DT requirement/NN for/IN oxidative/JJ events/NNS during/IN cell/NN cycle/NN entry/NN in/IN T/NN lymphocytes/NNS and/CC have/VBP hypothesised/VBN that/IN reactive/JJ oxygen/NN species/NNS may/MD act/VB as/IN intracellular/JJ signalling/VBG agents/NNS during/IN lymphocyte/NN activation/NN ./. 
In/IN the/DT current/JJ study/NN ,/, cysteamine/NN ,/, an/DT aminothiol/NN compound/NN with/IN antioxidant/JJ activity/NN ,/, has/VBZ been/VBN used/VBN to/TO further/RB investigate/VB the/DT role/NN of/IN oxidative/JJ signalling/NN during/IN lymphocyte/NN activation/NN ./. 
Treatment/NN of/IN normal/JJ human/JJ peripheral/JJ blood/NN lymphocytes/NNS with/IN cysteamine/NN in/FW vitro/FW was/VBD found/VBN to/TO inhibit/VB proliferation/NN in/IN a/DT dose-dependent/JJ manner/NN ,/, with/IN essentially/RB complete/JJ inhibition/NN occurring/VBG at/IN a/DT dose/NN of/IN 400/CD microM/NN ./. 
This/DT inhibitory/JJ effect/NN was/VBD limited/JJ to/TO the/DT first/JJ 2/CD h/NN after/IN mitogenic/JJ activation/NN ,/, localizing/VBG the/DT time-frame/NN of/IN action/NN of/IN cysteamine/NN to/TO within/IN the/DT commitment/NN period/NN ./. 
It/PRP therefore/RB was/VBD of/IN interest/NN to/TO establish/VB which/WDT ,/, if/IN any/DT ,/, commitment/NN events/NNS were/VBD affected/VBN by/IN oxidative/JJ signalling/NN during/IN cell/NN cycle/NN entry/NN ./. 
Taking/VBG the/DT IL-2/NN gene/NN as/IN a/DT candidate/NN ,/, we/PRP examined/VBD the/DT effect/NN of/IN cysteamine/NN treatment/NN on/IN early/JJ gene/NN expression/NN during/IN lymphocyte/NN activation/NN ,/, and/CC on/IN the/DT activity/NN of/IN transcription/NN factors/NNS AP-1/NN ,/, NF-kappa/NN B/NN ,/, NF-AT/NN and/CC Oct1/NN ,/, whose/WP$ functions/NNS are/VBP required/VBN for/IN expression/NN of/IN the/DT IL-2/NN mRNA/NN ./. 
Cysteamine/NN treatment/NN inhibited/VBD both/CC expression/NN of/IN the/DT IL-2/NN mRNA/NN and/CC secretion/NN of/IN IL-2/NN into/IN the/DT culture/NN medium/NN ./. 
The/DT inhibitory/JJ effect/NN of/IN cysteamine/NN may/MD be/VB mediated/VBN at/IN least/JJS in/IN part/NN by/IN an/DT effect/NN on/IN transcription/NN factor/NN function/NN ,/, as/IN the/DT DNA/NN binding/NN activities/NNS of/IN AP-1/NN and/CC NF-kappa/NN B/NN extracted/VBN from/IN mitogen-stimulated/JJ cells/NNS were/VBD significantly/RB inhibited/VBN by/IN cysteamine/NN treatment/NN ./. 
Interestingly/RB ,/, Oct1/NN and/CC NF-AT/NN DNA/NN binding/NN activity/NN were/VBD not/RB affected/VBN by/IN cysteamine/NN treatment/NN ,/, suggesting/VBG that/IN oxidative/JJ signalling/NN processes/NNS operate/VBP in/IN a/DT selective/JJ manner/NN ./. 
The/DT identification/NN of/IN regulatory/JJ proteins/NNS ,/, such/JJ as/IN transcription/NN factors/NNS ,/, as/IN molecular/JJ targets/NNS for/IN oxidative/JJ signalling/NN provides/VBZ further/JJ evidence/NN to/TO implicate/VB oxidative/JJ signalling/NN as/IN being/VBG intimately/RB involved/VBN in/IN the/DT G0/NN to/TO G1/NN phase/NN transition/NN in/IN T/NN lymphocytes/NNS ./. 
UI/LS -/: 91175240/CD 
TI/LS -/: Sex/NN and/CC age/NN distribution/NN of/IN 1,25(OH)2D3/NN receptors/NNS in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS from/IN normal/JJ human/JJ subjects/NNS ./. 
AB/LS -/: Specific/JJ receptors/NNS for/IN 1,25/CD Dihydroxyvitamin/NN D3/NN have/VBP been/VBN described/VBN in/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NNS )/) ./. 
We/PRP have/VBP tried/VBN to/TO find/VB out/RP whether/IN these/DT receptors/NNS could/MD show/VB any/DT difference/NN in/IN sex/NN or/CC age/NN distribution/NN ./. 
Twenty/CD two/CD healthy/JJ men/NNS aged/JJ 21-66/CD yr/NN (/( mean/NN +/-/CC SD/NN 41.0/CD +/-/CC 13.6/CD )/) and/CC nineteen/CD healthy/JJ women/NNS aged/JJ 22-60/CD yr/NN (/( 38.9/CD +/-/CC 13.9/CD )/) have/VBP been/VBN studied/VBN ./. 
The/DT mean/NN dissociation/NN constant/NN (/( Kd/NN )/) was/VBD similar/JJ in/IN both/DT sexes/NNS (/( 1.35/CD +/-/CC 0.70/CD x/NN 10(-10)/CD M/NN in/IN males/NNS ,/, 1.13/CD +/-/CC 0.66/CD x/NN 10(-10)/CD M/NN in/IN females/NNS )/) ,/, but/CC the/DT concentration/NN of/IN binding/VBG sites/NNS (/( Nmax/NN )/) was/VBD significantly/RB lower/JJR in/IN females/NNS (/( 2.32/CD +/-/CC 0.92/CD fmol/10/CD (/( 7/CD )/) PBMC/NNS vs/CC 4.43/CD +/-/CC 1.38/CD fmol/10(7)/NN PBMC/NNS in/IN males/NNS ;/: p/NN =/JJ 0.0001/CD )/) ./. 
Neither/CC Kd/NN nor/CC Nmax/NN were/VBD significantly/RB correlated/VBN with/IN age/NN ./. 
No/DT difference/NN was/VBD found/VBN between/IN pre/JJ and/CC postmenopausal/JJ women/NNS ./. 
Further/JJ studies/NNS are/VBP needed/VBN to/TO elucidate/VB if/IN this/DT sex/NN difference/NN in/IN PBMC/NN receptors/NNS for/IN 1.25/CD Dihydroxyvitamin/NN D3/NN is/VBZ of/IN any/DT pathophysiological/JJ relevance/NN ./. 
UI/LS -/: 96226053/CD 
TI/LS -/: Expression/NN of/IN Id2/NN and/CC Id3/NN mRNA/NN in/IN human/JJ lymphocytes/NNS ./. 
AB/LS -/: Helix-loop-helix/JJ (/( HLH/JJ )/) transcription/NN factors/NNS are/VBP involved/VBN in/IN cellular/JJ growth/NN and/CC differentiation/NN ./. 
The/DT Id/NN (/( inhibitor/NN of/IN DNA/NN binding/NN and/CC differentiation/NN )/) HLH/JJ proteins/NNS ,/, in/IN a/DT dominantly/RB negative/JJ fashion/NN ,/, regulate/VBP transcriptional/JJ activities/NNS of/IN basic/JJ HLH/JJ proteins/NNS ./. 
We/PRP examined/VBD by/IN northern/JJ|NN hybridization/NN the/DT expression/NN of/IN Id2/NN and/CC Id3/NN mRNA/NN in/IN human/JJ leukemia/lymphoma/NN lines/NNS and/CC patient/NN samples/NNS ,/, as/RB well/RB as/IN resting/VBG and/CC activated/VBN normal/JJ human/JJ lymphocytes/NNS from/IN peripheral/JJ blood/NN (/( PBL/NN )/) ./. 
The/DT Id2/NN mRNA/NN was/VBD abundantly/RB expressed/VBN in/IN 5/12/CD T-cell/NN and/CC 3/4/CD B-cell/NN lines/NNS ,/, and/CC Id3/NN mRNA/NN was/VBD detected/VBN in/IN 4/12/CD T-cell/NN and/CC 3/4/CD B-cell/NN lines/NNS ./. 
Interestingly/RB ,/, Id2/NN ,/, but/CC not/RB Id3/NN ,/, mRNA/NN was/VBD strongly/RB expressed/VBN in/IN 4/5/CD T-cell/NN lines/NNS infected/VBN with/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) (/( ATL-1k/NN ,/, MT-2/NN ,/, S-LB1/NN )/) and/CC type/NN II/CD (/( Mo/NN )/) ./. 
Another/DT unexpected/JJ finding/NN was/VBD that/IN T-cell/NN leukemias/NNS and/CC T-cell/NN lines/NNS often/RB expressed/VBD either/CC Id2/NN or/CC Id3/NN mRNA/NN ./. 
In/IN addition/NN ,/, resting/VBG PBL/NN constitutively/RB expressed/VBD prominent/JJ levels/NNS of/IN Id2/NN mRNA/NN ,/, but/CC not/RB Id3/NN mRNA/NN ./. 
Upon/IN PHA-stimulation/NN ,/, Id2/NN expression/NN decreased/VBD and/CC Id3/NN levels/NNS increased/VBD with/IN biphasic/JJ kinetics/NNS ./. 
Taken/VBN together/RB ,/, our/PRP$ studies/NNS revealed/VBD three/CD unexpected/JJ findings/NNS which/WDT require/VBP further/JJ analysis/NN :/: (/( 1/LS )/) expression/NN of/IN Id2/NN mRNA/NN is/VBZ often/RB associated/VBN with/IN lymphocytic/JJ transformation/NN by/IN HTLV-I/NN or/CC -II/CD ;/: (/( 2/LS )/) T-cells/NNS usually/RB express/VBP either/CC Id2/NN or/CC Id3/NN mRNA/NN ,/, but/CC B-cells/NNS often/RB express/VBP both/DT simultaneously/RB ;/: (/( 3/LS )/) non-dividing/JJ ,/, normal/JJ PBL/NN express/VBP high/JJ levels/NNS of/IN Id2/NN and/CC no/DT Id3/NN mRNA/NN ;/: and/CC with/IN the/DT onset/NN of/IN cellular/JJ proliferation/NN ,/, levels/NNS of/IN Id2/NN mRNA/NN decrease/VBP while/IN levels/NNS of/IN Id3/NN mRNA/NN increase/VBP ,/, suggesting/VBG that/IN regulation/NN of/IN expression/NN of/IN these/DT closely/RB related/JJ genes/NNS is/VBZ disparate/JJ ./. 
UI/LS -/: 96082168/CD 
TI/LS -/: Salicylates/NNS inhibit/VBP lipopolysaccharide-induced/JJ transcriptional/JJ activation/NN of/IN the/DT tissue/NN factor/NN gene/NN in/IN human/JJ monocytic/JJ cells/NNS ./. 
AB/LS -/: Binding/NN of/IN plasma/NN Factor/NN VII/VIIa/NN to/TO the/DT tissue/NN factor/NN (/( TF/NN )/) receptor/NN initiates/VBZ the/DT coagulation/NN protease/NN cascades/NNS ./. 
TF/NN expression/NN by/IN circulating/VBG monocytes/NNS is/VBZ associated/VBN with/IN thrombotic/JJ and/CC inflammatory/JJ complications/NNS in/IN a/DT variety/NN of/IN diseases/NNS ./. 
Transcriptional/JJ activation/NN of/IN the/DT human/JJ TF/NN gene/NN in/IN monocytic/JJ cells/NNS exposed/VBN to/TO bacterial/JJ lipopolysaccharide/NN (/( LPS/NN )/) is/VBZ mediated/VBN by/IN binding/NN of/IN c-Rel/NN /p65/NN heterodimers/NNS to/TO a/DT kappa/NN B/NN site/NN in/IN the/DT TF/NN promoter/NN ./. 
Here/RB ,/, we/PRP report/VBP that/IN a/DT family/NN of/IN anti-inflammatory/JJ agents/NNS ,/, known/VBN as/IN the/DT salicylates/NNS ,/, inhibited/VBD LPS/NN induction/NN of/IN TF/NN activity/NN and/CC TF/NN gene/NN transcription/NN in/IN human/JJ monocytes/NNS and/CC monocytic/JJ THP-1/NN cells/NNS at/IN clinically/RB relevant/JJ doses/NNS ./. 
Furthermore/RB ,/, sodium/NN salicylate/NN blocked/VBD the/DT LPS-induced/JJ proteolytic/JJ degradation/NN of/IN I/NN kappa/NN B/NN alpha/NN ,/, which/WDT prevented/VBD the/DT nuclear/JJ translocation/NN of/IN c-Rel/NN /p65/NN heterodimers/NNS ./. 
In/IN contrast/NN ,/, two/CD other/JJ nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS ,/, ibuprofen/NN and/CC indomethacin/NN ,/, did/VBD not/RB inhibit/VB LPS/NN induction/NN of/IN the/DT TF/NN gene/NN ./. 
These/DT results/NNS indicated/VBD that/IN salicylates/NNS inhibited/VBD LPS/NN induction/NN of/IN TF/NN gene/NN transcription/NN in/IN monocytic/JJ cells/NNS by/IN preventing/VBG nuclear/JJ translocation/NN of/IN c-Rel/NN /p65/NN heterodimers/NNS ./. 
The/DT clinical/JJ benefits/NNS of/IN salicylates/NNS in/IN the/DT treatment/NN of/IN several/JJ diseases/NNS ,/, including/VBG atherosclerosis/NN and/CC rheumatoid/NN arthritis/NN ,/, may/MD be/VB related/JJ to/TO their/PRP$ ability/NN to/TO reduce/VB monocyte/NN gene/NN expression/NN ./. 
UI/LS -/: 96062272/CD 
TI/LS -/: Activation/NN of/IN the/DT signal/NN transducer/NN and/CC transcription/NN (/( STAT/NN )/) signaling/NN pathway/NN in/IN a/DT primary/JJ T/NN cell/NN response/NN ./. 
Critical/JJ role/NN for/IN IL-6/NN ./. 
AB/LS -/: The/DT T/NN cell/NN activation/NN is/VBZ initiated/VBN by/IN interaction/NN of/IN specific/JJ Ags/NNS with/IN TCR/NN ,/, followed/VBN by/IN activation/NN of/IN intracellular/JJ biochemical/JJ events/NNS leading/VBG to/TO activation/NN of/IN several/JJ genes/NNS ./. 
The/DT activation/NN of/IN signal/JJ transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT/NN )/) proteins/NNS in/IN a/DT primary/JJ TCR-mediated/JJ activation/NN of/IN T/NN cells/NNS have/VBP been/VBN explored/VBN ./. 
In/IN purified/VBN human/JJ peripheral/JJ blood/NN T/NN cells/NNS ,/, nuclear/JJ STAT/NN proteins/NNS were/VBD activated/VBN approximately/RB 3/CD h/NN after/IN activation/NN by/IN cross-linked/JJ anti-CD3/JJ Abs/NNS ./. 
These/DT STAT/NN proteins/NNS were/VBD detected/VBN by/IN using/VBG the/DT IFN-gamma-activated/JJ sequence/NN (/( GAS/NN )/) and/CC related/JJ oligonucleotides/NNS as/IN probes/NNS in/IN electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
Analysis/NN of/IN the/DT nuclear/JJ extracts/NNS with/IN anti-STAT/JJ Abs/NNS indicated/VBD that/IN they/PRP contained/VBD STAT-3/NN and/CC additional/JJ proteins/NNS crossreactive/JJ with/IN the/DT STAT/NN family/NN ./. 
The/DT induction/NN of/IN STAT/NN activity/NN was/VBD inhibited/VBN completely/RB by/IN pretreatment/NN with/IN either/CC cycloheximide/NN or/CC cyclosporin/NN A/NN ,/, thus/RB indicating/VBG that/IN the/DT induction/NN was/VBD due/JJ to/TO a/DT secondary/JJ factor/NN produced/VBN by/IN the/DT activated/VBN T/NN cells/NNS ./. 
As/IN neutralizing/NN anti-IL-6/JJ Abs/NNS effectively/RB down-regulated/VBD the/DT early/JJ induction/NN of/IN STAT/NN proteins/NNS and/CC as/IN exogenously/RB added/VBN IL-6/NN rapidly/RB activated/VBD DNA/NN binding/NN similar/JJ to/TO TCR-mediated/JJ bindings/NNS ,/, it/PRP can/MD be/VB concluded/VBN that/IN IL-6/NN is/VBZ the/DT factor/NN responsible/JJ for/IN the/DT activation/NN of/IN STAT/NN proteins/NNS in/IN a/DT primary/JJ T/NN cell/NN response/NN ./. 
UI/LS -/: 96046572/CD 
TI/LS -/: The/DT normal/JJ cell/NN cycle/NN activation/NN program/NN is/VBZ exploited/VBN during/IN the/DT infection/NN of/IN quiescent/JJ B/NN lymphocytes/NNS by/IN Epstein-Barr/JJ virus/NN ./. 
AB/LS -/: B/NN lymphocytes/NNS in/IN the/DT peripheral/JJ circulation/NN are/VBP maintained/JJ in/IN a/DT non-proliferative/JJ state/NN ./. 
Antigen/NN recognition/NN stimulates/VBZ limited/JJ proliferation/NN ,/, whereas/IN infection/NN with/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) results/VBZ in/IN continual/JJ proliferation/NN and/CC the/DT outgrowth/NN of/IN immortal/JJ cell/NN lines/NNS ./. 
Because/IN it/PRP is/VBZ not/RB clear/JJ at/IN which/WDT point/NN in/IN cell/NN cycle/NN the/DT peripheral/JJ B/NN lymphocytes/NNS are/VBP arrested/VBN ,/, we/PRP characterized/VBD the/DT expression/NN of/IN several/JJ cell/NN cycle-associated/JJ genes/NNS in/IN quiescent/JJ and/CC stimulated/VBN cells/NNS ./. 
We/PRP show/VBP that/IN the/DT expression/NN of/IN four/CD cell/NN genes/NNS ,/, cdc-2/NN ,/, cyclin/NN E/NN ,/, CD23/NN ,/, and/CC cyclin/NN D2/NN ,/, are/VBP up-regulated/VBN approximately/RB 100-fold/RB as/IN a/DT result/NN of/IN EBV-mediated/JJ immortalization/NN ./. 
Because/IN these/DT genes/NNS play/VBP a/DT positive/JJ role/NN in/IN cell/NN proliferation/NN ,/, we/PRP suggest/VBP that/IN this/DT regulatory/JJ switch/NN contributes/VBZ to/TO controlling/VBG entry/NN into/IN the/DT cell/NN cycle/NN ./. 
Transient/JJ stimulation/NN of/IN quiescent/JJ B/NN lymphocytes/NNS with/IN either/CC a/DT cocktail/NN of/IN anti-CD40/NN ,/, anti-IgM/NN ,/, and/CC IL4/NN ,/, or/CC EBV/NN results/VBZ in/IN the/DT rapid/JJ expression/NN of/IN the/DT same/JJ four/CD genes/NNS ,/, suggesting/VBG that/IN ,/, after/IN infection/NN ,/, EBV/NN exploits/VBZ the/DT normal/JJ program/NN of/IN B-lymphocyte/NN cell/NN cycle/NN activation/NN ./. 
UI/LS -/: 96011839/CD 
TI/LS -/: Expression/NN of/IN the/DT chemokine/NN receptor/NN BLR2/EBI1/NN is/VBZ specifically/RB transactivated/VBN by/IN Epstein-Barr/JJ virus/NN nuclear/JJ antigen/NN 2/CD ./. 
AB/LS -/: In/IN our/PRP$ attempt/NN to/TO identify/VB chemokine/NN receptors/NNS that/WDT are/VBP related/JJ to/TO Burkitt/NN 's/POS lymphoma/NN receptor/NN 1/CD (/( BLR1/NN )/) and/CC are/VBP expressed/VBN in/IN activated/VBN lymphocytes/NNS we/PRP used/VBD RT-PCR/NN resulting/VBG in/IN the/DT isolation/NN of/IN a/DT cDNA/NN encoding/VBG a/DT seven/CD transmembrane/NN receptor/NN termed/VBN BLR2/NN ./. 
The/DT protein/NN shows/VBZ significant/JJ sequence/NN similarities/NNS to/TO the/DT family/NN of/IN G-protein/NN coupled/JJ chemokine/NN receptors/NNS and/CC turned/VBD out/RP to/TO be/VB identical/JJ to/TO the/DT recently/RB described/VBN receptor/NN EBI1/NN ./. 
Northern/NN blot/NN analysis/NN revealed/VBD that/IN BLR2/NN mRNA/NN could/MD be/VB highly/RB stimulated/VBN in/IN mitogen-/NN and/CC anti-CD3-treated/JJ peripheral/JJ blood/NN lymphocytes/NNS ./. 
BLR2-specific/JJ mRNA/NN could/MD be/VB detected/VBN in/IN all/DT Epstein-Barr/JJ virus/NN positive/JJ B/NN cell/NN lines/NNS ./. 
We/PRP show/VBP that/IN transcription/NN of/IN the/DT BLR2/NN gene/NN could/MD be/VB specifically/RB induced/VBN in/IN Epstein-Barr/JJ virus/NN negative/JJ BL/NN 41/CD cells/NNS via/IN estrogen-mediated/JJ activation/NN of/IN Epstein-Barr/JJ virus/NN nuclear/JJ antigen/NN 2/CD ,/, a/DT key/JJ regulator/NN of/IN viral/JJ and/CC cellular/JJ genes/NNS in/IN immortalized/VBN B/NN cells/NNS ./. 
Our/PRP$ data/NNS suggest/VBP an/DT involvement/NN of/IN BLR2/NN in/IN the/DT regulation/NN of/IN migration/NN in/IN activated/VBN lymphocytes/NNS and/CC in/IN viral/JJ pathogenesis/NN ./. 
UI/LS -/: 96009598/CD 
TI/LS -/: A/DT central/JJ role/NN for/IN a/DT single/JJ c-Myb/NN binding/NN site/NN in/IN a/DT thymic/JJ locus/NN control/NN region/NN ./. 
AB/LS -/: Locus/NN control/NN regions/NNS (/( LCRs/NNS )/) are/VBP powerful/JJ assemblies/NNS of/IN cis/JJ elements/NNS that/WDT organize/VBP the/DT actions/NNS of/IN cell-type-specific/JJ trans-acting/JJ factors/NNS ./. 
A/DT 2.3-kb/JJ LCR/NN in/IN the/DT human/JJ adenosine/NN deaminase/NN (/( ADA/NN )/) gene/NN first/JJ intron/NN ,/, which/WDT controls/VBZ expression/NN in/IN thymocytes/NNS ,/, is/VBZ composed/VBN of/IN a/DT 200-bp/JJ enhancer/NN domain/NN and/CC extended/JJ flanking/NN sequences/NNS that/WDT facilitate/VBP activation/NN from/IN within/IN chromatin/NN ./. 
Prior/RB analyses/NNS have/VBP demonstrated/VBN that/IN the/DT enhancer/NN contains/VBZ a/DT 28-bp/JJ core/NN region/NN and/CC local/JJ adjacent/JJ augmentative/JJ cis/JJ elements/NNS ./. 
We/PRP now/RB show/VBP that/IN the/DT core/NN contains/VBZ a/DT single/JJ critical/JJ c-Myb/NN binding/NN site/NN ./. 
In/IN both/CC transiently/RB cotransfected/VBN human/JJ cells/NNS and/CC stable/JJ chromatin-integrated/JJ yeast/NN cells/NNS ,/, c-Myb/NN strongly/RB transactivated/VBD reporter/NN constructs/NNS that/WDT contained/VBD polymerized/JJ core/NN sequences/NNS ./. 
c-Myb/NN protein/NN was/VBD strongly/RB evident/JJ in/IN T/NN lymphoblasts/NNS in/IN which/WDT the/DT enhancer/NN was/VBD active/JJ and/CC was/VBD localized/JJ within/IN discrete/JJ nuclear/JJ structures/NNS ./. 
Fetal/JJ murine/NN thymus/NN exhibited/VBD a/DT striking/JJ concordance/NN of/IN endogenous/JJ c-myb/NN expression/NN with/IN that/DT of/IN mouse/NN ADA/NN and/CC human/JJ ADA/NN LCR-directed/JJ transgene/NN expression/NN ./. 
Point/NN mutation/NN of/IN the/DT c-Myb/NN site/NN within/IN the/DT intact/JJ 2.3-kb/JJ LCR/NN severely/RB attenuated/VBD enhancer/NN activity/NN in/IN transfections/NNS and/CC LCR/NN activity/NN in/IN transgenic/JJ thymocytes/NNS ./. 
Within/IN the/DT context/NN of/IN a/DT complex/NN enhancer/NN and/CC LCR/NN ,/, c-Myb/NN can/MD act/VB as/IN an/DT organizer/NN of/IN thymocyte-specific/JJ gene/NN expression/NN via/IN a/DT single/JJ binding/VBG site/NN ./. 
UI/LS -/: 95403454/CD 
TI/LS -/: A/DT regulatory/JJ element/NN in/IN the/DT human/JJ interleukin/NN 2/CD gene/NN promoter/NN is/VBZ a/DT binding/VBG site/NN for/IN the/DT zinc/NN finger/NN proteins/NNS Sp1/NN and/CC EGR-1/NN ./. 
AB/LS -/: Activation/NN of/IN the/DT interleukin/NN 2/CD (/( IL-2/NN )/) gene/NN after/IN antigen/NN recognition/NN is/VBZ a/DT critical/JJ event/NN for/IN T/NN cell/NN proliferation/NN and/CC effector/NN function/NN ./. 
Prior/JJ studies/NNS have/VBP identified/VBN several/JJ transcription/NN factors/NNS that/WDT contribute/VBP to/TO the/DT activity/NN of/IN the/DT IL-2/NN promoter/NN in/IN stimulated/VBN T/NN lymphocytes/NNS ./. 
Here/RB we/PRP describe/VBP a/DT novel/JJ regulatory/JJ element/NN within/IN the/DT IL-2/NN promoter/NN located/JJ immediately/RB upstream/RB of/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cell/NN (/( NFAT/NN )/) domain/NN ./. 
This/DT region/NN (/( termed/VBN the/DT zinc/NN finger/NN protein/NN binding/NN region/NN (/( ZIP/NN )/) )/) serves/VBZ as/IN binding/VBG site/NN for/IN two/CD differently/RB regulated/VBN zinc/NN finger/NN proteins/NNS :/: the/DT constitutively/RB expressed/VBN transcription/NN factor/NN Sp1/NN and/CC the/DT inducible/JJ early/JJ growth/NN response/NN protein/NN EGR-1/NN ./. 
In/IN unstimulated/JJ cells/NNS which/WDT do/VBP not/RB secrete/VB IL-2/NN ,/, only/RB Sp1/NN binds/VBZ to/TO this/DT region/NN ,/, while/IN in/IN stimulated/VBN IL-2/NN secreting/NN cells/NNS the/DT inducible/JJ EGR-1/NN protein/NN recognizes/VBZ this/DT element/NN ./. 
In/IN Jurkat/NN T/NN cells/NNS ,/, the/DT ZIP/NN site/NN serves/VBZ as/IN an/DT activator/NN for/IN IL-2/NN gene/NN expression/NN ,/, and/CC a/DT combination/NN of/IN ZIP/NN and/CC NFAT/NN binding/NN sites/NNS is/VBZ required/VBN for/IN maximal/JJ IL-2/NN promoter/NN activity/NN ./. 
These/DT results/NNS suggest/VBP a/DT critical/JJ role/NN of/IN the/DT ZIP/NN site/NN for/IN IL-2/NN promoter/NN activity/NN ./. 
UI/LS -/: 95385995/CD 
TI/LS -/: Activation/NN of/IN the/DT HIV-1/NN enhancer/NN by/IN the/DT LEF-1/NN HMG/NN protein/NN on/IN nucleosome-assembled/JJ DNA/NN in/FW vitro/FW ./. 
AB/LS -/: Lymphoid/NN enhancer-binding/JJ factor/NN 1/CD (/( LEF-1/NN )/) is/VBZ a/DT regulatory/JJ high/JJ mobility/NN group/NN (/( HMG/NN )/) protein/NN that/WDT activates/VBZ the/DT T/NN cell/NN receptor/NN alpha/NN (/( TCR/NN alpha/NN )/) enhancer/NN in/IN a/DT context-restricted/JJ manner/NN in/IN T/NN cells/NNS ./. 
In/IN this/DT paper/NN we/PRP demonstrate/VBP that/IN the/DT distal/JJ region/NN of/IN the/DT human/JJ immunodeficiency/NN virus-1/NN (/( HIV-1/NN )/) enhancer/NN ,/, which/WDT contains/VBZ DNA-binding/JJ sites/NNS for/IN LEF-1/NN and/CC Ets-1/NN ,/, also/RB provides/VBZ a/DT functional/JJ context/NN for/IN activation/NN by/IN LEF-1/NN ./. 
First/RB ,/, we/PRP show/VBP that/IN mutations/NNS in/IN the/DT LEF-1-binding/JJ site/NN inhibit/VBP the/DT activity/NN of/IN multimerized/JJ copies/NNS of/IN the/DT HIV-1/NN enhancer/NN in/IN Jurkat/NN T/NN cells/NNS ,/, and/CC that/IN LEF-1/GAL4/NN can/MD activate/VB a/DT GAL4-substituted/JJ HIV-1/NN enhancer/NN 80-/CD to/TO 100-fold/RB in/FW vivo/FW ./. 
Second/RB ,/, recombinant/JJ LEF-1/NN is/VBZ shown/VBN to/TO activate/VB HIV-1/NN transcription/NN on/IN chromatin-assembled/JJ DNA/NN in/FW vitro/FW ./. 
By/IN using/VBG a/DT nucleosome-assembly/JJ system/NN derived/VBN from/IN Drosophila/FW embryos/NNS ,/, we/PRP find/VBP that/IN the/DT packaging/NN of/IN DNA/NN into/IN chromatin/NN in/FW vitro/FW strongly/RB represses/VBZ HIV-1/NN transcription/NN and/CC that/IN repression/NN can/MD be/VB counteracted/VBN efficiently/RB by/IN preincubation/NN of/IN the/DT DNA/NN with/IN LEF-1/NN (/( or/CC LEF-1/NN and/CC Ets-1/NN )/) supplemented/VBN with/IN fractions/NNS containing/VBG the/DT promoter-binding/JJ protein/NN ,/, Sp1/NN ./. 
Addition/NN of/IN TFE-3/NN ,/, which/WDT binds/VBZ to/TO an/DT E-box/NN motif/NN upstream/JJ of/IN the/DT LEF-1/NN and/CC Ets-1/NN sites/NNS ,/, further/RB augments/VBZ transcription/NN in/IN this/DT system/NN ./. 
Individually/RB or/CC collectively/RB ,/, none/NN of/IN the/DT three/CD enhancer-binding/JJ proteins/NNS (/( LEF-1/NN ,/, Ets-1/NN ,/, and/CC TFE-3/NN )/) could/MD activate/VB transcription/NN in/IN the/DT absence/NN of/IN Sp1/NN ./. 
A/DT truncation/NN mutant/NN of/IN LEF-1/NN (/( HMG-88/CD )/) ,/, which/WDT contains/VBZ the/DT HMG/NN box/NN but/CC lacks/VBZ the/DT trans-activation/JJ domain/NN ,/, did/VBD not/RB activate/VB transcription/NN from/IN nucleosomal/JJ DNA/NN ,/, indicating/VBG that/IN bending/NN of/IN DNA/NN by/IN the/DT HMG/NN domain/NN is/VBZ not/RB sufficient/JJ to/TO activate/VB transcription/NN in/FW vitro/FW ./. 
We/PRP conclude/VBP that/IN transcription/NN activation/NN by/IN LEF-1/NN in/FW vitro/FW is/VBZ a/DT chromatin-dependent/JJ process/NN that/WDT requires/VBZ a/DT functional/JJ trans-activation/NN domain/NN in/IN addition/NN to/TO the/DT HMG/NN domain/NN ./. 
UI/LS -/: 95370270/CD 
TI/LS -/: HIV-1/NN envelope/NN glycoproteins/NNS induce/VBP activation/NN of/IN activated/VBN protein-1/NN in/IN CD4+/JJ T/NN cells/NNS [/( published/VBN erratum/NN appears/VBZ in/IN J/NNP Biol/NNP Chem/NNP 1995/CD Dec/NNP 1/CD ;/: 270/CD (/( 48/CD )/) :/: 29038/CD ]/) 
AB/LS -/: Activation/NN of/IN CD4/NN positive/JJ T/NN cells/NNS is/VBZ a/DT primary/JJ requirement/NN for/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) entry/NN ,/, efficient/JJ HIV/NN replication/NN ,/, and/CC progression/NN to/TO AIDS/NN ,/, Utilizing/VBG CD4/NN positive/JJ T/NN cell/NN lines/NNS and/CC purified/VBN T/NN cells/NNS from/IN normal/JJ individuals/NNS ,/, we/PRP have/VBP demonstrated/VBN that/IN native/JJ envelope/NN glycoproteins/NNS of/IN HIV/NN ,/, gp/NN 160/CD ,/, can/MD induce/VB activation/NN of/IN transcription/NN factor/NN ,/, activated/VBN protein-1/NN (/( AP-1/NN )/) ./. 
The/DT stimulatory/JJ effects/NNS of/IN gp160/NN are/VBP mediated/VBN through/IN the/DT CD4/NN molecule/NN ,/, since/IN treatment/NN of/IN gp160/NN with/IN soluble/JJ CD4-IgG/NN abrogates/VBZ its/PRP$ activity/NN ,/, and/CC CD4/NN negative/JJ T/NN cell/NN lines/NNS fail/VBP to/TO be/VB stimulated/VBN with/IN gp160/NN ./. 
Immunoprecipitation/NN of/IN the/DT gp/NN 160-induced/JJ nuclear/JJ extracts/NNS with/IN polyclonal/JJ antibodies/NNS to/TO Fos/NN and/CC Jun/NN proteins/NNS indicates/VBZ that/IN AP-1/NN complex/NN is/VBZ comprised/VBN of/IN members/NNS of/IN these/DT family/NN of/IN proteins/NNS ./. 
The/DT gp160-induced/JJ AP-1/NN complex/NN is/VBZ dependent/JJ upon/IN protein/NN tyrosine/NN phosphorylation/NN and/CC is/VBZ protein/NN synthesis-independent/JJ ./. 
This/DT stimulation/NN can/MD also/RB be/VB abolished/VBN by/IN inhibitors/NNS of/IN protein/NN kinase/NN C/NN ,/, but/CC it/PRP is/VBZ unaffected/JJ by/IN calcium/NN channel/NN blocker/NN or/CC cyclosporine/NN A/NN ./. 
This/DT gp160/NN treatment/NN adversely/RB affects/VBZ the/DT functional/JJ capabilities/NNS of/IN T/NN cells/NNS :/: pre-treatment/NN of/IN CD4+/JJ T/NN cells/NNS with/IN gp160/NN for/IN 4/CD h/NN at/IN 37/CD degrees/NNS C/NN inhibited/VBD anti-CD3-induced/JJ interleukin-2/NN secretion/NN ./. 
Effects/NNS similar/JJ to/TO gp160/NN were/VBD seen/VBN with/IN anti-CD4/JJ mAb/NN ./. 
The/DT aberrant/JJ activation/NN of/IN AP-1/NN by/IN gp160/NN in/IN CD4/NN positive/JJ T/NN cells/NNS could/MD result/VB in/IN up-regulation/NN of/IN cytokines/NNS containing/VBG AP-1/NN sites/NNS ,/, e.g./FW interleukin-3/NN and/CC granulocyte/NN macrophage/NN colony-stimulating/JJ factor/NN ,/, and/CC concurrently/RB lead/VBP to/TO T/NN cell/NN unresponsiveness/NN by/IN inhibiting/VBG interleukin-2/NN secretion/NN ./. 
